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This is a multidisciplinary research project in the field of bioconjugation chemistry. 
Bioconjugation chemistry, in its fundamental aspects, refers to the site specific covalent 
modification of bio-molecules adding or modulating desired characteristics. The recent 
advances in bioconjugation approaches have enabled the progressive construction of 
ground-breaking monoclonal antibodies (mAbs) biotherapies, such as antibody drug 
conjugates (ADCs) and bispecific antibodies. However, there is still a long list of 
limitations encountered by the currents approaches such as poor plasma stability, post-
modification structural stability and heterogeneity of the produced conjugates, which are 
usually tackled by expensive and complex biological-based techniques. Therefore, in 
this study, we aimed to develop novel conjugation chemistry suitable for the 
construction of antibody-protein conjugates with promising anti-cancer activity.    
Production of protein conjugates is usually achieved through targeting thiolate groups of 
their cysteine residues. We aimed to develop an effective reduction method for 
activation of thiolates towards conjugation reactions. We developed and evaluated a 
novel one-pot method by using water soluble azide-derivatised ethylene glycols (PEG-
azides) to quench excess trialkylphosphines prior to thiol alkylation reactions. The rates 
of oxidation of trialkylphosphines with a series of PEG-azides were determined and the 
applicability of this in situ method was evaluated in conjugation reactions. 
We have developed a novel rebridging approach of the reduced disulfide bonds of 
mAbs, based on an aryl bis-haloacetamide scaffold. The proposed scaffold was 
developed according to our findings related to the impact of a vicinal acetamide group 
on the reactivity and stability of various electrophiles. Interestingly, rebridging of mAbs 
with the bis-haloacetamide linkers has revealed a high efficiency in rebridging heavy-
light and intra-heavy-heavy disulfide bonds affording half antibody (75 kDa) as a major 
rebridged product. Rebridging conditions were optimised and utilised to obtain 
rebridged bi-functional half antibody (75 kDa) modified with bio-orthogonal chemistry. 
The stability of the rebridged mAbs and the difference in reactivity and selectivity 
amongst bis-haloacetamide linkers with reduced mAbs have been thoroughly studied. 
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Moreover, we have developed an elegant bis-rebridging platform based on bis-
haloacetamide scaffold. The bis-o-dihaloacetamide PEG linker has been applied in 
generating mAb conjugates with other proteins, including immunomodulating proteins 
and antibody fragments in an adaptable procedure with a very good yield. The 
promising findings imply the applicability of this approach to construct mAb 
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1.1 Bioconjugation chemistry 
Over billions of years, nature has developed post-ribosomal protein modification 
processes, which are known as post-translational modifications (PTMs). PTMs are 
covalent modification events of proteins that take place either by hydrolytic break down 
of proteins or by attachment of specific functionalities to one or more amino acids of 
proteins.1 These events take part after ribosomal protein synthesis, in order to amend the 
physicochemical characteristics of proteins, modulate their activity, and control the 
process of protein–protein interaction.2 For instance, the glycosylation process of 
proteins or the attachment of carbohydrates to proteins is one of the most adopted 
biological tools to improve the solubility of proteins, and more importantly to modulate 
protein–receptor interactions (Figure 1.1 A).3 Other natural PTMs include 
phosphorylation, ubiquitination, methylation, nitrosylation, acetylation, lipidation and 
proteolysis.4 In attempts to mimic these natural PTMs, scientists have made significant 
efforts to covalently amend proteins with various functionalities.5 
In its most central aspect, bioconjugation chemistry is a multidisciplinary field, which 
refers to site specific chemical manipulation of biomolecules of interest, thus covalently 
adding unique functionalities in order to fulfil the requirements in demand. The process 
of synthesis of bioconjugates mainly aims to create new complexes which possess 
properties of each constituent taking part. One of the obvious examples of the 
application of bioconjugation chemistry is the fluorescently-labelled antibodies. 
Fluorescently-labelled antibodies bind specifically to a desired antigen and with the 
added fluorescent properties, they can be visually detected unlike unlabelled antibodies 
(Figure 1.1 B).6,7 
Amongst the variety of biomolecules, proteins are the central to what bioconjugation 
chemistry is all about. A great deal of efforts has been devoted to develop specialized 
site-specific reagents and procedures to selectively modify proteins for unending 
number of biological and therapeutic applications. Commercially, a huge number of 
reagents are available at present, to fulfil the aforementioned applications and other 
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purposes.8 One example of biological applications is to provide a means to specifically 
track intracellular proteins which ultimately could afford a better understanding of 
biological processes and help in developing opportunistic targets for therapeutic 
interventions. Moreover, bioconjugation chemistry has played a chief role in the 
development of vast ground-breaking bio-therapeutics with promising targeted 
approaches particularly in cancer treatment.5  
 
Figure 1.1. Site-specific protein modification of antibodies. A) An example of natural post-translation 
modification of proteins by N-glycosylation of antibodies at CH2 domain which is carried out inside the 
rough endoplasmic reticulum. B) An example of bioconjugation chemistry by chemical attachment of a 
fluorophore to antibodies (fluorescently labelled antibodies) which is widely applied in diagnostic assays. 
1.2 Applications of protein conjugates 
Recently, the applications of bioconjugation chemistry products have been hugely 




1) Analysis and quantification;  
2) Detection and imaging of bio-targets;  
3) Therapeutics, vaccines and immune modulation. 
These applications will be further describe in the following Sections (1.2.1-1.2.3). There 
are ever-increasing number of applications of bioconjugation chemistry including 
capture, purification, catalysis and chemical modification of specific biomolecules. 
1.2.1 Analysis and quantification 
Assay of targeted analyte, in complex mixture of other analytes, is one of the most 
prevalent direct applications of bioconjugation chemistry. This can be mainly achieved 
via employing a chemically modified antibody (fluorescently labelled antibody, 
enzyme-linked antibody, or biotinylated antibody) possessing high affinity toward the 
analyte of interest. 
Enzyme-linked immunosorbant assay (ELISA) system is the most well-known sensitive 
bioassays that used to quantify a specific antigen through using enzyme-linked 
antibody.9 This assay is performed through subsequent steps starting by adding samples 
of analytes to the wells with captured specific antibody, and allowing the target analyte 
(antigen) to bind to the captured antibodies. Then, a primary antibody is added which 
binds to a different epitope on the antigen. A secondary enzyme-linked antibody is 
added which binds to the primary antibody. Finally, specific substrate which is catalysed 
by the enzyme generating detectable product will be added (Figure 1.2). An essential 
washing step is required between the above mentioned procedural steps. 
 
Figure 1.2. ELISA procedure using enzyme-linked antibody to quantify the target analytes (antigens). 
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1.2.2 Detection and imaging of biomolecules 
Conjugated proteins with a fluorophores or radiolabel are usually employed in detection 
and imaging techniques. Labelled proteins can be either followed in vitro (for instance, 
immunofluorescence) or in vivo (for instance, molecular imaging techniques).  
Western blots are considered the golden standard used for the in vitro detection of 
certain biomolecules. This techniques is based on employing secondary antibody–
enzyme conjugates and streptavidin–enzyme conjugates for the recognition of certain 
proteins. The procedure involves separation of protein sample based on their molecular 
weight using SDS polyacrylamide gel electrophoresis (PAGE), followed by transferring 
the separated proteins to nitrocellulose membrane for immunochemical detection. Then, 
a binding step of the primary antibodies or biotinylated primary antibodies to the target 
protein is followed by a secondary binding step through using secondary antibody–
enzyme conjugate or streptavidin–enzyme conjugates, respectively. In either of the 
aforementioned procedures, a subsequent detection step through using specific substrate 
is followed to develop a detectable signal of at the site of binding.10 
In vivo imaging tools, such as positron emission tomography (PET) continues to grow 
mainly in clinical diagnosis, staging, and prognosis of cancer disease, certain brain 
diseases and dementias. In this technique, gamma rays are indirectly generated and 
detected to obtain internal organs images. Positron-emitting radionuclide, in particular 
18F (fluoro group) is linked to certain compounds, such as deoxyglucose to create the 
radiopharmaceutical agent, 2-deoxy-2-18F-fluoro-β-D glucose (18F-FDG). 18F-FDG is 
the most widely used radioactive drug in the detection of malignancies. After injection 
to the patient, 18F-FDG is circulated inside the target cells by glucose transporters and 
trapped within those cells.11 However, FDG are nonspecific for cancer tissue and can 
also be up taken by inflamed or infected lesions and, of course, by normal 
tissues/organs. Thus, the interpretation of obtained imaging results might not be 
accurate.  
Recently, immuno-positron emission tomography, imparts selectively through 
attachment of the radiolabel to monoclonal antibody (mAb) or mAb fragments. 
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Radiolabelled mAbs bind to specific antigens that is expressed differently on tumour 
cells, therefore, the imaging procedure will address questions regarding the presence, 
location, and size of the malignant neoplasm.12,13 Zeglis et al. introduced radiolabeled 
antibodies to attain pre-targeted PET imaging tool. They used tumor homing 
antibodies that attached to trans-cyclooctene (TCO) group in a mouse xenograft 
tumor model. TOC-mAb could selectively and rapidly react with a radiolabeled 
tetrazine ring through Diels–Alder click chemistry, thus affording a visible antibody 
to be detected by PET scanner (Figure 1.3).14 Rashidian et al. on the other hand, have 
used 18F-labelled antibody fragments for PET imaging. The 18F-labelled antibody 
fragments were constructed through sortase-mediated installing of TCO into the protein 
of interest, followed by selectively reacting it with a tetrazine- labeled FDG.  
The previously described approaches provide an efficient and selective method of 
imaging through utilising 18F-labeled antibodies and their fragments with improved level 
of specificity over the conventional FDG-based imaging.15 
 
Figure 1.3. Diels–Alder click reaction of tumor-homing antibody-Trans-cyclooctyne (TCO) conjugate 
with radiolabelled tetrazine affording radiolabeled antibody accumulated in tumor site in order to be 





1.2.3 Therapeutic conjugates and conjugate vaccines  
Therapeutic proteins are hugely disseminated class of drugs with wide range of 
therapeutic indications. More than 200 normal and modified therapeutic proteins have 
been approved by the European Union and the USA for clinical use.16 Unfavourable 
drawbacks of employing native proteins have been encountered, ranging from 
pharmacokinetics properties and short half-life to immunogenicity and allergic 
reactions. One of the well-recognised adopted chemical modifications of therapeutic 
proteins is the covalently attachment of PEG - a process known as PEGylation. 
PEGylation is usually performed to address the limitations of using native bio-
therapeutics, including instability, short half-life, and immunogenicity. PEGs are non-
toxic, hydrophilic, nonimunogenic and uncharged polymer. PEGylated proteins have 
displayed enhanced pharmacokinetic properties in vivo.17  
Perhaps the best known example of PEGylated protein is Cimzia® (certolizumab pegol). 
Cimzia® is a humanized monoclonal Fab′ fragment against human tumor necrosis factor 
alpha (TNFα) which covalently bound to an approximately 40-kDa PEG molecule 
through alkylation of the cysteine residues in the hinge region using a branched 
maleimide-PEG affording a defined conjugate of approximately 91 kDa (Figure 1.4). 
The conjugate binds to TNFα and neutralize its activity, which is well-known 
inflammatory mediator and indicated mainly for the treatment of Crohn‘s disease and 
severely active cases of rheumatoid arthritis.18 
Conjugate vaccines are another growing class of medical compounds which typically are 
consisting of a polysaccharide antigen (weak antigen) bound to a carrier molecule such 
as bovine serum albumin (BSA), keyhole limpet hemocyanin (KLH), tetanus toxoid, 
diphtheria toxoid, and tuberculin purified protein derivative (PPD) through various 
chemical conjugation methods. Conjugate vaccines are constructed to improve the 




Figure 1.4. The structure of Cimzia
® 
conjugate, which is a humanized Fab′ fragment against TNFα that is 
chemically conjugated with two PEG chains. Figure adapted from reference (
7
). 
Many of the invasive infection-causing bacteria (such as Salmonella typhi, Haemophilus 
influenzae type b (Hib), Streptococcus pneumoniae and Neisseria meningitidis) have 
outer polysaccharide capsule as virulence mechanism, providing protection against 
complement system and phagocytosis. Purified capsular polysaccharides are 
unsatisfactory and insufficient immunogenic agents when administrated as vaccines to 
protect against invasive infections. Hib plain polysaccharide alone has been evaluated as 
a vaccine, however, it has induced relatively low titers of serum antibodies that are 
insufficient to protect against invasive infectious disease. The limited immunogenicity of 
polysaccharides is due to the lack of T-cells recognition (only recognized by B-cells). 
Therefore, induction of T-independent response which prevents the proper development 
of B-cells i.e. class-switched antibody production and avidity maturation.19  
Hib conjugate was the first approved conjugate vaccine in clinical practice. It was 
approved in the USA in 1987, and shortly it has been licensed in infant immunisation 
schedule. Hib conjugate vaccine has found to be effective in reducing the incidence of 
Hib infectious diseases in childhood.20,21 
Recently, one of the most vital applications of bioconjugation chemistry in human 
therapeutics is the chemical conjugation of mAb with cytotoxic drugs, which known as 
Antibody Drug Conjugates (ADCs). ADCs are modern targeted approaches in cancer 
therapy in which the mAb leads the cytotoxic drug to malignant cells, whereupon the 
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cytotoxic payload performs certain cellular killing mechanism. Four ADCs have been 
approved by the FDA for treatment of various refractory and metastatic malignancies 
and around 60 are under investigation in clinical trials.22 
1.3 Antibody drug conjugates  
The basis of traditional cancer therapy is to remove and kill cancer cells either by 
surgery, radiation or the non-selective conventional chemotherapy drugs. Surgery and 
radiation therapy could be effective in solid and localised tumor, while non-selective 
conventional chemotherapy drugs are mainly used in metastatic cancer types. 
Conventional chemotherapeutic drugs are generally directed toward rapidly proliferating 
cancerous cells, but can also kill other normal dividing cells. Adopting non-selective 
conventional chemotherapy drugs - as the name implies - is associated with non-
avoidable severe side effects.23 
Traditional chemotherapeutic agents can be classified into three major families based on 
their mode of action: 
 Antimetabolites family, such as purine analogues (6-mercaptopurine and 6-
thioquanine), folate analogues (methotrexate), and fluoropyrimidine  (5-FU) 
which still remains the cornerstone for treatment of colorectal cancer.24,25 
 Antimicrotubule (mitotic inhibitor) family, such as vinca alkaloids (vinblastine 
and vincristine) which mainly interacts with tubulin protein and disrupt 
microtubule function, and eventually causing metaphase arrest.26 
 The third major family is DNA damaging agents, such as alkylating agent 
(nitrogen mustard) which are one of the oldest class of anticancer drugs and DNA 
intercalating agents (anthracyclines).27,28  
Tyrosine kinases inhibitors (Imatinib) are recently introduced group of anti-cancer agents 
that interfere with the signaling cascade mediated by tyrosine kinases. Tyrosine kinases 
can be either activated in response to external or internal stimuli, subsequently they 
convey the stimuli intracellular, and eventually govern different biological processes 
such as growth, differentiation, metabolism, and apoptosis.29 
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A great number of research has been conducted to obtain in depth mechanistic 
understanding of cancer at the cellular level. These efforts have facilitated the discovery 
of differentially expressed antigens that could be selectively targeted in cancer therapy 
using mAbs. Shortly thereafter, mAb has been hugely disseminated in treatment of 
various inflammatory diseases and cancer. Perhaps the most crucial feature of mAbs is 
their high specificity to target antigens that are either overexpressed, mutated or 
selectively expressed on cancer tissue.30  
Over the last two decades, mAbs have been considered as a well-deserved mainstream 
branch in treatment of various types of cancer. As of October 2017, there are 61 mAbs in 
clinical use after been approved by FDA and/or EMA, approximately 40% of the 
approved mAbs are used for the treatment of cancer.31  
1.3.1 Monoclonal antibodies (mAb) 
Antibodies (Immunoglobulins, Igs) are 150 kDa heterodimeric glycoproteins comprise of 
four polypeptide chains: two identical heavy chains and two identical light chains 
(Figure 1.5).  Each heavy chain is comprised of one variable (VH) and three constant 
domains (CH1, CH2, CH3), while each light chain is composed of only a single variable 
(VL) and a constant (CL) domain. Variable domain is responsible for antigen binding and 
therefore, this region displays high level of variation in amino acid composition. Each 
variable domain is composed of three regions of high sequence variability, 
(complementarity determining regions, or CDRs) and four regions of relatively high 
sequence consistency (framework regions, or FRs). Each heavy and light polypeptites 
chains are held together through non-covalent interactions and covalent inter-chain 
disulfide bonds to construct a bilaterally symmetric structure of antibody.32 
Light chain can be either κ or    chain type. Igs are divided into five main classes 
according to the type of constant domains of the heavy chain:  IgM, IgG, IgA, IgD, and 
IgE. IgG is the major class found in human body with the longest serum half-life in 
comparison with all other Igs classes. Moreover, amongst the five classes of Igs, IgG is 
the most extensively studied and used in therapeutic application. Four IgG subclasses 
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(IgG1, IgG2, IgG3 and IgG4) were identified based on structural, antigenic and functional 
differences in the constant domain of the heavy chain (mainly CH1 and CH3).
33
 
In order to facilitate the early study of the structure of antibody, digestion enzymes, such 
as papain, were used. Papain digests IgG into two Fab fragments, and a single Fc 
fragment. The Fab consists of a variable fragment (Fv: VH and VL domains), and a 
constant fragment (Fc: CL and CH1 domains). Fc fragments specify effector functions of 
antibody, including activation of complement system through binding to C1q and 
phagocytosis via binding to Fc receptors (Fc R).  In addition to be responsible for the 
effector function, CH2-CH3 domains of Fc region determine the serum level of IgGs 
through binding to the Fc neonatal receptor (FcRn).34  
It worthwhile mentioning that IgG1 has 4 solvent exposed inter-chain disulfide bonds 
holding heavy-light and heavy-heavy chains along with another 12 intra-chain disulfide 
bonds that are not solvent accessible and buried within each domain of the 12 domains 
(Figure 1.5).35 
 
Figure 1.5. General bilaterally symmetric structure of IgG. Blue stars indicate glycosylation sites of CH2 
domain of the Heavy chain.  
Once mAbs bound to their specific receptors, mAbs initiate cell death through different 
pathways, including complement-dependent cytotoxicity (CDC) or antibody dependent 
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cell-mediated cytotoxicity (ADCC). Moreover, mAbs interfere with downstream 
signaling events associated with these receptors, such as growth and regulation of 
differentiation of cells (Figure 1.6).30 
 
Figure 1.6. Interaction of mAbs with cancer cells and their mechanism of causing cell death . A) ADCC 
involves interaction of Fc domain with Fc R on immune effector cells mainly, natural killer cells (NK). 
NK cells releases perforin and other enzymes to lyse cancer cells in addition to pro-inflammatory 
mediators, such as IFN  to activate nearby antigen presentation and adaptive immune responses.
36
 B) 
CDC involves complement C1q binding to CH2 domain of Fc region, which in turn activate the classical 
pathway of complement activation. Complement activation result in construction of membrane attack 
complex (MAC) and cellular lysis .
37
 C) Signal transduction changes of these receptors on cancer cells 
which might normalise the malignant symptoms and sensitise cells to cytotoxic drugs.
38
 CLTs: cytotoxic 
lymphocytes. 
Early used mAbs were of murine origin and therefore immunogenicity and triggering 
Human Anti-Mouse Antibody (HAMA) response were the major problems encountered 
with using mAbs in the clinical practice. In attempt to overcome the immunogenicity 
problem, genetically engineered types of mAb were employed in clinical practice: 
Chimeric mAb (where the constant regions of human antibody are combined with a 
murine variable region) or humanization (where only the murine CDR regions used and 
sewn onto a human antibody). The current state of the art immunogenicity mitigation is 
the so-called fully human mAbs, which was made possible by two widely employed 




In 1997, a major breakthrough occurred in clinical oncology when rituximab (Rmab) 
was approved as a first mAb in the treatment of cancer. Rituximab, the largest-selling 
biologic drug in clinical oncology, is a chimeric monoclonal antibody that binds to CD20 
antigen on both normal B cells, and on most low-grade and some higher grade B-cell 
lymphomas. It is primarily used in combination with standard chemotherapies in the 
treatment of patients with non-Hodgkin‘s B-cell lymphomas and chronic lymphocytic 
leukemia.42 
The second monoclonal antibody that has proven high efficacy in clinical oncology is 
Trastuzumab (Tmab), a humanised mAb anti-HER2 (human epidermal growth factor 
receptor 2) receptor. It is primarily used in conjunction with chemotherapy for patients 
with human HER2 positive breast cancer.42 
There are 12 mAbs that have received FDA approval for the treatment of different solid 
tumors and hematological malignancies, in addition to numerous therapeutic antibodies 
in their early- and late-stage clinical trials.30 Nonetheless, studies have shown that most 
of the available mAbs have demonstrated suboptimal clinical activity and as a result, 
they are used in conjunction with chemotherapy.38,43 Thereby, researchers are focused on 
empowering the activity of mAb through different approaches to take advantage of their 
specificity that has amended most of the unavoidable side effects associated with 
conventional anticancer therapeutics. 
Accordingly, immunoconjugates between mAb and an effector molecule have been 
produced, either between an antibody and an enzyme (to activate a prodrug), a cytotoxic 
drug, or a radioisotope (Figure 1.7). 
As mentioned earlier, mAbs have been employed in ADCs as a vehicle for targeting a 
cytotoxic drug toward cancer cells. By fulfilling the theory of magic bullet of Paul 
Ehrlich, ADCs provide a selective mean of delivery of cytotoxic payloads to cancer 





Figure 1.7. Immunoconjugates types between A) an antibody and an enzyme (capable of activating a 
prodrug), B) an antibody and a toxin, C) an antibody and a radioisotope. 
1.3.2 Cytotoxic mechanism of ADCs 
ADCs exert their cytotoxicity through internalisation into cancer cells with the process of 
receptor-mediated endocytosis after selectively recognizing specific receptors on cancer 
cells. Normally, cells continuously internalise their surface receptors through receptor-
mediated endocytosis. Clathrin-dependent endocytosis is the chief mechanism for the 
internalisation of cell surface receptors. Briefly, endocytosis generally starts when a 
ligand binds a cell-surface receptor, which initiates an array of subsequent steps, starting 
from selection of receptors by adaptor proteins for internalisation, to the movement of 
clathrin from the cytoplasm to adaptor protein-enriched regions of the membrane. Then 
polymerization of clathrin takes place, followed by inward budding of the plasma 
membrane and formation of early endosomes, which either recycle the receptor back to 
plasma membrane or routed to lysosomes. Lysosomes have acidic and proteolytic-rich 
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environment, therefore the cytotoxic drugs are degraded from ADCs and released into 
the cell to exert certain killing mechanism. It might kill neighbor cells through bystander 
effect (Figure 1.8).44,45 
 
Figure 1.8. Cytotoxic mechanism of ACDs. The process starts when the mAb component recognizes and 
binds to a specific antigen on cancer cell, followed by rapid internalisation of the antigen -ADC complex. 
The endosomes are routed to lysosomes where the ADC is degraded leading to the release of the cytotoxic 
drug, then the drug binds to its target, either DNA or tubulin and cause cellular apoptosis. It may also be 
released or pumped through the cell membrane which leads to bystander effect.  
1.3.3 The anatomy of ADCs 
ADCs are composed of three major components as shown in Figure 1.9: 
1) An antibody targeting a receptor that expressed differently on cancer cell. 
2) A cytotoxic payload that is considered too toxic to be utilized as stand-alone therapy. 




Figure 1.9. The Anatomy of ADCs. ADCs are composed of three main parts: 1) mAb that specifically 
binds to antigens expressed on cancer cells. 2) Cytotoxic drug that usually binds to tubulin or DNA  and 
leads to cellular apoptosis. 3) Stable linker that ideally attach the cytotoxic drugs at specific sites on mAb 
and release it through the endosomal-lysosomal pathway.  
Choosing the tumor antigen is the first step in the assembly process of ADCs. Antigens 
must be found on the cell surface and expressed differently on cancer cells i.e. highly or 
specifically expressed on cancer cells. In addition, ideally, targeted antigen must undergo 
endocytosis to internalize the ACDs inside the cell to be able to release the cytotoxic 
payload. Antibodies, should display high binding affinity to the target antigen (Kd<10 
nM) and preferably it should not be immunogenic.46  
Once the antigen and the mAb selected, the next essential step is to develop the 
conjugation method (linkers) to construct the ACD. Innovations in linker development 
are centered on plasma stability and cellular release of the cytotoxic drug. Ideally, the 
linker should have maximum plasma stability, yet should allow rapid release of the 
cytotoxic drug inside the cancer cell. The linkers have three sub-components: a 
functional group to attach to a specific site on mAb, a spacer which mostly deemed as 
hydrophilic moiety of the linker, and a trigger that specifically release the cytotoxic drug 
once ADC reached intended cancer cells.47 Linkers can be divided into two major types: 
cleavable and non-cleavable linkers. As lysosome has an acidic environment and filled 
with lysosomal enzymes, cleavable linkers have been designed based on the encountered 
lysosomal conditions: acid-labile linkers and proteases cleavable linkers, respectively. A 
third type of the cleavable linker is the disulfide linkers which release the cytotoxic 
payloads based on the high cellular level of reduced glutathione. The release of cytotoxic 
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drugs with non-cleavable linker depends on the degradation of the ADC complex inside 
the cell to release the cytotoxic agents with attached amino acids. Non-cleavable linkers 
afford higher plasma stability over the cleavable linkers.48,49 
The cytotoxic drug, the third component of the ADC, must meet certain criteria of 
potency and stability in order to be selected as cytotoxic payload of ADCs. The cytotoxic 
payload should display high potency and normally the selected cytotoxic drug can‘t be 
used as such. Additionally, it should be resistant to multidrug resistance protein 1 
(MDR1), which is well-known resistance mechanism mediating drug efflux. And lastly, 
it should be amendable to chemical modification to be attached to the linker.45 
Currently, there are two major categories of cytotoxic drugs fulfilling the required 
aforementioned criteria: microtubule inhibitors and DNA-damaging agents. Commonly 
used microtubule inhibitors are derived from auristatins, and maytansinoids. Microtubule 
inhibitors binds to tubulin, inhibits their polymerization, and eventually cause cell cycle 
arrest and apoptosis.50 DNA-damaging cytotoxic agents, include duocarmycin and 
calicheamicin analogous, bind to DNA in the double-helix minor groove, initiate double-
strand breaks in DNA and ultimately leading to cellular death.43 
1.3.4    First generation of approved ADCs 
1.3.4.1  Gemtuzumab ozogamicin (Mylotarg®) 
Gemtuzumab ozogamicin (Mylotarg®) was approved by FDA in 2000 for the treatment 
of CD33 positive Acute Myeloid Leukemia (AML) patients. It comprises of Anti-CD33 
antibody that is chemically linked through its lysine residues to calicheamicin cytotoxic 
payload. It was voluntarily withdrawn from the market in 2010 after post-approval 
confirmatory trials. It has been found that the risks outweighed the benefits of using 
Mylotarg® in treatment of AML patients. Nevertheless, it was reintroduced in 2017 with 
a new dosing regimen.51 
The construction of ADC gemtuzumab ozogamicin was achieved through random 
acetylation of lysine residues of gemtuzumab humanized mAb (IgG4) using a cleavable 
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hydrazone linkers. Drug antibody ratio (DAR) is around 2–3 calicheamicin moieties per 
antibody and approximately 50% of ADCs are unconjugated mAb (naked).52  
Conjugation through lysine residues produces random and complex of ADCs species, 
therefore the stability of these conjugates, their pharmacokinetic (PK) properties and 
their associated biological responses will vary among the patients.53 
1.3.4.2 Brentuximab vedotin (Adcetris®) 
Brentuximab vedotin was approved in 2011 for the treatment of Hodgkin‘s lymphoma 
and anaplastic large cell lymphoma.54 It composed of Anti-CD30 chimeric mAb that is 
chemically linked through its cysteine residues to auristatin derivative drug, Monomethyl 
Auristatin E (MMAE). CD30 is a tumor necrosis factor receptor considered as a primary 
diagnostic marker in Hodgkin‘s lymphoma with no noticeable expression on healthy 
tissue and non-activated lymphocytes.55 Chemical conjugation of Anti-CD30 mAb with 
MMAE was achieved using enzymatic cleavable linker (maleimidocaproyl-valine-
citrulline-para-aminobenzyl). A maleimide functionality mediates binding to the reduced 
Anti-CD30 mAb cysteine residues, and the stable peptide is the trigger sub-component 
of the linker which remains stable in plasma and releases MMAE via proteolysis at the 
active site.55 DAR ratio is around 2–8 MMAE moieties per antibody with a small amount 
of naked antibody.56 
1.3.4.3 Ado-trastuzumab emtansine (Kadcyla®) 
Ado-trastuzumab emtansine (Kadcyla®) was approved in 2013 by FDA for the treatment 
of HER2-positive metastatic breast cancer patient. It comprises Anti-HER2 mAb 
(Trastuzumab) that is chemically linked through its solvent accessible lysine residues to 
the tubulin disrupting cytotoxic drug, maytansine (DM1).  HER2 overexpression has 
been found in approximately 20–30% of breast cancers, which is referred to as HER2-
positive subtype.57 
Trastuzumab is chemically conjugated to DM1 through non-cleavable linker, 
succinimidyl 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (SMCC) forming 
amide bonds with a DM1 average of 3.5 per antibody.58 
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1.4 Traditional conjugation chemistries employed in the construction of 
protein-conjugates   
Amongst the available biomolecules including proteins, carbohydrates, and nucleic 
acids, proteins are indeed at the centre of what bioconjugation chemistry is all about and 
ADCs are considered as one of the most essential applications of protein bioconjugates. 
Traditional protein modification has been widely achieved through targeting 
functionalities found in the side chains of the natural amino acids. Among these amino 
acids, two main amino acids namely lysine and cysteine, are the most widely targeted 
residues. 
 
Figure 1.10. The chemical structure of the most widely modified residues in protein conjugation reaction, 
lysine and cysteine amino acids. 
1.4.1 Conjugation chemistries targeting amine side chains of lysine  
Coupling to amine group-containing amino acids, such as lysine and amino group in the 
N-terminus are considered one of the oldest and most common functional group targeted 
in cross-linking reaction of biomolecules. The  -amine group of lysine has pKa value of 
about 10, thus most of lysine amino groups are protonated at physiological pH and are 
located on the surface of the protein. Given that protonation significantly decreases their 
reactivity, basic buffers of high pH are required to deprotonate amino groups.  -amine 
group of lysine has been modified by increasing number of chemical reagents, such as 
activated esters (N-hydroxysuccinimides (NHS), sulfo-NHS, acyl azides), 
isothiocyanates, isocyanates, and aldehydes. Among these reagents, NHS esters and the 
water soluble sulfo-NHS are the most widely applied ones.59,60 
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Given that proteins have other different reactive nucleophiles, such as sulfhydryl group 
of cysteine, and hydroxyl group of tyrosine, the selectivity of aforementioned 
electrophilic groups is not only limited to amine group of lysine, particularly, when 
these nucleophiles are solvent-reachable groups and found on the surface of the protein. 
1.4.1.1 Isocyanates and Isothiocyanates 
Amine groups readily react with isocyanates and isothiocyanates to form stable ureas 
and thioureas, respectively (Figure 1.11 A). Isothiocyanate-based reagents are 
commercially more accessible and stable analogues of isocyanates. 
Fluorescein isothiocyanate (FITC), which is more stable analogue of isocyanates, has 
been introduced for fluorescent labelling of antibodies by Riggs and co-workers in 1958. 
Shortly thereafter, these labelling reagents have been widely disseminated in diverse 
bioconjugation fields and proved to be effective for specifically labelling of proteins.61–64  
 
Figure 1.11. Reactive amine-based bioconjugation chemistries . A) Reaction of isothiocyanates with 
amine group forming thiourea. B) Reaction of NHS activated ester with amine group forming amide 




1.4.1.2 NHS and sulfo-NHS activated esters  
N-Hydroxysuccinimide (NHS) activated esters were introduced by Anderson and co-
workers as a new approach in construction of the peptide bonds.60 NHS esters were 
among the first reagents employed in diverse bioconjugation applications. Nowadays, 
NHS esters are the most disseminated reagents used in covalent protein modification. In 
comparison with isothiocyanates, NHS esters are more selective for amine group 
labelling, and can be pursued at faster rates and lower buffer pHs to afford more stable 
conjugate products.65–68  
NHS ester and the water soluble sulfo-NHS react with amino group, forming an acylated 
product (Figure 1.11 B). Sulfhydryl and hydroxyl groups can also react with NHS 
activated esters, but the conjugated products of these reactions are unstable in aqueous 
environments especially in the presence of amine nucleophiles. The optimum pH for 
reactions of NHS-esters in aqueous buffers was found to be between pH 7 to 8. Given 
the abundance of solvent-reachable surface lysine on most proteins, the reaction 
unfavourably results in a mixture of labelled products at multiple protein positions.69  
One of the well-known examples of employing NHS-activated ester in covalent protein 
modification is the commercially available Ado-trastuzumab emtansine (Kadcyla®). The 
construction of the ADCs was achieved through functionalization of lysine residues on 
Tmab with NHS activated ester bearing maleimide function group to be further 
conjugated to the sulfhydryl group of DM1 drug (Figure 1.12).70 
1.4.1.3 Aldehydes  
Amine groups undergo nucleophilic addition reaction with aldehyde groups forming 
imine functionality (Schiff base) which then can be selectively reduced using a mild 
reducing agent, such as sodium cyanoborohydride, to give a stable alkyl amine bond 
(Figure 1.11 C). This approach is not as popular in protein conjugations as  activated 





Figure 1.12. Trastuzumab emtansine conjugation scheme. Firstly, modification of lysine residues on 
Tmab with NHS activated ester, followed by conjugation of the sulfhydryl of DM1 drug with the 
activated Tmab. SMCC:  succinimidyl 4-(N-malemidomethyl) cyclohexane-1-carboxylate (SMCC) linker. 
DM1: Maytansine, tubulin disrupting cytotoxic drug.  Figure adapted from reference (
71
). 
However, reductive amination is widely applied approaches in carbohydrate–protein 
conjugates construction.72 Glycoprotein conjugate vaccines, such as Menactra 
(meningococcal diseases), HIBTiter (Haemophilus influenzae type b associated 
diseases), and Prevnar (pneumococcal diseases) are FDA approved conjugate vaccines 
that are routinely used for the prevention of invasive bacterial infections. The carrier 
protein, Cross-Reactive-Material-197 (CRM197), is a mutant non-toxic version of the 
diphtheria toxin is cross-linked to bacterial polysaccharide through reductive amination 
at lysine moieties and N-terminus.73,74 
1.4.2 Conjugation chemistries targeting thiol side chains of cysteine   
Sulfhydryl group has been deemed as the most disseminated functionality employed for 
biomolecules conjugation owing to two main reasons. Firstly, the high nucleophilicity of 
cysteine‘s thiolate group (pKa of thiolate group 8.3). Secondly, the relative rare 
abundance of cysteine amino acid in proteins (1–2%) which provide site-specific 
modification of proteins.75,76 Given that most cysteine amino acids are tied up in 
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disulfide bridges, free thiols can be generated by selectively reducing cystine disulfides 
with reducing agent or can be introduced through site specific mutagenesis in the 
sequence of the protein of interest providing a single reactive site.77,78 
1.4.2.1 Maleimide derivatives 
The double bond of maleimides ring undergoes alkylation reaction with thiolate group 
of cysteine forming stable thioether bonds. Maleimide coupling chemistry is highly 
specific for thiols functional group at pH range between 6.5 -7.5.79 
Owing to the very fast kinetics and high selectivity toward protein cysteine residues, 
coupling of maleimide to cysteine of proteins is considered the most widely 
disseminated applied strategy for bioconjugation application.80–82  
Currently, the FDA-approved ADCs: Brentuximab vedotin (Adcetris®) (Figure 1.13) 
and PEGylated conjugate Cimzia®, are the examples of modified protein therapeutics 
which have been constructed based on thioether linkage between maleimide group and 
thiolate group of either Brentuximab or TNFα, respectively.83  
Nonetheless, it becomes widely known that maleimide−thiol conjugates formed through 
Michael addition, are not stable and might slowly undergo retro-Michael addition to 
reform maleimide and in the presence of free thiols, as in most biological environment, a 
new thiol conjugate will be assembled. In case of ADCs, retro-Michael reaction is 
associated with mitigation of the efficacy, and most importantly, undesired off-target 
toxicity due to the de-attachment of the cytotoxic payloads.84 
In addition to retro-addition, thiosuccinimide ring might undergo irreversible hydrolysis 
and ring opening to provide succinamic acids derivatives. However, it has been 
proposed that intentionally hydrolysing succinimide ring will stabilise the conjugates 




Figure 1.13. Brentuximab Vedotin conjugation scheme. Firstly, reduction of interchain disulfide bonds on 
brentuximab, followed by conjugation of the sulfhydryl of brentuximab with maleimide activated MMAE 
is a microtubule inhibitor derived from auristatins. MMAE:  Monomethyl Auristatin E.  
Lyon et al. reported a method for intentional hydrolysis of succinimide ring and ring-
opening in order to stabilise thiol-maleimide conjugates and prevent thiol exchange in 
plasma through incorporation of a primary amine in close proximity to the succinimide 
ring. They proposed a mechanism involving intramolecular base catalysis by the amine 
group.86 
On the other hand, Fontaine et al. argued that intentionally hydrolysing succinimide ring 
by the closely positioned amine is due to the electron withdrawing inductive effect. 
Given that amine groups are largely protonated at physiological pH, thus they are unable 
to act as a general base. To confirm their hypothesis, they found that incorporation of 
other electron withdrawing groups in close proximity to succinimide ring has increased 




Figure 1.14. Reversible thiol-maleimide alkylation reaction. Thiosuccinimide ring might undergo retro -
Michael addition (undesirable) or hydrolysis and ring opening (desirable). Grey circle refers to the 
cytotoxic payloads, pink circle refers to proteins of biological system, such as human serum albumin 
(HAS). 
1.4.2.2 α-Haloacetyl derivatives 
Since the introduction of iodoacetamide in 1935, α-haloacetyl compounds have been 
widely used in the crosslinking, bioconjugation, and immobilization of cysteine-
containing proteins and peptides.87,88 
The reactivity of this group is attributed the electrophilic characteristics of the central 
carbon which come from the direct attachment to electron-withdrawing group, the 
carbonyl group, and to the electronegative halogen atom. Nucleophiles, such as thiols 
undergo nucleophilic substitution reaction of the halogen with simultaneous formation 
of a thioether bond. Among α-haloacetate, the order of reactivity toward sulfhydryl 
group of cysteine is I > Br > Cl > F, fluorine displays almost negligible reactivity 
(Figure 1.15).  
Although maleimide-based chemistry is more prevalent because of their higher kinetics, 
α-haloacetyl-based bioconjugation chemistry is usually preferred in certain applications 
where the stability and size of the conjugates are fundamental aspects. α-Iodoacetyl-
based chemistry is commercially available and widely applied, including cross-linkers, 




Figure 1.15. Cross-linking of cysteine residues of proteins using α-haloacetyl compounds to afford 
thioether linkage. 
The reactions of thiolate group with haloacetamides are performed under physiological 
and alkaline conditions (pH 7.2– 9.0). It is important to perform iodoacetamides 
reaction under dark conditions in order to prevent free iodine generation, which might 
react with other amino acid such as tyrosine, histidine and tryptophan residues. It is 
worthwhile to mention that iodoacetyl groups might react with amine groups, 
particularly at basic conditions and when all cysteine residues have been consumed.89 
1.4.2.3 Vinyl sulfone derivatives 
Vinyl sulfone undergoes Michael addition reaction with thiolate group of cysteine 
forming a stable thioether linkage. These reactions require slight basic conditions to be 
performed. Perhaps the most important advantage of using vinyl sulfone chemistry is 
their superior stability compared with maleimide-based bioconjugation (Figure1.16).90–92  
Vinyl sulfone-mediated cross-linking have been used mainly for PEGylation of proteins 
with functionalised PEG derivatives.93 
 
Figure 1.16. Cross-linking of cysteine residues of proteins using vinyl sulfone compounds through 
Micheal addition reaction to afford thioether linkage. 
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In summary, despite the large number of conjugation chemistries targeting lysine and 
cysteine amino acids, each mentioned strategy has drawbacks ranging from specificity 
toward certain side chains to the stability of the constructed conjugates. 
Given that ADCs are deemed as promising therapeutic approach in the field of 
oncology, significant efforts have been made to modify the conjugation strategies to 
attain homogeneous, well-defined and stable antibodies conjugates. 
1.5 The next generation of ADCs: Improved homogeneity and stability 
The first generation ADCs‘ conjugation methods were predominantly achieved on 
solvent reachable reactive amino acid residues with nucleophilic properties, in particular 
lysine and cysteine. Lysine and reduced cysteine based-conjugation result in a range of 
0-8 conjugated drugs per antibody. Indeed, use of conventional conjugation methods 
produces heterogeneous mixture of ADC species and their pharmacokinetic (PK) and 
pharmacodynamic (PD) properties are likewise heterogeneous. Heterogeneity of ADCs 
species has a number of drawbacks, such as competitive inhibition of conjugated mAbs 
by unconjugated mAbs, and increment of clearance of ADCs species with high DAR 
ratio. In contrast, homogeneous mixture of ADC species would have more predicted 
batch-to-batch consistency, predicted PK properties and more importantly, improved 
therapeutic index.94,95  
Due to the earlier mentioned drawbacks associated with first generation of ADCs, 
improved, sites-specific, and stable conjugation approaches have been optimised to attain 
the next generation of homogeneous ADCs with preferable safety characteristics and 
superior therapeutic window properties.96 Most of the recent reports suggested DAR of 
four as a preferable target in ADC construction.97 
1.5.1  THIOMAB drug conjugates  
Cysteine is the most disseminated target for bioconjugation owing to two main reasons. 
Firstly, the high nucleophilicity of thiolate group of cysteine. Secondly, the relative rare 
abundance of cysteine amino acid in proteins (1–2%).75,76 
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Reduction of the disulfide bonds to produce free thiolate have many drawbacks that 
should be considered, most importantly, the structural stability of the reduced antibody.95 
One of the earliest approaches to tackle these issues is genetically modifying mAbs with 
engineered cysteine residues, also known as THIOMABs. Genentech pioneered 
THIOMABs for site-specific and defined conjugation with cytotoxic payloads. 
THIOMABs allow production of a homogeneous mixture of ADC species with defined 
number of loaded cytotoxic drugs. Nonetheless, choosing site of introduction of cysteine 
is essential and difficult step as it affect the structure and function of antibody.98 
Anti-MUC16 antibodies with engineered reactive cysteine residues (HC-A114C), were 
conjugated with monomethyl auristatin E (MMAE) to construct THIOMAB drug 
conjugates (TDCs). It was directly compared in vitro and in vivo with the traditional anti-
MUC16 ADCs. Anti-MUC16 ADCs and TDCs displayed comparable in vitro 
cytotoxicity and similar efficiency in vivo against a transplant xenograft model of 
ovarian cancer. However, the latter showed wider therapeutic window and superior 
safety properties in animal models with lower liver and bone marrow toxicity. The 
improved safety profile can be attributed to the absence of high-drug loaded ADC 
species and the greater stability of the TDC in circulation.95  
Choosing the engineering site of cysteine has an essential impact on the stability and the 
efficacy of ADCs. Ben-Quan Shen et al. argued that conjugation to buried engineered 
cysteine residues (less solvent accessible) affords more stable conjugates. Moreover, the 
environment surrounding the conjugation site displayed a profound effect on the stability 
of ADCs, where conjugation in positively charged environment accelerates the 
hydrolysis of succinimide to succinic acid, and the later has superior plasma stability 
toward retro-addition reaction and drug release.85 
1.5.2 Unnatural amino acids 
In addition to the engineered cysteine amino acid, antibodies with engineered 
selenocysteine and noncanonical amino acids, such as acetylphenylanaline have been 
employed as alternative approaches for construction of homogeneous ADC species. 
Selenium or selenocysteine (34Se, 79 Da), the twenty-first amino acid, has selenolate 
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group which has lower pKa (5.2) than thiolate group (8.3), which renders it a stronger 
nucleophile.99 Anti-HER2 (selenomab) with a C-terminal selenium residue was produced 
and conjugated with MMAF derivative peptides using iodoacetamide. Their stability and 
efficacy were tested both in vitro and in vivo, using selenocysteine as a reactive target 
offered highly stable selenomab-drug conjugates and demonstrated improved potency 
and selectivity (mouse models of breast cancer).96 
Acetylphenylanaline, on the other hand, contains a keto group which can be conjugated 
to auristatin derivative bearing alkoxy-amine to attain an oxime ligation. p-
acetylphenylalanine was site-specifically incorporated into an anti-HER2 antibody in 
two sites on antibody constant region (Figure 1.17). The mutant antibody was conjugated 
to an auristatin derivative in 4 days through a stable oxime linkage. The resulting 
conjugates displayed similar pharmacokinetics to unconjugated antibodies, more potent 
in vitro cytotoxic activity against HER2 positive cancer cells, and complete tumor 
regression in 14 days in rodent xenograft models.100 
 
Figure 1.17. Site-specific conjugation approach using oxime ligation, which attaches alkoxyamine linked 
with payloads (     ) to p-acetylphenylalanine-tagged mAb. 
Zimmerman and his group used a different unnatural amino acid, namely p-azidomethyl-
L-phenylalanine providing the antibody with azide functionality. They demonstrated that 
site-specific incorporation of p-azidomethyl-L-phenylalanine enabled the conjugation of 
two MMAF drug per antibody using strain-promoted azide−alkyne cycloaddition 
(SPAAC). The constructed ADC of trastuzumab exhibited potent cytotoxicity against 




1.5.3 Enzymatic techniques 
Enzymatic techniques were also utilized as another strategy to attain site specific 
antibody drug conjugation. Mainly, two enzymes were used in homogeneous ADCs 
construction, glycotransferases and transglutaminases.102  
Mutated glycotranferases used to link a modified sugar moiety to the oligosaccharide 
attached to Asn-279 of the Fc fragment of human IgG antibodies. A mutated 
glycotranferase has been produced to transfer a modified galactose having a chemical 
group at the C2 position, such as ketone or azide to degalactosylaed G0 form 
antibodies.103 
Transglutaminase from Streptoverticillium mobaraense, catalyzes the formation of a 
covalent bond between a glutamine side chain and a primary amine, but it does not 
recognize naturally occurring glutamines in the Fc constant regions of antibodies, so 
engineered glutamine tag into antibody were produced. Anti-M1S1-vc-MMDA 
conjugate were produced using transglutaminase enzyme into engineered glutamine. 
Both in vitro and in vivo activities were evaluated, and the results demonstrated that 
conjugation through this strategy does not affect activity and affinity of antibody.104 
NEB Therapeutics established another enzymatic method using Sortase A enzyme. 
Sortase A is Staphylococcus aureus enzyme that catalyzes transpeptidation reactions. It 
cleaves between threonine and glycine of LPETG sequence forming LPET-enzyme 
adduct. Then, it forms a bond between poly-glycine residues and threonine of LPET. The 
developed technology is termed SMAC technology (Sortase Mediated Antibody 
Conjugation), was established to produces a stable and homogeneous ADC species. The 
strategy involve engineering the antibody with incorporation of LPETG peptide, and 
subsequently the conjugation via addition of Sortase A and a poly-glycine linked-





Figure 1.18. Site-specific enzymatic conjugation approach using Sortase A enzyme, which attaches poly-
glycine-linked payloads (     ) to LPETG-tagged mAb. 
1.5.4 Disulfide rebridging strategies 
Most proteins do not have free cysteine, and cysteine can either be introduced through 
mutagenesis or via reduction of disulfide bond using reducing agents.106–108  
Although, genetic-based and enzymatic-based methods have been increasingly 
developed, these methods are expensive, require complex expression and purification 
tactics, and none of them has found its way to the market yet. On the other hand, 
according to many studies, the currently adopted monoalkylation of the reduced disulfide 
bonds using maleimide-based approaches also have major limitations. Primarily, the 
stability of the conjugates in plasma in the presence of competing glutathione and 
albumin which would eventually release free cytotoxic drug in plasma.109  
Recently, an elegant approach has been proposed to covalently rebridge the free thiolate 
anions derived from the reduced disulfide bonds to attain stable and defined antibodies-
conjugates with maintained post-reduction structure of antibodies. One of the earliest 
examples of rebridging reagents that have been suggested in construction of ADCs is 
bis-sulfone cross-linker (Figure 1.19). The mechanisms of bis-alkylate disulfide bonds 
using bis-sulfone reagents and the other developed rebridging agents are further 




Figure 1.19. Rebridging approach of the reduced disulfide bonds of mAb using functionalised bis -sulfone 
reagent to form three carbon bridges between the two reduced cysteine of mAbs.  
1.6 Bioorthogonal cross-coupling reactions using unnatural functional 
groups 
The previously mentioned bioconjugation reactions are mainly devoted to covalently 
attach fluorescent label, PEGs, isotope, affinity tags, or cytotoxic payloads to certain 
amino acids of proteins in vitro. Another intended application of conjugation chemistry 
is to cross-couple individual proteins to attain chemically-linked protein-protein 
entities.110,111 
Moreover, in the coming years, scientific applications of bioconjugation chemistry are 
increasingly moving toward bioorthogonal cross-linking of proteins and biomolecules 
with tracking probe inside living cells and animals providing vivid, functional and 
dynamic sensors to measure diverse intracellular physiological interactions (in vivo). 
Thus, for the sake of in vivo labeling applications, bioconjugation approaches have to 
obey certain necessities, including being specific, of high yield, non-toxic, of good 
kinetics and most importantly, to be biocompatible with normal biological processes 
(bioorthogonal).112 In simplified terms, biomolecules in cells can be tagged with benign 
functionalities, such as azide group by incubating the cells with metabolic precursor 
bearing azide group. Then, the tagged biomolecule is reacted with a tracking probe 
carrying a complementary functional group.113   
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Azides are small, unnatural group, stable toward most reaction conditions and only 
decompose and release nitrogen at high temperature. Moreover, they do not interfere or 
react with nucleophiles present in biomolecules. For these mentioned reasons, azides are 
considered outstanding group and widely applied in bioconjugation cross-coupling 
reactions.114 
1.6.1 Staudinger ligation & traceless Staudinger ligation 
The Staudinger ligation, developed by Bertozzi and co-workers in 2000, was the first 
reaction developed for in vivo bioconjugation applications. In this reaction, azides react 
with phosphines to form aza-ylide intermediate. In the presence of water, this 
intermediate hydrolyses readily to a primary amine and phosphine oxide. However, in 
the presence of ester group within the phosphine structure and in close proximity of aza-
ylide intermediate, it reacts with the intermediate forming amide bond rather than 
hydrolysis (Figure 1.20 A).115  
Traceless Staudinger ligation, on the other hand, has the same reaction principle but 
affords an advantage over the normal Staudinger ligation. The phosphine moiety is 
removed from the final conjugated product (during hydrolysis) and thereby allowing the 









1.6.2 Azide-Alkyne cycloaddition ‘Click’ reaction  
The relatively slow kinetics of Staudinger ligation is one of the main drawback limiting 
the wide applicability of this ligation in biological systems. To this end, researchers 
aimed to find a substitute bioorthogonal reaction replacing Staudinger ligation. 
Cycloaddition reactions were viewed as promising alternative to Staudinger ligation. 
Huisgen developed the [3+2] cycloaddition between an azide and an acyclic alkyne 
groups in 1963.117 However, this reaction required high heat in order to overcome the 
activation energy to perturb the alkyne‘s linear bond angle (180º) forming triazole ring 
with bond angle of 120º (Figure 1.21 A). In order to decrease the required heat to 
perform cycloaddition reactions, Cu(I) was employed as a catalyst, but it is associated 
with cellular toxicity which halt its applicability in bioorthogonal bioconjugation 
chemistry.118  
However, azide-alkyne cycloaddition reaction found the way back to popularity in 
bioconjugation chemistry when stained-induced cycloaddition was introduced. The use 
of cyclooctyne (1.1) (the bond angle is ⁓ 160 ) will reduce the required heat for the 
reaction and thus it can be performed at room temperature with significant acceleration 
of reaction rate (Figure 1.21 B). Furthermore, the addition of flouro and di-flouro (1.2) 
increases the rate of the cycloaddition reaction 60 times. Nowadays, the most widely 
used activated-cyclooctyne are  dibenzocyclooctyne-based derivatives (1.3) which 
showed similar rate of cycloaddition reaction to di-flourocyclooctyne (1.2), these stained 





Figure 1.21. Cycloaddition reaction of azides and alkynes groups (copper-free ‗Click‘reaction). A) Azide-
alkyne cycloaddition reaction. B) Strain-induced azide-cyclooctyne cycloaddition reaction. C) Mechanism 
of Cycloaddition reaction of azides-labelled biomolecule and probe-bearing dibenzocyclooctyne group 
affording triazole ring.  Figure adapted from reference (
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).  
In Summary, bioconjugation chemistry is receiving huge attention with increasing 
number of applications enabling the recent growth of bio-therapeutics, ADCs, bispecific 
antibodies, and chemical biology methods. Protein conjugates (mainly mAbs 
conjugates) are usually achieved through conventional chemistries to label cysteine and 
lysine amino acids, with noticeable growing in the genetic engineering-based 
approaches. However, recent advances in bioconjugation methods have shed light on the 
limitations of the current approaches, including:  
 the poor plasma stability of conjugates, mainly maleimide-based conjugates,  
 the lack of specificity of the available reagents and the heterogeneity of the 
constructed products,  
 and the limited versatility of chemical-based methods to construct new bio-
therapeutics, such as bispecific antibodies provided that most of well-applied 
methods are based on genetics and biological methods.    
 the complexity of the genetics and biological methods, which require complex and 
expensive expressing and purification methods with questionable reduced 
bioactivity of fusion protein. 
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1.7 Aims and objectives  
In this project we aimed to develop of a novel and improved conjugation chemistry to 
construct stable and well-defined antibody-protein conjugates. 
Our first objective in this study is to develop effective reduction method for activation of 
thiols towards conjugation. Chapter 2 describes the development and evaluation of PEG-
azides as water soluble reagents for quenching of excess TCEP prior to thiol alkylation 
reactions. 
The next objective of our study is to develop new and improved rebridging chemistry to 
maintain the post reduction structure of mAbs and construct antibody-protein 
conjugates. Chapter 3 describes the evaluation of using sulfonates as electrophilic 
scaffold and the factors affecting their aqueous stability and reactivity, most importantly 
the nature of acceptor groups.    
Then, we aimed to evaluate a novel bis-haloacetamide scaffold to be employed as 
rebridging approach. Chapter 4 describes the development and evaluation of aqueous 
stability and reactivity of various bis-haloacetamide linkers. In addition, the synthesis, 
aqueous stability and reactivity aryl bis-haloacetamide linkers bearing azide group were 
described in Chapter 4. 
Then, in Chapter 5 we thoroughly evaluated the biological application of various aryl 
bis-haloacetamide linkers to rebridge reduced mAbs, their selectivity toward reduced 
disulfide bonds. In addition, we reported the comprehensive evaluation of the stability 
and characterisation the rebridged mAbs. We also developed a novel approach to obtain 
bi-functional mAbs (Figure 1.22). The described work offers a novel and promising bis-
haloacetamide-based rebridging linkers that could be hugely applied in the construction 




Figure 1.22. Rebridging approach of the reduced disulfide bonds of mAb using functionalised bis -
haloacetamide reagents. 
Our last objective of this study is to develop bis-rebridging agent that can be employed 
in the construction mAb-protein conjugates (immunoconjuagtes). In Chapter 6 we 
described the development of bis-dihaloacetamide PEG linker and evaluation of the 
factors affecting the construction of immunoconjugates of a unique microbial immune 
evasion protein (staphylococcal binder of immunoglobulin (Sbi)). The described 
chemical platform in chapter 6 offers a novel conjugation method based to generate site-
specific, homogeneous, antibodies conjugates in applicable procedure and good yield 
which can be widely applied in the development of bio-therapeutics. 
The suitability of our developed bis-dihaloacetamide PEG approach in the construction 







2 The use of alkyl azides to quench trialkylphosphine-based 
reducing agents 
2.1  Introduction    
The labelling of proteins via their nucleophilic amino acids, in particular cysteine 
residues is one of most disseminated approach in bioconjugation chemistry. Provided 
that most cysteine amino acids are tied up in disulfide bonds, free cysteine (thiol) can be 
generated by reducing cystine disulfide bonds with reducing agents prior to alkylation 
with Michael acceptors, such as maleimides (Figure 2.1).77,78,119 
 
Figure 2.1. General conjugation strategy of protein labeling by reduction of disulfide bonds prior to 
alkylation of the obtained thiols using Michael acceptors.   
Disulfide reducing agents employed in protein conjugation can be divided into two main 
groups: thiol reductants, such as dithiothreitol (DTT, 2.1) and phosphine reductants, 
such as the water soluble tris(2-carboxyethy)phosphines (TCEP, 2.2) and tris(3-
hydroxypropyl)phosphine (THPP, 2.3). 
 
DTT (2.1), water soluble thiol reductants, has been used widely in protein conjugation 
chemistry. The mechanism of disulfide bonds reduction by thiol agents takes place via 
thiolate exchange where DTT nucleophilic agent attacks on the disulfide bond of the 
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protein to reduce the first sulfur atom of the protein and generate reductant-protein 
disulfide intermediate with the second sulfur atom. Then, the second free thiol of DTT 
attacks intermediate disulfide bond to afford two reduced thiols groups with DTT being 
converted into disulfide-containing 6-membered ring (Figure 2.2 A).120 Thiol reductants 
should be removed before performing thiol-alkylation reactions as they compete directly 
with thiol-alkylating agents, thus significantly reduce the yield of protein conjugates 
products. In addition, thiol reductants have a number of drawbacks that have derived 
researchers to consider the alternative phosphine-based reducing agents.  
 
Figure 2.2. A) Mechanism of reversible reduction of disulfide bonds using DTT (2.1). B) Mechanism of 
irreversible reduction of disulfide bonds using TCEP (2.2). 
Historically, phosphine reductants such as TCEP (2.2) have been practically overlooked 
for long time before a convenient method for their synthesis was published, and they 
became commercially available.121 In aqueous solutions, TCEP‘s phosphine atom attacks 
on the first target sulfur atom to generate the first thiol fragment with thiophosphonium 
salt being generated on the first target sulfur atom. Subsequently, a rapid hydrolysis step 
releases the second thiol and phosphine oxide (Figure 2.2 B). The reduction of disulfide 
bonds with TCEP is stoichiometric and irreversible due to the generated strong 
phosphine oxide bond.119  
39  
 
Adopting reduction using TCEP offers a number of advantages over thiol-based 
reducing agents. Generally, TCEP is odorless and more stable toward aerial oxidation. 
Thiol reductants showed reversible reduction of disulfide bonds and their activity is 
questioned at acidic pH. TCEP is a more efficient reducing agent than DTT with 
superior redox potential as it irreversibly reduces disulfide bonds. Metals, such as Ni2+ 
can catalyze oxidation of DTT, but not TCEP. In protein purification, Ni2+ columns are 
employed to purify His-tag linked protein, thus free Ni2+ will be eluted with protein 
which in turn will reduce the efficiency of the reduction of protein using DTT. 
Moreover, TCEP has poor metal ion-chelation properties compared to DTT, so therefore 
has lower potential to interfere in biochemical studies.122–124  
Tris(3-hydroxypropyl)phosphine (THPP, 2.3) is another water soluble alkyl phosphine 
that has similar properties to TCEP and has been used in bioconjugation chemistry.125 
TCEP (2.2) is widely reported to be compatible with Michael acceptors, such as 
maleimide, therefore a purification prior to conjugation is not required.126,127 However, 
there are many indications from literature that this might not be the case. This raised 
fundamental questions regarding the compatibility of trialkylphosphine with Michael 
acceptors and whether the yield of maleimide-protein labelling would be significantly 
reduced in the presence of trialkylphosphines.  
Visser et al. used TCEP to stabilise thiolate groups and found that it did not interfere 
significantly with the maleimide-base thiol alkylation. However, they have used up to 
17.5-fold excess of maleimide to perform the coupling reaction.128 On the other hand, 
when lower equivalents of maleimide were utilised in the fluorescent labelling of 
myosin, Getz et al. found that the level of labelling significantly decreased in the 
presence of TCEP.120 These reports suggested the need to further investigate the stability 
of maleimide linkers in the presence of TCEP.  
This debate was recently resolved as it has been shown that both TCEP and THPP react 
with N-ethylmaleimide (2.4) under typical bioconjugation conditions to form the ylene 




Figure 2.3. The reaction between TCEP (2.2) and THPP (2.3) with the Michael acceptor, N-
ethylmaleimide (2.4) forming the ylene adduct (2.5) and N-ethylsuccinimide (2.6), respectively. 
Therefore, it was shown to be essential to remove trialkylphosphines prior addition of 
Michael acceptors. There are a number of available methods for the removal of 
phosphines from proteins; however, each has drawbacks that should be considered. 
Dialysis and gel filtration are commonly employed procedure before performing protein 
conjugation. However, adopting such protocols is associated with loss of protein and 
potential for re-oxidisation of the protein through long exposure to oxidizing 
condition.130 Alternatively, agarose gel-immobilized TCEP is commercially available 
and can be used to reduce the interested protein followed by filtration of the solid 
support. However, some reports claimed the low yield of recovery and the possibility of 
cationic protein loss due to electrostatic interaction with TCEP carboxylate moieties.131  
Recently, Henkel et al. have reported an elegant in situ approach utilizing 4-
azidobenzoic acid (4-ABA, 2.7) to quench excess TCEP through a Staudinger reaction 
(Figure 2.4). Thus, excess trialkylphosphine will be oxidise to phosphine oxide without 
the need for a purification step prior to thiol alkylation using Michael acceptor.132,133 
Nevertheless, the poor solubility of 4-azidobenzoic acid (2.7) limits the practical 




Figure 2.4. The mechanism of Staudinger reaction between TCEP (2.2) with 4-azidobenzoic acid (2.7) 
Given the importance of effective phosphine removal prior to addition of Michael 
acceptors and the elegance of using alkyl azide to achieve this, we sought here to 
evaluate and optimise one-pot method of using water-soluble azide-bearing ethylene 
glycols to quench excess trialkylphosphines. 
2.2 Synthesis of azide-containing ethylene glycols of increasing molecular 
mass 
We set out to investigate the use of more water soluble alkyl azides to promote the 
oxidation of phosphines. Polyethylene glycols are known to be water soluble derivatives 
of hydrocarbons. As such, we set out to synthesise a series of azide-containing ethylene 
glycols to evaluate the impact of the polymer length on their aqueous solubities. The 
diazide derivatives 2.10-2.13 were synthesised in a good yields accoding to previously 




Figure 2.5. Chemical synthesis of the PEG-azides 2.10-2.13. a) (i) 4-Toluenesulphonyl chloride, pyridine, 
DCM, room tempreture, 3h, (ii) NaN3, acetone/water (3:1), room temperature overnight. 
2.3 Determination of the mass and molar solubilites of PEG-azides and 4-
azidobenzoic acid 
The aqueous solubilites of 4-azidobenzoic acid (2.7) and the synthesised PEG-azides 
(2.10-2.13) were measured in water and in aqueous buffer Tris.HCl (100 mM, pH 7) 
Table 2.1. All PEG-azides were found to be readily soluble in water and aqueous buffer 
Tris.HCl. The compounds displayed increasing aqueous solubility with increasing 
molecular weight, ranging from 20 mg/mL for di-PEG azide (2.10) up to 100 mg/mL for 
penta-PEG azide (2.13). It is worth mentioning that PEG-azides showed higher 
solubility values in Tris.HCl buffer. 
On the other hand, 4-azidobenzoic acid (2.7) has a dramatically lower solubility of 0.5 
mg/mL under typical bioconjugation conditions. Thus, in order to improve its solubility, 
different solvent systems were used including Tris.HCl (100 mM) at pH 8 and 50% 









Table 2.1. Aqueous mass and molar solubilites of 4-azidobenzoic acid (2.7) and PEG-azides (2.10-2.13) 


















0.42 2.6 0.5 3 
 
(2.10) 
20 100 25 125 
 
(2.11) 
50 205 60 246 
 
(2.12) 
70 240 88 304 
 
(2.13) 
100 300 130 356 
 




Given the aqueous solubility of PEG-azides were measured at typical conjugation 
conditions; we set out to evaluate the impact of the polymer length on TCEP oxidation 
rate. As such, we aimed to measure the rate of oxidation of TCEP and THPP by 
following the disappearance of phosphine signal and appearance of phosphine oxide 
signal using 31P NMR. 
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Firstly, the rate of aerial oxidation of TCEP was evaluated. A solution of TCEP (100 
mM) in Tris.HCl buffer (100 mM, pH 7) was held at 37°C and the mixture analysed at 





P NMR spectrum of TCEP control reaction analysed at times A) 3 minutes and B) 63 
minutes. No peak corresponding to phosphine oxide (57 ppm) was observed. 
No oxidation of TCEP was observed under these conditions, indicating that spontaneous 
oxidation does not contribute to TCEP oxidation under the studied conditions (Figure 
2.6). Having demonstrated that TCEP is stable under the studied conditions, we next 
tend to measure the rates of TCEP oxidation. A solution of TCEP and each azide-PEG 
(10 equiv.) in 100 mM Tris.HCl buffer was held at 37°C and analysed by 31P NMR 








P NMR spectrum of TCEP reaction with penta-PEG azide (2.13) analysed every 10 minutes. Phosphine oxide peak was observed at 57 ppm.  
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The level of TCEP oxidation was calculated by comparison of integrals corresponding 
to the phosphine (15 ppm) and phosphine oxide (57 ppm). Penta-PEG azide (2.13) 
showed higher rates of reaction with TCEP with almost complete oxidization within 40 
minutes (Figure 2.7). All the PEG-azides (2.10-2.13) showed complete TCEP oxidation 
within 60 minutes. 
The percent of remaining TCEP was calculated using Equation 2.1. PEG-azides 
reactivity rates with TECP reflect and correlated positively with their solubility profile 
with di-PEG azide (2.10) was found to be the least reactive one, possibly due to its 
lower aqueous solubility (Figure 2.8).  
                                   
        
                           (Equation 2.1) 
Where; 
Ip= Integration of phosphine peak at δ 16 ppm. 
Ipo= integration of phosphine oxide peak at δ 57 ppm.                                                                                                                                       

























Figure 2.8. Oxidation rates of TCEP in the presence of the PEG-azides (250 mM) in Tris.HCl buffer (100 






P NMR spectrum of TCEP reaction with 4-ABA (2.7) analysed every 10 minutes. Phosphine oxide peak was observed at 57 ppm. 
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Unfortunately, direct comparison between TCEP oxidizing rate between 4-ABA (2.7) 
and the PEG-azides (2.10-2.13) was not possible owing to the limited solubility of the 
former. Therefore, the rate of TCEP oxidation was determined using only 3 equivalents 
of 4-ABA (2.7) in Tris-HCl buffer (pH 8) (Figure 2.7). Under these conditions, 4-ABA 
(2.7) oxidised TCEP at a comparable rate to di-PEG azide (2.10), with complete 
consumption of THPP observed after 60 minutes (Figure 2.9). 
Lastly, all the PEG-azides (2.10-2.13) were effective in oxidation of THPP under similar 
conditions previously used to study the oxidation of TCEP, however oxidation occurred 
at much higher rates and complete oxidation of THPP was observed in less than 5 




P NMR spectrum of THPP reaction with A) penta-PEG azide (2.13) and B) di-PEG azide 





2.5 The application of PEG-azides towards improving protein conjugation 
yields (experiment carried out by Terrence Kanter)134,135  
Given that solubility and reactivity rates of PEG-azides (2.10-2.13) with TCEP (2.2) 
were now known, the applicability of using PEG-azide approach in a protein 
conjugation was then evaluated. Fluorescent labelling of yeast enolase using the 
commercially available N-(5-fluorescinyl)maleimide was evaluated in the presence or 
absence of the tetra-PEG azide (2.12).  
As such, denatured yeast enolase was reduced with TCEP 2.2 (1, 5 or 10 equiv.) and 
then incubated directly with N-(5-fluorescinyl)maleimide. In parallel experiment, 
denatured yeast enolase was reduced with TCEP 2.2 (1, 5 or 10 equiv.) and then 
incubated with the tetra-PEG azide 2.12 for 1 h before being incubated with N-(5-
fluorescinyl)maleimide. From the results obtained, it was demonstrated that the degree 
of fluorescent labelling of yeast enolase was decreased with increasing the equivalents 
of TCEP in the absence of PEG-azide 2.12 (Figure 2.11 A). On the other hand, when 
PEG-azide 2.12 was used to quench excess TCEP prior to commencing protein 
labelling, significant levels of fluorescence were obtained (Figure 2.11 A) for all the 
tested equivalents of TCEP. Similar results were obtained when THPP (2.3) was used as 
the reducing agent, as level of labelling of yeast enolase was significantly increased in 
the presence of PEG-azide 2.12 regardless of the used concentration of THPP (Figure 
2.11 B).  
 
Figure 2.11. SDS-PAGE analysis of application of PEG-azides in labelling of yeast enolase with 
fluorescein-maleimide. Yeast enolase (11 mM) in Tris.HCL buffer (500 mM, pH = 7.2, 5 mM EDTA) 
was reduced with TCEP or THPP (1, 5 or 10 equiv.) for 45 minutes at room temperature then reacted with 
N-(5-fluorescinyl)maleimide (1 mM) for 18 h at 37 °C. In a parallel experiment, reduced yeast enolase 
was treated with PEG-azide 2.12 for 1 hr at 37 °C prior to addition of N-(5-fluorescinyl)maleimide (1 
mM) for 18 h at 37 °C.  
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2.6 Conclusion  
In conclusion, a series of water soluble PEG-azides were synthesised and their rate of 
reactivity with trialkylphosphines were investigated under the commonly used protein 
conjugation conditions with Michael acceptors, such as maleimide. It was shown that 
the increased aqueous solubility of the PEG-azides (2.10-2.13) correlated positively with 
their increased abilities to oxidise TCEP within one hour of incubation. Moreover, the 
provided soluble PEG-azides approach to quench excess TCEP offers practical 
advantages over the previously reported 4-ABA-based approach, particularly the poor 
aqueous solubility issues.  
Furthermore, it has been found that the incubation of reduced protein with PEG-azides, 
such as 2.12 prior to the addition of the maleimide label, permits the use of higher TCEP 













3 Evaluation of aryl-sulfonate derivatives as thiolate-reactive 
alkylating agents  
3.1 Introduction  
Cysteine targeted bioconjugation using the maleimide-based approaches have certain 
drawbacks, most importantly, the poor plasma stability of the attained protein 
conjugates. Therefore, we set out to evaluate sulfonate-based cysteine conjugation 
approach as alternative method for monoalkylation of cysteine as these products would 
exhibit improved plasma stability. 
Successful development of a cysteine targeted alkylating agent for bioconjugation 
depends in part on understanding the factors affecting electrophile reactivity. Although 
sulfonate chemistry has been known for a long time, it has been largely overlooked and 
underutilised in the area of bioconjugation chemistry. The primary objective of this 
work was to study the aqueous stability (hydrolysis rates) and reactivity of sulfonate 
derivatives twords cysteine (thiolate). The main emphasis is to evaluate various 
parameters affecting compound reactivity including pKa of the corresponding sulfonic 
acid, chain length and the nature of electrophilic group (acceptor group), as well as the 
pH of the reaction.   
Sulfonyl ester derivatives are reactive species owing to the low pKa of the corresponding 
sulphonic acid. They are susceptible to nucleophilic substitution (SN1 or SN2) reactions. 
Generally, the nucleophilic reagent (Nu) attacks the substrate at the electrophilic atom 
which is accompanied by liberation of the leaving group (X) (Figure 3.1 A). The thiolate 
group (RS ) of cysteine (nucleophile) attacks the carbocation attached to sulfonate 
group (k1) with the latter being liberated and stabilised by resonance (Figure 3.1 B). 
However, as bioconjugation reactions are carried out in aqueous solvent systems, 
hydroxyl groups (OH ) will compete with thiolates and result in hydrolysis of sulfonate 
groups (k2).
79,136–138 Therefore, it is essential to evaluate the aqueous stability (hydrolysis 
rates) of sulfonate derivatives under the typical conjugation conditions to determine 




Figure 3.1. A) General Mechanism of nucleophilic substitution reactions  (SN2). B) Thiolate alkylation 
with sulfonyl ester (tosylate) affording thioether linkage with liberation of sulfonic acid anion (k1). 
Sulfonyl ester (tosylate) hydrolysis (k2). 
3.2 Factors affecting the aqueous stability of sulfonate esters 
3.2.1 Impact of aryl substitution on the aqueous stability of sulfonates  
In order to evaluate the aqueous stability of sulfonates under a range of conditions, a 
series of arylsulfonates independently substituted at meta-, and para-positions with a 
range of groups were chosen based on the pKa values of the corresponding sulfonic acid. 
The substituted sulfonates chosen in this study are shown in Table 3.1, along with the 
pKa values of their corresponding sulfonic acid. Hammett σ values (also known as 
substituent constant) of the chosen substituents are also listed in Table 3.1. The 
substituent constant relates to the electronic (inductive and resonance) impact of a 
substituent.  Electron-withdrawing groups, such as nitro group have positive σ value, 
while electron-donating substituents, such as methyl group have a negative σ value. 
Each substituent will exert different effects related to its regiochemistry relative to the 




Table 3.1. The predicted pKa values of the chosen sulfonic acid derivatives. 
a
 values obtained from 
Scifinder. 
b 
values were obtained from literature (
140,141
).  

























The synthesis of each of the sulfonate esters was accomplished in anhydrous DCM to 
prevent hydrolysis of the respective acid chloride, with pyridine employed as base to 
neutralise the generated HCl. The reactions were left overnight at room temperature, 
except for the 2-methoxyethyl 4-nitrobenzenesulfonate (3.5) which was carried out over 
2 h. The reactions were then subjected to standard work-up (EtOAc) and the products 
were purified by silica gel chromatography. The yields obtained of sulfonate products 




Figure 3.2. Chemical synthesis of ethoxy-sulfonate derivatives 3.1-3.5. (a) Anhydrous DCM, anhydrous 
pyridine.  
The aqueous stability of sulfonate derivatives (3.1-3.5) was determined at pH 7, this pH 
is typically used in conjugation reactions. Stability was also determined at more basic 
pH‘s (8 and 8.5) which is close to the pKa of the cysteine thiol group and would be 
expected to result in higher rates of alkyltion by the sulfonate derivatives.  
1H-NMR (solvent suppression experiment at 4.7 ppm) analysis was performed over 4 
days to test the stability and to calculate the hydrolysis rates (Figure 3.3). The 
percentage (%) remaining of 2-methoxyethyl 4-nitrobenzenesulfonate (3.5) was 
calculated using Equation 3.1. The percentage remaining of each sulfonate derivative 
(3.1-3.4) was calculated accordingly.  
                                    
  
        
                    (Equation 3.1)   
Where; 
Is= Integration of the aromatic sulfonate peak at δ 8.45 ppm which corresponds to the 
aromatic protons of sulfonate group of 3.5 (2 x NO2CCH). 
Isa= Integration of the aromatic sulfonic acid peak at δ 8.35 ppm which corresponds to 
the aromatic protons of sulfonate group of sulfonic acid (2 x NO2CCH). 
 
The remaining percentage of sulfonate derivatives (3.1-3.5) over 4 days at pH 7, 8 and 
8.5 were calculated using Equation 3.1 and compared as shown in (Figure 3.4). The 
hydrolysis rates of ethyloxy-sulfonate derivatives were obtained and found to be 
independent of the solution pH (Table 3.2). Moreover, the rates of hydrolysis showed a 
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direct correlation with the pKa values, so the lower the pKa, the greater the hydrolysis 
rate (Table 3.2). 
 
 
Figure 3.3.  
1
H NMR spectra of 2-methoxyethyl 4-nitrobenzenesulfonate (3.5) over 4 days at A) pH 7 and 
B) 8.5. Arrows indicate the aromatic peaks that were followed to calculate hydrolysis rates  using Equation 
3.1, maroon arrows correspond to aromatic protons of sulfonate group of 2-methoxyethyl 4-
nitrobenzenesulfonate (2 x NO2CCH), while green arrows correspond to aromatic protons of sulfonate 








































































































Figure 3.4. Percentage remaining sulfonates (3.1-3.5) over 4 days. Stability was appraised in phosphate buffer (100 mM, pH 7, 8 or 8.5) using solvent 
suppression method. 



















































































































































Electron-rich methyl-substituted arylsulfonate displayed higher aqueous stability (lower 
hydrolysis rates) compared to the electron-withdrawing halogen-substituted 
arylsulphonate derivatives. The presence of a strong electron withdrawing group 
(resonance effect) at the para-position (3.5) significantly increases the hydrolysis rates 
(decreases the hydrolytic stability) (Table 3.2). Lastly, it is worth noting that both the 3-
Br (3.3) and 3-Cl (3.4) substituted arylsulfonates which have the same predicted pKa‘s, 
showed comparable hydrolysis rates. 
Table 3.2. Calculated hydrolysis rates (h
-1
) of sulfonate derivatives 3.1-3.5. 

































Further evaluation of the impact of each substituent on hydrolysis rates was then done 
by fitting the hydrolysis rates to the Hammett equation (Equation 3.2) against Hammett 
σ values which provided reasonable correlation, but non-linear correlation (R2 = 0.86). 
The non-linearity can be attributed to different factors, such as the regiochemistry of the 
substituents (meta- and para-positions), and experimental errors,142 which can be 
possibly improved by increasing the number of the experimental trails (Figure 3.5).   
From the equation, the reaction constant   was 0.5786 (  ˃ 0), which indicate that the 
hydrolysis of sulfonates is favoured by electron withdrawing group to stabilise the 
negative charge of the generated sulfonic acid anion.  
                                                                                            (Equation 3.2) 
 
Figure 3.5. The correlation between log hydrolysis rates (h
-1
) and Hammett sigma σ values. 
3.2.2 Evaluation of the effect of electrophile chain length of sulfonates on 
hydrolysis rates (propyloxy derivatives) 
Next, we sought to evaluate the impact of the length of the electrophile carbon chain on 
the aqueous stability of sulfonates. Based upon the previously determined hydrolysis 
results for ethyloxy-sulfonate derivatives, we selected the most, intermediate, and least 
stable sulfonate derivatives, 4-methyl (3.6), 3-chloro (3.7), and 4-nitro (3.8) propyloxy 
sulfonates, respectively, to be further evaluated in this Section. The synthesis procedure 
was again accomplished in anhydrous DCM, with pyridine being employed as base. The 
reactions were left overnight at room temperature, except for 3-methoxypropyl 4-
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nitrobenzenesulfonate derivative (3.8) which was only left for 2 h. The reactions were 
then subjected to standard work-up (EtOAc) and the products were purified by silica gel 
chromatography, to give the sulfonates 3.6-3.8 in very good yields which ranged from 
82-96% (Figure 3.6).  
 
Figure 3.6. Chemical synthesis of propyloxy-sulfonate derivatives 3.6-3.8. a) Anhydrous DCM, 
anhydrous pyridine. 
The stability of the propyloxy sulfonate derivatives 3.6-3.8 was then evaluated using a 
similar 1H-NMR method that was employed earlier to determine the stability of 
ethyloxy sulfonate derivatives. Stability of propyloxy sulfonate derivatives was directly 
compared to the ethyloxy analogues. The Propyloxy sulfonates derivatives 3.6-3.8 
showed lower aqueous stability in comparison to the relative ethyloxy sulfonate 
analogues. Moreover, the percentages of remaining of sulfonate derivatives 3.6-3.8 
reflect inherent substituent effects which directly correlate with their pKa values. 
(Figure. 3.7). 
3.2.3 Sulfonate ester acetamide derivatives  
α-Halocacetamide electrophiles are amongst the earliest alkylating reagents used for the 
modification of the cysteines in keratin back in 1935. Since then, protein alkylation with 
these electrophiles has been extensively disseminated in a range of applications, such as 
protein mass spectroscopy and peptide mapping.143 In an attempt to mimic α-
halocacetamide electrophiles, we set out to appraise the influence of amide group as a 

































































































Figure 3.7.  Percentage remaining of sulfonates (3.1, 3.4-3.8) in aqueous buffer over 4 days. Stability was appraised in phosphate buffer (100 mM, pH 7, 8 or 
8.5) using solvent suppression method. 
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The synthesis of sulfonyl ester acetamide derivatives 3.9 and 3.10 was carried out 
according to the previously followed synthesis procedure. The reactions were left only 
for 2 h. Then, the reactions were subjected to standard work-up (EtOAc) and the 
products were purified by silica gel chromatography (Figure 3.8). 
 
Figure 3.8. Chemical synthesis of acetamide sulfonate derivatives 3.9 and 3.10. a) Anhydrous DCM, 
anhydrous pyridine, 2 h.  
The stability of tosyl acetamide (3.9) was evaluated at a single pH (pH 8) using the 
previously mentioned 1H-NMR method. The aqueous stability was conducted at only 
one pH, given that the conducted hydrolysis rates of ethyloxy and propyloxy solufonate 
derivatives 3.1-3.8 were found to be pH independent. As shown in Figure 3.9, the 
presence of α-amide group as part of the electrophile stabilises the tosyl acetamide (3.9) 
toward hydrolysis in comparison to the 3-methoxypropyl 4-methylbenzene sulfonate 
(3.6). 






























Figure 3.9. Percentage remaining of sulfonates (3.1, 3.4-3.8, and 3.9) in aqueous buffer over 4 days. 
Stability was appraised in phosphate buffer (100 mM, pH 8) using solvent suppression method. 
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In summary, the hydrolysis profile of the synthesised sulfonate derivatives has been 
appraised. Propyloxy sulfonate derivatives displayed lower aqueous stability than 
ethyloxy sulfonate analogues, while the tosyl acetamide sulfonate 3.9 displayed higher 
stability than 3.6 under the evaluated conditions. It can be concluded that the presence 
of alkyl group next to the electrophilic center (carbocation) increases the reactivity of 
sulfonate derivative towards hydroxide group (hard nucleophile), whereas the presence 
of α-amide group reduces the reactivity of sulfonate derivative towards the hydroxide 
group.  
3.3 Reactivity rates of sulfonates with the thiol containing nucleophile 
glutathione 
Next, we sought to test the reactivity of sulfonate derivatives 3.4, 3.7, and 3.8 towards a 
thiol nucleophile and subsequently compare rates of hydrolysis to rates of thiol 
alkylation.  
Reduced glutathione 3.23 ( 3 equiv.), cysteine containing tripeptide, was incubated with 
each sulfonate derivative at room temperature in phosphate buffer (100 mM, pH 7.5) 
(Figure 3.10). Excess equivalents of glutathione were employed to account for areal-
oxidation of the reduced glutathione. In a parallel experiment, each sulfonate derivative 
was held in phosphate buffer (100 mM, pH 7.5). In the absence of glutathione, to 
evaluate hydrolysis.  
 
Figure 3.10. Reaction of glutathione (3.23, 3 equiv.) with sulfonate derivatives in aqueous in phosphate 
buffer (100 mM, pH 7.5). 
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The percentage of remaining sulfonates in the presence and absence of glutathione over 
2 days was calculated using a 1H-NMR method similar to those used previously to 
determine the aqueous stability of sulfonate derivatives. As such, the rate of hydrolysis 
of 3-methoxypropyl 4-nitrobenzene sulfonate (3.8) was calculated to be 0.063 h-1 (half-
life = 27.5 h), whereas the rate of reaction with glutathione was calculated by 
subtracting the % of remaing sulfonates in the presence of glutathione, from the % of 
remaining sulfonates in the absence of glutathione and found to be 0.004 h-1 (Figure 3.11 
A and B). These results suggest that higher equivalent of sulfonate ester linkers is 
required in bioconjugation reactions to compensate the hydrolytic instability of them 
and achieve higher labelling yields. 
The reaction rates of 2-methoxyethyl 3-chlorobenzene sulfonate (3.4) and 3-
methoxypropyl 3-chlorobenzene sulfonate (3.7) with glutathione (3 equiv.) were found 
to be 0.002 and 0.003 h-1, respectively (Figure 3.11 A and B).  



























































Figure 3.11. A) Percentage remaining of sulfonates 3.4, 3.7, and 3.8 in absence of glutathione in aqueous 
phosphate buffer (100 mM, pH 7.5). B) Percent of remaining of sulfonates 3.4, 3.7, and 3.8 in presence of 
glutathione (3.23, 3 equiv.) in aqueous phosphate buffer (100 mM, pH 7.5). Data presented as mean ±SD 
of 3 independent experiments.    
Consistent with previous results the presence of the α-amide group reduced the rate of 
hydrolysis of the tosylate group, as less than 6% hydrolysis was observed over 2 days at 
pH 7.5 (Figure 3.12 A). As such, the rate of reactivity with glutathione can be obtained 
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by assuming that rate the of hydrolysis is negligible. Glutathione (3 equiv.) was held 
with tosyl acetamide (3.9) in phosphate buffer (100 mM, pH 7.5) and analysed using 1H 
NMR (Figure 3.12 B). Surprisingly, tosyl acetamide (3.9) reacted completely with 
glutathione in less than 10 h and the rate of reactivity was found to be 0.161 h-1 (Figure 
3.13).  
Our obtained results are consistant with the previously established reactivity of alkyl 
halides with thiolate group of cysteine.144 Dahl and Mckinley-Mckee (1981) have 
reported the parameters affecting the reaction rates of alkyl halides with the thiolate of 
cysteine. A range of different α-substituents were chosen and the rates of their reactivity 
were determined. They proved that the nature of α-substituents has crucial impact on the 
reactivity of the electrophile when the same leaving group was compared.144 It has been 
shown that α-haloacetamides are more reactive than α-haloacids, and both are far more 
reactive than α-halo-alkyl derivatives towards the thiolate anion. The order of reactivity 
of thiolate group towards electrophiles is as follows:  
 R-CH(X)-CONH2 > R-CH(X)-COOH > R-CH2(X) > R-CH(X)-CH2OH. Where X is 
the same halogen.144 
Therefore, in comparison to the alkyl tosylates 3.1 and 3.6, the reactivity rate of tosylate 
derivative with appended α-amide functionality 3.9 towards glutathione has been 






Figure 3.12. A) 
1
H NMR spectrum of tosyl acetamide (3.9) in the absence of glutathione. B) 
1
H NMR 
spectrum of tosyl acetamide (3.9) in the presence of glutathione (3 equiv.). Arrows indicate the aromatic 
peaks that have been followed to calculate reactivity rates using Equation 3.1. Red arrows correspond to 
the aromatic protons of sulfonate group of tosyl acetamide (3.9) (2 x SO2CCH) while green arrows 





The significant increase observed in the reactivity rates of tosyl acetamide (3.9) in 
comparison to alkyl tosylates 3.1 and 3.6 can be explained by considering the hard-soft 
acid base model (HSAB). A hard nucleophile, such as a hydroxide group will primarily 
react with a hard electrophile, while a soft nucleophile (lower electronegativity) such as 
thiolate group predominantly reacts faster with a soft electrophile. The presence of 
vicinal amide group renders the partial positive charge on the carbocation less dense, 
and therefore, more reactive towards thiolate nucleophile.145  



























































Figure 3.13. A) Percentage remaining of sulfonates (3.1, 3.6, and 3.9) over 2 days at pH 7.5. Stability was 
appraised in phosphate buffer (100 mM, pH 7.5) using solvent suppression method. B) Percentage 
remaining of sulfonates (3.1, 3.6, and 3.9) in the presence of glutathione (3.23, 3 equiv.) in aqueous 





The introduction of acetamide group had a significant effect on reaction rates of the 
tosylate (3.9) with glutathione. Thus, we next aimed to study the impact of steric 
hindrance of the bulky leaving group on their reactivity rate.  
Accordingly, mesyl acetamide (3.10) was synthesised according to the previously 
mentioned method (Figure 3.8) and its stability and reactivity rate with reduced 
glutathione (3.23, 3 equiv.) were determined. Over a period of 48 h, mesyl acetamide 
(3.10) was stable in water with no detected peaks of hydrolysis (Figure 3.14 A).  
Again, the reaction rates with glutathione can be calculated assuming that the hydrolysis 
rate is neglibable. 1H-NMR (solvent suppression experiment at 4.7 ppm) analysis over 2 
days was used to calculate the reaction rates of 3.10 with glutathione (Figure 3.14 B). 
The percent (%) of remaining mesyl acetamide (3.10) was calculated using Equation 
3.3.  
                                      
  
        
                (Equation 3.3) 
Where; 
Is= Integration of the peak at δ 3.2 ppm which corresponds to the methyl protons of 
mesylate group of 3.10 (CH2OSO2CH3). 
Isa= Integration of the sulfonic acid peak at δ 2.65 ppm which corresponds to the methyl 
protons of mesylate group of mesylic acid (HOSO2CH3). 





Figure 3.14. A) 
1
H NMR spectrum of mesyl acetamide (3.10) in the absence of glutathione. B) 
1
H NMR 
spectrum of mesyl acetamide (3.10) in the presence of glutathione (3.23, 3 equiv.), arrows indicate the 





Surprisingly, both tosyl acetamide (3.9) and mesyl acetamide (3.10) showed comparable 
reactivity rates with glutathione 3.23 (3 equiv.) which are 0.161 and 0.159 h-1, 
respectively (Figure 3.15). According to the predicted pKa of 4-toluenesulfonic acid (-
0.43±0.50) and methanesulfonic acid (1.75±0.50), tosyl acetamide (3.9) is expected to 
be more reactive than mesyl acetamide (3.10). However, the comparable reactivity 
results obtained could be attributable to the bulky tosylate leaving group in comparison 
to the mesylate group to account for the similar reaction rates observed with glutathione.  




























Figure 3.15. Percentage remaining of sulfonates (3.9, 3.10) in the presence of glutathione (3.23, 3 equiv.) 
in phosphate buffer (100 mM, pH 7.5). Data are represented as mean ±SD of n=3. 
3.4 Stability of sulfonates in the presence of TCEP 
Considering that most cysteine residues in proteins are paired in disulfide bonds, a 
reduction step is typically required before commencing thiol alkylation. Phosphines 
reductants, such as the water soluble TCEP (2.2), which were investigated in Chapter 2, 
are widely used reducing agents in protein conjugation. It is essential to evaluate the 
compatibility of sulfonate derivatives with TCEP to determine whether a quenching step 
in between is necessary during the conjugation reaction. 
Thus, we set out to evaluate the stability of sulfonate derivatives in the presence of 
TCEP. The 3-methoxypropyl-3-chlorobenzene sulfonate (3.7), and tosyl acetamide (3.9) 
were held with TCEP 2.2 (3 equiv.) and analysed by 1H NMR over 2 days. In a parallel 
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experiment, 3-methoxypropyl-3-chlorobenzene sulfonate (3.7) was held in phosphate 
buffer (100mM, pH 7.5) without TCEP. As only hydrolysis peaks were observed by 1H 
NMR (Figure 3.16), 3-methoxypropyl-3-chlorobenzene sulfonate (3.7) was found to be 
stable in the presence TCEP.  
 
Figure 3.16. Stability of 3-methoxypropyl3-chlorobenzene sulfonate (3.7) in the presence of TCEP (2.2, 3 
equiv.). 
1
H NMR spectra of 3-methoxypropyl-3-chlorobenzene sulfonate (3.7) in the absence and 
presence of TCEP. Arrows in the expanded region indicate the aromatic peaks of sulfonic acid 
(hydrolysis) that obtained  in the absence and presence of TCEP after 24 h.  
Again, 1H NMR experiment was used to determine the reaction rate of tosyl acetamide 
(3.9) with TCEP (Figure 3.17 A). In contrast to 3-methoxypropyl-3-chlorobenzene 
sulfonate (3.7), the tosyl acetamide (3.9) was found to react with TCEP, possibility 
through nucleophilic substitution of tosylate anion to afford an ylide or ylene product.  
The rate of reactivity of tosyl acetamide (3.9) with TCEP was found to be 0.096 h-1 
(Figure  3.17 B). Therefore, since tosyl acetamide is not stable in the presence of TCEP, 
it is necessary to use our previously mentioned quenching method in Chapter two to 







































Figure 3.17. Stability of tosyl acetamide (3.9) in the presence of TCEP (2.2, 3 equiv.). A)
 1
H NMR 
spectrum of tosyl acetamide (3.9) in the presence of TCEP. Arrows in the expanded region indicate the 
aromatic peaks that were followed to calculate reactivity rates using Equation 3.1. B) Percentage 
remaining of tosyl acetamide (3.9) in presence of TCEP (3 equiv.) in aqueous phosphate buffer (100 mM, 
pH 7.5). 
3.5 Reactivity of selected sulfonates with proteins 
Finally, as the aqueous stability and reactivity rates have been evaluated, we sought to 







was selected as a model protein as it is small (10 kDa) and has only one cysteine residue 
at its N-terminus. Thiol alkylation of the cysteine group of Sbi IV-Cys was investigated 
using protein mass spectroscopy. This mass spectrometric analysis was performed on an 
Agilent 6520 CHIPCube Q-TOF LC/MS. 
Sbi IV-Cys (2 mg/mL) in Tris.HCl buffer (100 mM, 150 mM NaCl, 5mM EDTA, pH 
7.5) was reduced using TCEP 2.2 (2 equiv.) for 1 h at room temperature, then the 
reduced Sbi IV-Cys was held with the penta-PEG azide 2.13 (5 equiv.) for 1 h at room 
temperature to quench excess TCEP before incubation with sulfonate derivatives (10 
equiv.) at room temperature overnight. Excess linkers were then removed by buffer 
exchange [3 times, using Amicon® Ultra-0.5mL (3 kDa) centrifugal filter] and analysed 
by mass spectroscopy. 
From the MS analysis obtained, one can identify that approximately less than 10 % of 
Sbi IV-Cys labelling was observed when 3-methoxypropyl-4-nitrobenzene sulfonate 
(3.8) was employed. These results suggest that higher equivalents should be used to 
compensate the higher hydrolysis rate of 3-methoxypropyl-4-nitrobenzene sulfonate 
(3.8) (Figure 3.18 C). 3-methoxypropyl-4-methylbenzene sulfonate (3.6) showed no 
detectable labelling of Sbi IV-Cys (Figure 3.18 B).   
Conversely, the acetamide sulfonate derivatives showed a higher level of protein 
labelling compared to alkyl sulfonate derivatives. Tosyl acetamide (3.9) showed highest 
labelling level with almost complete thiol alkylation of the protein. These results are in 
line with the previously determined reaction rates using glutathione (Figure 3.19 A). 
Surprisingly, the mesyl acetamide (3.10) showed a lower efficiency of labelling of Sbi 







Figure 3.18. Deconvoluted protein MS spectra of Sbi IV-Cys (2 mg/mL, 0.187 mM) reacted with 
sulfonates 3.6 and 3.8 (1.87mM, 10 equiv.) at pH 7.5.  A) Sbi IV-Cys control. B) Sbi IV-Cys reaction 
with 3-methoxypropyl-4-methylbenzene sulfonate (3.6) at pH 7.5 with no detection of product peak. C) 
Sbi IV-Cys reaction with 3-methoxypropyl-4-nitrobenzene sulfonate (3.8) at pH 7.5, yielding a mass of 



























Figure 3.19. Deconvoluted protein MS spectra of Sbi IV-Cys (2 mg/mL, 0.187 mM) reacted with 
sulfonates 3.9 and 3.10 (1.87mM, 10 equiv.) at pH 7.5.  A) Sbi IV-Cys reaction with tosyl acetamide (3.9) 
at pH 7.5, yielding a mass of 10844.25 Da. with difference of 115.35 Da. B) Sbi IV-Cys reaction mesyl 
























3.6 Conclusion  
In this Chapter we aimed to find alternative thiolate alkylating method in order to tackle 
the drawbacks of the currently wide-applied approaches, mainly maleimide-based 
conjugation methods. Maleimide-based approaches has been widely used due to their 
specificity and outstanding reaction kinetics;146 therefore, it has been employed in cross-
linking, fluorescent labeling and in PEGylation reactions. As mentioned earlier (see 
Section 1.4.2.1), the major drawback of this approach is the instability of the constructed 
conjugates through retro-Michael addition mechanism to reform maleimide, which leads 
to the assembly of a new thiol conjugate in the presence of free thiols.84 
We evaluated the potential use sulfonate derivatives as cysteine alkylating agents 
through understanding the factors affecting their electrophilic reactivity. The nature of 
the α-substituent groups was found the most essential factor affecting both the aqueous 
stability and the reactivity of sulfonate derivatives. The α-amide group was the best 
identified acceptor group amongst the studied ethyloxy and propyloxy sulfonate 
derivative. Based on the evaluated hydrolysis rates, reactivity rates and protein 
functionalisation of the synthesised range of sulfonates (3.1-3.10), tosyl acetamide (3.9) 
provided the most promising results. This included low hydrolysis rate, high reaction 
rates with glutathione, and almost complete protein labelling. 
 However, due to the relatively slow kinetics obtained with tosyl acetamide (3.9) in 
compared to the known maleimide-based approaches,146,147 we can conclude that the 
presence of the α-amide group renders sulfonate derivatives better electrophilic groups, 







4 Bis-haloacetmide derivatives as a novel disulfide rebridging 
agents 
4.1 Introduction  
Antibody drug conjugates (ADCs) are one of the cutting-edge antibody-based 
therapeutic approaches, which have attracted substantial attention over the last two 
decades. ADCs comprise a mAb which is employed as a vehicle to direct a cytotoxic 
drug to a specific malignant cell or tissue. The construction of ADCs requires specific 
linker characteristics in order to attain plasma-stable antibody drug conjugates. 
The construction of the first-generation of ADCs utilised the inherent nucleophilic 
functionality of the amino acid residues within the antibody, mainly cysteine and lysine 
amino acids. In order to generate cysteine-based conjugates, a pre-reduction step of 
inter-chain disulfide bonds is required. The IgG1 subclass of IgGs is the most abundant 
one in human serum and most common type employed in mAb-based therapeutics.148 
IgG1 has a total of four inter-chain disulfide bonds, two inter-chain disulfide bonds are 
between heavy/light chains and two inter-chain between heavy/heavy chains in the 
hinge region.148 A great number of studies have shown the importance of the 4 inter-
chain disulfide bonds, not only to maintain the structure of mAbs and optimal antigen 
binding, but also to preserve the effecter function of mAbs. A reduction in CDC and 
ADCC were observed for a chimeric mouse/human IgG when a mutated IgG lacking of 
inter heavy chain disulfide bonds was tested. It has been found that even partial 
reduction of the four inter-chain disulfide bonds of IgG resulted in a dramatic reduction 
in their complement fixation function and CDC.149–151 
Given that disulfide bonds are essential to maintain the proper folding, structure and 
more importantly, the function of mAbs, it is essential to maintain the post-reduction 
structure of recombinant antibodies prior to the construction of mAb conjugates. In 
attempts to avoid the complex and expensive genetic re-engineering of mAbs to 
maintain the post-reduction structure of mAbs and retain a defined conjugation 
approach, Abzena has pioneered a novel approach of producing homogenous and stable 
ADCs based on rebridging of the reduced inter-chain disulfide bonds. ThioBridge® 
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technology is a bis-sulfone-based reagent which re-anneals the reduced inter-chain 
disulfide bonds of mAbs forming a 3-carbon bridge, and by doing so, ThioBridge® 
maintains the post-reduced disulfide structure of the antibody. The accessible reduced 
disulfide bonds are cross-linked through sequential addition-elimination mechanism, 
first starting by Michael addition of a thiolate group of the reduced disulfide bond, 
followed by elimination of p-toluene sulfinic acid generating the second Michael 
acceptor (α-β unsaturated carbonyl) as shown in Figure 4.1. The vicinal thiolate group 
then reacts through a second Michael addition to form a 3-carbon linkage between the 
two cysteine thiols.152,153 
 
Figure 4.1. Addition-elimination mechanism of a bis-sulfone linker (ThioBridge®) coupled with 
cytotoxic drug ( ) in cross-linking the reduced inter-chain disulfide bonds of mAbs affording 3-carbon 
bridges. 
Given that the primary aim of using bis-sulfone linkers is to attain better plasma stability 
of the ADCs, the increased plasma stability has been appraised by comparing 
fluorescently-labeled trastuzumab using a maleimide linkage, with fluorescently-labeled 
bis-alkylated trastuzumab.152 The latter displayed significant serum stability over 5 days 
in the presence of high concentrations of albumin.152 Moreover, it has been confirmed 
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that using bis-sulfone reagent bearing MMAE in the construction of ADCs of 
trastuzumab, fully retained binding activity of trastuzumab to the HER2 receptor, and 
displayed potent antiproliferative activity in HER2 positive cell lines.152  
Shortly following the development of ThioBridge® technology, a number of different 
rebridging reagents have been developed to tackle the drawbacks of bis-sulfone reagents, 
including the slightly basic pH requirement to commence the rebridging, poor solubility 
of the reagents and the slow reaction kinetics and time taken between reduction of the 
disulfide and completion of re-annealing process which has potential to affect the 
structure of the protein. 
As such, more reactive re-annealing reagents were developed utilizing the inherent 
reactivity of maleimide derivatives towards thiolates to attain what is known as bis-
reactive maleimide linkers or next-generation maleimide, such as dibromomaleimide 
(4b). Bis-reactive maleimide linkers were developed as disulfide rebridging agent 
through 2-carbon bridge to attain bis-thiomaleimide linkage.154 The fast reaction kinetics 
of bis-reactive maleimide derivatives offers higher protein structure integrity and broader 
reaction pH range (6-8) compared to bis-sulfone derivatives.  
 
Other 3,4-dihalosubstituted maleimide derivatives, such as dichloro (4c) and 
diiodomaleimide (4d) have been also evaluated and the latter has showed superior 
reactivity rates towards thiolates. 3,4-Dithiomaleimide reagents were also assessed as 
rebridging agents and among them, dithiophenolmaleimide (4e) showed comparable 
reactivity rate to dibromomaleimide (4b) and due to the higher stability of 
dithiophenolmaleimide toward TCEP in comparison to dihalomaleimides, 4e was 





Bis-sulfone reagents and dibromomaeimide derivatives are deemed as the earliest and 
most established rebridging reagents for reduced disulfides. Nonetheless, each has 
associated drawbacks. For example, poor water solubility of these reagents and lack of 
selectivity between reduced disulfides bonds and unpaired cysteine residues under 
reducing conditions. This has been demonstrated by Smith et al. where they used the 
dibromomaleimide (4b) reagent to mono-alkylate a single cysteine residue (in high 
yield) in a mutated protein followed by second thiol-alkylation of different thiol-
containing peptides, such as glutathione (Figure 4.2 A). However, they also demonstrate 
the usefulness of dibromomaleimide (4b) in cross-linking a disulfide bond of peptide 
hormone Somatostatin generating a bisthiomaleimide with a 2-carbon bridge (Figure 4.2 
B).155  
 
Figure 4.2. A) Mono-labeling of thiol group with dibromomaleimide (4b) reagent. B) Cross-linking of 
the disulfide bond of somatostatin by dibromomaleimide (4b) reagent forming bisthiomaleimide 2-carbon 
bridge. 
Therefore, many researchers seek to find alternative rebridging agents with different 
molecular scaffolds to overcome the limitations of the aforementioned rebridging agents. 
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One example of other scaffolds are the pyridazinedione-based compounds, such as 
dibromopyridazinedione (4f), which cross-links disulfide bonds through a 2-carbon 
bridges.153  
 
Taking advantage of the stability of dithiophenolmaleimide in the presence of TCEP, di-
TECP-substituted dithiophenolpyridazinedione (4g) has been synthesized as both 
reducing agent and stable cross-linker at the same time (Figure 4.3 A). Lee et al. used di-
TCEP-substituted dithiophenolpyridazinedione as dual agent in the cross-linking of a 
Fab from trastuzumab.156 Moreover, they attempted to minimize disulfide scrambling 
(intra-disulfide cross-linking) through using 4g, which was incubated with full mAb, 
trastuzumab, to fully cross-link the four disulfide bond and reduce the scrambling of 
them (intra-chain cross-linking of heavy/heavy disulfide bonds).156 
Maruani et al. went a step further by developing pyridazinedione-based linkers with two 
functionalities can be introduced on each N atom of the pyridazinedione ring. They 
produced  dibromopyridazinediones (4h) bearing two reactive, clickable handles: alkyne 
and strained alkyne handles for sequential copper catalysed ‗Click‘reaction and stain-



















Figure 4.3. A) Di-TECP-substituted dithiophenolpyridazinedione (4g) with dual reduction and rebridging 
activities of mAb disulfide bonds. B) Dibromopyridazinediones (4h) with two different reactive, clickable 
handles for dual chlick reactions. 
Rebridging strategies are considered elegant approaches that enable the introduction of 
reactive functional groups to the reduced mAbs while maintaining the well-define post-
reduction structure of them. Despite the recent advances and considerable research 
efforts in this area, the aforementioned rebridging approaches either through forming 2- 
and 3-carbon bridges still have practical limitations that needed to be further addressed. 
With all major emphasis being on fully cross-linking the heavy-light and heavy-heavy 
inter-chain disulfide bonds to attain a fully cross-linked antibody (150 kDa), the 
previously described re-bridging methods have overlooked the potential advantages of 
construction of a half-antibody (75 kDa) as an intended product. In addition, to the best 
of our knowledge, the previous rebridging approaches have shown no significant 
TCEP: reducing handle  
Dithiophenolpyridazinedione: 
rebridging agent  
Cyclooctyne: for stain-
promoted ‗Click‘reaction  
TCEP: reducing 
handle  





selectivity between heavy-heavy and heavy-light disulfide bonds. Therefore, site-
selective protein labelling to attain a hetero-bifunctioanal mAb is still an unresolved 
challenge.  
Therefore, this work set out to evaluate haloacetamide derivatives as next-generation 
rebridging agents with emphasis on the hetero rebridging of full mAbs. 
As described previously in Chapter 3, tosylate derivatives with α-amido group, such as 
(3.9), displayed superior reactivity rates with the thiolate anion of cysteine, as well as 
being relatively stable towards hydrolysis. Given that electrophiles with an α-amido 
group and bearing halogens as the leaving group (which is a better leaving group than 
tosylate anion) are ideal to attain fast reaction kinetics towards thiolates group of 
proteins. As such, we postulated that α-halo-acetamide derivatives would be more 
suitable for cross-linking of a protein. Therefore, in this Chapter we sought to evaluate 
the use of aryl bis-haloacetamides as rebridging agents of reduced disulfide bonds.  
 
The concept of cross-linking biomolecules using alkyl-halides is well-established and 
has been used since the discovery of nitrogen mustard (Mechlorethamine) as an 
alkylating agent in 1942. These compounds exert their biological activity by alkylation 
of DNA, cross-linking two helical strands, thus preventing DNA replication which 
ultimately leads to cellular death (Figure  4.4).157 
The two distinct reactive alkyl-chloride functionalities of these alkylating agents permits 
cross-linking of DNA, RNA and proteins and by doing so, disturbs the normal structure 




Figure 4.4. Cross-linking mechanism of a nitrogen mustard (Mechlorethamine) with N-7 of guanine base 
of DNA which leads to cell cytotoxicity. 
Inspired by nitrogen mustard agents, herein we first aimed to evaluate two different 
scaffolds, namely N,N-di-chloroacetyl amido derivatives ((ClCH2CO)2NR) (4.1 and 4.2) 
as agents for rebridging reduced disulfide bonds of mAbs, in order to maintain their 
structural integrity, optimal antigen binding and normal effector functions. 
 
4.2 N,N-Di-(chloroacetyl)-amido derivatives as rebridging agent of reduced 
disulfide bonds 
Herein, 2-chloro-N-(2-chloroacetyl)-N-(2-methoxyethyl)acetamide (4.1) was postulated 
as a bis-alkylating linker which permit bis-alkylation of reduced disulfide cysteine 




Figure 4.5. The proposed mechanism of rebridging of the reduced disulfide bonds using 2-chloro-N-(2-
chloroacetyl)-N-(2-methoxyethyl)acetamide (4.1) linker. 
Accordingly, several synthesis methods were followed in order to synthesise 2-chloro-
N-(2-chloroacetyl)-N-(2-methoxyethyl)acetamide (4.1) (Figure 4.6).  
 
Figure 4.6. Our attempts to synthesise 2-chloro-N-(2-chloroacetyl)-N-(2-methoxyethyl)acetamide (4.1) 
through acetylation of 2-chloro-N-(2-methoxyethyl)acetamide (4.3) in absence or presence of a base, such 
as pyridine or TEA. 
As such, pyridine (2.5 equiv.) was used as a base and added to a reaction mixture of 2-
chloro-N-(2-methoxyethyl)acetamide (4.3) and 2-chloroacetyl chloride in DCM. The 
reaction left stirring for 24 h, however, a complex mixture of products was obtained and 
none of the products obtained could be defined. However, according to Shatsauskas et 
al. they reported that they used pyridine as a base in acylation reaction of their amine 
starting material, 3-aminopyridin-2(1Н)-one (4i) with 2-chloroacetyl chloride resulted in 




Figure 4.7. The previously described procedures to synthesise N,N-di-chloroacetyl amido derivative. A) 
(a) 2-chloroacetyl chloride, pyridine, DCM, 15 h.
158
 B) (b) 2-chloroacetyl chloride, reflux, 3 h.
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Next, in attempt to follow the procedure similar to that described by Chan et al., TEA 
(2.5 equiv.) was added over a period of 4 h to a reflux of  reaction 2-chloro-N-(2-
methoxyethyl)acetamide (4.3) and 2-chloroacetyl chloride mixture in DCM.160 
Following work-up and purification, a mixture of undefined products was obtained, 
though the desired product could not be confirmed by 1H NMR. An example of the 
purified unknown product is shown in Figure 4.8 A, which has a 1H NMR spectrum 
similar to the desired product.  
Lastly, a base-free reaction was performed as follows. A mixture of 2-chloro-N-(2-
methoxyethyl)acetamide (4.3) was refluxed with excess 2-chloroacetyl chloride in dry 
toluene for 24 h. After 24 h of reflux, the reaction mixture was subjected to standard 
work up (DCM) and analysed using MS. Only the starting material (4.3) was identified 
in addition to the product of elimination of the methoxy group, with expected mass 
(M+H+) = m/z 120.0216 and found = m/z 120.0228 (Figure 4.8 B). 
However, according to Khraiwesh et al. they described synthesis procedure of N,N-bis-
(chloroacetyl)-derivative (4l) by refluxing their amine starting material, 2-amino-3-
chloro-1,4-naphthoquinone (4k) in excess 2-chloroacetyl chloride at high temperatures 





Figure 4.8. A) 
1
H NMR spectrum of one of the unidentified separated product of 2-chloro-N-(2-
methoxyethyl)acetamide (4.2) synthesis trail using TEA as a base. B) MS spectra of the reaction crude of 
the base- free trail showing the mass of the starting material (4.3) and a product of methoxy group 
elimination.  
As it was not possible to prepare 2-chloro-N-(2-chloroacetyl)-N-(2-
methoxyethyl)acetamide (4.1) linker, in part due to the presence of the methoxy group 
which was susceptible to both basic and acidic elimination. We decided to attempt 
synthesis of more stable aryl N,N-di-(chloroacetyl)amido derivative (4.2) based on the 
observation of Khraiwesh et al. As all these methods were attempted on aromatic 
amines (aniline derivatives), we moved towards synthesis of aniline bearing N,N-bis-
(chloroacetyl) group as an alternative scaffold, which also imparts the advantage of 






4.3 2-chloro-N-(2-chloroacetyl)-N-phenylacetamide (4.2) as rebridging 
agent of reduced disulfide bonds 
We next attempted to synthesise 2-chloro-N-(2-chloroacetyl)-N-phenylacetamide (4.2) 
as a more stable N,N-di-(chloroacetyl)-amido derivative.  
Synthesis of  2-chloro-N-(2-chloroacetyl)-N-phenylacetamide (4.2) was attempted by 
refluxing 2-chloro-N-phenylacetamide (4.5) with 5 equivalents of 2-chloroacetyl 
chloride in dry toluene for 24 h according to the procedure described by Khraiwesh et 
al.159 Following standard work-up, 2-chloro-N-(2-chloroacetyl)-N-phenylacetamide (4.2) 
was obtained in 50% yield as confirmed by NMR (1H and 13C) and MS. 
In attempt to improve the yield, the reaction was repeated using higher equivalents of 2-
chloroacetyl chloride and longer refluxing time (for 48 h), the yield of the reaction 
significantly increased (75%), indicating that 2-chloroacetyl chloride might be 
evaporating while refluxing in toluene (Figure 4.9).  
 
Figure 4.9. Chemical synthesis of 2-chloro-N-(2-chloroacetyl)-N-phenylacetamide (4.2). a) Dry toluene, 
48 h and reflux. 
Next, we aimed to evaluate the reactivity of the prepared 4.5 and 4.2 linkers, along with 
the commercially available linker towards strong nucleophiles, such as thiophenol.   
4.3.1 Reactivity of 4.3, 4.4 and 4.7 linkers toward with thiophenol  
Thiophenol (4.6) was chosen as a strong thiol-nucleophile to initially evaluate the 





As such, thiophenol initially reacted with 2-chloro-N-phenylacetamide (4.5) to evaluate 
the tested condition. Thiophenol (6 equiv.) was added to a solution of 2-chloro-N-
phenylacetamide (4.5) in a mixture of MeCN (1 mL) and Tris.HCl buffer (100 mM, pH 
7.5, 1 mL). The reaction was evaluated by MS after 6 h, and the product of alkylation 
4.7 was confirmed by HRMS (m/z 266.0583 (M+Na+)). 
 
Satisfied that the product of thiophenol and chloro-acetamide reaction can be confirmed 
under the evaluated conditions [MeCN and Tris.HCl buffer pH 7.5 (1:1)], thiophenol 
was then reacted with 2-chloro-N-(2-chloroacetyl)-N-phenylacetamide (4.2). The 
reaction was monitored by HRMS and the product of alkylation 4.8 was confirmed by 
HRMS (m/z 416.0708 (M+Na+)). 
 
Lastly, the commercially available 2-chloro-N-(2-chloroacetyl)-N-(3,4,5-
trimethoxyphenyl)acetamide (4.9) was also reacted with thiophenol under the described 





Figure 4.10. Chemical reaction of 2-chloro-N-(2-chloroacetyl)-N-(3,4,5-trimethoxyphenyl)acetamide 
(4.9) with thiophenol (4.6). a) Mixture of MeCN (1 mL) and Tris.HCl buffer (100 mM, pH 7.5, 1 mL) at 
room temperature 6 h. 
With this initial reactivity test, we concluded that N,N-di(chloroacetyl)amino derivatives 
are reactive towards thiolate group of the strong nucleophile thiophenol, thus we sought 
to evaluate the stability and glutathione reactivity of these N,N-di(chloroacetyl)amino 
derivatives in the following Sections. 
4.3.2 Stability of N,N-di(chloroacetyl)amido derivatives and their reactivity with 
glutathione 
As mentioned previously, one advantage of employing aromatic amines (aniline 
derivatives) is that they possess additional functionalisation sites to attain bi-functional 
linkers. Thus, we sought also to synthesise another N,N-bis-(chloroacetyl)-amido 
derivative possessing an ester functionality in order to evaluate the impact of the 
presence of this functionality on the stability and reactivity of this class of compounds 
toward thiol nucleophiles. Carrying out these experiments by using functionalised N,N-
bis-(chloroacetyl)-amido derivatives would enable us to gather more practical results 
towards the  applicability of these linkers in rebridging of reduced disulfide bonds of 
mAbs. 
As such, ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) was 
synthesized following similar method to the previously mentioned method to attain 4.2 
linker. Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) was obtained in 




Having successfully synthesised 4.11, we next sought to evaluate its usefulness as a 
rebridging agent by evaluating its stability and reactivity towards thiol nucleophiles. 
Ester functionalised derivative, ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate 
(4.11)  was deemed as a better linker to be further evaluated as rebridging agents. 
Particularly, because of the presence of ester group, which could give preliminary 
indications regarding the development of bi-functional rebridging agents. 
As protein labelling conjugation reactions are carried out under aqueous conditions, it 
was important to evaluate the aqueous stability of these linkers. As shown earlier in 
Chapter 3, sulfonate-bearing α-amide groups (3.9 and 3.10) exhibited high aqueous 
stability, thus we postulated that α-halo-acetamide derivatives are stable under the 
typical conjugation conditions.  
Before evaluating the aqueous stability of ethyl 4-(2-chloro-N-(2-
chloroacetyl)acetamido)benzoate (4.11), the aqueous stability of α-haloacetamide 
derivatives 4.12 was initially evaluated, as we considered starting with the simple 
structure of ethyl 4-(2-chloroacetamido)benzoate (4.12) would enable us to assign the 
required peaks needed to be followed in order to attain the hydrolysis rates of 4.11. 
 
The stability of ethyl 4-(2-chloroacetamido)benzoate 4.12 was studied by 1H NMR 
(solvent suppression experiment at 4.7 ppm). Compound 4.12 (1 mg/mL) was held in 
phosphate buffer (100 mM, pH 7.5) containing 10% DMF-d7. 
1H-NMR spectra were 
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acquired at time 0, 24, 48 and 96 h. The stability of ethyl 4-(2-
chloroacetamido)benzoate (4.12) was assessed by following the change in the 
integration of α-methylene protons at δ 4.38 ppm. The high aqueous stability of 4.12 
over 4 days was confirmed as no change in the integration of α-methylene protons could 
be observed along with no clear hydrolysis peak being observed (Figure  4.11).  
 
Figure 4.11. Stability of ethyl 4-(2-chloroacetamido)benzoate (4.12)  linker in aqueous buffer. 
 1
H NMR 
spectra of ethyl 4-(2-chloroacetamido)benzoate 4.12 (1.00 mg/ml, 4.15 mM) in phosphate buffer (100 
mM, pH 7.5) over 4 days. Arrow indicates the signals of α-methylene protons that were followed at δ 4.38 
ppm (ClCH2CONH) over 4 days. 
Then, the stability of Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) 
under similar aqueous conditions was evaluated. Ethyl 4-(2-chloro-N-(2-
chloroacetyl)acetamido)benzoate 4.11 (1 mg/mL) was dissolved in phosphate buffer 
(100 mM, pH 7.5) containing 30% DMF-d7 and held at room temperature overnight. 
The hydrolysis of one acetamide arm of ethyl 4-(2-chloro-N-(2-
chloroacetyl)acetamido)benzoate (4.11) to afford ethyl 4-(2-chloroacetamido)benzoate 
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(4.12) was confirmed by both 1H NMR and MS, which indicated that 4.11 is not stable 




Figure 4.12. A) Hydrolysis of ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) in aqueous 
buffer. (a) Tris.HCl buffer (100 mM, pH 7.5, 30 % DMF) at room temperature overnight. B) 
1
H NMR 
spectrum of ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) held in aqueous buffer 
overnight showing only spectrum of ethyl 4-(2-chloroacetamido)benzoate (4.12) with its assigned  peaks. 
C) MS spectra of Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) held in aqueous buffer 







The poor stability of N,N-di(chloroacetyl)amido derivatives under aqueous conditions 
has been observed previously where imide derivatives displayed slow hydrolysis rates 
below pH 7 and faster rates at pH above 7.161 Donskikh et al. studied the hydrolysis of 
N-(o-carboxyphenyl)-phthalimide over a range of pHs to attain N-phthalanthranilic acid. 
They proposed the mechanism of hydrolysis starting by rate limiting step of attacking of 
hydroxyl ion towards the carbon atom of the carbonyl group. In addition, they confirm 
the high stability of the obtained  N-phthalanthranilic acid as it required high 
temperature and alkaline conditions to be completely hydrolysed (Figure 4.13).161  
 
Figure 4.13. The mechanism of alkaline hydrolysis of N-(o-carboxyphenyl)-phthalimide.
161 
Given the poor hydrolytic stability of ethyl 4-(2-chloro-N-(2-
chloroacetyl)acetamido)benzoate (4.11), we tend to evaluate if  the rate of hydrolysis of 
the imide derivative 4.11 is faster than the rate of reactivity with thiolates and whether 
N,N-di(chloroacetyl)amino derivatives are still possible rebridging candidates. Thus, 
ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) was reacted with 
reduced glutathione.  
Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) was dissolved in THF 
and added gradually to glutathione aqueous solution. The reaction was held overnight at 
room temperature. Acetamide-glutathione adducts were purified using C-18 column. 
Only mono glutathione-adduct (hydrolysis of the second chloroacetamide arm) was the 
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obtained product (4.13). We proposed that the rate of thiol alkylation (k2) is faster than 
the rate of hydrolysis (k1). However, we were not able to identify the order of these 
reactions. Moreover, the final separated product 4.13 could be possibly formed as a 
result of the hydrolysis of the 4.14 conjugate (Figure 4.14). 
 
Figure 4.14. The proposed mechanisms of hydrolysis of compound 4.11 in the presence of glutathione 
under aqueous conditions to afford the mono-glutathione conjugate 4.13.  
Given the instability of ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) 
and possibly its alkylated products in aqueous buffer, it was concluded that these 




4.4 Aryl bis-haloacetamide derivatives as rebridging linkers 
As it is not possible to utilise N,N-di-(chloroacetyl)-amido derivatives as disulfide 
rebridging agents, and considering the observed aqueous stability of the α-
haloacetamide derivative 4.12, we next sought to investigate aryl bis-haloacetamides as 
an alternative scaffold for rebridging of the reduced inter-chain disulfide bonds of 
mAbs.  
α-Haloacetamide derivatives have previously been reported as DNA-cross-linkers. 
Tabone et al. have evaluated oligodeoxynucleotides-bearing an α-haloacetamide as 
DNA-cross-linkers. Various factors addressing the extent of DNA cross-linked by the 
haloacetamide-bearing oligodeoxynucleotides have been addressed, including the 
reactivity of the halogen. They  found that the best cross-linking yields were associated 
with α-bromoacetamide derivatives.162 Later, a series of bis-bromoacetyldiamines were 
evaluated as electrophiles, which cross-link DNA complementary strands via alkylation 
of deoxyguanosine bases (Figure 4.15). Of these electrophiles, the N,N'-bis-
bromoacetyl-1,2-diaminebenzene (4.29) displayed higher yields of cross-linking of 
complementary DNA strands, the proposed mechanism of cross-linking 
oligodeoxynucleotides strands using N,N'-bis-bromoacetyl-1,2-diaminebenzene (4.29) is 
shown in Figure 4.15.163 
 
Figure 4.15. The mechanism of cross-linking reaction between complementary oligodeoxynucleotides  
strands using N,N'-bis-bromoacetyl-1,2-diaminebenzene (4.29),   which was selective for the 
complementary N7 of 2-deoxyguanosine. 
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Herein, we sought to evaluate aryl bis-haloacetamide derivatives as disulfide bond 
rebridging linkers that may operate according to the method shown in Figure 4.16. 
 
Figure 4.16. Our proposed approach of rebridging of reduced inter-chain disulfide bonds of mAb using 
bis-haloacetamide linkers. 
4.4.1 Synthesis of the aryl bis-haloacetamide derivatives 4.15 and 4.16 
Bis-haloacetamide derivatives 4.15 and 4.16 were synthesised by N-acetylation of the 
corresponding di-amines using 2-chloroacetyl chloride at room temperature for 2 h to 
give the products 4.15 and 4.16 in yields of 89% and 79%, respectively.  
 
4.4.2 The aqueous stability of bis-haloacetamide  
With both bis-haloacetamide derivatives 4.15 and 4.16 in hand, it was necessary to 
evaluate their stability under the typical conjugation conditions (aqueous buffer) and in 
the presence of reducing agents (such as TCEP). As shown previously, stability of ethyl 
4-(2-chloroacetamido)benzoate (4.12) in aqueous buffer was studied using 1H NMR 
over 4 days and found to be stable (Figure  4.11).  
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Following the 1H NMR solvent suppression method used for compound 4.12, the 
aqueous stability of both methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) and methyl 
3,4-bis(2-chloroacetamido)benzoate (4.16) aqueous stability was appraised in phosphate 
buffer (100 mM, pH 7.5) containing 30% DMF-d7. The stability of 4.15 and 4.16 were 
assessed by following the change in integrals of α-methylene protons at δ 4.43 ppm (2 x 
ClCH2CONH) (Figure 4.17 A and B). 
 
 
Figure 4.17. Stability of bis-chloroacetamide linkers in aqueous buffer. A) 
1
H NMR spectrum of methyl 
3,5-bis(2-chloroacetamido)benzoate 4.15 (1.00 mg/ml, 3.14 mM) and B) methyl 3,4-bis(2-
chloroacetamido)benzoate 4.16 (1.00 mg/ml, 3.14 mM) in aqueous phosphate buffer over 4 days. Arrows 






Both methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) and methyl 3,4-bis(2-
chloroacetamido)benzoate (4.16) were found to be relatively stable in aqueous buffer, 
with less than 20% hydrolysis observed within 24 h. Methyl 3,5-bis(2-
chloroacetamido)benzoate (4.15) showed superior aqueous stability over methyl 3,4 -
bis(2-chloroacetamido)benzoate (4.16) with the results plotted in (Figure  4.18). 









































Figure 4.18. Percentage remaining of haloacetamide 4.12 (1.00 mg/ml, 4.15 mM), 4.15 (1.00 mg/ml, 3.14 
mM) and 4.16 (1 mg/ml, 3.14 mM) over 4 days. Stability was determined in phosphate buffer (100 mM, 
pH 7.5) containing 10-30% DMF-d7. % of remaining was calculated by measuring the change in the 
integration of α-methylene using 
1
H NMR solvent suppression method. 
4.4.3 The aqueous stability of aryl bis-haloacetamides in the presence of TCEP 
As the primary sought-after use of these bis-haloacetamide linkers is the rebridging of 
reduced cysteine residues that were paired up in disulfide bonds and as phosphines 
reductants, such as the water soluble TCEP (2.2) are broadly used as reductants in 
protein conjugation, we set out to evaluate the stability of Methyl 3,5-bis(2-
chloroacetamido)benzoate (4.15) in presence of TCEP (2.2).  
As such, methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) was incubated with 3 equiv. 
of TCEP in Tris.HCl buffer and held at room temperature. 1H-NMR spectra were 
acquired after 12 and 24 h and it was observed that methyl 3,5-bis(2-
chloroacetamido)benzoate (4.15)  reacted with TCEP (2.2), as the signal at δ 4.21 ppm 
corresponding to α-methylene protons (2 x ClCH2CONH) had disappeared over time.  
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In order to follow the rate of the reaction, next both TCEP (2.2) and Methyl 3,5-bis(2-
chloroacetamido)benzoate (4.15) were held together and in phosphate buffer (pH 7.5). 
1H-NMR spectra were acquired every 30 minutes (Figure 4.19 A). The half-life of 3,5-
bis(2-chloroacetamido)benzoate (4.15) in presence of TCEP (2.2) was found to be 108.3 
minutes (Figure 4.19 B). 
 



























Figure 4.19. Stability of methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) in presence of TCEP (2.2). A) 
1
H NMR spectrum of methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) in presence of TC2P (2.2, 3 
equiv.) in aqueous phosphate buffer, arrows indicate the followed disappearance of signal peak at δ 4.21 
ppm of α-methylene protons and appearance of signal peaks at δ 2.5 ppm to obtain the reactivity rate. B) 
Percentage remaining of methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) (1.00 mg/ml, 3.14 mM) in 





A preparative scale reaction was then performed to characterise the product of the 
reaction between TCEP (2.2) and methyl 3,5-bis(2-chloroacetamido)benzoate (4.15). 
Methyl 3,5-bis(2-chloroacetamido)benzoate in THF was added gradually to a solution of 
TCEP in phosphate buffer (pH 7.5) and held overnight (room temperature). The reaction 
was purified using a C-18 reverse column to give the TCEP adduct (Figure 4.20 A), 
which was characterised using NMR (1H, 13C, MS and IR (absence of distinctive peak 
of C=P, usual range of 1180−1230 cm−1) (Figure 4.20 B). 
 
 
Figure 4.20. A) acetamide-TCEP adduct. B) IR spectrum of acetamide-TCEP adduct confirming the 







The confirmed instability of the bis-chloroaceatmide 4.15 in the presence of TCEP 
demonstrates the necessity of employing our azide quenching method developed in 
Chapter 2. 
4.4.4 Investigation of the reactivity of methyl 3,5-bis(2-chloroacetamido)benzoate 
(4.15) and methyl 3,4-bis(2-chloroacetamido)benzoate (4.16) towards reduced 
glutathione 
Having determined previously that the bis-chloroaceatmides 4.15 and 4.16 were both 
relatively stable under aqueous conditions, we next sought to determine their reactivity 
towards glutathione.  
As such, methyl 3,5-bis(2-chloroacetamido) benzoate (4.15) and methyl 3,4-bis(2-
chloroacetamido) benzoate (4.16) were treated with GSH (6 equiv.) in phosphate buffer 
at pH 7.5 containing 10% DMF-d7 and the rates of reaction were calculated using 
1H 
NMR spectroscopy (solvent suppression method) based on the disappearance from the 
signal of acetamide protons (2 x ClCH2CONH) at δ 4.3 ppm and the appearance of a 
signal at δ 3.46 ppm which corresponds to the acetamide-glutathione product. The 
percentage remaining of each linker was determined using ratio of integration of the 
peak at δ 4.3 ppm to the sum of integration of the peaks at δ 4.3 and 3.46 ppm. Reaction 
rates of acetamide linkers with GSH were calculated by fitting to a first-order kinetic 
equation to natural log transformed percent remaining data (Equation 4.1). The half-life 
of the bis-acetamide linkers in the presence of glutathione was calculated using 
Equation 4.2.140 
                                                                    (Equation 4.1) 
                                                                                                  (Equation 4.2) 
The rates of reaction of methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) and methyl 
3,4-bis(2-chloroacetamido)benzoate (4.16) with GSH were calculated to be 0.009 and 
0.04 min-1, respectively (Figure 4.21). The calculated half-lives of reaction of methyl 
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3,5-bis(2-chloroacetamido)benzoate (4.15) and methyl 3,4-bis(2- chloroacetamido) 
benzoate (4.16) were 50 and 23 minutes, respectively.  








































Figure 4.21. Percentage remaining of methyl 3,5-bis(2-chloroacetamido)benzoate 4.15 (1.00 mg/ml, 3.14 
mM) and methyl 3,4-bis(2- chloroacetamido) benzoate 4.16 (1.00 mg/ml, 3.14 mM) in presence of GSH 
(5.79, 18.8 mM, 6 equiv.) in phosphate buffer (100 mM, pH 7.5). 
Interestingly, the differences in regiochemistry of the acetamide groups relative to each 
other on the benzene ring (ortho- and meta-positions) showed a significant difference in 
both aqueous stability and reaction rates with glutathione. One possible explanation for 
such differences is the 3D structures of each compound. Methyl 3,5-bis(2-
chloroacetamido)benzoate (4.15) is predicted to have a planar conformation (Figure 
4.22 A). Thus, steric hindrance could slow the backside attack of thiolate at the carbon 
attached to halogen (through an SN2 mechanism) mainly in methyl 3,5-bis(2-
chloroacetamido)benzoate (4.15) compound. This might explain the greater reactivity of 
methyl 3,4-bis(2-chloroacetamido)benzoate (4.16) which is not planar and might afford 





Figure 4.22. A) 3D structure of methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) showing its planner 
conformation. B) 3D structure of methyl 3,4-bis(2-chloroacetamido)benzoate (4.16) showing its non-
planner conformation allowing better backside attack of thiolate anion at the α-methylene carbon (2 x 
ClCH2CONH) attached to halogen (green).  
4.4.5 Aqueous stability of the glutathione conjugates (4.17-4.19) in buffer 
As a major drawback of the well-known maleimide-based conjugation approach is the 
susceptibility of the reaction products to retro-Michael reactions and their associated 
poor plasma stability, we sought to determine the aqueous stability of our glutathione-
acetamide conjugates. To this end, both bis-glutathione conjugates 4.17 and 4.18 were 
prepared on a larger scale, purified using a C-18 reverse column and fully characterised 





The stability of these glutathione-conjugates was then evaluated in 100 mM phosphate 
buffer at pH 7.4 using HPLC-UV over 4 weeks and compared against the glutathione-
Mal conjugate 4.19. Both of the conjugates were found to be more stable at room 
temperature over 4 weeks compared to glutathione-Mal conjugate (77% remain after 4 
weeks). 
 
A further stability test was then carried out under similar conditions (pH 7, 4 weeks) in 
the presence of DTT (50 mM) to imitate nucleophiles found under plasma conditions. 
The overall stability of glutathione-conjugates were slightly reduced in the presence of 
DTT. Furthermore, Mal-glutathione was found to be the least stable conjugate (Figure 
4.21 A). Unfortunately, a direct comparison of Mal-glutathione with the bis-acetamide-
glutathione conjugates was not possible due to the presumed formation of a DTT-
maliemide adduct interfering  with HPLC analysis. Therefore, the stability of Mal-
glutathione in the presence of DTT was further analysed using 1H NMR which showed 
approximately more than 50 % loss over the four weeks (Figure 4.23 B). 
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3.5-glutathione (4.17) with DTT
3.4-glutathione (4.18) with DTT
 
 
Figure 4.23. A) Percent remaining of glutathione-conjugates (1.0 mg/ml, 1.2 mM) in the presence and 
absence of DTT (50 mM) over 4 weeks in aqueous phosphate buffer (100 mM, pH 7). Data presented as 
mean± SD of three independent samples. B) 
1
H NMR spectrum analysing the stability of Mal-glutathione 
(1.0 mg/ml, 2.3 mM) in the presence of DTT over the four weeks (28 days). Arrows indicated the 







4.5 The synthesis and evaluation of bis-bromo- and bis-iodo-acetamide 
derivatives 
Bromides and iodides are known to be better leaving groups than chlorides, therefore, 
bromo- and iodo-acetamide derivatives undergo faster substitution reactions. As such, 
we next set out to synthesise bromo- and iodo-acetamide derivatives and to evaluate 
their aqueous stability and reactivity with reduced glutathione and compare these 
compounds to the corresponding chloride derivatives. 
Ethyl 4-(2-bromoacetamido)benzoate (4.20) was synthesised by N-acetylation of 
benzocaine with 2-bromoacetyl bromide (2.2 equiv.) at room temperature for 2 h (69% 
yield). Ethyl 4-(2-iodoacetamido)benzoate (4.21) was synthesised by refluxing Ethyl 4-
(2-chloroacetamido)benzoate (4.12) with KI in dry acetone for 3 h (90% yield) (Figure 
4.24).  
 
Figure 4.24. Chemical synthesis of ethyl 4-(2-bromoacetamido)benzoate (4.20) and ethyl 4-(2-
iodoacetamido)benzoate (4.21). a) TEA, DCM, 2 h. b) KI, dry acetone, reflux, 3h. 
The aqueous stability of ethyl 4-(2-bromoacetamido)benzoate (4.20) and ethyl 4-(2-
iodoacetamido)benzoate (4.21) were then determined in phosphate buffer (pH 7.5) 
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containing 30% DMF-d7 using a similar 
1H-NMR solvent suppression method as 
described earlier.  
The stability of 4-(2-bromoacetamido)benzoate (4.20) and ethyl 4-(2-
iodoacetamido)benzoate (4.21) were assessed by following the change in integration of 
α-methylene protons at δ 4.10 ppm (BrCH2CONH) and at δ 3.99 ppm (ICH2CONH), 
respectively. Both ethyl 4-(2-bromoacetamido)benzoate (4.20) and ethyl 4-(2-
iodoacetamido)benzoate (4.21) found to be stable as no change in the integration of  α-
methylene protons was displayed after 4 days, along with no clear hydrolysis peak being 
observed (Figure  4.25 A and B). The observed aqueous stability results are comparable 
to the earlier observed aqueous stability of ethyl 4-(2-chloroacetamido)benzoate (4.12) 
(Figure  4.11).  
To investigate the impact of regiochemistry, methyl 3,5-bis(2-haloacetamido)benzoate 
and methyl 3,4-bis(2-haloacetamido)benzoate derivatives 4.22-4.25 were synthesised 
using similar methods to those described earlier for the synthesis of the mono-
haloacetamide derivatives 4.20 and 4.21. The aqueous stability of compounds 4.22-4.25 
were then determined using a similar 1H NMR method used for the mono-haloacetamide 






Figure 4.25. Stability of haloacetamide 4.20 and 4.21 in aqueous buffer. A) 
1
H NMR spectrum of ethyl 4-
(2-bromoacetamido)benzoate 4.20 (1.00 mg/ml, 3.51 mM) in phosphate buffer over 4 days. Arrow 
indicates the signals that were followed at δ 4.10 ppm for acetamide proton (BrCH2CONH) over 4 days. 
B) 
1
H NMR spectrum of ethyl 4-(2-iodoacetamido)benzoate (4.21) (1 mg/ml, 3 mM) in phosphate buffer 
over 4 days, arrow indicates the signals that were followed at δ 3.99 ppm for acetamide protons 





Both of the meta-substituted linkers, methyl 3,5-bis(2-bromoacetamido)benzoate (4.22) 
and methyl 3,5-bis(2-iodoacetamido)benzoate (4.24), were found to be very stable over 
4 days as no hydrolysis peaks were observed. On the other hand, the ortho substituted 
derivatives methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) and methyl 3,4-bis(2-
iodoacetamido)benzoate (4.25) were found to be less stable under the same conditions. 
The percent (%) of remaining of methyl 3,5-bis(2-haloacetamido)benzoate and methyl 
3,4-bis(2-haloacetamido)benzoate derivatives 4.22-4.25 were determined by following 
the change in the integration of acetamide protons at δ 4.27 ppm (BrCH2CONH) for 
bromo-acetamide derivatives and at δ 3.95 ppm (ICH2CONH) for iodo-acetamide 
derivatives (Figure 4.26). 
Ethyl 4-(2-haloacetamido)benzoate derivatives were very stable over time in aqueous 
phosphate buffer. The meta-substituted methyl 3,5-bis(2-haloacetamido)benzoate 
derivatives 4.15, 4.22 and 4.24 showed high  aqueous stability in phosphate buffer with 
only a slight decrease in the stability of bromo-and iodo-derivatives in comparison to the 
chloro-derivative. The percentage remaining of 4.15, 4.22 and 4.24 after 4 days was 
found to be 98%, 80% and 90%, respectively. On the other hand, the ortho-substituted 
methyl 3,4-bis(2-haloacetamido)benzoate derivatives 4.16, 4.23 and 4.15 showed 
reduced aqueous stability in phosphate buffer with a considerable decrease in the 
stability of the bromo-and iodo-derivatives in comparison to the chloro-derivative. The 
percentage remaining of 4.16, 4.23 and 4.25 after 4 days were found to be 70%, 25% 
and 20%, respectively (Figure 4.26). 
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Figure 4.26. Comparison of the aqueous stability of haloacetamide derivatives 4.12, 4.15, 4.16, and 4.20-
4.25 over 4 days. Stability was determined in phosphate buffer (100 mM, pH 7.5) in the presence of 10% 
DMF-d7 using 
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4.5.1 Determination of the reactivity of methyl 3,5-bis(2-haloacetamido)benzoate 
(4.22 and 4.24) and methyl 3,4-bis(2-haloacetamido)benzoate (4.23 and 4.25) 
towards glutathione 
Next, we sought to measure the reaction rates of ethyl 4-(2-bromoacetamido)benzoate 
(4.19) and ethyl 4-(2-iodoacetamido)benzoate (4.20) towards glutathione in phosphate 
buffer (pH 7.5) containing 10% DMF-d7 using the 
1H NMR method employed 
previously. In both cases, the glutathione alkylation reactions were found to be 
completed within 3 minute when 3 equiv. of glutathione was employed. Therefore, 
direct comparison with ethyl 4-(2-chloroacetamido)benzoate (4.9) using 3 equiv. of 
GSH was not possible as the reaction rates could not be measured.  
As such, lower equivalent of glutathione (1.1 equiv.) was then employed to measure the 
reaction rates of 4.19 and 4.20. The reaction rates were calculated based on the 
disappearance of the peak from acetamide protons (XCH2CONH) and the appearance of 
a peak at δ 3.43 ppm which corresponds to the formed acetamide-glutathione adduct 
(Figure  4.27 A and B). The percentage remaining of each linker was determined using 
ratio of integral of the acetamide peak to the sum of integral of acetamide peaks and the 
peak at 4.01 or 3.8 ppm. Reaction rates of acetamide linkers 4.19 and 4.20 with 
glutathione were calculated by fitting to a first-order kinetic equation to natural log 
transformed percent remaining data (Equation 4.1). The half-life of acetamide linkers 
4.19 and 4.20 in the presence of glutathione was then calculated using Equation 4.2. 
Both ethyl 4-(2-bromoacetamido)benzoate (4.20) and ethyl 4-(2-
iodoacetamido)benzoate (4.21) showed similar rates of reaction with glutathione and 
their half-lives in the presence of glutathione (1.1 equiv.) were both 0.75 minutes. By 
comparison, the half-life of ethyl 4-(2-chloroacetamido)benzoate (4.9) in the presence of 






Figure 4.27. Study of reactivity of ethyl 4-(2-bromoacetamido)benzoate (4.19) and ethyl 4-(2-
iodoacetamido)benzoate (4.20) towards glutathione. 
1
H NMR spectrum of A) ethyl 4-(2-
bromoacetamido)benzoate 4.19 (1.00 mg/ml, 3.51 mM) and B) ethyl 4-(2-iodoacetamido)benzoate (4.20)  
(1 mg/ml, 3 mM) in the presence of glutathione (1.1 equiv.) in aqueous phosphate. Arrow indicates the 
followed acetamide peaks at δ 4.02 ppm for bromo-acetamide or at 3.86 ppm for iodo-acetamide and at 










































Figure 4.28. Percentage remaining of ethyl 4-(2-chloroacetamido)benzoate (4.12) (1.00 mg/ml, 4.15 mM) 
in the presence of glutathione (3 equiv.); ethyl 4-(2-bromoacetamido)benzoate 4.20 (1.00 mg/ml, 3.51 
mM) and ethyl 4-(2-iodoacetamido)benzoate 4.21 (1 mg/ml, 3 mM) in presence of glutathione (1.1 
equiv.)  in phosphate buffer (100 mM, pH 7.5). 
The rates of reaction of methyl 3,5-bis(2-bromoacetamido)benzoate (4.22), methyl 3,5-
bis(2-iodoacetamido)benzoate (4.24), methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) 
and  methyl 3,4-bis(2-iodoacetamido)benzoate (4.25) with glutathione (2.2 equiv.) were 
not measurable using the 1H NMR method, as complete thiol alkylation occurred within 
the first 3 minutes of the addition of these linkers to the aqueous solution of glutathione.  
With the aqueous stability and glutathione reactivity of our linkers in hand, the 
following Sections set out to evaluate the impact of other chemical factors on their 
reactivity. 
4.5.2 The synthesis and evaluation of N-benzyl-2-haloacetamide derivatives 
Next, we aimed to study the importance of direct attachment of the acetamide to the 
conjugated system (aryl amides), and evaluate if benzyl amides (alkyl amides) share 
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similar stability and reactivity characteristics. To this end, the stability and glutathione 
reactivity of benzyl derivatives, N-benzyl-2-chloroacetamide (4.26) and N-benzyl-2-
bromoacetamide (4.27) were appraised using a similar 1H NMR method described 
previously and the rates of reaction of those linkers with glutathione (and half-lives) 
were calculated using Equation 4.1 and 4.2.  
 
It was found that N-benzyl-2-chloroacetamide (4.26) and N-benzyl-2-bromoacetamide 
(4.27) demonstrated good aqueous stability under the same evaluated conditions (4 days, 
room temperature, pH 7.5). However, 4.26 and 4.27 were found to be significantly less 
reactive with glutathione in comparison to ethyl 4-(2-chloroacetamido)benzoate (4.14) 
and ethyl 4-(2-bromoacetamido)benzoate (4.20) (Figure  4.29 and Table 4.1).  
One can conclude from these results that aryl amides are more reactive towards 
glutathione (thiolate group) than alkyl amide derivatives. Therefore, we intended to 
carry on our further investigation of haloacetamide linkers focusing on aryl amides 
derivatives.  
The difference in the reaction rates of the haloacetamide group between the aryl amides 
and alkyl amides towards glutathione have been studied by J st et al., where they 
investigated the impact of 11 moieties attached to different electrophiles (α-
haloacetamide being amongst them) and how the substituents affected their reactivity 
towards glutathione and inhibitory activity towards certain enzymes. Both aromatic and 
benzylic amides were among the moieties tested. The aryl amides showed superior 
reactivity rate with glutathione while benzylic amides were not reactive under the tested 






































Figure 4.29. Percentage remaining of ethyl 4-(2-chloroacetamido)benzoate 4.12 (1.00 mg/ml, 4.15 mM) 
and N-benzyl-2-chloroacetamide 4.26 (1.00 mg/ml, 5.47 mM) in presence of glutathione (3 equiv.); ethyl 
4-(2-bromoacetamido)benzoate 4.20 (1.00 mg/ml, 3.51 mM) and N-benzyl-2-bromoacetamide 4.27 (1.0 
mg/ml, 4.4 mM) in presence of glutathione (1.1 equiv.) in aqueous phosphate buffer (100 mM, pH 7.5). 
The employed lower equivalent of glutathione (1.1 equiv.) precludes the completion of the reaction 
observed with 4.27 linker. 














) 0.01 0.1 0.1 0.004 0.02 
Half Life (minutes) 33.01 0.7537 0.7538 54.43 1.54 
glutathione 
(equivalent) 
3 1.1 1.1 3 1.1 
 
4.5.3 The impact of aryl substitution on the aqueous stability and reactivity of 
bis-haloacetamide linkers towards glutathione 
Given that aryl acetamide derivatives are more reactive linkers, next we set out to 
further investigate the impact of aryl substitution on the stability and reactivity of bis-
haloacetamide linkers (aryl amides). 
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As shown in previous Sections of this Chapter, aryl bis-haloacetamide linkers bearing an 
ester substituent were proposed as rebridging cross-linkers of reduced disulfide bonds. 
In this Section, we wanted to appraise the impact of aryl substitution (ester group) on 
the stability and reactivity of bis-haloacetamide linkers by directly comparing them to 
the non-substituted aryl bis-haloacetamide linkers 4.28-4.31. 
 
As such, N,N'-(1,3-phenylene)bis(2-haloacetamide) (4.28 and 4.30) and N,N'-(1,2-
phenylene)bis(2-haloacetamide) (4.29 and 4.31) linkers were synthesised using similar 
methods to the methods described earlier to synthesis analogous ester derivatives 4.22-
4.25. Both aqueous stability and reactivity of N,N'-(1,3-phenylene)bis(2-haloacetamide) 
and N,N'-(1,2-phenylene)bis(2-haloacetamide) derivatives towards glutathione were 
carried out using similar 1H NMR methods as described earlier. 
N,N'-(1,3-phenylene)bis(2-chloroacetamide) 4.38 and N,N'-(1,2-phenylene)bis(2-
chlorocetamide) 4.39 showed a greater aqueous stability in comparison to the bromo- 
and iodo-analogues. The N,N'-(1,3-phenylene)bis(2-haloacetamide) and N,N'-(1,2-
phenylene)bis(2-haloacetamide) derivatives 4.28-4.31 were found to be more reactive 
towards glutathione compared to chloro-analogues. Similar to the results for 4.22-4.25 
(aryl bis-haloacetamide linkers bearing an ester substituent), meta-substituted acetamide 
linkers 4.28 and 4.30 showed higher hydrolytic stability and lower reactivity rates with 
glutathione in comparison to ortho-substituted acetamide linkers 4.29 and 4.31 (Figure 
30 A and B). 
One can conclude that the rates of hydrolysis and rates of reaction of ester-substituted 
bis-haloacetamide linkers (both ortho- and meta-substituted haloacetamide) 4.22-4.25 
towards glutathione have slightly increased in comparison to the non-substituted bis-
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haloacetamide linkers 4.28-4.31. The observed results can be attributed to the impact of 
the electron withdrawing effect of the carbonyl group (CO) directly linked to the 
aromatic ring. Nevertheless, this negligible impact of the presence of ester functionality 
on reactivity of aryl bis-haloacetamide linkers permits the attachment of a ‗clickable‘ 
handle to them, such as an azide group (see Section 4.6) or other required functionality, 
with no impairment of the aqueous stability or reaction rates with thiolates (such as 
glutathione). 
 
4.6 Aryl bis-haloacetamide linkers bearing azide group 
Having studied the aqueous stability and reactivity of bis-haloacetamide linkers towards 
glutathione, we next set out to investigate a bis-haloacetamide based rebridging 
approach and expand its application. Given that the chief use of bis-haloacetamide 
rebridging chemistry is to construct ADCs (as discussed earlier in Section 4.1), we set 
out to synthesise and evaluate bis-haloacetamides bearing an azide group, which can be 
subsequently used in a cross-coupling reaction with alkyne group (‗Click‘ reaction, see 
Section 1.6.2). There are a huge number of therapeutics and imaging applications which 
could be made available through the use ‗Click‘ chemistry to selectively link a cytotoxic 













Figure 4.30. A) Percentage remaining of the N,N'-(1,3-phenylene)bis(2-haloacetamide) and N,N'-(1,2-phenylene)bis(2-haloacetamide) derivatives over 4 days. 
Stability was determined in phosphate buffer (100 mM, pH 7.5) containing 10% DMF-d7 using 
1
H NMR solvent suppression method. B) Percentage remaining of 
the N,N'-(1,3-phenylene)bis(2-haloacetamide) and N,N'-(1,2-phenylene)bis(2-haloacetamide) derivatives  in the presence of glutathione (1.1 equiv.) in aqueous 
phosphate buffer (100 mM, pH 7.5). We were unable to be measured the rates of 4.31 using the 
1
H NMR method as complete thiol alkylation occurred within the 
first 3 minutes of the addition of these linkers to the aqueous solution of glutathione.  
A) B) 

















































































4.6.1 Synthesis of azide containing aryl bis-haloacetamide linkers  
In order to introduce an azide functionality to our bis-haloacetamide linkers, an azide-
containing spacer of polyethylene glycol was initially synthesised as these are known to 
be water soluble derivatives of hydrocarbons. As such, Synthesis of 2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethan-1-amine (4.46) was achieved over 3 steps with 40% 
yield starting from tetraethyleneglycol (2.19) (Figure  4.31).  
Firstly, tosylation reaction of tetraethyleneglycol (2.19) was achieved using 4-
toluenesulphonyl chloride, overnight (85% yield). Then, 1,11-diazido-3,6,9-
trioxaundecane (2.11) was synthsised through a substitution reaction with NaN3 (82% 
yield). Lastly, a selective reduction to the mono-amine using triphenylphosphine (Ph3P) 
was performed to obtain 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine 4.46 
(56% yield) (Figure 4.31). 
 
Figure 4.31. Synthesis of 2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine (4.46). a) 4-
toluenesulphonyl chloride, pyridine, DMC, b) NaN3, acetone/water (3:1),37 , o/n, c) Ph3P, 5% HCl. 
Then, synthesis of N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-
1,2-phenylene)bis(2-iodoacetamide) (4.35) was achieved over 4 steps. Starting with 
acetylation of 3,4-diaminobenzoic acid using 2-chloroacetyl chloride (90% yield), 
followed by synthesis of activated ester using N-hydroxysuccinimide (45% yield). In the 
following step the activated ester (4.45) was reacted with 2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethan-1-amine (4.46)  for 1 h (40% yield) to attain N,N'-(4-
((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-
iodoacetamide) (4.37), and finally it was converted to iodo-derivatives by reflux with KI 




phenylene)bis(2-iodoacetamide) (4.33) was achieved using the same 4 steps described 
with 28% overall yield. 
 
Figure 4.32. Synthesis of N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-
phenylene)bis(2-iodoacetamide) (4.35). a) ClCOCH2Cl, THF, b) NHS, EDC.HCl, THF, c) 2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethan-1-amine, THF, d) KI, dry acetone, reflux, 3 h. 
In order to synthesise  the bromo-derivative N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-bromoacetamide) 
(4.34), an analogous pathway was followed from N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-chloroacetamide) 
(4.37) using KBr. However, the rate of the reaction was lower, with only 75% of chloro-
derivative (4.37) converted to the bromo-derivative (4.34) after refluxing for 2 days 
(confirmed by 1H NMR). Therefore, for complete conversion of the chloro-derivative 
(4.37) to the desired bromo-derivative (4.34), reflux of the reaction with KBr was held 




Figure 4.33. Synthesis of N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-
phenylene)bis(2-bromoacetamide) (4.34). a) KBr, dry acetone, reflux, 4 days. 
N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-
bromoacetamide) (4.32) was synthesised using the same KBr reflux method for 4 days 
with 51% yield.  
4.6.2 Stability and GSH reactivity of azide-bearing bis-haloacetamide linkers 
N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-
haloacetamide) and N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-
1,3-phenylene)bis(2-haloacetamide) derivatives 4.32-4.35 stability was determined in 
phosphate buffer at pH 7.5 containing 10% DMF-d7 using a similar 
1H-NMR solvent 
suppression method the described previously. 1H-NMR spectra were acquired at time 0, 
24, 48 and 96 h. Over four days, all azide-bearing linkers were stable with less than 15 
% overall hydrolysis (Figure 4.34). Overall, amide-based linkers (4.32-4.35) displayed 
excellent aqueous stability to compared to the ester-substituted bis-haloacetamide 
linkers (4.22-4.25) (Figure 4.34). It is worthwhile mentioning that the presence of 
(PEG)3 also significantly increased the aqueous solubility of 4.32-4.35 linkers as only 

















































Figure 4.34. Comparison of the aqueous stability of aryl bis -haloacetamide linkers. Percentage remaining 
of the bis-haloacetamide derivatives (4.22-4.25 and 4.32-4.35) over 4 days. Stability was appraised in 
phosphate buffer (100 mM, pH 7.5) with final concentration of 10% DMF-d7 using solvent suppression 
method. 





haloacetamide) linkers 4.32-4.35 with glutathione (2.2 equiv.) in phosphate buffer (pH 
7.5) containing 10% DMF-d7. All bis-haloacetamide bearing azide group 4.32-4.35 
reacted readily with glutathione within less than 10 min (Figure 4.35).  
Similar to 4.22-4.25 (aryl bis-haloacetamide linkers bearing an ester substituent), meta-
acetamide linkers 4.32 and 4.33 showed higher aqueous stability and lower reactivity 
rates with glutathione in comparison to ortho-acetamide linkers 4.34 and 4.35. 








































Figure 4.35. Percentage remaining of the bis-haloacetamide derivatives 4.32 and 4.43 (1.0 mg/ml, 1.7 
mM), 4.33 and 4.35 (1.00 mg/ml, 1.45 mM) in the presence of glutathione (1.1 equiv.) in aqueous 




All the aryl bis-haloacetimide derivatives tested showed very rapid thiolate alkylation 
reaction rates with glutathione [less than 20 minutes for the slowest non-substiteted bis-
haloacetamide derivatives (4.28-4.31)]. The aryl bis-haloacetimides bearing ester group 
found to be very reactive and we were unable to measure the reaction rates with 
glutathione using the 1H NMR method. On the other hand, aryl bis-haloacetimides 
bearing an amide group were found to be slightly less reactive, which can be partly 
attributed to the smaller inductive effect of the N atom (CONH), while the steric 
influence of the bulky (PEG)3 group could also attribute to the slower reaction rates with 
glutathione (Table 4.2). 
In conclusion, in this Chapter, we were able to synthesise and evaluate the stability and 
glutathione reactivity of alkyl and aryl bis-haloacetamide linkers. We found that aryl 
bis-haloacetamide linkers are the most reactive towards thiolate alkylation. Different 
parameters were addressed in this Chapter, including the regiochemistry of the 
haloacetamide groups relative to each other and aryl substitution. Both meta- and ortho- 
aryl bis-haloacetamide linkers are reactive towards glutathione and relatively stable in 
aqueous buffer. Both bis bromo-and iodo-acetamide linkers have similar aqueous 
stability and reactivity profile towards thiolate alkylation of glutathione. Aryl 
substitution has not significantly affected the reactivity rates, which enabled us to 
synthesise and evaluate aryl bis-haloacetamide linkers bearing azide group.  
Lastly, we synthesised glutathione conjugates of aryl bis-haloacetamide derivatives, and 
studied the stability of bis-glutathione conjugates in aqueous buffer and in the presence 
of DTT over 4 weeks. We found that the constructed conjugates are very stable in the 
presence and the absence of DTT, we can conclude that the various aryl bis-
haloacetamide linkers provided in this Chapter hold promising advantages over the 
available conjugation approaches. Therefore, these linkers, summarised in Table 4.2, 






Table 4.2. Summary of the aqueous stability and glutathione reactivity of aryl bis -haloacetamide linkers.  
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within 3 minutes 
78% remains 
unhydrolysed 













































5 Rebridging of reduced disulfide bonds of monoclonal antibodies 
using bis-haloacetamide linkers  
5.1 Introduction 
The monoclonal antibody therapeutic Trastuzumab (Tmab) was approved by FDA in 
1998 for HER2 positive breast cancer patients.167 HER2 overexpression or gene 
amplification has been found in approximately 20–30% of breast cancer patients, which 
is referred to as the HER2 positive subtype.57 
Trastuzumab is a recombinant humanized mAb which binds with high affinity to the 
extracellular domain of the HER2 receptor. It was the first approved biological 
therapeutic drug for the treatment of the HER2 positive subtype. It is widely 
acknowledged that using trastuzumab, either as a single agent therapy or in combination 
with conventional chemotherapy, has produced remarkable clinical benefits as it has 
significantly improved the prognosis and increased the survival of HER2 subset of 
breast cancer patients.168,169 
5.1.1 The HER2 receptor 
HER2 is a 185-kDa receptor that belongs to the HER family (HER-1-4). HER family of 
receptors are transmembrane receptors with embedded tyrosine kinases. These receptors 
have 3 main domains: extracellular ligand binding domain, a transmembrane domain 
and (apart from HER-3) an intracellular tyrosine kinase domain that interacts with 
multiple intracellular signaling molecules. The intracellular tyrosine kinase domains are 
triggered by both homo- and hetero-dimerization, which is mainly induced by specific 
ligands binding to the extracellular domain.170–172 
HER2 is unique among HER family receptors and is known as an ‗orphan receptor‘, 
because it has no known endogenous ligand. HER2 can adopt the active conformation 
without ligand binding when it homo- or hetero-dimerises with another HER2 or one of 
the other HER family receptors, leading to autophosphorylation of tyrosine residues 
within their intracellular domain. Active HER2 receptors modulate a number of 
signaling pathways, in particular PI3K/AKT and RAS/MEK/MAPK pathways that are 
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involved in cell proliferation, differentiation and survival of both normal and malignant 
breast cells (Figure 5.1).173 
Clinically, cancer drug therapy for the HER2 positive subtype of breast cancer patients 
can be classified into two major groups: Humanized monoclonal antibodies directed 
against the HER2 extracellular domain (Trastuzumab), or against HER2 dimerization 
(Pertuzumab); and or a drug molecule against the tyrosine kinase domain 
(Lapatinib).174,175 
 
Figure 5.1. HER2 signaling pathways in breast cells and the site of action of the currently available anti-
HER2 receptors drugs . Trastuzumab mAb binds and blocks the extracellular domain of HER2, in 
particular domain IV, while Pertuzumab inhibits dimerization of HER2 receptor by binding to domain II 




5.1.2 Mechanism of action of Trastuzumab  
Interaction of Trastuzumab with the HER2 receptor prevents HER2-receptor 
dimerization, which increases endocytotic destruction of the receptor and eventually 
interferes with downstream signaling pathways, (mainly the PI3K/ AKT pathway) 
therefore promoting cellular apoptosis.177  
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In addition to the aforementioned impacts of Trastuzumab interactions with the HER2 
receptors on cancer cells, studies have proved that it also activates antibody-dependent 
cellular cytotoxicity (ADCC). Several preclinical studies suggested that trastuzumab 
activates immune effector cells, mostly NK cells where animals with deficiency of Fc R 
expression on effector cells displayed significant loss of therapeutic response to 
Trastuzumab treatment.177 Given that overexpression of HER2 has been directly linked 
with the increased angiogenesis process, one of the proposed mechanism of action of 
Trastuzumab is inhibition of angiogenesis and induction of normalization and regression 
of the vasculature.178,179 
Since it has introduced in 1998, Trastuzumab has significantly improved the outcomes 
of HER2 positive patients‘ treatment. It is worthwhile mentioning that resistance to 
trastuzumab, however, has reduced the beneficial response to this therapy. 
Approximately, 70% of the patients who initially responded to trastuzumab therapy, 
developed resistance within one year of starting their therapy, while about 65% of 
HER2 positive patients did not benefit from the treatment.180  
Different mechanisms of resistance to Trastuzumab have been reported. Notably, the 
increase in insulin-like growth factor-I receptor (IGF-IR) signaling. IGF-IR is a tyrosine 
kinase receptor that is over-expressed and activated in breast cancer cells. Nhta et al.  
have demonstrated that HER2 interacts, and forms hetero-dimers, with IGF-IR in 
Trastuzumab resistant cells. By IGF-I stimulation, the level of phosphorylation of the 
HER2 receptor in resistant cells is enhanced. Moreover, they found that by inhibition of 
IGF-IR, the sensitivity of resistant cells to trastuzumab increased.181 Steric hindrance 
was also postulated as another resistance mechanism of cancer cells where the level of 
expression of the membrane-associated glycoprotein MUC4 was found to be increased 
to sterically hinder Trastuzumab accessibility to HER2.182,183 
Trastuzumab is a well-established biological drug, which has been approved since 1998, 
however, with the limited advantages of Tmab as a mono therapy and its associated 
resistance, researchers have focused on enhancing the activity through conjugation to 
cytotoxic drugs as discussed earlier in Section 1.3.4.3. Given that the activity of Tmab 
129  
 
has been extensively studied in vitro and in vivo and it has been already widely applied 
in maleimide-based chemical conjugation, we chose it as a good model to evaluate our 
newly developed rebridging strategy.  
With all the aqueous stability and glutathione reactivity results from aryl bis-
haloacetamide linkers in hand (Chapter 4), the disulfide rebridging activity of bis-
haloacetamide linkers in cross-linking reduced proteins will be investigated in this 
Chapter.  
5.2 Optimisation of the TCEP reduction of Tmab 
Prior to evaluating cross-linking of Tmab using bis-haloacetamides, we set out to 
optimise the reduction conditions of Tmab to obtain either fully or partially reduced 
Tmab with reducing agents, such as TCEP (2.2).  
Reduction of Tmab inter-chain disulfide bonds with TCEP will produce multiple 
possible products, the nature of which depend mainly on the equivalents of TCEP 
employed.  It has been found that the reduction of disulfide bonds of the IgG1 subclass 
of IgGs will proceed in the following order: heavy-light disulfide bonds, upper-heavy-
heavy and then lower-heavy-heavy disulfide bonds.148 A heterogeneous mixture of 
reduced fragments was observed with the non-specific reduction of antibodies using 
TCEP, even when lower equivalents were employed.122 
To this end, we first sought to evaluate the impact of different reduction parameters, 
such as concentration of protein, time and incubation temperature, in order to obtain 
optimum reduction conditions. Reduction of mAbs is essential step to be optimised and 
evaluated, thus, enabling consistent rebridging of the inter-chain disulfide bonds of 
Tmab. Figure 5.2 represents the expected reduced species based on the employed 
equivalents of TCEP and the molecular mass of the bands that would be observed by 
SDS-PAGE under non-reducing conditions.  
As described earlier, it has been demonstrated in the literature that heavy-light disulfide 
bonds are more susceptible towards reduction and therefore reduced first. Evaluation of 
the products of reduction by using SDS-PAGE (non-reducing) is not straight forward as 
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heavy-heavy chains are still associated together by non-covalent interactions and we are 
not able to separate them under non-reducing conditions (50 and 25 kDa). As a result, in 
order to interpret the level of the reduction, the disappearance of the 150 and 125 kDa 
bands (reduction of heavy-light chains) will be followed. 
 
Figure 5.2. The possible products species of mAbs reduced with 1, 2 or 4 equivalents of TCEP with the 
masses of the observed bands under non-reducing conditions (dark gray represents the major products).  
Firstly, in order to optimise the partial reduction of Tmab (only heavy-light disulfide 
bonds), the impact of Tmab concentration of on the rate of reduction was evaluated. By 
selectively reducing heavy and light disulfide bonds, a band at around 100 kDa would 
be observed under non-reducing condition. However, as the samples were resolved by 
SDS-PAGE under non-reducing conditions and without heating (still folded), they 
might run at different molecular weight and do not match perfectly with the ladder. 
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Moreover, intact non-reduced sample of Tmab was run under the same tested conditions 
(non-reducing gels, unheated sample) to confirm that what we would observe is due to 
the performed reduction process. 
Two sets of concentrations were appraised: 1 mg/mL and 10 mg/mL. Tmab was reduced 
with either 2.2 or 2.5 equivalents of TCEP (2.2) at 4 . At 10 mg/mL concentration of 
Tmab (concentrated solution), a superior reduction rate was obtained as observed with a 
115 kDa band (corresponds to heavy-heavy chains) obtained as the major product 
(Figure 5.3, lane 5-8). In contrast, at 1 mg/mL concentration of Tmab, slower reduction 
rates were observed as most of Tmab remains as intact antibody as observed at 185 kDa. 
Moreover, one can note that longer incubation of Tmab with TCEP (reduction time 
increased to 2 h), the selectivity of the heavy-light disulfide bonds was reduced as more 
of the 80 kDa band (corresponding to HC-LC fragment) was observed which implies 
that the a proportion of heavy-heavy disulfide bonds have been reduced (Figure  5.3, 
lane 6 and 8). 
 
Figure 5.3. SDS-PAGE analysis of optimisation of Tmab reduction using TCEP (2.2) varying 
concentration of Tmab and reduction time. L: protein ladder. Lane 1-4: Tmab (1.0 mg/mL, 6.9 µM), Lane 
5-8: Tmab (10 mg/mL, 69 µM) in Tris.HCl buffer (100 mM, 150 mM NaCl, 5 mM EDTA, pH 7.5). Lane 
1: Tmab reduced with 2.2 equiv. of TCEP (1.52 µM) for 1 h, lane 2: Tmab reduced with 2.2 equiv. of 
TCEP (1.52 µM) for 2 h, lane 3: Tmab reduced with 2.5 equiv. of TCEP (1.72 µM) for 1 h, lane 4: Tmab 
reduced with 2.5 equiv. of TCEP (1.72 µM) for 2 h, lane 5: Tmab reduced with 2.2 equiv. of TCEP (15.2 
µM) for 1 h, lane 6: Tmab reduced with 2.2 equiv. of TCEP (15.2 µM) for 2 h, lane 7: Tmab reduced with 
2.5 equiv. of TCEP (17.2 µM) for 1 h, lane 8: Tmab reduced with 2.5 equiv. of TCEP (1.72 µM) for 2 h, 
at 4   lane 9: Tmab control (non-reducing dye). HC: heavy chain, LC: light chain. Protein samples were 
resolved by non-reducing SDS-Page (10% gel). 
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Next, as the rate of reduction has significantly affected by the concentration of Tmab,              
a 5 mg/mL concentration was chosen to be evaluated in order to optimise the reduction 
conditions and minimise the non-specific reduction of heavy-heavy inter-chain disulfide 
bonds. One can note that the rate of TCEP reduction of heavy-heavy inter-chain 
disulfide bonds was reduced at 5 mg/mL concentration as more intact antibody was 
observed at 185 kDa MW. In addition, 2 hours of reduction is required to obtain greater 
proportion of reduced heavy-light disulfide bonds (115 kDa band). In conclusion, TCEP 
preferably reduces heavy-light inter-chain disulfide bonds but also reduces a fraction of 
heavy-heavy inert-chain disulfide bonds which explains the presence of a distinct band 
at 80 kDa (HC-LC) (Figure 5.4, lane 1-5).  
 
Figure 5.4. SDS-PAGE analysis of optimisation of Tmab reduction using TCEP (2.2) varying the 
reduction time. L: protein ladder. Tmab (5 mg/mL, 34 µM), in Tris.HCl buffer (100 mM, 150 mM NaCl, 
5 mM EDTA, pH 7.5). L: protein ladder, lane 1: Tmab control (non -reducing dye), lane 2: Tmab reduced 
with 2 equiv. of TCEP (6.8 µM) for 1 h at 4 , lane 3: Tmab reduced with 2 equiv. of TCEP (6.8 µM ) for 
2 h at 4 , lane 4: Tmab reduced with 2.2 equiv. of TCEP (7.5 µM) for 1 h at 4 , lane 5: Tmab reduced 
with 2.2 equiv. of TCEP (7.5 µM) for 2 h at 4 , lane 6:  Tmab reduced with 5 equiv. of TCEP (17 µM) 
for 2 h at room temperature. Protein samples were resolved by non-reducing SDS-Page (10% gel). 
Next, we sought to fully reduce Tmab (the 4 inter-chain disulfide bonds) at both room 
temperature and 37 . Analysis of the reduction condition by SDS-PAGE showed Tmab 
reduction with 5 equivalent of TCEP at room temperature for 2 h was sufficient to fully 
reduce the heavy-heavy and heavy-light disulfide bonds, as demonstrated by the 
disappearance of the 150 and 125 kDa bands in Figure  5.5,  lane 3. However, in order 
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to reduce only heavy-light disulfide bonds, a lower temperature (4 ) is required to 
selectively reduce these disulfide bonds without minimum reduction of heavy-heavy 
disulfide bonds (Figure 5.5, lane 2). 
 
Figure 5.5. SDS-PAGE analysis of optimisation of Tmab reduction using TCEP (2.2). Lane 1-4: Tmab 
(5.0 mg/mL, 34 µM) in Tris.HCl buffer (100 mM, 150 mM NaCl, 5 mM EDTA, pH 7.5). L: protein 
ladder, lane 1: Tmab control (non -reducing dye), lane 2: Tmab reduced with 2.2 equiv. of TCEP (7.5 
µM) for 2 h at 4 , lane 3: Tmab reduced with 5 equiv. of TCEP (17 µM) for 2 h at room temperature, 
lane 4: Tmab reduced with 10 equiv. of TCEP (34 µM) for 2 h at 37 . Protein samples were resolved by 
non-reducing SDS-Page (10% gel). 
5.3 Disulfide bond rebridging of fully reduced Trastuzumab  
Having optimised the reduction conditions required to obtain fully reduced Tmab (5 
equiv. for 2 h at room temperature) we next sought to determine the efficiency of bis-
haloacetamide linkers to rebridge the fully reduced Tmab and characterise the obtained 
product.  
Initially, we attempted to cross-link fully reduced Tmab using the bromo-linkers, methyl 
3,5-bis(2-bromoacetamido)benzoate (4.22), methyl 3,4-bis(2-bromoacetamido)benzoate 
(4.23),  N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28), and N,N'-(1,2-
phenylene)bis(2-bromoacetamide) (4.29). As such, Tmab (5 mg/mL) in Tris.HCl (100 
mM, pH 7.5) containing 150 mM NaCl and 5 mM EDTA, was reduced by incubation 
with TCEP 2.2 (5 equiv.) for 2 h at room temperature. The reduced Tmab was incubated 
with 5 or 8 equiv. of each bis-bromoacetamide linker (4.22, 4.23, 4.28 and 4.29) and 
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held at room temperature overnight. Excess linkers were used to account for the 
remaining TCEP. 
 
The products of reaction were then resolved and analysed by using SDS-PAGE under 
reducing conditions. Unexpectedly, the major product of cross-linking was half-
antibody observed at (75 kDa) for all bis-bromoacetamide linkers (4.22, 4.23, 4.28 and 
4.29) (Figure 5.6). These results suggest that these bis-haloacetamide linkers react 
differently to the existing rebridging linkers (4a-4f) by rebridging HC-LC disulfide but 
not inter-chain HC-HC disulfide bonds. 
Given that sufficient equivalents of reducing agents were used to fully reduce Tmab 
along with excess linkers were employed to quench excess TCEP and rebridge the four 
disulfide bonds, it is expected to obtain fully bridged Tmab (150 kDa), therefore we 




Figure 5.6. SDS-PAGE analysis of cross-linking of fully reduced Tmab (5.0 mg/ml, 34 µM) in Tris.HCl 
buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA ,with bis-bromoacetamide linkers. 
Tmab was reduced with 5 equiv. of TCEP 2.2 (170 µM) for 2 h at room temperature and incubated with 5 
(17 µM) or 8 equiv. (27.2 µM) of each linker. L: protein ladder, lane 1: Tmab incubated with 5 equiv. of 
methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 2: Tmab incubated with 8 equiv. of methyl 3,4-
bis(2-bromoacetamido)benzoate (4.23), lane 3: Tmab incubated with 5 equiv. of methyl 3,5-bis(2-
bromoacetamido)benzoate (4.22), lane 4: Tmab incubated with 8 equiv. of methyl 3,5-bis(2-
bromoacetamido)benzoate (4.22), lane 5: Tmab incubated with 5 equiv. of N,N'-(1,2-phenylene)bis(2-
bromoacetamide) (4.29), lane 6: Tmab incubated with 8 equiv. of N,N'-(1,2-phenylene)bis(2-
bromoacetamide) (4.29), lane 7: Tmab incubated with 5 equiv. of N,N'-(1,3-phenylene)bis(2-
bromoacetamide) (4.28), lane 8: Tmab incubated with 8 equiv. of N,N'-(1,3-phenylene)bis(2-
bromoacetamide) (4.28). HC: heavy chain, LC: light chain, LC-LC: light chain homodimers, HC-HC: 
heavy chain homodimers. Protein samples were resolved by reducing SDS-PAGE (4-12% gel). Bands 
annotation is based on the protein MS results. 
In order to have more thorough characterisation of the product obtained from Tmab 
cross-linking, reactions of methyl 3,4-bis(2-haloacetamido) benzoate (4.23) with Tmab 
was further analysed by protein MS.  
MS of control Tmab (reduced) was first obtained, which showed the LC peak with a 
mass of 23,439.18 Da (Figure 5.7 A) and two peaks corresponds to the two main 
glycoforms of the HC with masses of 50,590.03 and 50,754.90 Da (Figure 5.7 B) with a 
difference of 161.87 Da, which represents N-glycosylation difference (extra galactose 
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sugar moiety). Tmab is IgG1 mAb, which is glycosylated at CH2 domain of Fc region at 
Asn297 amino acid residues.184  
According to MS results of rebridging reaction with 4.23 linker, the major cross-linked 
product of Tmab is a half-antibody with 2 linkers attached. The only possible 
explanation for the observed molecular weight is that the linker has rebridged both the 
inter-chain heavy-light disulfide and intra-chain heavy-heavy disulfide bonds (Figure 
5.8 A). The expected mass of two cross-linked disulfide is calculated as 74,524.49 Da, 
and was observed at 74,528.03 Da (Figure 5.8).  
 
 
Figure 5.7. Deconvoluted protein MS spectra of Tmab. A) Control MS spectrum of Tmab light chain. 
Showing a peak at 23,439.18. B) Control MS spectrum of Tmab heavy chain showing two peaks at 


























Figure 5.8. A) Schematic representation of the produced half antibody with two rebridged disulfide 
bonds, intra-chain heavy-heavy and heavy-light chains. B) Deconvoluted spectrum protein MS of Tmab. 
Full spectrum of Tmab cross-linked with 4 equiv. of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) 
showing a major peak at 74,528.03 Da. C) Expansion of the spectrum at 74 kDa region showing major 
peaks at 74,528.03 Da and 74,689.24 Da. 




















According to MS results of rebridging reaction with 4.29 linker, the major cross-linked 
product of Tmab is a half-antibody with 2 linkers attached, which again implies that the 
linker 4.29 has rebridged both the inter-chain heavy-light disulfide and intra-chain 
heavy-heavy disulfide bonds. Thus, similar cross-linking results were obtained and half-
antibody (75 kDa) is the major product. The expected mass of two cross-linked disulfide 
is calculated as 74,572.81 Da, and was observed at 74,572.57 Da (Figure 5.9). 
 
Figure 5.9. Deconvoluted spectrum protein MS of cross -linked Tmab with N,N'-(1,2-phenylene)bis(2-
bromoacetamide) (4.29). A) Full view MS spectrum of cross -linked Tmab showing a major peak at 





















Rebridging of fully reduced Tmab can result either in fully cross-linked Tmab (inter-
chain bridges between heavy chains) or half-antibody (intra-chain bridges between 
heavy chains). Construction of half-antibody species (75 kDa) with bis-haloacetamide 
linkers is due to the preference of formation of intra-chain bridges. 
To the best of our knowledge, bis-haloacetamide linkers react differently with fully 
reduced mAb (the four disulfide bonds) in comparison to next generation maleimide 
linkers mainly, dibromomaleimide (4b). Nevertheless, 4b reagent produced fully 
bridged mAb (150 kDa) as a major product, but it has also produced minor proportion of 
half-antibody, the so-called disulfide bond shuffling as described by Schumacher et al. 
They proposed in situ protocol of conjugation to avoid disulfide bond shuffling.185 Also, 
Lee et al. proposed using di-TCEP-substituted dithiophenolpyridazinedione compound 
(4e) to minimize disulfide shuffling (intra-disulfide cross linking).156 
For detailed comparison between different linkers in this discussion, we are using both 
ortho- and meta-substituted linkers acronyms to refer to the regiochemistry of the two α-
haloacetamide groups relative to each other, regardless of the aryl substituent. 
Compared to ortho-substituted linker, both meta-substituted linkers, methyl 3,5-bis(2-
bromoacetamido)benzoate (4.22) (Figure 5.6, lane 3-4) and N,N'-(1,3-phenylene)bis(2-
bromoacetamide) (4.28) (Figure 5.6, lane 7-8) displayed higher proportion of cross-
linked light- light chains and heavy-heavy chains as displayed as distinct bands around 
100 kDa and 50 kDa revealed under reducing conditions. While ortho-substituted 
linkers, methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) and N,N'-(1,2-
phenylene)bis(2-bromoacetamide) (4.29) showed more selective rebridging of heavy-
light and intra-heavy heavy disulfide bonds with very minor proportion of cross-linked 
light-light chains and heavy-heavy chains. As observed by both the SDS-PAGE analysis 
and protein MS. 
At this stage we sought to evaluate whether the reaction pH is influencing the observed 
preference of the bis-haloacetamide linkers to form intra-chain heavy-heavy cross-
linking. As such, Tmab (5 mg/mL) in conjugation Tris.HCl buffer (100 mM, 150 mM 
NaCl, 5 mM EDTA, pH 6, 7.5, or 8) was reduced by incubation with TCEP 2.2 (5 
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equiv.). Tmab was incubated with 5 equiv. of each bis-bromoacetamide linkers (4.22, 
4.23, 4.28 and 4.29) and held at room temperature overnight.   
Resolving of the reaction products by SDS-PAGE revealed that changing the pH has 
showed similar reaction products to those previously observed at pH 7.5. The cross-
linked half-antibody product at pH 6 and 8 was the major observed product (Figure 
5.10). 
However, as the percentage of conversion to half-antibody product (HC-LC) at pH 7.5 
was the highest with lower proportion of unreacted heavy and light chains compared 
with the other pHs, this pH was considered the optimum to carry rebridging experiments 
at (Figure 5.10, lane 5-8). 
It is expected to have higher availability of thiolate anion at more basic pH (pKa of 
thiolate is 8.3), however, the possible explanation of the reduced the efficiency of the 
cross-linking (higher proportion of unreacted HC and LC were observed under reducing 
conditions) is the reduced aqueous stability of the bis-haloacetamide linkers at alkaline 
conditions (Figure 5.10, lane 9-12). On the other hand, working under relative acidic 
conditions, have shown less optimum results, which can be attributed to the lower 
availability of thiolate anion at this pH (pKa of thiolate is 8.3)186 (Figure  5.10, lane 1-4). 
It is worth pointing out that the observed preference of the reactivity of meta-substituted 
and ortho-substituted likers have not changed at more acidic or basic conditions. Ortho-
substituted likers gave lower fraction of the cross-linked inter-heavy-heavy and light-




Figure 5.10. SDS-PAGE analysis of cross-linking of fully reduced Tmab (5.0 mg/ml, 34 µM) in Tris.HCl 
buffer (100 mM, 150 mM NaCl, 5mM EDTA, pH 6, 7.5, or 8) incubated with bis-haloacetamide linkers. 
Tmab (34 µM) was reduced with 5 equiv. of TCEP (170 µM) for 2 h at room temperature and incubated 
with (17 µM, 5 equiv.) of each linker. Lane 1, 5 and 9: Tmab incubated with 5 equiv. of methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23), Lane 2, 6 and 10: Tmab incubated with 5 equiv. of methyl 3,5-bis(2-
bromoacetamido)benzoate (4.22), Lane 3, 7 and 11: Tmab incubated with 5 equiv. of N,N'-(1,2-
phenylene)bis(2-bromoacetamide) (4.29), Lane 4, 8 and 12: Tmab incubated with 5 equiv. of N,N'-(1,3-
phenylene)bis(2-bromoacetamide) (4.28). HC: heavy chain, LC: light chain, LC-LC: light chain 
homodimers, HC-HC: heavy chain homodimers. Protein samples were resolved by reducing SDS-PAGE 
(10% gel). 
With optimized reduction and cross-linking conditions (5 equiv. TCEP for 2 h, 5 equiv. 
of bis-bomoacetamide linkers overnight at pH 7.5), we intended to compare the 
efficiency of bis-iodoacetamide linkers in the rebridging of reduced disulfide bonds of 




As such, Tmab (5 mg/mL) in Tris.HCl (100 mM, 150 mM NaCl, 5 mM EDTA, pH 7.5) 
was reduced by incubation with TCEP 2.2 (5 equiv.) for 2 h at room temperature. The 
reduced Tmab was incubated with 5 equivalents of each bis-iodoacetamide linker (4.24, 
4.25, 4.30 and 4.31) and held at room temperature overnight. The reaction products 
were then revealed by SDS-PAGE. 
Similar results were observed with the iodo-acetamide linkers to those observed with 
their bromo analogues. The major product of cross-linking of Tmab with bis-
iodoacetamide linkers is half-antibody (Figure 5.11). In similar manner to the 
corresponding bis-bromoacetamides, meta-substituted linkers, methyl 3,5-bis(2-
iodoacetamido)benzoate (4.24) (Figure 5.11, lane 4) and N,N'-(1,3-phenylene)bis(2-
iodooacetamide) (4.30) (Figure 5.11, lane 6), displayed higher proportion of light-light 
chain and heavy-heavy chain homodimers when compared with the ortho-substituted 
linkers 4.25 and 4.31 (Figure 5.11, lane 3 and 5).   
 
Figure 5.11. SDS-PAGE of cross-linking of fully reduced Tmab (5 mg/ml, 34 µM) in Tris.HCl buffer 
(100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, with bis-iodoacetamide linkers. Tmab 
was reduced with 5 equiv. of TCEP 2.2 (170 µM) for 2 h at room temperature and incubated with (17 µM, 
5 equiv.) of each linker. L: protein ladder, lane 1: Tmab control (Non-reducing dye), lane 2: Tmab control 
(reducing dye), lane 3: Tmab incubated with 5 equiv. of methyl 3,4-bis(2-iodooacetamido)benzoate 
(4.25), Lane 4: Tmab incubated with 5 equiv. of methyl 3,5-bis(2-iodoacetamido)benzoate (4.24), Lane 5: 
Tmab incubated with 5 equiv. of N,N'-(1,2-phenylene)bis(2-iodoacetamide) (4.31), Lane 6: Tmab 
incubated with 5 equiv. of N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.30). HC: heavy chain, LC: 
light chain, LC-LC: light chain homodimers, HC-HC: heavy chain homodimers. Protein samples were 
resolved by reducing SDS-PAGE (10% gel). 
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With the encouraging and consistent rebridging results observed with the tested bis-
haloacetamide linkers, the produced fully rebridged half antibody (75 kDa) offers a 
number of advantages over intact antibody, most importantly the smaller size and better 
tissue penetration, which could find interesting new applications in the oncology field 
(see Chapter 9). Moreover, the reproducibility and good rebridging capabilities of aryl 
bis-haloacetamide linkers have promoted us to evaluate them as a promising rebridging 
approach (the following Sections).  
5.4 Disulfide bond rebridging of Trastuzumab with azide modified bis-
haloacetamide linkers 4.32-4.35 
Having established suitable conditions for the disulfide rebridging of Tmab using model 
bis-haloacetamide linkers, we now wanted to investigate the reactivity of bis-
haloacetamide linkers functionalised with bio-orthogonal chemistries, which are suitable 
for cross-coupling reactions, such as the ‗Click‘ reaction.  
As such, we sought to appraise the efficiency of the azide derivatised bis-haloacetamide 
linkers 4.32-4.35 in rebridging reduced disulfide bonds. First, Tmab (5 mg/mL) in 
conjugation buffer Tris.HCl (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM 
EDTA, was reduced by incubation with TCEP 2.2 (5 equiv.) for 2 h at room 
temperature. The reduced Tmab was incubated with 5 equiv. of each of the azide 
derivatised bis-haloacetamide linkers 4.32-4.35 and held at room temperature overnight. 
The reaction products were then resolved separately using SDS-PAGE (Figure 5.12 A), 




One can note that the major product of cross-linking is again the half-antibody (HC-LC) 
(Figure 5.12 A). Moreover, in a similar manner to the corresponding bis-
bromoacetamides (4.22, 4.23, 4.28 and 4.29), ortho-substituted linkers N,N'-(4-((2-(2-(2-
(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-haloacetamide) 
(4.34-4.35) showed superior rebridging of inter-chain heavy-light disulfide bonds (half-
antibody) with only minor light-light chain and heavy-heavy chain homodimer 
formation (Figure  5.12 A, lane 1 and 3).  
In order to further characterise the products obtained from Tmab cross-linking with 
N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-
iodoacetamide) (4.35) linker, the reaction was analysed by protein MS. The expected 
mass of two rebridged disulfide bonds (intra heavy-heavy and inter heavy-light disulfide 
bonds) is calculated as 75,060.46 Da and was observed as 75,059.82 Da (Figure 5.12 B). 
The obtained results suggested a high efficiency for our azide derivatised bis-
haloacetamide linkers in rebridging the reduced disulfide bonds of Tmab. Therefore, 
these linkers provide azide-functionalised Tmab (Tmab-azide) that could be applied in 





Figure 5.12. A) SDS-PAGE analysis of cross-linking of reduced Tmab (5 mg/ml, 34 µM) in Tris.HCl 
buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA with 5 equiv. of TCEP (150 µM) 
for 2 h at room temperature and incubated with (17 µM, 5 equiv.) of each linker overnight. L: ladder, lane 
1: Tmab incubated with 5 equiv. of 4.34, lane 2: Tmab incubated with 5 equiv. of 4.32, lane 3: Tmab 
incubated with 5 equiv. of 4.35, lane 4: Tmab incubated with 5 equiv. of 4.33 at room temperature 
overnight. B) Deconvoluted spectrum protein MS of rebridged Tmab with 4.35 linker showing a major 
peak at 75,059.82 Da. 
5.5 Disulfide bond rebridging of partially reduced Trastuzumab  
Having established the efficiency of bis-haloacetamide linkers in rebridging fully 










Deconvoluted Mass (amu) 
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evaluate the utility of employing our bis-haloacetamide linkers in selectively cross-
linking only heavy-light disulfide bonds. By capping only heavy-light disulfide bonds 
initially, we might be subsequently able to introduce a different functionality through 
rebridging heavy-heavy disulfide bonds using a different bis-haloacetamide linker (this 
will be further discussed in Section 5.8).  
As discussed earlier in Section 5.2, we established the necessary reduction conditions 
for TCEP to selectively reduce heavy-light disulfide bonds with minimum reduction of 
heavy-heavy disulfide binds (lower equivalents of TCEP, 2h at 4 ).  
As such, two protocols were evaluated to construct the rebridged heavy-light chains of 
Tmab: A direct in situ reduction method and a portion-wise reduction method (Figure 
5.13). 
 
Figure 5.13. The two methods investigated to attain rebridged heavy-light chains of Tmab (cross-linked 
heavy-light disulfide bonds). 
Initially we sought to evaluate the direct reduction method. As such, Tmab (5 mg/mL, 
0.034 µmol) in Tris.HCl buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM 
EDTA, was reduced with TCEP 2.2 (2.2 equiv.) for 2 h at 4 . The reduced protein was 
then incubated with 2.2 equiv. of bis-bromoacetamide linkers (4.22, 4.23, 4.28 and 
4.29). The reaction products were resolved by using SDS-PAGE analysis. 
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None of the linkers evaluated showed complete rebridging of heavy-light disulfide 
bonds, as confirmed by the presence of unreacted heavy and light chains (under 
reducing gel conditions). The ortho-substituted linkers methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23) (Figure 5.14, lane 5) and N,N'-(1,2-phenylene)bis(2-
bromoacetamide) (4.29) (Figure 5.14, lane 7) displayed higher conjugation yields in 
comparison to the meta-substituted linkers 4.22 and 4.28. These latter linkers (meta-
linkers) displayed higher amount of light-light chain and inter-heavy-heavy chain cross-
linking in line with what was observed earlier.  
The incomplete rebridging of the reduced heavy-light disulfide bonds we observed with 
bis-bromoacetamide linkers could possibly be attributed to the incomplete reduction of 
heavy-light disulfide bonds as observed before with TCEP reduction of Tmab (see 
Figure 5.4). 
 
Figure 5.14. SDS-PAGE of analysis of partially reduced Tmab (5 mg/mL, 34 µM) cross-linking in 
Tris.HCl buffer (100 mM, 150 mM NaCl, 5 mM EDTA, pH 6, 7.5, or 8) with bis-bromoacetamide linkers 
(7.5 µM) using direct method. Tmab (34 µM) was reduced with 2.2 equiv. of TCEP (75 µM) for 2 h and 
incubated with (7.5 µM) of each linker at room temperature overnight. L: ladder, lane 1, 5 and 9: Tmab 
incubated with 2.2 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 2, 6 and 10: Tmab 
incubated with 2.2 equiv. of methyl 3,5-bis(2-bromoacetamido)benzoate (4.22), lane 3, 7 and 11: Tmab 
incubated with 2.2 equiv. of N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.29), lane 4, 8 and 12: Tmab 
incubated with 2.2 equiv. of N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28). Protein samples were 
resolved by reducing SDS-PAGE (10% gel). 
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In an attempt to evaluate if the pH of the reaction might influence the reaction products, 
the protocol was evaluated at two other pHs, 6 and 8. Neither of the these pHs resulted 
in improved rebridging, as pH 7.5 was optimum for rebridging heavy-light disulfide 
bonds as the cross-linked HC-LC band was observed as the major product (Figure 5.14, 
lane 5-8). Consistent with what we observed earlier, a higher degree of unreacted (non-
linked) heavy and light chains were still observed at pH 6 and 8) (Figure 5.14, lane 1-4 
and 9-12). 
Next, in order to improve the yield of the rebridged heavy-light chains product, we 
rationalised that using portion-wise reduction followed by the sequential cross-linking 
would mitigate the non-selective reduction of heavy-heavy disulfide bonds and afford 
higher conjugation yield of heavy-light disulfide bonds, through a reduction in the 
number of unpaired inter-chain disulfide bonds present at any given time. 
As such, Tmab (5 mg/mL, 0.033 µmol) in Tris.HCl buffer (100 mM, pH 7.5) containing 
NaCl (150 mM), and  EDTA (5 mM), was initially reduced by incubation with TCEP 
2.2 (1 equiv.) for 2 h at 4 . 1 equiv. of bis-bromoacetamide linkers was added then to 
the reduced protein and held at room temperature overnight. Then, a second reduction 
step with TCEP (1 equiv.) for 2 h at 4  was performed prior to incubation with the bis-
bromoacetamide linkers (1 equiv.) at room temperature overnight. The reaction products 
following both the first and second rebridging steps were the resolved using SDS-
PAGE.   
To our delight, optimum rebridging results of first heavy-light inter chain disulfide 
bonds of Tmab were obtained (Figure 5.15, lane 1-4), as almost equal band intensity of 
HC and HC-LC was observed, mainly with ortho-substituted linkers (Figure 5.15, lane 1 
and 4).  
However, the second reduction and rebridging step has not displayed as optimum results 
as the first reduction and rebridging step as non-reacted HC and LC bands were 
observed (Figure 5.15, lane 5-8), which possibly reflects the minor non-selective 
reduction of heavy-heavy disulfide bonds followed by rebridging of intra and inter-chain 
disulfide bonds of heavy chain.  
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To confirm this suggestion, the sample were resolving under non-reducing gel 
conditions, where the presence of half-antibody (HC-LC) and heavy-heavy (HC-HC) 
bands represent the rebridging of intra- and inter-chains heavy-heavy disulfide bonds, 
respectively (Figure 5.15, lane 9-12), therefore confirming our assumption regarding the 
minor and non-selective reduction of heavy-heavy disulfide bonds. 
 
Figure 5.15. SDS-PAGE of partially reduced Tmab (5 mg/mL, 34 µM) cross-linking in Tris.HCl buffer 
(100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, with bis-bromoacetamide linkers using 
portion-wise method. Tmab (5 mg/mL, 34 µM) was reduced with 1 equiv. of TCEP (34 µM) for 2 h and 
incubated with 1 equiv. of bis -bromoacetamide linkers (3.4 µM) at room temperature overnight (Lane 1-
4). Lane 1: Tmab incubated with 1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), Lane 2: 
Tmab incubated with 1 equiv. of methyl 3,5-bis(2-bromoacetamido)benzoate (4.22), Lane 3: Tmab 
incubated with 1 equiv. of N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.29), Lane 4: Tmab incubated 
with 1 equiv. of N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28). Tmab was further reduced with 1 
equiv. of TCEP (34 µM) for 2 h and incubated with 1 equiv. of bis -bromoacetamide linkers (3.4 µM) at 
room temperature overnight (Lane 5-8) in same order of lane 1-4. Lane (9-12): same samples as in lane 5-
8 under non-reducing conditions.  
In order to more thoroughly characterise the product obtained from the cross-linking, 
reaction of methyl 3,5-bis(2-bromoacetamido)benzoate 4.22 (2.2 equiv.) using the direct 
method was further analysed by protein MS. According to MS results, the major cross-
linked product of Tmab is the half-antibody with one linker rebridging the inter-chain 
heavy-light disulfide bond. The expected mass of Tmab with a rebridged heavy-light 





Figure 5.16. Deconvoluted spectrum protein MS of cross -linked Tmab with 2.2 equiv. methyl 3,5-bis(2-
bromoacetamido)benzoate (4.22). Full view MS spectrum of cross -linked Tmab showing a peak at 
74,277.53 Da corresponds to rebridged heavy-light chains of Tmab. 
In conclusion, provided that both methods evaluated showed comparable rebridging of 
the heavy-light disulfide bonds, the first direct in situ protocol is more manageable and 
easier to follow. The cross-linked heavy-light disulfide bonds of Tmab can be further 
used to produce bifunctional azide-linked Tmab (Section 5.8).  
5.6 Selectivity of bis-haloacetamide linkers towards cross-linking heavy-
heavy and heavy-light disulfide bonds 
From the previously observed rebridging results of fully and partially reduced Tmab 
using bis-haloacetamide linkers, a different rebridging manner was observed especially 
with meta-substituted linkers where they tend to cross-link the inter-chain heavy–heavy 
disulfide bonds and light-light chains forming homo-dimers as a minor reaction 
products.  
To evaluate the selectivity difference of reaction towards the reduced inter-chain 
disulfide bonds between ortho- and meta-substituted bis-haloacetamides linkers, all of 
the four inter-chain disulfide bonds of Tmab were reduced prior to incubation with 
limited equivalents of bis-haloacetamide each linker (2 equivalents). 
As such, Tmab (5 mg/mL) in Tris.HCl buffer (100 mM,  
pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, was reduced by incubation with 
TCEP (4 equiv.) for 2 h at room temperature. The reduced Tmab was then incubated 
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with 2 equiv. of each bis-bromoacetamide linker and held at room temperature 
overnight. The reaction products were resolved using SDS-PAGE analysis.  
The ortho-substituted methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), and N,N'-(1,2-
phenylene)bis(2-bromoacetamide) (4.29) were observed to display a higher selectivity 
towards rebridging heavy-light disulfide bonds (Figure  5.17 A, lane 3 and 5). On the 
other hand, the meta-substituted methyl 3,5-bis(2-bromoacetamido)benzoate (4.22) and 
N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28) have showed less selectivity towards 
cross-linking heavy-light disulfide bonds, and higher proportion of rebridged heavy-
heavy disulfide bonds (Figure  5.17 A, lane 4 and 6).  
Percent conversion to each product was calculated using Gel Image studio 5.2 to 
estimate the percent conversion of Tmab into each product [inter-chain heavy-heavy 
(100 kDa), or inter-chain heavy-light (75 kDa)]. Clearly, the ester derivatised methyl 
3,4-bis(2-bromoacetamido)benzoate (4.23) had higher percentage of half antibody 
(20%) in comparison to methyl 3,5-bis(2-bromoacetamido)benzoate (4.22) (10%) 
(Figure 5.17 B). On the other hand, unsubstituted bromo-linkers 4.28 and 4.29 did not 
display a clear selectivity manner towards the reduced disulfide bonds (Figure 5.17 B). 
Similar experiment was repeated with bis-iodoacetamide linkers to evaluate their 
selectivity towards rebridging the reduced disulfide bonds of Tmab. Fully reduced Tmab 
was incubated with only 2 equivalents of each bis-iodoacetamide linker (4.24, 4.25, 
4.30, 4.31, 4.33 and 4.35) and held at room temperature overnight. The reaction 
products were resolved using SDS-PAGE analysis. Bis-iodoacetamide linkers (4.24, 
4.25, 4.30, and 4.31) did not, however, display analogous pattern of selectivity toward 































Figure 5.17. A) SDS-PAGE analysis representing the selectivity of bis-bromoacetamide linkers in cross-
linking Tmab (5 mg/mL, 34 µM) in Tris.HCl buffer reduced with 4 equiv. of TCEP (136 µM) and 
incubated with (6.8 µM, 2 equiv.) of each bis-bromoacetamide linker at room temperature overnight. L: 
protein ladder, lane 1: Tmab control (non-reducing dye), Lane 2: Tmab control (reducing dye), Lane 3: 
Tmab incubated with 2 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), Lane 4: Tmab 
incubated with 2 equiv. of methyl 3,5-bis(2-bromoacetamido)benzoate (4.22), Lane 5: Tmab incubated 
with 2 equiv. of N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.29), Lane 6: Tmab incubated with 2 
equiv. of N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28). Protein samples were resolved by reducing 
SDS-Page (10% gel). B) Percent conversion of Tmab into various cross -linked products analysed using 






On the other hand, azide modified bis-iodoacetamide linkers (4.33 and 4.35) displayed 
an interesting manner of selectivity, as meta-substituted linker 4.33 (Figure 5.18, lane 
5), displayed less fraction of rebridged heavy-light disulfide bonds in comparison with 
ortho-substituted linker 4.35 (Figure 5.18, lane 6), which prompted us to further analyse 
the reaction by MS to investigate the possibility for rebridging intra-chain heavy-heavy 
disulfide bonds.  
As shown in Figure 5.19, expansion at the heavy chain region revealed that the major 
obtained product is cross-linked heavy chain with one linkers attached. The only 
possible explanation for the observed molecular weight is that the linker has rebridged 
the intra-chain heavy-heavy disulfide bonds, the expected masses of cross-linked heavy 
chain with one azide linker is calculated as 51,027.16 Da and 51,188.28 Da 
(glycoforms) and they were observed at 51,026.31 Da and 51,189.24 Da (Figure 5.19 
B). In contrast, ortho- substituted linker 4.35 displayed lower ability in rebridging of the 
intra-chain heavy-heavy disulfide bonds (Figure 5.18, lane 6 and Figure 5.19 A). 
 
Figure 5.18. SDS-PAGE gel evaluating selectivity of bis-iodoacetamide linkers in cross-linking Tmab (5 
mg/mL, 34 µM) in Tris.HCl buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, 
reduced with 4 equiv. of TCEP (136 µM) and incubated with (6.8 µM, 2 equiv.) of each bis -
iodooacetamide linker at room temperature overnight. L: protein ladder, lane 1: Tmab incubated with 2 
equiv. of methyl 3,4-bis(2-iodoacetamido)benzoate (4.25), lane 2: Tmab incubated with 2 equiv. of 
methyl 3,5-bis(2-iodoacetamido)benzoate (4.24), lane 3: Tmab incubated with 2 equiv. of N,N'-(1,2-
phenylene)bis(2-iodoacetamide) (4.31), lane 4: Tmab incubated with 2 equiv. of N,N'-(1,3-
phenylene)bis(2-iodoacetamide) (4.30). lane 5:  Tmab incubated with 2 equiv. of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) (4.33). lane 6:  Tmab 
incubated with 2 equiv. of N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-
phenylene)bis(2-iodoacetamide) (4.35). Protein samples were resolved by reducing SDS-Page (10% gel). 
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According to the observed pattern of reactivity of different bis-haloacetamide linkers, 
we concluded that the parameters affecting the selectivity of bis-haloacetamide linkers 
toward cross-linking the different reduced disulfide bonds of mAbs are: Firstly, the 
regiochemistry of the α-haloacetamide group related to each other (ortho or meta), 
secondly, the size of the halogen group and thirdly, the size of the aryl substituent, either 
the azide-(PEG)3 or the small ester group.  
The factors have contributed to the observed preference of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) 
(4.33) towards cross-linking intra-chain heavy-heavy disulfide bonds are the bigger size 
of the halogen (iodo vs. bromo), and the presence of bulk azide-(PEG)3 through amide 
linkage, which significantly reduced  its reactivity towards heavy-light disulfide bonds. 
This mainly explains why methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) with small 
halogen (Br) and small ester functionality (COOMe) displayed higher selectivity toward 





Figure 5.19. Deconvoluted protein MS spectra of Tmab cross-linked with 2 equiv. of A) N,N'-(4-((2-(2-
(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-iodoacetamide) (4.35) showing 
major peak at 50,594.97 Da and 50,756.09 Da (unfunctionalised heavy chain), B) N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) (4.33) showing major 
peaks at 51,026.31 Da and 51,189.24 Da [cross-linked Tmab (Tmab-N3)]. 
5.7 Mechanistic understanding the cross-linking of reduced disulfide bonds 
using bis-haloacetamide linkers 
Interestingly, with all the performed MS analysis on Tmab reaction products with bis-
haloacetamide linkers, we did not see any mono-labelling of light chain or heavy chain, 
which lead us to propose that cross-linking of the reduced disulfide using bis-




















limiting step and both thiolates groups should be in close proximity or associated 
together in order to be cross-linked with bis-haloacetamide linkers.  
As such, in order to investigate our hypothesis if both thiolate groups should be in close 
proximity or associated to be cross-linked with bis-haloacetamide linkers, we incubated 
Tmab with 4 equiv. of TCEP prior to incubation with 2 equiv. of bis-haloacetamide 
linkers in the presence of 2% or 4% SDS. SDS (2%) is mainly used to denature the 
proteins and negatively charge them prior to SDS-PAGE analysis. 
Two linkers were evaluated, methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) which 
found to be more selective towards cross-linking of inter-chain heavy-light disulfide 
bonds and N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-
phenylene)bis(2-iodoacetamide) (4.33) which found to be more selective towards cross-
linking of intra-chain heavy-heavy disulfide bonds. 
 
Figure 5.20. SDS-PAGE gel evaluating the selectivity of linkers in cross-linking Tmab (5 mg/mL, 34 
µM) in Tris.HCl buffer (100 mM, pH 7.5) which has reduced with 4 equiv. of TCEP (136 µM). L: protein 
ladder, lane 1: Tmab incubated with 2 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 
2:  Tmab incubated with 2 equiv. of N,N'-(4-((2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-
1,3-phenylene)bis(2-iodoacetamide) (4.33), lane 3: Tmab incubated with 2 equiv. of 4.23 in the presence 
of 2% SDS, lane 4:  Tmab incubated with 2 equiv. of 4.33 in the presence of 2% SDS, lane 5: Tmab 
incubated with 2 equiv. of 4.23 in the presence of 4% SDS, lane 6:  Tmab incubated with 2 equiv. of 4.33 
in the presence of 4% SDS. Protein samples were resolved by reducing SDS-Page (10% gel). 
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Performing the cross-linking of heavy and light chains in the presence of SDS (2% and 
4%) denature Tmab heavy and light chains and separate them and therefore exposes 
intra-chain disulfide bonds. As expected, the presence of SDS (2% and 4%) resulted in 
loss of the cross-linking of heavy-light chain capabilities of bis-haloacetamide linkers 
(4.23 and 4.33) as indicated by the absence of half antibody band (Figure 5.2, lane 8-
11). Therefore, the presence of cysteine amino acids in close proximity (associated) is a 
prerequisite in order for the cross-linking by bis-haloacetamide linkers to take place, 
which can be related to the several factors, including the pKa value of the thiolate 
groups.187 
Next, we wanted to evaluate the cross-linking of fully reduced Tmab in the presence of 
SDS (2%) in comparison to the control rebridging agent DiBr-Mal (4b). To this end, 
Tmab was reduced with 5 equivalent of TCEP followed by cross-linking with 5 
equivalent of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) linker and the control 
rebridging agent DiBr-Mal (4b). Samples were taken after 3 h and after 16 h 
(overnight). In parallel experiment, SDS (2%) was added to the conjugation buffer, and 
Tmab was reduced with 5 equivalent of TCEP followed by cross-linking with 5 
equivalent of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) or DiBr-Mal (4b). 
Using SDS (2%) leads to denaturate the tertiary structure of Tmab, which resulted in 
loss of the cross linking of heavy-light chains and reduced significantly heavy-heavy 
cross-linking with both methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) and the 
control rebridging agent DiBr-Mal (4b) (Figure 5.21, lane 3-4 and 7-8). These results 
demonstrate that the reduced thiolates should be in close proximity in order to be cross-




Figure 5.21. SDS-PAGE of Tmab (5 mg/mL, 34 µM) conjugation with methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23) and DiBr-Mal (4b) linkers in the absence and presence of SDS (2%) in 
Tris.HCl buffer (100 mM, 150 mM NaCl, 5 mM EDTA, pH 7.5). Tmab was reduced with 4 equiv. of 
TCEP (170 µM) for 2 h at room temperature and then incubated with (17 µM, 5 equiv.) of each linker at 
room temperature. L: protein ladder, lane 1 and 5: Tmab incubated with 5 equiv. of methyl 3,4-bis(2-
bromoacetamido) benzoate (4.23) linker, lane 2 and 6: Tmab incubated with 5 equiv. of DiBr-Mal (4b), 
lane 3 and 7: Tmab incubated with 5 equiv. of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) linker 
in the presence of SDS (2%), lane 4 and 8: Tmab incubated with 5 equiv. of DiBr-Mal (4b) in the 
presence of SDS (2%). Protein samples were resolved by reducing SDS-Page (10% gel). 
Analysis of Tmab reaction with methyl 3,4-bis(2-bromoacetamido)benzoate (4.23)  
linker in the presence of (SDS, 2%) using protein MS revealed the absence of half-
antibody product (75 kDa ) consistent with the SDS-PAGE analysis (Figure  5.22). 
However, interestingly, despite that there was no detected mono-labelling product of 
light chain (expected mass 23,765.02 Da), only intra-chain disulfide bond cross-linking 
was observed. The only possible explanation for this behaviour is through rebridging of 
the intra-chain disulfide bond of the light chain, which is not accessible to reduction 
under native conditions and only susceptible to reduction and cross-linking when Tmab 
has been denatured (the expected mass of cross-linked intra chain disulfide bond of light 




Figure 5.22. Deconvoluted protein MS spectra of cross-linking intra-chain disulfide bond of the light 
chain of Tmab with methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) in the presence of 2% SDS 
showing a major peak at 23,685.78 Da. 
To sum up, disulfide rebridging with bis-haloacetamides occurs mainly if the reduced 
disulfide bonds are in close proximity and the absence of mono-labelling of the heavy 
and light chains as shown by MS implies that the second vicinal thiolate group is 
increasing the reactivity of the first thiolate and the second alkylation is very rapid step. 
Also, as the denaturation step of Tmab exposes the buried intra-chain disulfide bonds 
and thus, the available linkers will either react with the reduced intra-chain disulfide 
bonds or with the already exposed reduced thiolate (reduced inter-chain heavy-light or 
heavy-heavy disulfide bonds). Based on the MS results obtained, which shows that bis-
haloacetamide linkers selectively reacted with the reduced intra-chain disulfide bonds, 
thus it demonstrate the validity of our proposed cross-linking mechanism. 
5.8 Production of a bi-functional Tmab half antibody: Tmabbis(o-HL-OMe,m-
HHintra-N3) 
Firstly, in order to more thoroughly describe the conjugation reaction products, we 
sought to use annotation system describing the constructed products of Tmab, which 
refers to the regiochemistry of the linkers (o: ortho, m: meta), the position of the 
rebridged disulfide bond (HL: heavy-light, HHinta: inta-chain heavy-heavy disulfide 
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Herein, we propose a dual labelling approach to develop a bi-functional mAb which can 
afford a possible wide range of applicable opportunities in developing diagnostic and 
therapeutic tools.  Previously, we demonstrated the usefulness of bis-haloacetamide 
linkers in rebridging the reduced disulfide bonds of Tmab in high yields and the 
selectivity manner of various linkers towards either heavy-heavy or heavy-light 
disulfide bonds has been discussed. Therefore, we next sought to produce bi-functional 
Tmab functionalised with a bio-orthogonal group (an azide group), which is suitable for 
‗Click‘ reaction with a cyclooctyne derivatised cytotoxic drug, fluorescent probe or 
radiolabel.  
We rationalised that using portion-wise (sequential) reduction followed by the cross-
linking would mitigate the non-selective reduction of inter-chain heavy-heavy disulfide 
bonds and afford higher conjugation yield of heavy-light disulfide bonds.  
As such, Tmab (5 mg/mL, 0.033 µmol) in conjugation buffer Tris.HCl (100 mM, pH 
7.5) containing 150 mM NaCl, and 5 mM EDTA, was initially reduced by incubation 
with TCEP 2.2 (2.2 equiv.) for 2 h at 4 . Then, 2.2 equiv. of methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23) was then incubated with the reduced protein and held 
at room temperature overnight. Subsequently, a second reduction step using TCEP (2.2 
equiv.) for 2 h at 4  was performed, prior to incubation with N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) 





Figure 5.23. SDS-PAGE of bifunctional cross-linking of Tmab (5 mg/ml) in Tris.HCl buffer (100 mM, 
pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, using sequential method. Tmab was reduced with 
2.2 equiv. of TCEP for 2 h and incubated with 2.2 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate 
(4.23) at room temperature overnight (lane 1). Functionalised Tmab bis-(o-HL-OMe) was further reduced with 
2.2 equiv. of TCEP for 2 h and incubated with 4 equiv. of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) (4.33) at room 
temperature overnight (lane 2). Protein samples were resolved by reducing SDS-Page (10% gel). 
The cross-linked Tmab was analysed by protein MS. To our delight, we were successful 
to obtain the bi-functional Tmab product as a major product with expected mass of 
74,712.60 Da, and was observed at 74,711.99 Da (Figure 5.24 A). 
Expansion around 74 kDa region, revealed two major peaks at 74,711.99 Da and 
74,874.13 Da (Figure 5.24 B) with a difference of 162.14 Da, which represents N-
glycosylation difference (extra galactose sugar moiety).  
Peaks correspond to rebridged Tmab half antibody (heavy-light disulfide bond and  inta-
chain heavy-heavy disulfide bond) with either two methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23) or two N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) 
(4.33) were also detected, the masses were observed at 74,524 Da and 74,898 Da, 






Figure 5.24. Deconvoluted protein MS spectra of bi-functional cross-linking of Tmab with methyl 3,4-
bis(2-bromoacetamido)benzoate (4.23) and N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-iodoacetamide) (4.33) using sequential 
method. A) Full view MS spectrum of cross -linked Tmab showing major peak at 74,711.99 Da. B) 
Expansion of the spectrum at 74 kDa region. Showing major peaks at 74,711.99 Da and 74,874.13 Da.  
The earlier observed reduction optimisation results using TCEP, suggests that selective 
reduction of inter-chain heavy-light disulfide bonds was not possible even if the 
reduction was performed at lower temperature in order to slow down the reaction and 
increase the selectively, which raise a fundamental question of ranking order of disulfide 
bond susceptibility to reduction. 
A) 
B) 


















 It has been found that the inter-chain heavy-light disulfide bonds were more susceptible 
to reduction than the inter-chain heavy-heavy disulfide bonds, and the upper disulfide 
bond of the two inter chain heavy-heavy disulfide bonds was more susceptible than the 
lower one.148 
When two different linkers were used in sequential reduction and cross-linking 
reactions, as described in above. The production of fully rebridged half antibody with 
two different linkers as a major product, suggests the consistency with our previous 
finding regarding the selective reduction of heavy-light disulfide bonds when lower 
TCEP equivalents were employed (Figure 5.25 a).  
However, the presence of Tmab half antibody fully labelled with two methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23) suggested that a small fraction of Tmab upper bond of 
the two inter chain disulfide bond has reduced with TCEP which might followed by 
disulfide bond rearrangement (Figure  5.25 b) to obtain fully rebridged half antibody 
with the same linker. Given that Tmab has light chain of κ type, the observed results can 
be explained by what Hongcheng Liu et al. have found. They subjected mAbs to 
different reduction concentration of DTT and found that IgG1κ displayed smaller 
susceptibility difference between heavy-light and heavy-heavy disulfide bonds 










5.9 Investigation into the reaction of bis-haloacetamide linkers towards 
other antibodies: Rituximab 
5.9.1 Introduction  
With optimised reduction and rebridging conditions of Tmab in hand, we set out to 
evaluate the versatile applicability of our bis-haloacetamide linkers on different mAb. 
As such, Rituximab (Rmab) mAb was chosen as another model of well-established and 
widely used mAb in hemato-malignancies since it has been approved in 1997.  
Rmab was the first approved mAb in cancer clinical practice. It was approved initially 
for the treatment of relapsed or refractory, CD20-positive, low-grade non-Hodgkin's B-
cell lymphomas (NHL).188 Later, Rmab was approved in 2006 for the treatment of 
rheumatoid arthritis (RA).189 Rituximab is a chimeric anti-CD20 mAb engineered via 
expressing murine variable regions against the CD20 antigen (anti-CD20) with human 
constant regions of IgG antibody.190    
NHL is the most common hematological malignancy in adults and approximately 85% 
of all NHLs cases are B-cell lymphomas. Fortunately, B-cell lymphomas are 
characterized by high level of expressed surface proteins, such as CD19, CD20, and 
CD22, which afford vital targets of potential therapeutic approches.191 CD20 is 
overexpressed in majority of B-cells malignancies with more than 90% of all NHLs 
cases are CD20 positive.192 CD20 is a 33-37 kDa, non-glycosylated phosphoprotein 
which is expressed selectively on the surface of almost all B-cells, including non-
malignant cells.193 CD20 is a transmembrane receptor that is selectively expressed on B-
cells but not on either the precursor lymphoid cells nor on plasma cells. CD20 plays role 
in the development and differentiation of B-cells.194  
5.9.2 Disulfide bond rebridging of fully reduced Rituximab: Rmabbis-[(o-HL,o-HHintra)-
OMe]  
Initially we sought to evaluate the capability of the bis-bromoacetamide linkers to cross-
link fully reduced Rmab.  
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As such, Rmab (5 mg/mL, 0.035 µmol) in Tris.HCl (100 mM, pH 7.5), was initially 
reduced with TCEP 2.2 (5 equiv.) for 2 h at room temperature. The reduced Tmab was 
incubated with 5 equivalent of each bis-bromoacetamide linkers (4.22, 4.23, 4.28 and 
4.29) and held at room temperature overnight. The reaction products were resolved using 
SDS-PAGE (Figure 5.26). 
 
Figure 5.26. SDS-PAGE analysis of cross-linking of fully reduced Rmab (5 mg/mL, 35 µM) in Tris.HCl 
buffer with bis-bromoacetamide linkers. Rmab was reduced with 5 equiv. of TCEP 2.2 (175 µM) for 2 h 
at room temperature and then incubated with (17.5 µM, 5 equiv.) of each linker overnight. L: protein 
ladder, lane 1: Rmab incubated with 5 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 
2: Rmab incubated with 5 equiv. of methyl 3,5-bis(2-bromoacetamido)benzoate (4.22), lane 3: Rmab 
incubated with 5 equiv. of N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.29), lane 4: Tmab incubated 
with 5 equiv. of N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28). HC: heavy chain, LC: light chain, 
LC-LC: light chain homodimers, HC-HC: heavy chain homodimers. Protein samples were resolved by 
reducing SDS-PAGE (10% gel). 
Interestingly, the major product of cross-linking was again half-antibody observed at (75 
kDa) for all bis-bromoacetamide linkers (4.22, 4.23, 4.28 and 4.29) (Figure 5.26). 
Moreover, in similar observed manner, both meta-substituted linkers, methyl 3,5-bis(2-
bromoacetamido)benzoate (4.22) (Figure 5.26, lane 2) and N,N'-(1,3-phenylene)bis(2-
bromoacetamide) (4.28) (Figure 5.26, lane 4) displayed higher proportion of cross-linked 
light-light chains and heavy-heavy chains as displayed as distinct bands around 50 kDa 
and 100 kDa revealed under reducing conditions. While ortho-substituted linkers methyl 
3,4-bis(2-bromoacetamido)benzoate (4.23) and N,N'-(1,2-phenylene)bis(2-
bromoacetamide) (4.29) showed more selective rebridging of heavy-light disulfide bonds 
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with only a very minor proportion of cross-linked light-light chains and inter-chain 
heavy-heavy disulfide bonds (Figure 5.26, lane 1 and 3).  
Protein MS was performed next to confirm the rebridging consistency of bis-
haloacetamides linkers. The MS showed a major peak at 74,036.03 Da corresponding to 
bridged Rmab half-antibody with two linkers (rebridging both intra-chain heavy-heavy 
disulfide bonds and inter-chain heavy-light disulfide bonds) (Figure 5.27). 
 
Figure 5.27. Deconvoluted protein MS spectra of Rmab control showing major peaks 23036.26 and 
50521.24 Da at and cross-linked Rmab with 5 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate 
(4.23) showing a major peak at 74,036.03 Da. 
5.9.3 Preliminary investigation of the higher order structure of Rmabbis-[(o-HL,o-
HHintra)-OMe]  
With the rebridged half antibody characterised in Figure 5.27, we next sought to 
determine the secondary structure of the constructed Rmab conjugate (Rmabbis-[(o-HL,o-
HHintra)-OMe]) using CD analysis. Circular dichroism (CD) spectroscopy is a commonly 
used method for evaluating high order structure of proteins. CD spectrum using a 
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Chirascan spectrophotometer was used analyse the secondary structure difference 
between native Rmab and the cross-linked Rmab-OMe (Rmabbis-[(o-HL,o-HHintra)-OMe]). 
In addition, another cross-linked Rmab was prepared using a similar method as described 
above to obtain fully rebridged half antibody with the azide derivatised linker (4.35) to 
construct the cross-linked Rmab-N3 (Rmabbis-[(o-HL,o-HHintra)-N3]). The Rmab samples were 
buffer exchanged into phosphate buffer (10 mM, pH 7.4) before CD analysis. CD spectra 
measured between 205 and 260 nm were acquired at 25  (Figure 5.28). 
 
Figure 5.28. CD spectrum of Rmab samples over range of 205-260 nm wavelength at 25   showing 
different spectrum of the cross-linked Rmab comparing to the control Rmab.  
CD spectra of the cross-linked Rmab were found to be different from CD spectra of the 
control Rmab (Figure 5.28). By deconvoluting the representative spectra using CDNN 
software, the secondary structure composition of α-helix and β-sheet of rebridged Rmab 
were found to be different from the control Rmab (Table 5.1).  
There are various different factors that affects CD spectrum, such as concentration of 
the sample, presence of excipients (although cross-linked Rmab samples were purified 
by spinning down in phosphate buffer (3 times)), as well as the molecular weight of the 
protein which would include the molecular weight of the linkers in the rebridged Rmab 


























deemed as the largest source of variability in CD measurement.195 Therefore, we could 
not draw a clear conclusion from the obtained CD measurements.  
Table 5.1. Deconvoluted CD data Rmab samples (acquired at 25 ) over the range of 205-260 nm. Data 
obtained using CDNN software. 
mAb Rmab Rmab-OMe Rmab-N3 
wavelength 
range 
205-260 nm 205-260 nm 205-260 nm 
Helix 5.10%  9.90%  13.90%  
Antiparallel 42.10%  31.70%  26.10%  
Parallel 5.50%  5.60%  5.70%  
Beta-Turn 17.10% 17.20% 17.60% 
Rndm. Coil 35.20% 35.10% 34.90% 
Total Sum 105.00% 99.50% 98.10% 
Next, thermal stability was also assessed using CD spectrum by following changes in 
the spectrum with increasing temperature. As such, variable temperature CD was 
performed over the temperature range of 25-90 . Variable temperature circular 
dichroism data for Rmab samples, which shows the changing in the structural 
abundance of α-helix and β-sheet as a percentage of the total protein with temperature 
increasing are shown in (Figure 5.29).  
Melting temperature (unfolding of proteins) is generally indicative of the thermal 
stability of the proteins and the tendency of proteins to aggregate and precipitate. One 
can note that melting temperature of Rmab samples (between 70-75  ) have not 
significantly changed among the different Rmab samples, which indicates that the 
overall thermal stability of the cross-linked Rmab has not been affected and likewise the 





Figure 5.29. Variable temperature CD data for Rmab samples showing structural abundance of α-helix, 
and β-sheet as a percentage of the total protein. Measured over a temperature range of 25-90 . 
We aimed next to evaluate the tertiary structure of Rmab and compare it to the cross-
linked by using DLS technique. DLS (Dynamic light scattering) technique is commonly 
used to study the tertiary structure of proteins as well as the presence of protein 
aggregates. DLS analysis was carried out to compare particle size of native Rmab and 
Rmabbis-[(o-HL,o-HHintra)-OMe], which will give us more understanding of the tertiary 
structure of mAb. As such, the average particle size of the Rmab and cross-linked Rmab 





























































significant difference between average particle size of control and cross-linked Rmab, 
we can conclude that the rebridged half-antibodies are associated together in solution 
and presented as intact antibody. Moreover, no apparent protein aggregates were 
observed in both samples. 
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Figure 5.30. Hydrodynamic radius distribution by intensity for Rmab and cross -linked Rmab at 2 mg/mL, 
indicating that there is a major peak for Rmab and cross -linked Rmab-OMe with methyl 3,4-bis(2-
bromoacetamido) benzoate (4.23) at 14.92 nm and 12.00 nm, respectively. 
5.10 Stability of rebridged Rmab half antibody: Rmabbis-[(o-HL,o-HHintra)-OMe] 
under reducing conditions and after 2 months at 4  
Stability of the conjugated mAb in plasma is one of the major concerns and obstacles of 
construction of ADCs, especially maleimide based ADCs. It is widely acknowledged 
that maleimide−thiol conjugates, are not stable and might slowly undergo retro-Michael 
addition to reform maleimide. A new thiol conjugate will form in the presence of 
circulating peptides and proteins in biological environment, particularly albumin and 
glutathione (see Section 1.4.2.1).84,196 
To this end, we aimed next to test the stability of the fully rebridged half antibody, 
previously characterised in Figure 5.27, in plasma mimicking conditions [20 µM 
glutathione, 600 µM human serum albumin (HSA)]. Fully rebridged half antibody 
(Figure 5.31, lane 1) has been buffer exchanged to fresh buffer (pH 7.4) by repeated 
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diafiltration, then glutathione (20 µM final concentration) and HSA (600 µM final 
concentration) were added.  
The sample was incubated at 37°C for 7 days. The stability was monitored by SDS-
PAGE analysis, which revealed that the cross-linked Rmab was stable over seven days 
in plasma mimicking conditions with no new bands corresponding to the formation 
adducts between HSA or glutathione with heavy or light chains of Rmab (expected 
masses around 115, 90, 50 and 25 kDa) were observed (Figure 5.31, lane 2-6). 
 
Figure 5.31. Stability of fully rebridged half antibody (Rmabbis-[(o-HL,o-HHintra)-OMe]) in plasma mimicking 
condition. SDS–PAGE analysis of cross-linked Rmab following incubation in plasma mimicking 
conditions for 0, 1, 3, 5 and 7 days (lanes 2-6, respectively). Protein samples were resolved by reducing 
SDS-PAGE (10% gel). 
Next, fully rebridged half antibody, previously characterised in Figure 5.27, was buffer 
exchanged into fresh buffer (pH 7.4) and held at 4  for two months. The stability was 
monitored by SDS-PAGE, which revealed the complete stability of the conjugate after 2 




Figure 5.32. Stability of fully rebridged half antibody (Rmabbis-[(o-HL,o-HHintra)-OMe]) after storage at 4 . 
SDS–PAGE analysis of rebridged Rmab following incubation in fresh buffer at 4  after 0, 1, 2, 4, 6 and 
8 weeks (lanes 1-6, respectively). Protein samples were resolved by reducing SDS-PAGE (10% gel). 
5.11 Cross-linking of human complement protein C3dg 
Having demonstrated the efficiency of bis-haloacetamide linkers in cross-linking 
disulfide bond of mAbs, we sought to demonstrate the usefulness of these reagents in 
cross-linking wider range of proteins and studying protein-protein interactions by 
chemically cross-linking proteins together affording more stable interactions.  
Recently, it has been observed by our collaborators that human complement protein 
C3dg forms homo-dimers in solution through formation of disulfide bridges. In attempt 
to further elaborate this observation and understand how it is related to the role of this 
protein in human body, we sought to chemically cross-link C3dg protein using bis-
haloacetamide linkers to be further tested by our collaborators. 
As such, C3dg protein (wild-type) was incubated with 0.75 equiv. of methyl 3,4-bis(2-
haloacetamido) benzoate linkers (4.22-4.25) linkers at room temperature overnight, the 
reaction products were resolved using SDS-PAGE (Figure  5.33, lane 3-6).  
A new distinct band around 60 kDa was observed with all the evaluated linkers, which 
corresponds to the homo-dimer of C3dg protein (Figure 5.33, lane 3-6). However, 
higher molecular weight protein band were mainly observed with meta-substituted 
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methyl 3,5-bis(2-bromoacetamido) benzoate (4.22) and methyl 3,5-bis(2-
iodoacetamido) benzoate (4.24) (Figure  5.33, lane 4 and 6).  
 
Figure 5.33. Cross-linking of C3dg (2 mg/ml, 5 µM) with linkers bis-haloacetamide linkers (4.22, 4.23, 
4.24, 4.25). L: protein ladder, lane 1: control (non-reducing dye), lane 2: C3dg incubated with 5 kDa 
PEG-maleimide (10 equiv.), lanes 3: C3dg incubated with 0.75 equiv. methyl 3,4-bis(2-bromoacetamido) 
benzoate (4.23), lane 4: C3dg incubated with 0.75 equiv. methyl 3,5-bis(2-bromoacetamido) benzoate 
(4.22), lanes 5: C3dg incubated with 0.75 equiv. methyl 3,4-bis(2-iodoacetamido) benzoate (4.25), lane 6: 
C3dg incubated with 0.75 equiv. methyl 3,5-bis(2-iodoacetamido) benzoate (4.24) at room temperature 
overnight. Protein samples were resolved by reducing SDS-Page (10% gel). 
Next, we sought to evaluate cross-linking of C3dg using a range of equivalents (0.5, 
0.75 and 1.5 equiv.) of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) in order to 
evaluate their influence on the percentage of conversion to the homo-dimers.  
One can note that with incremental increase of the equivalents of methyl 3,4-bis(2-
bromoacetamido) benzoate (4.23), there is observed increase of newly formed (distinct) 
band at similar molecular weight of C3dg (Figure  5.34, lane 2-4). This observed pattern 




Figure 5.34. Cross-linking of C3dg (2 mg/ml, 5 µM) with methyl 3,4-bis(2-bromoacetamido) benzoate 
(4.23) linker. L: protein ladder, lane 1: control (non-reducing dye), lanes 2: C3dg incubated with 0.5 
equiv. methyl 3,4-bis(2-bromoacetamido) benzoate (4.23), lane 3: C3dg incubated with 0.75 equiv. 
methyl 3,4-bis(2-bromoacetamido) benzoate (4.23), lane 4: C3dg incubated with 1.5 equiv. methyl 3,4-
bis(2-bromoacetamido) benzoate (4.23) at room temperature overnight. Protein samples were resolved by 
reducing SDS-Page (15% gel). 
To further characterise the obtained results, protein MS was performed. A native protein 
showed a single peak at 34,7742.28 Da (Figure 5.35 A). Cross-linked C3dg with 3,4-
bis(2-bromoacetamido) benzoate (4.23) showed a major peak at 34988.40 Da, which 
corresponds to C3dg with one cross-linked intra-disulfide bond and a minor peak at 
69,730.48 Da, Which correspond to the cross-linked homo-dimer of C3dg (Figure  5.35 
B). These results revealed that the lower band seen in lane 2-4 previously is rebridged 
intra-disulfide bond C3dg (Figure 5.30, lane 2-4).  
C3dg homo-dimers were separated from the cross-linked monomer by using SEC to 
obtain the pure dimer of C3dg to be further tested by our collaborators (purification of 





Figure 5.35. Deconvoluted spectrum protein MS of Cross-linking of C3dg with bis-haloacetamide 
linkers. A) Native C3dg showing a peak at 34,742.28. B) Cross-linked C3dg with 0.5 equiv. of methyl 
3,4-bis(2-bromoacetamido) benzoate (4.23) showing a cross-linked monomer peak at 34,988.40 Da and 




























From the detailed and thorough evaluation of the applicability of aryl bis-haloacetamide 
linkers in rebridging mAbs, such as Tmab and Rmab, we can conclude the following: 
1. Reduction conditions of the 4 disulfide bonds of Tmab were optimised to obtain 
fully and partially reduced Tmab. 
2. An interesting rebridged half antibody (rebridging both intra-chain heavy-heavy 
disulfide bonds and inter-chain heavy-light disulfide bonds) of mAbs was 
observed as a major product using bis-haloacetamide linkers. 
3. It has been demonstrated that well-defined and stable rebridging of half 
antibodies were obtained with these linkers. 
4. Functionalisation of mAbs with clickable handle (azide) was achievable 
affording a mAbs with clickable handle to be used in azide cyclooctyne 
cycloaddition reaction. 
5. Selectivity of different bis-haloacetamide linkers towards the reduced disulfide 
bonds of mAbs was studied, which enabled us to better understand the order of 
the reduction susceptibility of disulfide bonds and to successfully construct 
hetero bi-functional mAbs. 
6. Applicability of aryl bis-haloacetamide linkers in cross-linking of different 










6 Synthesis of an immunomodulating antibody conjugate: 
Trastuzumab–Sbi 
6.1  Introduction 
6.1.1 The human complement system  
The human complement system is a large family of related proteins and proteolytic 
fragments that is deemed to be an essential part of innate immunity and a regulator of 
adaptive immunity against microbes. In addition to the vital inflammatory resolving role 
of this system through mediating the clearance of apoptotic cellular debris and antigen-
antibody complexes (immune complexes).197,198 This system comprises more than 30 
components, including proteins, receptors and regulators presented on cell surfaces or in 
plasma. These components play a vital role in innate immune response as well as they 
mount an effective adaptive immune response.  Therefore, any deficiency of the 
complement components predisposes the patient to bacterial infection and immune 
complex diseases.199 
A great amount of research has been undertaken on the complement system and its 
components. These studies provide immense insights into each component of this 
system and the essential role of the complement system in inflammatory diseases. It has 
become apparent that inappropriate or uncontrolled activation of the complement system 
has a significant impact on various inflammatory diseases. Currently there are two anti-
complement drugs are on the market, with many more under development for various 
infectious, inflammatory, and degenerative diseases.200,201 
6.1.1.1 Complement activation pathways 
Complement activation can be initiated through three distinct pathways, these are the 
classical (CP), lectin (LP), and alternative pathways (AP) as shown in Figure 6.1. 
The classical pathway is initiated by recognition of the C1q molecule of the antigen-
antibody complex of IgG or IgM antibodies, which triggers self-activation of C1r to 
activate the proteolytic C1s (Figure 6.1). C1s cleaves C4 into C4a and C4b, and C2 into 
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C2a and C2b, to assemble C4bC2a which is known as C3 convertase.202 In the lectin 
pathway, mannan-binding lectins (MBLs) which are pattern recognition molecules, bind 
to mannose or other bacterial carbohydrate motifs. Recognition of bacterial 
carbohydrates trigger activation of MBL-associated serine proteases (MASPs) which 
have a similar role to C1r and C1s in assembling C3 convertase.203  
 
Figure 6.1. Complement activation pathways. Regardless of the initiators of each pathway, all three 
pathways aim to form C3 convertase which activates the central component of the complement system 
C3. C5 convertase will then be constructed to cleave C5 and form C5b-C9 membrane attack complex 
(MAC). C3a and C5a are well-known chemotactic agents. 
However, in the alternative pathway, activation occurs spontaneously and continuously 
at a low rate via C3 associating with a water molecule (hydrolysis) forming C3 (H2O), 
which in turn activates factor B (fB) and factor D (fD). Factor D, a serine protease in 
serum, can enzymatically cleave factor B to Bb affording C3bBb which is an alternative 
pathway C3 convertase. C3 convertase can be stabilised in plasma via binding to 
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properdin, which is a positive regulator of the alternative pathway. The alternative 
pathway functions as an amplification loop for the other pathways.200,204,205 The 
spontaneous hydrolysis of the thioester bond of C3 is known as a tick-over mechanism, 
which ensures and maintains a low level of complement activation in the fluid phase to 
constantly screen for any pathogenic invasion.206 
Regardless of the initiation of the three pathways, they will all merge at C3 convertase 
construction which activates C3, an essential component of the complement system. C3 
convertase cleaves C3 into C3a, a chemotactic agent, and C3b which opsonises cell 
surfaces. The latter will bind C3 convertase to assemble C5 convertase which in turn 
releases C5b and the proinflammatory C5a. The generated C5b binds to C6 and 
subsequently C7 and C8 in addition to 10-16 C9 molecules affording the membrane 
attack complex (MAC) C5b-C9, which leads eventually to cell death through lysis 
(Figure 6.1). 
6.1.1.2 Regulation of the complement system 
Given that the complement system does not discriminate between self and non-self cells, 
it is strictly controlled by a broad range of membrane-bound and fluid-phase inhibitors 
to prevent damage to self-cells.201  
The decay accelerating factor (DAF or CD55) is a membrane-bound inhibitor that 
promotes the degradation of C3 and C5 convertases, thereby interfering with the 
downstream activation processes, eventually restricting the assembly of the MAC on 
cells that express DAF.207 The membrane cofactor protein (MCP or CD46) is another 
membrane bound regulator which functions as a cofactor for serum factor I (fI). Other 
complement system membrane-bound regulators include the surfaced-expressed 
protectin (CD59), which blocks assembly of the MAC, and the surface-expressed CR1, 
which exhibits fI cofactor activity. fI is a serum factor that cleaves C3b to iC3b, which 
is further cleaved to C3c and C3dg.208 Factor H (fH) is the master plasma protein 
regulator of AP at the C3b level. It competes with fB and prevents it from binding to the 
C3b protein, in addition to accelerating the decay of the C3 convertase (C3bBb). The C-
terminus of factor H can bind to two ligands: C3b and surface-expressed polyanionic 
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glycosaminoglycans (GAGs), including sialic acid residues. However, the N-terminus 
domains of fH perform decay accelerating and fI cofactor activities, thereby protecting 
host self-cells from complement activation. Mutations and SNPs (single nucleotide 
polymorphisms) in fH have been widely associated with complement-mediated cellular 
damage which leads to a variety of human inflammatory diseases including age-related 
macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS).209–211 
Factor H-related proteins (FHR1-5) are a group of related proteins which are deemed to 
be positive regulators of the AP of the complement by competing with fH interaction 
with C3b and/or GAGs.212 
The C1 inhibitor is a fluid phase serine protease that irreversibly binds to and cleaves 
C1r, C1s, MASP-1, and MASP-2, thereby interfering with both classical and MBL 
pathways.199 
6.1.1.3 The C3 complement component  
The C3 component is the central and most abundant complement protein in serum and 
body fluids. It is present in a concentration of 1.2–1.5 mg/mL in circulation.213 C3 is a 
large protein of 1,400–1,800 amino-acid residues. C3 consists of two chains, a β-chain 
(residues 1–645, 75 kDa) and an α-chain (residues 650–1,641, 110 kDa) connected 
together covalently through a disulfide bond and non-covalent forces. The α-chain and 
β-chain of C3 protein form 13 domains. Perhaps the most important domain of the C3 
protein is the thioester‑containing domain (TED), where the thioester bond is buried 
deep between the TED and MG8 domains in order to prevent its access to the hydroxyl 
nucleophiles.214 
Upon activation by the C3 convertases, C3 is cleaved between Arg726 and Ser727 to 
remove the small anaphylatoxin domain (C3a) from the N-terminus of the α-chain to 
attain C3a and C3b fragments. This cleavage leads to noticeable conformational changes 
in the structure of C3 to displace the thioester moiety and expose it completely to the 
surface. Therefore, the solvent accessible thioester will covalently interact with other 
acceptor sites, such as pathogens and foreign structures. This process, which is known 
as opsonization, enhances phagocytosis via involvement of CR1, CR3, and CR4 
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receptors. Active C3b has a short serum half-life and is readily cleaved into iC3b 
fragments by fI in the presence of fH, CR1, or the membrane cofactor protein and 
further to C3dg. Lastly, C3dg is cleaved by tryptic enzymes to C3d and C3g.214,215  
Both iC3b and C3dg, but not C3b, can stimulate B cells via binding to CR2 receptor 
(also known as CD21) that is expressed on the B-cell to mount effective antibody 
production and an immune response, by dropping the threshold for B-cell activation by 
1000 to 10,000 fold.216,217 
In conclusion, complement system plays an essential role in both innate and adaptive 
immunity to protect against pathogenic infections. One of the opportunistic pathogens 
that causes significant infections in human is Staphylococcus aureus (S. aureus) which 
is an abundant bacteria of the skin microbiome of humans. S. aureus has developed an 
arsenal of protective mechanisms against innate and adaptive immunity, in particular 
against the complement system.  
6.1.2 Immune evasion mechanisms of Staphylococcus aureus 
The human pathogen S. aureus chiefly colonizes the moist squamous epithelium of 
anterior nares, but it can also be found in the gastrointestinal tract and on the skin. 
Approximately 30% of people carry S. aureus continuously, which mainly adheres to 
nasal mucosa, while around 70% of people host S. aureus intermittently.218 
S. aureus causes various infections ranging from superficial skin infection, such as 
abscesses and impetigo, to invasive life-threating infections such as septic arthritis, 
osteomyelitis and endocarditis. S. aureus has a tremendous ability to evade the human 
immune system owing to its ability to express different virulence factors breaching both 
innate and adaptive immune responses.219,220  
After breaching skin and squamous epithelium, S. aureus begins to confront early innate 
immune responses mediated by neutrophils. C5a, a proteolytic fragment of the C5 
complement protein, and formylated peptides secreted from growing bacterial cells 
initiate a strong inflammatory response at the site of invasion, which in turn recruits 
neutrophils from the blood to the site of inflammation. In response, S. aureus produces 
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the staphylococcal superantigen-like protein 7 (SSL-7) which binds to P-selectin 
glycoprotein ligand (PSGL)-1 on neutrophils and interferes with the binding of P-
selectin to neutrophils,  ultimately interfering with the migration of neutrophils to the site 
of infection.221 About 60% of S. aureus strains produce the chemotaxis inhibitory protein 
of S. aureus (CHIPS) which blocks the binding of C5a and formylated peptides on 
neutrophils to prevent their migration to the site of inflammation.222  
Following this, S. aureus produces a wide range of virulence factors, blocking 
opsonization of its surface in order to establish successful infection and subvert the 
phagocytic processes. Of these factors, protein A or Staphylococcal cell wall anchored 
protein A (SpA)  binds to the Fc  domain of IgGs thereby blocking the phagocytosis 
process.223 Clumping factor A (ClfA) is another dominantly expressed protein on the 
surface of S. aureus cells. It prevents opsonization and recognition of opsonins through 
coating the cell surface with fibrinogen.224 In addition to the previously mentioned 
surface proteins, about 90% of S. aureus strains express capsular polysaccharides, 
predominantly capsule types 5 or 8. The presence of the polysaccharide capsule reduces 
the phagocytosis S. aureus by forming a layer which creates a barrier on the bacterial 
cell surface against opsonins.225 
Production of coagulases is a hallmark of all the isolated S. aureus. These secreted 
proteins bind to and activate prothrombin to the enzymatically active staphylothrombin. 
Staphylothrombin activates fibrinogen to fibrin fibrils, generating a protective fibrin 
meshwork against phagocytes.226 
S. aureus also produces staphylokinase which is a plasminogen activator that binds in a    
1:1 ratio to the cell-bound plasminogen and activates the latter to the potent serine-
protease plasmin. Plasmin cleaves cell-bound C3b and IgG and disturbs the opsonization 
process.227 
In addition to the above mentioned virulence factors, S. aureus secretes cytolytic toxins 
that destruct the membranes of host leukocytes and kill neutrophils which results in the 
formation of abscess lesions.228 
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6.1.2.1 Staphylococcus aureus complement evasion mechanisms 
S. aureus produces an arsenal of complement evasion factors in order to avoid deposition 
of complement proteins on the bacterial cell surface; therefore, it is considered to be a 
chief  pathogen of complement evasion.229 Indeed, C3b deposition is the central host 
defense mechanism against S. aureus, with three out of the five complement receptors, 
namely CR1, CR3 and CRIg found to be the most relevant receptors for successful host 
defense.221 
S. aureus produces unique proteins targeting mainly the central complement 
components, namely C3 and C5.  Therefore, it interferes with the downstream signaling 
and activation pathways. The extracellular fibrinogen-binding protein (Efb) and the 
recently identified Efb-homologous proteins (Ehp) bind to the C3d domain of C3b, 
inducing conformational changes and deactivating C3, thereby  inhibiting the adaptive 
immune response, opsonophagocytosis and cellular lysis.230,231 Staphylococcal 
complement inhibitors (SCINs) are small proteins that bind to and stabilise C3 
convertase in a inactivel state, thereby blocking the downstream signaling and the three 
activation pathways.232,233 Unlike Efb and Ehp, SCINs can only bind to the C3 convertase 
but not to C3 or its fragments.232 
S. aureus produces two main inhibitors at the C5 level in order to subvert the assembly 
of MAC and the chemotaxis process. Staphylococcal superantigen-like protein 7 (SSL-7) 
binds with high affinity to C5, hinders its cleavage by C5 convertase, and consequently 
inhibits complement-mediated cellular lysis.234 The chemotaxis inhibitory protein of           
S. aureus (CHIPS) interferes with C5a, the complement inflammatory agent, through 
binding to C5a receptors on phagocytes. Given that C5a has a vital role in the 
inflammatory process, several studies have tested the potential employment of the 
CHIPS protein in the treatment of inflammatory diseases.222,235 
S. aureus has a cell wall binding protein, namely staphylococcal cell wall anchored 
protein A (SpA), which interferes at an early stage of complement activation. The SpA 
protein binds to the Fc domain of IgG protein and blocks C1q binding thereby  
interfering with the activation of the complement classical pathway.236 
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Interestingly, deep analysis of IgG binding activity of S. aureus proteins has revealed a 
second protein, in addition to SpA, with IgG binding capacity, namely Staphylococcus 
immunoglobulin-binding protein (Sbi).237 
6.1.3 The Staphylococcus immunoglobulin-binding (Sbi) protein   
Sbi is a 436-residue immune-evasion protein, expressed by several strains of S. aureus. 
From its N-terminus, Sbi consists of an extracellular region, followed by a cell wall 
spanning region (proline repeat region), and a C-terminus region (tyrosine-rich region, 
130-residue). The extracellular region consists of four globular domains (I-IV). Sbi I-II 
(residues 42-156) binds to the Fc region of IgG, interfering with C1q binding. However, 
Domains III and IV of Sbi (residues 150-266) are two novel C3-binding domains (Figure 
6.2).238  
In contrast with SpA, Sbi does not have the typical cell wall anchoring sequence 
(LPXTG).238 Therefore, Sbi can be found both anchored to the cell envelope by binding 
to lipoteichoic acid and as a secreted protein, but only the secreted form of Sbi can 
interact with C3 of complement proteins.239 
 
Figure 6.2. Full domains structure of Sbi protein. It comprises four extracellular globular domains (I-IV), 
the cell wall spanning domain (Wr) and the tyrosine rich region (Y). 
Sbi I-II domains bind to the Fc  domain of IgG, thus interfering with complement 
fixation and phagocytosis. Both domain I and II exhibit sequence homology with IgG-
binding domains of SpA (E, D, A, B and C ) with almost identical amino acids to those 
involved in Fc binding.240  
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Sbi III-IV domains on the other hand, interact with C3 mainly through C3dg sub-
domains. By binding to C3, Sbi interferes with all three complement activation pathways 
which converge at the C3 convertase.238 It has been shown that the secreted Sbi III-IV 
has a distinctive complement evasion mechanism through consumptive activation of the 
AP, which leads to futile cleavage of C3 away from the bacterial surface thereby 
avoiding C3b-mediated opsonization and C3a-mediated chemotaxis.238  Sbi I-II are 
known as IgG binding domains as discussed earlier, and it is known that the C3b 
fragment has a short half-life and a unique ability to covalently bind to other proteins 
through the displayed thioester bond. IgGs, on the other hand, are well-known 
transacylation targets of C3b and therefore, S. aureus provides another protective 
mechanism against the activated C3 protein.241,242 Moreover, it has been shown that Sbi 
III-IV binds to the active metastable C3b and thus prevents the normal turnover of the 
C3b fragment by fH and fI.243  
The proposed mechanism of Sbi III-IV in the consumption of C3 is via construction of a 
tripartite complex with C3b and complements regulatory proteins (FHR-1), which 
competitively antagonize the activity of factor H and stabilize the C3 convertase of AP. 
Ultimately, Sbi III-IV ensures that C3 is consistently activated and consumed, while 
stabilizing the nascent C3b fragments.243 
Taken together, the unique mechanism of Sbi III-IV provides great potential to be 
utilized as an immunomodulator of the complement AP to attain potential opsinization of 
a targeted antigen (as a vaccine), or through cellular lysis of cancer cells. As such, we set 
out to develop novel conjugation method to produce immunoconjugates of Sbi III-IV 
and the mAbs (Trastuzumab). It was postulated that immunoconjugates of Sbi III-IV and 
Tmab would activate AP of the complement system, causing selective and targeted 
opsinization of HER2 positive cancer cells with C3b, ultimately leading to cellular lysis 




Figure 6.3. Our proposed mechanism of the immunoconjugates of Trastuzumab-Sbi III/IV which activate 
the C3 component of complement system to selectively opsonize HER-2 positive cancer cells with C3b 
and ultimately causing cellular lysis. 
6.2 Synthesis of bis-dihaloacetamide (PEG)3 
The conjugate format of one Sbi III/IV-2xCys bound to Fab region of Tmab is what we 
are interested to initially develop and test (Figure 6.4). The proposed format will be 
achieved through binding of one Sbi III/IV-2xCys per Tmab, through specifically 
linking Sbi III/IV protein to the heavy-light disulfide bond of the Fab region (Figure 
6.4). Therefore, we sought to synthesise a tetra-haloacetamide linker, with two 
rebridging heads (bis-dihaloacetamide (PEG)3 linkers) for dual rebridging of heavy-light 
chains of Tmab and the 2 cysteine residues (at C-terminus of domain IV) of Sbi III/IV-
2xCys to construct immunomodulating conjugates. Bis-dihaloacetamide (PEG)3 linker 
will afford a simple, one pot approach without the need to use ‗Click‘ chemistry to 





Figure 6.4. Schematic representation of the conjugation format used to attain conjugation of Tmab and 
Sbi (            ). 
Given that ortho-linkers showed higher selectivity towards rebridging the reduced 
heavy-light disulfide bonds of Tmab as shown previously in Chapter 5, we sought to 
prepare ortho-bis-dihalooacetamide (PEG)3 6.1 and 6.2 linkers to bridge the disulfide 
bond of a certain protein and to attached it to the rebridged heavy-light chain of Tmab 
(Figure 6.4). 
As such, bis-o-dihaloacetamide (PEG)3 linkers (6.1 and 6.2) were synthesised over 4 
steps shown in Figure 6.5. First, acetylation of 3,4-diaminobenzoic acid using 2-
chloroacetyl chloride gave 4.44 in 90% yield, followed by synthesis of activated ester 
(4.45) using N-hydroxysuccinimide (45% yield). Next, the activated ester (4.45) was 
reacted with 1,11-Diamino-3,6,9-trioxaundecane (6.3) for 1 h (75% yield) to attain bis-
dichloroacetamide (PEG)3 (6.4), which was then converted to either iodo- or bromo- 




Figure 6.5. Synthesis of bis-dihaloacetamide (PEG)3 6.1 and 6.2 linkers. a) ClCOCH2Cl, THF, b) NHS, 
EDC.HCl, THF, c) 1,11-Diamino-3,6,9-trioxaundecane (6.3), THF, d) LiBr, dry acetone, reflux to give 
6.1, e) KI, dry acetone, reflux to give 6.2. 
6.3 The two employed strategies to produces Tmab-Sbi conjugate  
The two strategies that were evaluated to construct Tmab-Sbi conjugate with bis-
dihaloacetamide (PEG)3 linkers (6.1 and 6.2) are shown in Figure 6.6. Tmab-Sbi 
conjugate were constructed either through conjugation of functionalised Tmab with pre-
reduced Sbi III/IV-2xCys (strategy 1) or through conjugation of functionalised Sbi 






Figure 6.6.  Schematic representation of the strategies evaluated to produce Tmab-Sbi conjugate, either by the conjugation of functionalised Tmab with reduced 
Sbi (strategy 1) or through conjugation of functionalised Sbi with partially reduced Tmab (strategy 2). 
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6.4 Conjugation of functionalised Tmab with reduced Sbi (Strategy 1) 
As described previously in Chapter 5, optimum reaction yield were obtained when 1 
equivalent of reducing agent and linkers were employed. Therefore, we sought to 
initially optimise the reduction step (partially) of Tmab using 1 equivalent of TCEP. The 
reduction conditions followed by conjugation with bis-bromoacetamides (4.22, 4.23, 
4.28 and 4.29) will be evaluated initially in order to optimise the required conditions for 
bis-o-dihaloacetamide (PEG)3 6.1 and 6.2 linkers. 
We first set out to determine the optimum concentration of Tmab, as such a set of three 
concentrations of Tmab were evaluated: 2, 5 and 10 mg/mL. Tmab in conjugation 
Tris.HCl buffer (100 mM, pH 7.5) and concentrated to (2, 5, or 10 mg/mL). Tmab was 
first reduced (partially) by incubation with TCEP (1.1 equiv.) for 2 h at 4 , then 
incubated with 1.1 equiv. of each bis-bromoacetamide linker (4.22, 4.23, 4.28 and 4.29) 
and held at room temperature overnight. Reaction products were resolved using SDS-
PAGE. 
Attempting only 1.1 equivalent of TCEP followed by 1.1 equivalent of each linker 
would produce rebridged half-antibody product (75 kDa) of one Fab of Tmab, in 
addition to the unreacted second Fab (50 kDa, 25 kDa).  
By observing the intensity of the HC-LC (75 kDa under reducing conditions) and HC 
(50 kDa under reducing conditions) bands under reducing conditions, one can note the 
high yields obtained with most the performed reactions (equal bands intensity), 
particularly at 5 mg/mL concentration of Tmab (Figure 6.7, lane 9-12). Moreover, 
adopting a higher concentration (10 mg/mL), did not, however, improve the cross-
linking yield (Figure. 6.7, lane 17-20).  
Samples of the reactions were run also under non-reducing conditions to evaluate the 
cross-linking of intra-chain disulfide bonds of heavy chain (50 and 75 kDa bands under 
non-reducing condition). It can be concluded that the major products obtained is the 
desired rebridged half-antibody (heavy-light disulfide bonds) with one linker, while 
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rebridged half-antibody with two linkers (intra-chain heavy-heavy and heavy-light 
disulfide bonds) was found to be a very minor product.   
 
Figure 6.7. SDS-PAGE analysis of cross-linking of partially reduced Tmab in Tris.HCl buffer (100 mM, 
150 mM NaCl, 5 mM EDTA, pH 7.5) with bis -bromoacetamide linkers. Tmab was reduced with 1.1 
equiv. of TCEP for 2 h at 4  and incubated with 1.1 equiv. each linker at room temperature overnight. 
Lane 1, 9 and 17: Tmab incubated with 1.1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), 
Lane 2, 10 and 18: Tmab incubated with 1.1 equiv. of methyl 3,5-bis(2-bromoacetamido)benzoate (4.22), 
Lane 3, 11 and 19: Tmab incubated with 1.1 equiv. of N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.29), 
Lane 4, 12 and 20: Tmab incubated with 1.1 equiv. of N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28). 
Lane 5-8, 13-16, and 21-24 represent the same reactions in the same described order but run under non-
reducing conditions (non-reducing dye). 
Consistent with what we observed previously, the ortho-substituted linkers (4.23 and 
4.29) displayed almost 100% observed conversion to the desired product as equal bands 
of HC-LC and HC were observed under reducing conditions (Figure. 6.7, lane 9 and 
11).  
Further analysis of Tmab cross-linking reaction with ortho-substituted linkers (4.23 and 
4.29) at 5 mg/mL was performed with protein MS. Gratifyingly, both ortho-linkers 
displayed almost equal intensity of the half-antibody peak at 75 kDa (with one linker 
rebridging heavy-light disulfide bond) and the heavy chain peak at 50 kDa (uncross-





Figure 6.8. A) Deconvoluted protein MS spectrum of cross -linked Tmab with 1.1 equiv. of methyl 3,4-
bis(2-bromoacetamido) benzoate (4.23) showing major peak at half antibody at 74,384.17 Da and a peak 
at 50,765.12 Da (unfunctionalised heavy chain). B) Deconvoluted protein MS spectrum of cross -linked 
Tmab with 1.1 equiv. N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.27) showing two major peaks at 
50,756.23 Da (unfunctionalised heavy chain) and half-antibody at 74,442.24 Da. Both spectra showed 
light chain peak at 23,439.7 Da (unfunctionalised light chain).  
With optimum reduction and cross-linking methods in hand, we next sought to evaluate 
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6.4.1 Rebridging of partially reduced Tmab with bis-dihaloacetamide (PEG)3 
linker 
Having successfully established the selective reduction conditions, we next tend to 
evaluate their rebridging ability with partially reduced Tmab. As such, Tmab (5 mg/mL) 
in conjugation buffer Tris.HCl (100 mM, pH 7.5) was reduced by incubation with TCEP 
(1.1 equiv.) for 2 h at 4 . The reduced Tmab was then incubated with 1.1 or 2 
equivalents of bis-o-diiodoacetamide (PEG)3 linker (6.2) and held at room temperature 
overnight.  
SDS-PAGE analysis of the reaction products displayed inferior rebridging capability of 
heavy-light chains (75 kDa) with bis-o-diiodoacetamide (PEG)3 linker (6.2) (Figure 6.9, 
lane 1 and 2) compared to methyl 3,4-bis(2-bromoacetamido) benzoate (4.23), which 
was used as a positive control to confirm the optimum reduction condition (Figure 6.9, 
lane 3). Possibly, the cross-linking of heavy-light was decreased because of the non-
selective cross-linking of heavy-heavy chains with the second head of bis-o-
diiodoacetamide (PEG)3 linker (6.2) as observed by SDS-PAGE analysis of these 
reactions (higher MW bands around 125 and 150 kDa under reducing conditions) 
(Figure 6.9, lanes 1 and 2). 
 
Figure 6.9. SDS-PAGE of cross-linking of partially reduced Tmab (5.0 mg/ml, 34 µM) in Tris.HCl buffer 
(100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, with bis-o-diiodoacetamide (PEG)3 linker 
(6.2). Tmab was reduced with 1.1 equiv. of TCEP (37 µM) for 2 h at 4  and incubated with the linker at 
room temperature overnight. Lane 1: Tmab incubated with 1 equiv. of bis-o-diiodoacetamide (PEG)3 
linker (6.2), Lane 2: Tmab incubated with 2 equiv. of bis-o-diiodoacetamide (PEG)3 linker (6.2), Lane 3: 




We observed previously that bis-iodoacetamide linkers are more selective toward cross-
linking of heavy-heavy disulfide bonds, thus we proposed that bis-o-dibromoacetamide 
(PEG)3 linker (6.1)  would be more selective toward heavy-light disulfide bonds. 
To this end, Tmab (5 mg/mL) in Tris.HCl buffer was reduced by incubation with TCEP 
(1.1 equiv.) for 2 h at 4 . The reduced Tmab was incubated with 5 equivalents of bis-
dihaloacetamide (PEG)3 linkers and held at room temperature overnight. Both bis-o-
dihaloacetamide linkers (6.1 and 6.2) displayed similar level of rebridging of heavy-
light chains (75 kDa) (Figure 6.10, lanes 4 and 5). 
In comparison with methyl 3,4-bis(2-bromoacetamido) benzoate (4.23), both bis-
dihaloacetamide linkers (6.1 and 6.2) showed a lower degree of heavy-light chain 
rebridging and higher level of high molecular weight bands (at 125 kDa and 150 kDa) as 
observed by SDS-PAGE of the reaction products (Figure 6.10, lanes 4 and 5). 
 
Figure 6.10. SDS-PAGE of cross-linking of partially reduced Tmab (5.0 mg/ml, 34 µM) in Tris.HCl 
buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, with bis-o-dihaloacetamide (PEG)3 
linkers. Tmab was reduced with 1.1 equiv. of TCEP (37 µM) for 2 h at 4   and incubated with the 
linkers at room temperature overnight. Lane 1: Tmab control non-reducing dye, lane 2: Tmab control 
reducing dye, lane 3: Tmab incubated with 1.1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate 
(4.23), lane 4: Tmab incubated with 5 equiv. of bis-dibromoacetamide (PEG)3 linker (6.1), lane 5: Tmab 
incubated with 5 equiv. of bis-o-diiodoacetamide (PEG)3 linker (6.2). 
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In summary, despite the reduced level of LC-HC cross-linking, the optimised conditions 
were considered suitable to attempt the conjugation of Tmab with Sbi III/IV-2xCys. 
6.4.2 Tmab-Sbi conjugation  
With optimised selective reduction conditions of Tmab in hand, we sought next to 
attempt conjugation of Tmab and Sbi using the first proposed strategy. 
Conjugation of Sbi III/IV-2xCys with Tmab was evaluated by conjugation of reduced 
Sbi III/IV-2xCys (5 mg/mL) in Tris.HCl buffer with functionalised Tmab (5 mg/mL). 
Briefly, Tmab was reduced with 1.1 equiv. of TCEP for 2 h at 4  and reacted with bis-
dihaloacetamide (PEG)3  6.1 and  6.2 (5 equiv.) linkers for 3 h at room temperature. 
Excess reagent was removed by buffer exchange into conjugation buffer (100 mM, 150 
mM NaCl, 5 mM EDTA, pH 7.5). In tandem with this, Sbi III/IV-2xCys was reduced 
with 2 equiv. of TCEP for 1 h followed by quenching step using penta-PEG azide (2.13) 
for 1 h. Then, reduced Sbi III/IV-Cys (4 equiv.) was then added to functionalized Tmab 
and left at room temperature overnight. The reaction products were resolved by SDS-
PAG analysis. The estimated MW of the product would be around 90 kDa under 
reducing conditions. 
SDS-PAGE analysis of the reaction products revealed that the conjugation using this 
method did not work (Figure 6.11, lane 7 and 8). One possible explanation is the 
presence of off-target disulfide bonds of Tmab, which have reduced the yield of the 
production of half-antibody (75 kDa) as well as interfered with the conjugation step with 




Figure 6.11. SDS-PAGE representing conjugation of partially reduced Tmab and Sbi III/IV-2xCys in 
Tris.HCl buffer using bis-dihaloacetamide (PEG)3 linkers 6.1 and 6.2. Tmab was reduced with 1.1 equiv. 
of TCEP for 2 h at 4 . Sbi III/IV-2xCys was reduced with 2 equiv. of TCEP for 1 h followed by 
quenching step with hexa-diazide (10 equiv..) for 1 h. lane 1: Tmab control (non-reducing dye). lane 2: 
Tmab control (reducing dye), lane 3: Tmab was incubated with 1.1 equiv. of methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23) linker at room temperature for 3 h, lane 4: Tmab incubated with 5 equiv. 
of bis-o-diiodoacetamide (PEG)3 linker (6.2) at room temperature for 3 h, lane 5: Tmab incubated with 5 
equiv. of bis-dibromoacetamide (PEG)3 linker (6.1) at room temperature for 3 h, lane 6: Tmab was 
incubated with 1.1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) at room temperature 
overnight, lane 7: conjugation reaction of functionalised Tmab-diiodoacetamide with Sbi III/IV-2xCys (4 
equiv.) at room temperature overnight, lane 8: conjugation reaction of functionalised Tmab -
dibromoacetamide with Sbi III/IV-2xCys (4 equiv.) at room temperature overnight. Protein samples were 
resolved by reducing SDS-Page (10% gel). 
6.5 Conjugation of functionalised Sbi with partially reduced Tmab 
(Strategy 2) 
As we were not able to construct Tmab-Sbi conjugate using the first proposed strategy, 
we next sought to evaluate the conjugation of Tmab and Sbi protein through using the 
second strategy where functionalised Sbi will be conjugated to the partially reduced 
Tmab. 
As such, Sbi III/IV-2xCys (5 mg/mL) in Tris.HCl buffer (100 mM, pH 7.5) was reduced 
with TCEP 2.2 (2 equiv.) for 1 h. Then, quenching step using penta-PEG azide (2.13) 
for 1 h was followed by addition of bis-o-diiodoacetamide (PEG)3 linker 6.2 (5 equiv.) 
and incubation for 3 h at room temperature. Excess reagent was removed by buffer 
exchange into the conjugation buffer using Amicon® Ultra-15mL (3 kDa) centrifugal 
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filters. Meanwhile, Tmab (5 mg/mL) was reduced with TCEP 2.2 (1.1 equiv.) for 2 h at 
4 . Functionalised Sbi III/IV-2xCys (4 equiv.) was then added to the partially reduced 
Tmab and left at room temperature overnight. The reaction products were resolved using 
SDS-PAGE (Figure 6.12 B, lane 2).  
Immobilized metal affinity chromatography (IMAC) was performed to purify the 
reaction using Ni2+ column (1 mL HisTrap, FF) (Figure 6.12 A). The estimated MW of 
the product would be around 90 kDa under reducing conditions which matches with the 
obtained bands of between HC-HC band (100 kDa) and HC-LC band (75 kDa). As Sbi 
III/IV-2xCys is a his-tagged protein, IMAC purification was performed to separate 
Tmab-Sbi conjugate from unfunctionalised Tmab. IMAC purification was successful in 
the separation of unfunctionalised Tmab (Figure 6.12 A, lane 3) from Tmab-Sbi 
conjugate (Figure 6.12 A, lane 5).  
To our delight, we were able to construct Tmab-Sbi through using the second strategy, 
nevertheless, the obtained quite low overall yield of protein conjugate can be possibly 
attributed to is the short length of the PEG [(PEG)3] linker and the steric hindrance 
which make the association of the two large proteins difficult. Thus, a longer chain of 
the linker would be expected to reduce the steric hindrance when attempting to link Sbi 
III/IV-2xCys and Tmab and increase the obtained yield of the conjugate. To investigate 






Figure 6.12. A) Affinity chromatography purification of Tmab-Sbi conjugation reaction to separate 
unfunctionalised Tmab 3 from Tmab-Sbi conjugate 5. B) SDS-PAGE analysis of conjugation of partially 
reduced Tmab and Sbi III/IV-2xCys in Tris.HCl buffer (100 mM, pH 7.5) using bis-o-diiodoacetamide 
(PEG)3 linker (6.2). Lane 1: Tmab incubated with 1.1 equiv. of methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23), lane 2: Tmab conjugation with Sbi III/IV-2xCys at room temperature 
overnight before performing affinity chromatography purification, lane 3: collected early fractions (F1-4) 
of affinity chromatography purification, lane 4: collected eluted fractions (F16-23), lane 5: collected 
eluted fractions (F24-25), lane 6: collected eluted fractions (F26-33). Arrow indicates the expected band 






6.6 Synthesis of bis-o-diiodoacetamide (PEG)7 (6.5) 
Bis-diiodoacetamide (PEG)7 linkers (6.5) was postulated as a more water soluble than 
6.1 and 6.2 linkers with a longer chain length, permitting more amenable protein-protein 
conjugation. Given that both bromo- 6.1 and iodo-linkers 6.2 and showed comparable 
rebridging (see Figure 6.11), and as iodo-linker synthesis can be achieved more readily, 
we set out to synthesise the bis-o-diiodoacetamide (PEG)7 (6.5).  
The 1,23-diamino-3,6,9,12,15,18,21-heptaoxatricosane (6.6) was first synthesised over 3 
steps by tosylation reaction of 3,6,9,12,15,18,21-heptaoxatricosane-1,23-ditol (6.8) 
using 4-toluenesulphonyl chloride overnight (60% yield). Then, 1,23-diazido-
3,6,9,12,15,18,21-heptaoxatricosane (6.10) was synthsised by refluxing 6.9 with NaN3 
overnight (80.6% yield). Lastly, the azide groups were reduced to amines using 
triphenylphosphine (Ph3P) to obtain the di-amino(PEG)7 (6.6) (57% yield) (Figure 
6.13). 
 
Figure 6.13. Synthesis of di-amino(PEG)7 (6.6). a) p-TsCl, pyridine, DMC, b) NaN3, DMF, 80 , reflux, 
c) Ph3P, dry THF overnight, then H2O overnight. 
Then, bis-o-diiodoacetamide (PEG)7 linker (6.5) was synthesised by reacting the 
activated ester (4.45) with 1,23-diamino-3,6,9,12,15,18,21-heptaoxatricosane (6.6) to 
generate the bis-dichloroacetamide (PEG)7 (6.7) (89% yield), which was then was 
converted to bis-o-diiodoacetamide (PEG)7 derivative by refluxing with KI for 3 h 





Figure 6.14. Synthesis of bis-o-diiodoacetamide (PEG)7 (6.5). a) di-amine(PEG)7 (6.6) THF, b) KI, dry 
acetone, reflux 3 h. 
6.7 Application of bis-o-diiodoacetamide (PEG)7 (6.5) in construction of 
Tmabo-HL-PEG7-Sbio-bis-Cys conjugate (6.11) 
Having successfully synthesised bis-diodoacetamide (PEG)7 6.5, we set out to employ it 
to construct Tmab-Sbi conjugate using a similar conjugation method (strategy 2) as 
described in Section 6.5 
To this end, Sbi III/IV-2xCys (5 mg/mL) in Tris.HCl buffer was reduced with TCEP 2.2 
(2 equiv.) for 1 h, then, quenching step using penta-PEG azide (2.13) for 1 h was 
followed by addition of the bis-o-diiodoacetamide (PEG)7 linker 6.5 (5 equiv.) and 
incubation for 3 h at room temperature. Excess reagent was removed by buffer exchange 




Meanwhile, Tmab (5 mg/mL) was reduced with TCEP 2.2 (1.1 equiv.) for 2 h at 4 . 
The functionalised Sbi III/IV-2xCys (4 equiv.) was then added to the reduced Tmab and 
left at room temperature overnight.  
The reaction products were analysed using SDS-PAGE (reducing conditions) and 
revealed a band with estimated MW of 90 kDa which matches the expected mass of 
Tmab-Sbi conjugate (Figure 6.15, lane 6).  In line with what was proposed previously 
regarding the length of the chain of the linker, a significant increase in the yield of the 
conjugate was obtained with bis-o-diiodoacetamide (PEG)7 6.5 (Figure 6.15, lane 6) in 
comparison with bis-o-diiodoacetamide (PEG)4 6.2 (Figure 6.12, lane 2). 
IMAC purification was performed using Ni2+ column (1 mL HisTrap, FF) to separate 
Tmab-Sbi conjugate from unfunctionalised Tmab as Sbi III/IV-2xCys is a his-tagged 
protein. IMAC purification was successful in the separation of unfunctionalised Tmab 
(Figure 6.15, lane 7) from Tmab-Sbi conjugate (Figure 6.15, lane 8). 
 
Figure 6.15. SDS-PAGE analysis of conjugation of partially reduced Tmab and Sbi III/IV-2xCys in 
Tris.HCl buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, using bis-o-
diiodoacetamide (PEG)7 linker (6.5). Lane 1: Tmab control (non-reducing), lane 2: Tmab control (reduced 
dye), lane 3: Tmab incubated with 1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 4: 
Tmab incubated with 3 equiv. of bis-o-diiodoacetamide (PEG)7 linker (6.5), lane 5: Sbi III/IV-2xCys 
Incubated with 5 equiv. of bis-o-diiodoacetamide (PEG)7 linker (6.5), lane 6: Tmab conjugation with Sbi 
III/IV-Cys at room temperature overnight before affinity chromatography purification showing the correct 
estimated mass of the conjugate around 90 kDa, lane 7: combined early fractions of affinity 
chromatography purification, lane 8: combined eluted fractions of affinity chromatography with His-B 
buffer (1 mM imidazole) using Ni
2+
 column (1 mL HisTrap, FF). Protein samples were resolved by 
reducing SDS-Page (10% gel). 
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We rationalized that the observed HC-LC band (75 kDa) in the previously performed 
reaction can be mainly attributed to the incomplete removal of excess linker when spin 
filters were used (Figure 6.15, lane 6). Therefore, in order to evaluate the proposed 
hypothesis the same conjugation reaction was performed as mentioned above, but with a 
quick step of purification using Ni+2 column was proposed to remove excess linker from 
functionalised Sbi III/IV-2xCys solution prior to conjugation with partially reduced 
Tmab. 
The stability of the attached linker after performing IMAC was tested using protein MS 
to confirm that iodide groups did not hydrolyse during the process of purification. The 
expected mass of functionalised Sbi III/IV-2xCys. is calculated as 16,726.16 Da, and 
was observed at 16,727.07 Da (Figure 6.14 B).  
 
 
Figure 6.16. A) Deconvoluted protein MS spectrum of Sbi III/IV-2xCys control showing major peak at 
15,671.98 Da. B) Deconvoluted spectrum protein MS of functionalised Sbi III/IV-2xCys with bis-o-
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A significant reduction in the 75 kDa band (half-antibody) was observed when IMAC 
was conducted as a quick purification step before performing Tmab-Sbi conjugation 
(Figure 6.17 A, lane 4 vs. lane 8). The obtained results proved that using spin filters was 
not sufficient to remove excess linkers from the reaction mixture of Sbi III/IV-2xCys 
and confirm that quick purification step using Ni+2 column was sufficient to get the pure 
functionalised Sbi III/IV-2xCys.   
IMAC purification was further performed to purify the Tmab-Sbi conjugate using Ni2+ 
column (1 mL HisTrap, FF), which was successful in the separation of unfunctionalised 
Tmab from Tmab-Sbi conjugate (Figure 6.17 A and B, lane 5-7). 
It is worth pointing out the significant increase in the yield of Tmab-Sbi conjugate using 
bis-o-diiodoacetamide (PEG)7 linker (6.5) in comparison with bis-o-diiodoacetamide 
(PEG)3 linker (6.2) (Figure 6.17 A, lane 4 vs. lane 9). 
Having successfully improved the yield of conjugation and obtained the purified Tmab-
Sbi conjugate using Ni2+ column, however, unreacted Sbi III/IV-2xCys (Figure 6.17 A, 
lanes 6 and 7) was eluted with Tmab-Sbi and therefore a further purification step is 
necessary. 
We proposed that purification of Tmab-Sbi conjugate from unreacted Sbi III/IV-2xCys 
could be achieved through using protein A column (1 mL HiTrap Protein A, FF, GE 
Healthcare). Protein A column is widely used column for antibodies purification due to 
the high affinity of protein A (SpA) for human IgGs (see Section 6.1.2.1). We assumed 
that Tmab-Sbi would bind to protein A column, while un-reacted Sbi would be not bind 
and therefore separated from the desired product. To our surprise, we were not able to 
separate the reaction mixture by using protein A column and we could not extract the 
reaction products from the column. One possible explanation of what we experienced is 
the possible interaction between both S. aureus proteins, protein A (SpA) and Sbi. To 
the best of our knowledge, this interaction has not been studied before and need to be 





Figure 6.17. A) SDS-PAGE analysis of conjugation of partially reduced Tmab and Sbi III/IV-2xCys in 
Tris.HCl buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, using bis-o-
diiodoacetamide (PEG)7 linker (6.5). Lane 1: Tmab control (non-reducing), lane 2: Tmab control (reduced 
dye), lane 3: Tmab incubated with 1.1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 
4: Tmab conjugation with Sbi III/IV-2xCys at room temperature overnight before affinity 
chromatography purification step showing the correct estimated mass of the conjugate around 90 kDa, 
lane 5: collected early fractions (F1-5), lane 6: collected eluted fractions (F19-25), lane 7: collected eluted 
fractions (F27-29). Lane 8: Tmab conjugation reaction with Sbi III/IV-2xCys at room temperature 
overnight using bis-o-diiodoacetamide (PEG)7 linker (6.5) without the quick in between purification step 
(see Figure 6.15). Lane 9: Tmab conjugation reaction with Sbi III/IV-2xCys at room temperature 
overnight using bis-o-diiodoacetamide (PEG)3 linker (6.2) (see Figure 6.12). Protein samples were 
resolved by reducing SDS-PAGE (4-12% gel). B) Affinity chromatography purification of unconjugated 
Tmab (lane 5) from Tmab-Sbi conjugate (lane 6 and 7) using Ni
2+





Next, in order to separate Tmab-Sbi conjugate from Sbi III/IV-2xCys based on the large 
mass difference, size exclusion chromatography (SEC) was performed using a superdex 
column (200 pg, GE Healthcare). To our delight, unconjugated Sbi III/IV-2Cys. has 
been successfully separated from Tmab-Sbi III/IV-2Cys conjugate by using SEC 
(Figure 6.18 A and B, lane 5).  
 
 
Figure 6.18. A) SDS-PAGE analysis of conjugation of partially reduced Tmab and Sbi III/IV-2xCys in 
Tris.HCl buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, using bis-o-
diiodoacetamide (PEG)7 linker (6.5). Lane 1: Tmab incubated with 1.1 equiv. of methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23), lane 2: Tmab conjugation with Sbi III/IV-2xCys at room temperature 
overnight before affinity chromatography, lane 4: collected pure fractions (F19-25) before performing 
SEC, lane 5: size exclusion chromatography purification (F10-G5). B) Size exclusion chromatography 
purification of Sbi-Tmab conjugation reaction to separate unconjugated Sbi III/IV-2xCys from Tmab-Sbi 






However, the pure conjugate degraded, most probably between domain III and IV of 
Sbi, affording Tmab-Sbi IV as a final stable product (as indicated by the arrows) (Figure 
6.18 A, lane 5). Protein mass spectrum was conducted to confirm the degradation of 
Tmab-Sbi III/IV to attain Tmab-Sbi IV with an estimated mass of 157033 Da and the 
found mass was 156990.64 Da (Figure 6.19). 
The degradation of Tmab-Sbi III/IV-2Cys conjugate is, most probably, proteases-
dependent degradation, which mainly cleaved Sbi between the two domains, domain III 
and IV. Another possible mechanism of degradation of Sbi III-IV is through mAb-
mediated degradation. Both mechanism need to be further evaluated in future. 
 
Figure 6.19. Deconvoluted protein MS spectrum of Tmab-Sbi III/IV conjugate, showing a mass around 
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6.8 Conclusion and future work  
Construction of the immunomodulating Tmab conjugate, in order to improve the limited 
advantages that have attained from using Tmab as a single therapy, would provide a new 
and promising conjugates in breast cancer treatment to be further evaluated in vitro and 
in vivo against HER2 positive breast cancer. Inspired by the notion of ACDs, we aimed 
to utilise Tmab as a carrier of Sbi III-IV and the latter will activate the human 
complement protein C3 against cancer tissue. 
In this work we were able to chemically synthesise the re-bridging bis-o-diiodoacetamid 
(PEG)7 linker 6.5, which was used to construct the immunomodulating conjugate in 
feasible and easy to follow procedure without the need to use genetic engineering. 
Moreover, the purification steps were successful to separate the desired conjugate.  
With the unfortunate degradation of Sbi III-IV, in the future work, more effort will put 
to enhance the stability of Sbi and therefore construct a stable Tmab conjugate which 
includes the followings:  
1- Define the cleavage site and the degraded products. 
2- Further evaluate the protease-dependent mechanism and test the possibility of 
incorporation of different protease inhibitors during the conjugation process. 
3- Modify the sequence of Sbi III/IV at the cleavage site (sites) to prevent the 
degradation without influencing the activity of the protein. 
4- Test the possible mechanism of degradation of Sbi that is related to the actual 
conjugation to mAbs and if this a natural mechanism associated with this 
protein. 
Next, in vitro and in vivo evaluation of the immunoconjugate of Tmab-Sbi will be 
conducted against HER2 positive and negative breast cancer. The applicability of this 
work could be translated to different types of cancer, which provided a novel anti-cancer 




7 The chemical synthesis of Fc containing bi-specific antibody 
using Bis-dihaloacetamide PEG cross-linkers 
7.1 Introduction  
In general, diseases are not caused by a single defined factor but by the interactions 
between multiple underlying factors. Therefore, the simultaneous modulation of more 
than one factor can improve the efficacy of disease treatment with potential to prevent 
the development of biological resistance. Bi-specific antibodies (bsAbs) are a modified 
and potentially ground-breaking class of mAb biotherapies. As their name implies, 
bsAbs simultaneously recognise and engage with two different receptor targets, thus 
enabling more complex intervention mechanisms. Bi-specific antibodies have gained 
particular popularity in the field of oncology due to the limited and unconvincing 
benefits of employing native mAbs in cancer therapy. Recently, this field has gained 
substantial attention as more than 50 bsAbs are under investigation in clinical trials for 
various malignancies.244,245  
BsAbs were primarily constructed to recruit components of the immune system against 
cancer cells by reorienting effector cells against tumour cells, eliciting mAb Fc receptor 
function, or by activating T cell receptors (TCR). Amongst the effector cells, both T-
cells (usually through the CD3 receptor) and Natural Killer (NK) cells have recently 
begun to receive considerable attention in immunotherapeutic approaches.246   
T-cell engagers (BiTE) are a well-recognised subtype of bsAb that recruit the cytotoxic 
role of T-cells in cancer immunotherapy. BiTE has been shown to have a potential 
advantage in chemotherapy resistant cancer cells and quiescent stem cells.247 In addition, 
bsAbs can be used to target two separate disease receptors or mediators leading to 
substantial therapeutic effect (increased potency or efficacy), and suppression of 
biologic resistance and relapse.248  
Initially, bsAbs were produced by co-expression of two light and heavy chains in a 
single host cell line, also known as hybrid-hybridoma or quadroma technology. One 
example of the earliest approved bsAb with the entire IgG format is Catumaxomab, 
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which was the first approved bsAb. It was approved by the European Union in 2009 for 
the intraperitoneal therapy of patients with malignant ascites. Catumaxomab targets both 
Epithelial Cell Adhesion Molecule (EpCAM) antigen and also activates T-cells through 
binding to the T-cell surface protein CD3.249 Catumaxomab belongs to Triomab® class 
of bsAbs. The Triomab® family consists of two half antibodies:  a mouse IgG2a and a rat 
IgG2b (anti-CD3), which are constructed through fusion (hybridization) of different 
hybridoma cell lines (quadroma technology).250 One of the major restrictions of the this 
first generation bsAbs is the difficulty in the production of sufficient quantities of 
homogenous,  clinical-grade species of bsAbs.251 Other obstacles include the required 
complex methods of purification to sequester homodimers contaminants,252 as well as 
the activation of a human anti-mouse antibody (HAMA) response in the majority of 
treated patients owing to the  murine origin of mAbs. Researchers have therefore 
investigated alternative recombinant DNA techniques and chemical conjugation 
methods to overcome these drawbacks.  
BsAbs can be classified into different categories according to the resemblance of IgG 
antibody structure, molecular size, the presence of an Fc region, the construction 
methods used and the function (Figure 7.1).245 With more than 100 bsAbs construct, 
most of them were produced using recombinant technologies, with the most prominent 
difference being the molecular weight with these formats, which mainly depends on the 
presence or absence of an Fc region. The presence of an Fc region in bsAb format, 
usually referred to as ‗trifunctioal‘ antibody, not only exerts essential cytotoxic effector 
mechanisms, but also extends the plasma half-life of the construct and therefore 
precludes a multiple dosing regimen.253 Therefore, bsAbs can be classified into two 
major categories: bsAbs lacking of the Fc region and Fc containing bsAbs.  
7.1.1 Classes of bi-specific antibodies lacking of Fc region 
A plethora of different classes for the construction of bsAb has been proposed by using 
genetic engineering methods (recombinant technologies), in particular variable-fragment 
based formats. Variable fragment (Fv) with a short peptide chain connecting the VH and 
VL domains, also known as single-chain variable domain fragments (scFv) (Figure 7.1), 
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are commonly used as building blocks in creating variable-fragment bsAb, such as 
tandem single chain variable fragment molecules (taFvs), and diabodies (Dbs).244  
The taFvs format is constructed by the fusion of two scFv molecules using a flexible 
linker (Figure 7.1). Dbs, on the other hand, are constructed by expressing two different 
chains VH1-VL2 and VH2-VL1 within one cell. The two variable domains of each 
individual chain are connected via a short five-residue peptide linker to avoid mispairing 
of variable regions within one chain,  therefore allowing the desired crossover pairing of 
the two chains affording Dbs (Figure 7.1).254 
 
Figure 7.1. Schematic representation of the two well-known bispecific antibody classes lacking of the Fc 
region. Orange and green indicate different specificities (binds to different antigens). scFv: single-chain 
variable domain fragment, TaFvs: Tandem single chain variable fragments, Dbs: diabodies. 
Blinatumomab is the first clinically effective member of bispecific T engager (BiTE) 
antibodies (diabodies), which target cancer cells via binding to CD19 receptor on B-
cells and recruiting T-cells via CD3 receptor binging.  Blinatumomab is used in patients 
with relapsed/ refractory precursor B-cell acute lymphoid leukemia.255  
Recently, Hull et al. have developed an elegant chemical cross-linking approach without 
the need to incorporate unnatural amino acid or recombinant technologies. They were 
able to cross-link the disulfide bonds of mAb using rebridging approach affording a 
stable and homogenous bsAbs. This approach is based on using bis-(dibromomaleimide) 




7.1.2 Entire IgG classes: Fc region containing bi-specific antibodies 
BsAbs containing Fc region offer a range of advantages related to effector functions of 
this region, such as antibody-dependent cell-mediated cytotoxicity (ADCC), 
complement-dependent cytotoxicity (CDC). In addition, the presence of Fc region 
facilitates the purification steps and modulates both solubility and stability of the 
construct and more importantly, increases the plasma half-life mediated through FcRn 
receptors. 
One of the major obstacles to obtain bsAbs with IgG-like structure is the mispairing of 
heavy and light chains resulting in homodimer formation. Therefore, in order to produce 
bsAb with IgG-like format with minimal mispairing potential, Knobs-into-holes hetero-
dimerization technology has been developed as an elegant protocol for the production of 
bsAbs with two distinguished and independent Fab regions while maintaining the 
overall native IgG architecture. This technology is made possible through the 
introduction of complimentary mutations in the CH3 domains to promote the association 
(hetero-dimerization) between heavy chains of the two different antibodies (one 
antibody has a ‗knob‘ mutation and the other one has ‗hole‘ mutations) as shown in in 
Figure 7.2.257 This concept, however, has been modulated with different approaches, to 
assure the heterodimerization of heavy chains. These approaches cannot however, 
prevent the homodimersization of light chains. Thus, in order to maintain the native IgG 
structure without using unnatural domain junctions in order to stop homodimersization 




Figure 7.2. Schematic representation of some of the Fc-containing bsAbs classes. Orange and green 
indicate different specificities (binds to different antigens). DVD: dual variable-domain. 
Spiess et al. have developed a new approach to prevent the homodimersization of heavy 
and light chains. They separately have expressed half-antibodies (75 kDa) in two 
bacterial strains. Then, they combined these halves to generate a bispecific antibody.259 
In addition to the requirement for complex production and purification methods, 
accurate and complex quantitative analytical methods are also required. These analytical 
methods have to be capable of distinguishing between the product of interest and the 
product-related variants, such as covalently- and noncovalently- linked homodimers.260,261  
Alternatively, a different approach was developed to ameliorate bsAb mispairing 
complications through engineering a modified variable region to be able recognise and 
bind to two unrelated antigens through different binding sites on the antibody variable 
region. Therefore, a single kind of heavy and light chain is required. For instance, anti-
HER2 antibody has been developed by phage display. It can recognise HER2 receptor 
but also bind to a second and unrelated antigen, such as VEGF while preserving high 
binding affinity to HER2 receptor. This bsAb is known as ―two-in-one‖ antibody, or 
Dual Action Fab (DAF).244  
Differently, various approaches have maintained the normal IgG-structure of the mAb 
of interest and achieved bi-specificity through the addition of variable region-containing 
fragments, for example the fusing of a single-chain Fv fragment (scFv) to the C-
terminus of the heavy chain of antibodies. Alternatively, bsAb can be constructed 
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through the combining the variable domains VH2 and VL2 domains to the variable 
domains of the antibody in tandem, generating what is known as a dual variable-domain 
antibody (DVD) (Figure 7.2).262  
As shown previously, most of the recombinant technologies-based approaches were 
focused on using single chain variable building blocks of the Fab region which contain 
only antigen recognition domains of heavy and light chains, and lack constant regions of 
heavy and light chains. The natural construction of the Fab fragment affords a 
stabilising effect for the variable regions, ameliorating solubility characteristics, and 
preventing aggregation possibilities. For these reasons, Wu et al. developed another 
recent class of bsAbs was achieved through fusing the whole Fab region to the mAb of 
interest (Figure 7.2).263 The Fab-based bsAbs were noticeably more thermally stable than 
scFv-based bsAbs. Moreover, Fab-based bsAbs showed negligible susceptibility to 
aggregation, whereas the scFv-based bsAbs displayed substantial tendencies to form 
aggregates.263 
In general, chemical conjugation methods afford a reliable and facile approach for the 
construction of multiple formats of bsAb without the need for complex expression and 
purification technologies. 
Yu Cao et al. developed a chemical based approach to achieve different formats of the 
two major bsAbs categories, anti-HER2/anti-CD3 bsAbs lacking of the Fc region and Fc 
containing anti-HER2/anti-CD3 bsAbs. They incorporate p-acetylphenylalanine (non-
canonical amino acid residue) into anti-HER2 and anti-CD3 mAbs. Then the engineered 
mAbs have been reacted with bifunctional polymer affording oxime linkage and 
clickable handle (azide or ocyne functionalities).111 They produced multiple classes of 
monovalent or divalent bsAbs with and without the Fc region. IgG formats with Fc 
region have found to display enhanced cytotoxicity against HER2 positive cancer cells 
compared to Fab-based ones. Moreover, it has been found that anti-HER2/anti-CD3 
bsAbs showed enhanced efficacy against the xenograft model with low expression of 
HER2 cancer cells.111  
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In conclusion, despite the enhanced efficacy of Fc-containing bsAbs over the Fc-
deprived bsAbs, to the best of our knowledge there is no current chemical method 
suitable to construct bsAbs (trifunctional) without the need for mutagenesis, complex 
expression and purification technologies. 
7.2 The rationale for Tmab-IFab bsAb  
As discussed previously, provided that IgG-like classes of bsAbs seem to attract 
considerable attention with a wide range of offered advantages, herein we are devoted to 
provide an alternative novel approach for the chemical construction of the trifunctional 
anti-HER2/anti-CTLA-4 bsAb antibody with Tmab-IFab format using our previously 
established conjugation platform, bis-o-dihaloacetamide PEG linker. 
Our approach is based on the conjugation of the rebridged heavy-light chains of Tmab 
with the rebridged heavy-light chains of Fab of Ipilimumab (IFab) using bis-o-
dihaloacetamide PEG approach (Figure 7.3). The construct of Tmab-IFab will 
interact/block with the following: HER2 receptors on cancer cells (T1), CTLA-4 
receptors on T-cell (T2). In addition, the Fc region of mAb has the potential to interact 
with complement proteins and several effectors cells exerting the cytotoxic effector 
mechanisms of ADCC and CDC (T3). Given that this construct is expected to exert the 
three main cytotoxic mechanisms, it is referred to as a trifunctional antibody (Figure 
7.3).264 
Trastuzumab (Tmab), a well-established humanized mAb, binds the HER2 receptor, it is 
widely used in the treatment of HER2 positive subtype (for more details about Tmab see 
Section 5.1).  
Ipilimumab (Imab), a fully human monoclonal antibody against the CTLA-4 antigen, 
was licenced by the FDA in 2011 for the treatment of metastatic melanoma. Ipilimumab 
belongs to a group of drugs known as immune checkpoint inhibitors which are regarded 
as immunotherapy that regulates and activates the function of T-cells. CTLA-4 antigens 
are immune checkpoint molecules expressed on T-cells to bring about homeostasis and 





Figure 7.3. Schematic representation of anti-HER2/anti-CTLA-4 bsAb antibody (Trifunctional antibody) 
with mAb-Fab format that will be further constructed in this work. Orange represents mAb (anti-HER2) 
and green represents Fab (anti-CTLA-4). 
T-cells require two signals in order to be fully activated. The first signal occurs when a 
specific antigen is recognized by the T-cell receptor, while the second signal is more 
complex and mainly mediated via the interactions between ligands on antigen-
presenting cells, such as B7.1 and B7.2, with the CD28 receptor on T-cells. However, 
under certain circumstances, T-cells overexpress the negative regulator receptor CTLA-
4, which competes with CD28 in binding to B7.1 and B7.2. This ultimately prevents (in 
certain situations) specific T-cells from being fully activated. The binding and blocking 
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of CTLA-4 on the cell surface of T-cells using Ipilimumab could interrupt the negative 
signal of the CTLA-4 molecule, restarting the signalling mechanism through CD28 to 
restore T-cell activation.265,267,268 
There is considerable evidence supporting the essential role of the immune cells in the 
tumor microenvironment in either activation or inhibition of tumor growth in breast 
cancer and other types of cancer, which can be used as a prognostic indicator for breast 
cancer.269 Approximately 70-80% of the immune cells population in the breast cancer 
microenvironment are composed of T-lymphocytes.269 In light of the observed success 
of immunotherapy in treating various types of cancers, a growing amount of research 
has particularly shown the clinical benefits of immunotherapy in breast cancer.269,270 For 
instance, Ertumaxomab is a bsAb targeting against HER2 and CD3 which has shown a 
phase I clinical trial in HER2 positive metastatic breast cancer patients. Ertumaxomab 
provides an elegant therapeutic approach in the treatment of patients with low HER2 
antigen expression when trastuzumab treatment is insufficient.271  
Moreover, the combination of checkpoint inhibitors with conventional cancer therapy 
provides another promising approach in immunotherapy for breast cancer patients. 
Currently, there is a growing number of clinical trials utilising CTLA-4 inhibitors, such 
as Tremelimumab or Ipilimumab as a conjunctive therapy of different types for HER2 
negative breast cancer (NCT02536794 and NCT02381314). 
Altogether, in this work we sought to provide a novel chemical method to construct 
bsAbs of Tmab-IFab with immunomodulating function through re-activation of T-cells 
in breast cancer microenvironment. This conjugate has the potential to meet the 
limitations of using Tmab as a mono therapy or could be used in a wide range breast 
cancer subtypes. 
7.3 Construction of the Tmab-IFab bsAb 
The Fab region of Imab was produced using papain enzyme-based digestion method 
which cleaves mAbs into two Fab fragments and one Fc domain.272 Then the digested 
IFab was purified using protein A column (1 mL HiTrap Protein A, FF). 
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To this end, IFab (5 mg/mL) in Tris.HCl buffer was reduced with TCEP 2.2 (2 equiv.) 
for 1 h, quenching step using penta-PEG azide (2.13) for 1 h was followed by the 
addition of bis-o-diiodoacetamide (PEG)3 linker 6.2 (5 equiv.) and incubation for 3 h at 
room temperature. Excess reagent was removed by buffer exchange into conjugation 
buffer (100 mM Tris.HCl, 150 mM NaCl, 5 mM EDTA, pH 7.5). Meanwhile, Tmab (5 
mg/mL) was reduced with TCEP 2.2 (1.1 equiv.) for 2 h at 4 . Functionalised IFab (4 
equiv.) was then added to reduced Tmab and left at room temperature overnight. The 
reaction was purified using size exclusion chromatography (Superdex 200, GE 
Healthcare). The reaction products were then resolved separately using SDS-PAGE. 
The estimated MW of the desired product would be around 125 kDa under reducing 
conditions. Figure 7.4 A shows a distinct band around 125 kDa (lane 3). Size exclusion 
chromatography purification was successful in separation of functionalised IFab (50 
kDa) from the conjugate Tmab-IFab (HC-LC(Tmab)-IFab) (Figure 7.4, 5 and 6).  
However, the low yield of the protein conjugate can be possibly attributed to steric 
hindrance which creates difficulty in the conjugation of IFab and Tmab. Therefore, 
longer chain of linker is expected to improve the conjugation yield and reduce the 
hindrance when attempting to link Tmab with IFab (as showed previously in Chapter 6, 
Section 6.7, Figure 6.15). To next sought to investigate the using of 6.5 in the 






Figure 7.4. A) SDS-PAGE analysis of conjugation of partially reduced Tmab and IFab in Tris.HCl buffer 
(100 mM, 150 mM NaCl, 5 mM EDTA, pH 7.5) using bis-o-diiodoacetamide (PEG)3 linker (6.2). Lane 1: 
crossed-linked Ipilimumab-fab using bis-o-diiodoacetamide (PEG)3 linker (6.2, 4 equiv.), lane 2: Tmab 
incubated with 1.1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), Lane 3: Tmab 
conjugation with crossed-linked IFab at room temperature overnight before size exclusion 
chromatography purification, lane 4: size exclusion column purification collected fractions (FA7-A14), 
lane 5: size exclusion column purification collected fractions (FE7-F1), lane 6: size exclusion column 
purification collected fractions (FF9-G1). B) Size exclusion chromatography of Tmab-Fab conjugation 
reaction to separate functionalised IFab (lane 6) from Tmab-IFab conjugate (lane 5). 
Therefore, conjugation of Tmab and IFab was attempted by using 6.5 using a similar 





Tris.HCl buffer was reduced with TCEP 2.2 (2 equiv.) for 1 h, then, quenching step 
using penta-PEG azide (2.13) for 1 h was followed by addition of bis-o-
diiodoacetamide (PEG)7 linker 6.5 (5 equiv.) and incubation for 3 h at room 
temperature. Excess reagent was removed by buffer exchange into Tris.HCl conjugation 
buffer. Meanwhile, Tmab (5 mg/mL) was reduced with TCEP 2.2 (1.1 equiv.) for 2 h at 
4 . Functionalised IFab (4 equiv.) was then added to reduced Tmab and left at room 
temperature overnight.  
The conjugation reaction products were evaluated by SDS-PAGE, which revealed a 
band around the estimated MW of the product   125 kDa under reducing condition. 
(Figure 7.5, lane 6). In line with what we observed before, attempting longer chain 
linkers 6.5 has significantly increased the yield of the conjugate obtained in comparison 
with 6.2 linker (Figure 7.4, lane 6). 
 
Figure 7.5. SDS-PAGE analysis of conjugation of partially reduced Tmab and IFab in Tris.HCl buffer 
(100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, using bis-o-diiodoacetamide (PEG)7 
linker (6.5). Lane 1: Tmab control (non-reducing), lane 2: Tmab control (reduced dye), lane 3: Tmab 
incubated with 1.1 equiv. of methyl 3,4-bis(2-bromoacetamido)benzoate (4.23), lane 4: Tmab incubated 
with 3 equiv. of bis-o-diiodoacetamide (PEG)7 linker (6.5), lane 5: IFab incubated with 5 equiv. of bis-o-
diiodoacetamide (PEG)7 linker (6.5), lane 6: Tmab conjugation with IFab at room temperature overnight 





7.3.1 Optimisation of the conjugation method 
In order to optimise the conjugation yield and evaluate the first functionalisation step of 
IFab, we sought to evaluate the efficiency of functionalization step by protein MS 
(Figure 7.4). The MS spectrum showed the correct mass at 48,691.08 Da which 
represents IFab with linker attached (Figure 7.4 A and C). The performed MS reflected 




Figure 7.6. A) Schematic representation of functionalisation of IFab with bis-o-diiodoacetamide (PEG)7 
(6.5) linker. B) Deconvoluted protein MS spectrum of IFab control (non-reduced) showing major peaks at 
47,636.32 Da. C) Deconvoluted protein MS spectrum of functionalised IFab with bis-o-diiodoacetamide 
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Further optimisation of the conjugation reaction was performed by attempting to reduce 
the observed band half-antibody (HC-LC, 75 kDa) in Figure 7.5, lane 6. 
One possible explanation of the presence of this 75 kDa band is the incomplete removal 
of the excess linker using the VivaSpin sample concentrators, therefore, a quick step of 
purification using protein A column (1 mL HisTrap, FF) was performed before start 
conjugation of IFab with partially reduced Tmab.  
As such, another conjugation reaction was attempted using the same previously 
described procedure in Figure 7.5, but with a quick purification step using protein a 
column of functionalised IFab instead of using spin filters. A significant reduction in the 
half-antibody band (HC-LC) was observed when protein A was used as quick 
purification step before performing Tmab-Fab conjugation (Figure 7.7 A, lane 3). 
Therefore, buffer exchange using VivaSpin sample concentrators is not sufficient to 
remove excess linkers and a quick step of purification is not only essential to remove 
excess linkers but to improve the yield of conjugation. 
To our delight, the reaction products were purified using SEC, and the desired product 
(Tmab-IFab) was isolated with high purity (Figure 7.7 A, lane 4). The desired product 
fractions were combined together, final concentration was determined and from which 







Figure 7.7. A) SDS-PAGE analysis of conjugation of partially reduced Tmab with Ipilimumab-fab in 
Tris.HCl buffer (100 mM, pH 7.5) containing 150 mM NaCl, and 5 mM EDTA, using bis-o-
diiodoacetamide (PEG)7 linker (6.5). Lane 1: Tmab incubated with 1.1 equiv. of methyl 3,4-bis(2-
bromoacetamido)benzoate (4.23), lane 2: Tmab conjugation with IFab at room temperature overnight 
showing the correct estimated mass of the conjugate around 125 kDa with significant reduction of the 75 
kDa band (half-antibody) before performing size exclusion chromatography, lane 4: size exclusion 
column purification collected fractions (F6-G2), lane 5: size exclusion column purification collected 
fractions (G4-G13), lane 6: : size exclusion column purification collected fractions (H1-H7). B) Size 
exclusion chromatography of Tmab-Fab conjugation reaction to separate cross -linked IFab (lane 6) from 








7.4 Conclusion and future work  
Given that bsAbs are rapidly emerging as a promising future approach in 
immunooncology, a more an efficient and high yielding method for their production is 
of significant importance. The currently available methods require mutagenesis of native 
antibodies, or complex expression and purification procedures. With the lack of 
chemical-based method to construct bsAbs containing Fc region, herein a chemical 
conjugation method is described based on bis-diiodoacetamid (PEG)7 linker which was 
used to efficiently to construct the anti-HER2/anti-CTLA-4 Tmab-IFab trifunctional 
antibody.  
The described methods of conjugation and purification in this Chapter afford promising 
preliminary foundation for the applicability this conjugation method to produce various 
classes of rebridged, thus more stable, bsAbs in good yield ( 60%) through an easy 
adaptable procedure. 
As this work provides a proof of concept of the applicability of our elegant rebridging 
linker (6.5) in the vast field of bsAb, future work in this approach will be scaled up, the 
conjugate activity against HER2 positive cancer cell lines will be evaluated in vitro and 











8 Experimental  
8.1 General reagents  
Chemical reagents and solvents were purchased from Sigma-Aldrich, Fisher Scientific 
and Alfa Aesar unless otherwise stated. Anhydrous solvents were obtained from Sigma-
Aldrich. Deuterated solvents for NMR were purchased from Cambridge Isotope 
Laboratories and Sigma-Aldrich. Preparative reverse phase chromatography (C-18) was 
performed using Biotage® SNAP cartridge (KP-C18-HS, 30 g).   
Reagents that have been used in cell-culture (NaCl, imidazole, Tris base and glycine) 
were of molecular biology grade. Isopropyl thiogalactoside (IPTG) and Ampicillin 
sodium salt (BioReagent) were obtained from Fisher. Amicon® Ultra (3 and 10 kDa) 
centrifugal filters were purchased from Sigma-Aldrich.  
Trastuzumab (Herceptin) 150 mg vials and Rituximab (Mabthera) 100 mg vials were 
kindly provided as gifts from Qualasept ltd.  Sbi III/IV-Cys and Sbi IV-2xCys were 
over-expressed using the general expression procedure in the following Section. 
8.2 General methods 
8.2.1 Chemical synthesis  
All reactions were carried out at atmospheric pressure under argon with stirring at room 
temperature unless otherwise stated. Thin layer chromatography (TLC) was carried out 
on aluminium backed TLC plates silica gel 60 (0.25 mm thickness), viewed under UV 
light (wavelength 254 nm) or stained with potassium permanganate solution [potassium 
permanganate (3 g) and potassium carbonate (20 g) in 5% aqueous sodium hydroxide (5 
mL) and water (200 mL)] for a non-UV active compound. Silica gel column 
chromatography was performed on silica gel 60 Å (200-400 mesh) (Sigma-Aldrich). All 
compounds were prepared and purified to   94% purity as evaluated by HPLC 
[Chimatzo, detection wavelengths 280 nm and 214 nm, reverse phase (C18) column: 
HiQ sil C18 HS (150 x 4.60 mm)]. 
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Nuclear magnetic resonance spectra were recorded in deuterated solvents CDCl3, DMF-
d7 or DMSO-d6 (unless another solvent is mentioned) using Bruker Advance III (400 
and 500 MHz) spectrometers operating at ambient 20 °C probe. Data is reported for 1H 
as following: chemical shift in ppm (multiplicity, J coupling constant in Hz, number of 
protons); and for 13C: chemical shift in ppm. Multiplicity is presented as follows: s 
(singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), dt 
(doublet of triplets), td (triplet of doublet).  
High resolution mass spectrometry was obtained on a BrukerMicrOTOF electrospray 
ionisation mass spectrometer. Samples were prepared in acetonitrile solvent at a final 
concentration of 10 µg/mL. Infrared spectra were recorder on a PerkinElmer Spectrum 
65 FT-IR spectrometer. 
8.2.2 Standard work-up 
Standard work-up is usually performed before silica gel column chromatography 
purification to remove salts. It is performed by diluting the crude reaction in appropriate 
organic solvent (mentioned), washing with H2O, followed by washing with brine. The 
organic phases were then combined and dried over anhydrous MgSO4, filtered and the 
filtrate concentrated under reduced pressure. 
8.2.3 Protein over-expression 
8.2.3.1   Primary and secondary culture  
The general procedure for the recombinant proteins in this project is as follows. A single 
colony of E.coli BL21 (DE3) strain with an expression vector was picked and grown at 
37°C overnight with shaking at 180 rpm in a 100 mL of LB medium with final 
concentration of ampicillin 100 μg/mL.  
The overnight primary culture was then inoculated with 1-liter of LB medium 
containing ampicillin (100 μg/mL). Cells were grown at 37°C overnight with shaking at 
180 rpm. The expression of protein was generally induced during the exponential phase 
of bacterial growth (OD600≥0.7) by adding isopropyl thiogalactoside (IPTG) to the 
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culture to final concentration of 1 mM in the culture. The culture held at 37°C with 
shaking at 180 rpm for 3 h.  
8.2.3.2  Lysis and harvesting of cells  
Cells from the secondary culture (8.2.3.1) were harvested by centrifugation at 8000 g for 
25 minutes and suspended in HisA buffer (50 mM Tris, 300 mM NaCl and 50 mM 
Imidazole, pH 7.4). Cells were lysed by sonication. Cells were kept cold during the 
sonication cycles (6 cycles with 10 minutes interval between each sonication to cool 
down cells) at 80% amplitude for a total of 10 seconds. Then, the insoluble cell debris 
was removed by centrifugation at 60,000 g for 25 minutes at 4°C. 
8.2.3.3  AKTA purification  
The supernatant from 8.2.3.2 was collected and purified through immobilized metal 
affinity chromatography using nickel column (1mL, HisTrap HP, GE healthcare) 
attached to an AKTA purifier. The loaded column was washed with 15 column volumes 
of HisA buffer and the bound protein was eluted with a 0-100% gradient of HisB buffer 
(50 mM Tris, 300 mM NaCl and 1 M Imidazole, pH 7.4). 
8.2.3.4  Concentrator and concentration measurement  
Protein containing fractions from 8.2.3.3 were collected and appraised initially by SDS-
PAGE analysis. Collected fractions containing pure protein were concentrated using 
Amicon® Ultra-15mL (3 kDa) centrifugal filters and finally buffer exchanged into 
phosphate buffer saline (PBS) buffer or other conjugation buffer and stored at -20°C. 
Protein concentration was determined using BCA assay. Briefly, the concentration of 
protein was determinated against standard curve of BSA standards (2000, 1500, 1000, 
750, 500, 250, 125, 25 and 0 µg/mL) which were prepared according to manufacturing 
protocol (Pierce™ BCA Protein Assay Kit) (Figure 8.1). Absorbance was measured at 
550 nm using plate reader (FLUOstar OPTIMA plate reader, BMG LAB OPTIMA 
software 2.20R2). The concentration of the protein was calculated using Equation 8.1. 
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  Conc   g ml   
 Absorbance        
      
                                           (Equation 8.1) 
                
Figure 8.1. Standard curve of BSA standards (2000, 1500, 1000, 750, 500, 250, 125, 25 and 0 µg/mL) 
used in the BCA protein assay.  
8.2.4 SDS-PEGE gel electrophoresis  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
resolve protein samples according to the standard lab procedure using Invitrogen™ Mini 
Gel system. 4% stacking gel and 10% or 15% acrylamide gel (non-reducing glycine gel) 
were prepared using Novex gel cassettes (1.0 mm, invitrogen™). Recipes are stated in 
Table 8.1.  
Pre-cased Bis-Tris, 10-well protein gels (4-12%) were also used when required and run 
using MES SDS running buffer (NuPAGE™). 
Protein samples were mixed in 1:1 ratio with either 2x reducing loading dye sample 
buffer (0.5 M Tris-HCl, pH 6.8, 10% SDS, 50% glycerol, 2-mercaptoethanol, and 
0.18% bromophenol blue) or non-reducing loading dye (without 2-mercaptoethanol) and 
vortexed for 1 minute, then heated at 75  for 3 minutes. 
 
y = 0.0013x - 0.0525 
























Standrad concentration (µg/ml) 
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Table 8.1. Composition of SDS-PAGE gel, stacking and resolving gels, running buffer, Coomassie blue 
stain and destain solution. 
Stacking gel (4%) 2x 
gels 
Tris 0.5 M pH 6.8 (1.625 mL), H20 (4 mL), 
40% v/v Acrylamide/bis-acrylamide (0.625 
mL), 10% APS (31.25 μl), TEMED (6.25 μl). 
Resolving gel (15%) 
2x gels 
Tris 1.5 M pH 8.8 (3.125 mL), H20 (4.625 
mL), 40% v/v Acrylamide/bis-acrylamide 
(4.675 mL), 10% APS (62.5 μl), TEMED 
(5.625 μl). 
Resolving gel (10%) 
1x gels 
Tris 1.5 M pH 8.8 (1.25 mL), H20 (2.50 mL), 
40% v/v Acrylamide/bis-acrylamide (1.25 
mL), 10% APS (50 μl), TEMED (5 μl). 
Coomassie blue stain 40% Methanol, 0.1% (w/v) Brilliant blue 
R250, 10% Acetic acid, 50% H2O 
Running buffer 10X 
/L 
Tris Base (30.3 g), Glycine (143.75 g), SDS 
(10 g) 
Destain solution 25% Methanol, 10% Acetic acid, 65% H2O 
 
Protein samples (5-8 µL) were loaded onto each lane of acrylamide gels (4% stacking 
and 10 or 15% separating gel) and separated by electrophoresis at 80-100 mA using 1x 
glycine running buffer (Table 8.1). Gels were stained with Coomassie blue dye for 1 h 
before being destained (Table 8.1). Prestained Ladder (PageRuler™, ThermoFisher) 




Figure 8.2. Protein band profile of the prestained PageRuler™ ladder. A) Images are from 15% and 10% 
tris-glycine gel, B) Images are from a 4-12% Bis-Tris gel (Thermo Scientific). 
8.2.5 Protein LC-MS analysis  
The appraised protein sample was transferred to Amicon® Ultra-0.5mL (3 or 10 kDa) 
centrifugal filter which was subsequently spun at 14,000 g for 20 minutes (Eppendorf 
centrifuge 5415R). The filtrate was discarded and 500 µL of milli-Q water was added 
and spun at 14000 g for 20 minutes. This step was repeated two times to remove the salt 
present in the sample. The desalted and concentrated samples (1-10 mg/mL) were then 
reduced by the addition TCEP (2-3 equiv.). 
Mass spectrometric analysis was performed on Agilent 6520 CHIPCube Q-TOF LC/MS 
coupled to an Agilent 1200 series nanoflow LC (Agilent Technologies, California, 
USA). The CHIP we used is 43mm x 75um Zorbax 300SB-C8 5um with an enrichment 
column 4 mm 40 nl. The Time of flight MS scan range was from 100 – 4000 mass-to-
charge ratio (m/z) at an acquisition rate of 1 spectrum per second. The injection volume 
has been between 0.1 to 1 µL. The gradient flow over 12 minutes was done as follows: 
0-4 min from 3% B to 50% B, 4-5 min to 100% B, 5-11 min 100% B, 11-12 min from 
100% to 3% B.  Where mobile phase A: 100% H2O + 0.1% formic acid and B: 
Acetonitrile/H2O (90:10%) + 0.1% formic acid. Acquiring has been done over the mass 
range m/z 100 - 4000 and using Agilent MassHunter Qualitative Analysis software for 




8.3 Chapter 2 Experimental  
8.3.1 Chemical synthesis  
3,6-dioxaoctane-1,8-ditosylate (2.14) 
 
4-Toluenesulfonyl chloride 2.22 (3.30 g, 17.3 mmol, 2.6 equiv.) was added to a solution 
of triethylene glycol 2.18 (1.0 g, 6.7 mmol) in a mixture of anhydrous pyridine (1.3 mL) 
and anhydrous DCM (10 mL). The reaction mixture was left to stir under N
2
 overnight 
at room temperature. The solution was then concentrated under reduced pressure and 
subjected to standard work-up (EtOAc). The resultant solid powder was then purified by 
precipitation (DCM/petroleum ether) to give the 3,6-dioxaoctane-1,8-ditosylate (2.14) as 




C) were consistent with those 
previously reported.273 
1
H NMR (400 MHz, CDCl
3
): δ 7.78 (d, J = 8 Hz, 4H), 7.34–7.31 





): δ 144.76, 132.97, 129.76, 127.87, 70.62, 69.12, 68.68, 21.54. 














Sodium azide (1.14 g, 17.4 mmol, 4 equiv.) was added to a solution of 3,6-dioxaoctane-
1,8-ditosylate 2.14 (2.0 g, 4.3 mmol) in acetone/water (3:1, 24 mL), and the mixture was 
allowed to stir at 37°C overnight. The mixture was then concentrated under reduced 
pressure to remove the acetone and the product was extracted with ethyl acetate (3 × 20 





, concentrated and then purified by silica gel chromatography (10 to 60% 





C) were consistent with those previously reported.273 
1
H NMR (400 
MHz, CDCl
3
): δ 3.69–3.67 (m, 8H), 3.37 (t, J = 8Hz, 4H). 
13
C NMR (100 MHz, 
CDCl
3











m/z 223.0919. Found: m/z 223.0925. 
3,6,9-trioxaundecane-1,11-ditosylate (2.15) 
 
4-Toluenesulfonyl chloride 2.22 (2.50 g, 13.4 mmol, 2.6 equiv.) was added to a solution 
of tetraethylene glycol 2.19 (1.0 g, 5.2 mmol) in mixture of anhydrous pyridine (1 mL) 
and anhydrous DCM (10 mL). The reaction mixture was left to stir under N
2
 overnight 
at room temperature. The solution was then concentrated under reduced pressure and 
was subjected to standard work-up (EtOAc). The resultant residue was then purified by 
silica gel chromatography (10 to 60% EtOAc/petroleum ether) to give 3,6,9-





C) were consistent with those previously reported.273 
1
H NMR (400 MHz, CDCl
3
): 
δ 7.74–7.71 (m, 4H), 7.30–7.72 (m, 4H), 4.11–4.08 (m, 4H), 3.62–3.60 (m, 4H), 3.56–
3.43 (m, 8H), 2.38 (s, 6H). 
13
C NMR (100 MHz, CDCl
3
): δ 144.77, 132.90, 129.77, 



















Sodium azide (1.04 g, 16.0 mmol, 4 equiv.) was added to a solution of 3,6,9-
trioxaundecane-1,11-ditosylate 2.15 (2.0 g, 4.0 mmol) in acetone/water (3:1, 24 mL), 
the mixture was allowed to stir at 37°C overnight. The mixture was then concentrated 
under reduced pressure to remove the acetone and the product was extracted using ethyl 
acetate (3 × 20 mL). The organic extract was then washed with saturated brine solution, 
dried over MgSO
4
, concentrated and then purified by silica gel chromatography (10 to 










): δ 3.67–3.62 (m, 12H), 3.35 (t, J = 8 Hz, 4H). 
13
C NMR (100 MHz, 
CDCl
3











) = m/z 267.118159. Found: m/z 267.1228. 
3,6,9,12-tetraoxatetradecane-1,14-ditosylate (2.16) 
 
4-Toluenesulfonyl chloride 2.22 (2.07 g, 10.9 mmol, 2.6 equiv) was added to a solution 
of pentaethylene glycol 2.20 (1.0 g, 4.2 mmol) in mixture of anhydrous pyridine (0.8 
mL) and anhydrous DCM (10 mL), and the mixture was left to stir under N
2
 overnight at 
room temperature. The solution was then concentrated under reduced pressure and was 
subjected to standard work-up (EtOAc). The resultant residue was then purified by silica 
gel chromatography (10 to 60% EtOAc/petroleum ether) to give 3,6,9,12-





C) were consistent with those previously reported.273 
1
H NMR (400 MHz, 
CDCl
3
): δ 7.78 (d, 4H, J = 8 Hz), 7.33 (t, 4H, J = 8 Hz), 4.14 (t, 4H, J = 8 Hz), 3.68–
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3.65 (m, 4H), 3.60 (t, 12H, J = 8 Hz), 2.43 (s, 6H). 
13
C NMR (100 MHz, CDCl
3
): δ 











) = m/z 547.1672. Found: m/z 547.1666. 
1,14-Diazido-3,6,9,12-tetraoxatetradecane (2.12) 
 
Sodium azide (0.95 g, 15 mmol, 4 equiv.) was added to a solution of 3,6,9,12-
tetraoxatetradecane-1,14-ditosylate 2.16 (2.0 g, 3.7 mmol) in acetone/water (3:1, 24 mL) 
and the mixture was allowed to stir at 37°C overnight. The mixture was then 
concentrated under reduced pressure to remove the acetone and the product was 
extracted using ethyl acetate (3 × 20 mL). The organic extract was then washed with 
saturated brine solution, dried over MgSO
4
, concentrated and then purified by silica gel 
chromatography (10 to 60% EtOAc/petroleum ether) to give the diazide (2.12) as a 




C) were consistent with those 
previously reported.273  
1
H NMR (400 MHz, CDCl
3
): δ 3.68–3.65 (m, 16H), 3.37 (t, 4H, 
J = 4.0 Hz). 
13
C NMR (100 MHz, CDCl
3
): δ 70.65, 70.62, 70.57, 69.95, 50.64. HRMS 










) = m/z 311.1443. Found: m/z 311.1434. 
3,6,9,12,15-pentaoxaheptadecane-1,17-ditosylate (2.17) 
 
4-Toluenesulfonyl chloride 2.22 (1.73 g, 9.10 mmol, 2.6 equiv.) was added to a solution 
of anhydrous pyridine (0.76 mL) and hexaethylene glycol 2.21 (1.0 g, 3.5 mmol) in 
anhydrous DCM (10 mL), and the mixture was left to stir under N
2
 overnight at room 
temperature. The solution was then concentrated under reduced pressure and was 
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subjected to standard work-up (EtOAc). The resultant residue was then purified by silica 
gel chromatography (10 to 60% EtOAc/petroleum ether) to give 3,6,9,12,15-





C) were consistent with those previously reported.274 
1
H NMR (400 
MHz, CDCl
3
): δ 7.77 (d, 4H, J = 8 Hz), 7.32 (d, 4H, J = 8 Hz), 4.15–4.12 (m, 4H), 
3.68–3.55 (m, 20H), 2.42 (s, 6H, Me). 
13
C NMR (100 MHz, CDCl
3
): δ 144.70, 133.00, 











) = m/z 591.1934. Found: m/z 591.1928. 
1,17-Diazido-3,6,9,12,15-pentaoxaheptadecane (2.13) 
 
Sodium azide (0.91 g, 14 mmol, 4 equiv.) was added to a solution of 3,6,9,12,15-
pentaoxaheptadecane-1,17-ditosylate 2.17 (2.0 g, 3.4 mmol) in acetone/water (3:1, 24 
mL), and the mixture was allowed to stir at 37°C overnight. The mixture was then 
concentrated under reduced pressure to remove the acetone and the product was 
extracted using ethyl acetate (3 × 20 mL). The organic extract was then washed with 
saturated brine solution, dried over MgSO
4
, concentrated and then purified by silica gel 
chromatography (10 to 60% EtOAc/petroleum ether) to give the diazide (2.13) as a 




C) were consistent with those 
previously reported.275 
1
H NMR (400 MHz, CDCl
3
): δ 3.67–3.64 (m, 20H), 3.36 (t, J = 4 
Hz, 4H). 
13
C NMR (100 MHz, CDCl
3

















8.3.2 Determination of the mass and molar solubilities of PEG-azide 2.10-2.13 
and 4-ABA 2.7 
Mass solubility of each PEG-azide 2.10-2.13 was determined by gradual addition (100 
µl) of water or buffer until 500 mg of each PEG-azide was completely dissolved, the 
mixture was vortexed for about 30 second in between. The solubilities of each azide 
were reported as the minimum required volume of the solvent (water or buffer) to 
completely dissolve 500 mg of each PEG-azide.  
Mass solubility of 4-ABA 2.7 was determined by gradual addition (1000 µl) of water or 
buffer until 100 mg of 4-ABA 2.7 was completely dissolved, the mixture was vortexed 
for about 30 second in between. The solubility of 4-ABA 2.7 were reported as the 
minimum required volume of the solvent (water or buffer) to completely dissolve 100 
mg of 4-ABA 2.7.  
8.3.3 Determination of the rate of consumption of TCEP using 31P NMR 
spectroscopy 
For determination of rates of oxidation of TCEP in the presence of PEG-azide 2.10-
2.13, a solution of TCEP.HCl 2.2 (14.4 mg, 50.2 µmol, 50.2 mM, 1 mL) in Tris.HCl 
buffer (100 mM, pH 7) was mixed with a solution of each PEG-azide (0.5 mmol, 10 
equiv., 1 mL) in the same buffer, the held at 37  and analysed by 31P NMR 
spectroscopy after 3, 13, 23, 33, 43, 53 and 63 minutes. 
For determination of rates of oxidation of TCEP in the presence of 4-ABA 2.7, a 
solution of TCEP 2.2 (5.0 mg, 17 µmol, 17 mM, 1 mL) in Tris.HCl buffer (100 mM, pH 
8) was mixed with a solution of 4-ABA (52 mM, 3 equiv., 1 mL) in the same buffer, 
then held at 37  and analysed by 31P NMR spectroscopy after 3, 13, 23, 33, 43, 53 and 
63 minutes. 
The determination of the percentage of remaining of TCEP was performed using 




8.4 Chapter 3 Experimental  
8.4.1 Chemical synthesis  
2-(2-Methoxyethoxy)ethyl 4-methylbenzenesulfonate (3.1)  
 
4-Toluenesulphonyl chloride 2.22 (3.25 g, 17.1 mmol, 1.3 equiv.) was added to a 
solution of 2-methoxyethan-1-ol 3.11 (1.0 g, 13 mmol) in a mixture of anhydrous 
pyridine (1.25 mL, 15.8 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The mixture 
left to stir under N2 overnight at room temperature. The solution was then concentrated 
under reduced pressure and subjected to standard work-up (EtOAc). The resultant 
residue was then purified by silica gel chromatography (10 to 60% EtOAc/petroleum 
ether) to give the 2-methoxyethyl 4-methylbenzenesulfonate (3.1) as a colorless oil (2.7 




C) were consistent with those previously reported.276 
1H NMR (CDCl3, 400 MHz): δ 7.73 (d, J = 8.3 Hz, 2H), 7.28 (dt, J = 7.9, 0.7 Hz, 2H), 
4.14 – 4.04 (m, 2H), 3.56 – 3.45 (m, 2H), 3.24 (s, 3H), 2.38 (s, 3H). 13C NMR (CDCl3, 
101 MHz): δ 144.73, 133.00, 129.72, 127.86, 69.85, 68.99, 58.88, 21.52. ESI-HRMS: 
Expected for C10H15O4S (M+H
+) = m/z 231.0686. Found: m/z 231.069500. HPLC: 
column: HiQ sil C18 HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/minutes) 








2-(2-Methoxyethoxy)ethyl 4-fluorobenzenesulfonate (3.2) 
 
4-fluorobenzenesulphonyl chloride 3.13 (3.30 g, 17.1 mmol, 1.3 equiv.) was added to a 
solution of 2-methoxyethan-1-ol 3.11 (1.0 g, 13 mmol) in a mixture of anhydrous 
pyridine (1.25 mL, 15.8 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The mixture 
left to stir under N2 overnight at room temperature. The solution was then concentrated 
under reduced pressure and subjected to standard work-up (EtOAc). The resultant 
residue was then purified by silica gel chromatography (10 to 60% EtOAc/ petroleum 
ether) to give the 2-methoxyethyl 4-fluorobenzenesulfonate (3.2) as a colorless oil (2.8 
g, 91%). 1H NMR (CDCl3, 400 MHz):  δ 7.92 – 7.88 (m, 2H), 7.21 – 7.15 (m, 2H), 4.16 
– 4.14 (m, 2H), 3.55 – 3.51 (m, 2H), 3.25 (d, J = 1.5 Hz, 3H). 13C NMR (CDCl3, 100 
MHz): δ 166.96, 164.41, 130.74, 130.64, 116.54, 116.32, 69.80, 69.30, 58.91. ESI-
HRMS: Expected for C9H11O4SFNa (M+Na
+) = m/z 257.0254. Found: m/z 257.0266.  
2-(2-Methoxyethoxy)ethyl 3-bromobenzenesulfonate (3.3) 
 
3-bromobenzenesulphonyl chloride 3.15 (2.74 g, 10.8 mmol, 1.3 equiv.) was added to a 
solution of 2-(2-methoxyethoxy)ethan-1-ol 3.14 (1.0 g, 8.3 mmol) in a mixture of 
anhydrous pyridine (1.25 mL, 15.8 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). 
The reaction left to stir under N2 overnight at room temperature. The solution was then 
concentrated under reduced pressure and subjected to standard work-up (EtOAc). The 
resultant residue was then purified by silica gel chromatography (10 to 60% 
EtOAc/petroleum ether) to give the 2-(2-Methoxyethoxy)ethyl 3-
Bromobenzenesulfonate (3.3) as a colorless oil (2 g, 70.92%). 1H NMR (CDCl3, 400 
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MHz):  8.02 (t, 1H, J = 2 Hz), 7.83 (d, 2H, J = 8 Hz), 7.65 (d, 2H, J =8 Hz), 7.40 (t, 2H, 
J = 8 Hz), 4.21 (t, 2H, J=4.8 Hz), 3.67 (t, 2H, J=5.2 Hz), 3.54 (t, 2H, J=4 Hz), 3.45 (m, 
2H, J = 4 Hz), 3.31 (S, 3H). 13C NMR (CDCl3, 100 MHz):  δ 137.89, 136.72, 130.68, 
130.65, 126.40, 123.01, 71.73, 70.60, 69.89, 68.52, 58.94. ESI-HRMS: Expected for 
C11H15O5SBrNa (M+Na
+) = m/z 360.9721. Found: m/z 360.9743.  
2-methoxyethyl 3-chlorobenzenesulfonate (3.4) 
 
3-Chlorobenzenesulphonyl chloride 3.16 (3.57 g, 17.1 mmol, 1.3 equiv.) was added to a 
solution of 2-methoxyethan-1-ol 3.11 (1.0 g, 13 mmol) in a mixture of anhydrous 
pyridine (1.25 mL, 15.8 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The reaction 
was left to stir under N2 overnight at room temperature. The solution was then 
concentrated under reduced pressure and subjected to standard work-up (EtOAc). The 
resultant residue was then purified by silica gel chromatography (10 to 60% 
EtOAc/petroleum ether) to give the 2-methoxyethyl 3-chlorobenzenesulfonate (3.4) as a 
colorless oil (3 g, 91%). 1H NMR (CDCl3, 400 MHz): δ 7.86 (t, 1H, J =1.6), 7.75 (dt, J 
= 8, 1.6 Hz, 1H), 7.57 (dt, J = 8.0, 1.6 Hz, 1H), 7.44 (t, 1H,  J = 8.4), 4.17 (t, J = 4.8 Hz, 
2H), 3.53 (t, J = 4.8 Hz, 2H), 3.25 (s, 3H). 13C NMR (CDCl3, 100 MHz):  δ 137.77, 
135.32, 133.80, 130.40, 127.93, 125.92, 69.76, 69.72, 58.90. ESI-HRMS: Expected for 
C9H11O4SClNa (M+Na
+) = 272.9959 m/z. Found: 272.9992 m/z. HPLC: column: HiQ 
sil C18 HS (150 x 4.60 mm), Mobile phase: isocratic: (0.75 mL/minutes) 35% MeCN: 





2-(2-Methoxyethoxy)ethyl 4-nitrobenzenesulfonate (3.5)  
 
4-nitrobenzenesulphonyl chloride 3.17 (3.57 g, 17.1 mmol, 1.3 equiv.) was added to a 
solution of 2-methoxyethan-1-ol 3.11 (1.0 g, 13 mmol) in a mixture of anhydrous 
pyridine (1.25 mL, 15.8 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The reaction 
left to stir under N2 overnight at room temperature. The solution was then concentrated 
under reduced pressure and subjected to standard work-up (EtOAc). The resultant 
residue was then purified by silica gel chromatography (10 to 60% EtOAc/petroleum 
ether) to give the 2-methoxyethyl 4-nitrobenzenesulfonate (3.5) as a yellow solid (2 g, 
59%). 1H NMR (CDCl3, 400 MHz): δ 8.34 (d, J = 9.1 Hz, 2H), 8.07 (d, J = 9.0 Hz, 2H), 
4.5  (t, J = 4.4 Hz, 2H), 3.54 (t, J = 4.8 Hz, 2H), 3.22 (s, 3H). 13C NMR (CDCl3, 100 
MHz): δ 150.67, 141.96, 129.20, 124.23, 70.28, 69.69, 58.88. ESI-HRMS: Expected for 
C9H11O6SNNa (M+Na
+) = m/z 284.0199. Found: m/z 284.0196. HPLC: column: HiQ sil 
C18 HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/minutes) 35% MeCN: 65% 
water. Detection at 280 nm. Retention time: 15.178 minutes, purity: 97.9%. 
3-methoxypropyl 4-methylbenzenesulfonate (3.6) 
 
4-Toluenesulphonyl chloride 2.22 (2.87 g, 14.4 mmol, 1.3 equiv.) was added to a 
solution of 3-methoxypropan-1-ol 3.18 (1.0 g, 11 mmol) in a mixture of anhydrous 
pyridine (1.05 mL, 13.3 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The reaction 
left to stir under N2 overnight at room temperature. The solution was then concentrated 
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under reduced pressure and subjected to standard work-up (EtOAc). The resultant 
residue was then purified by silica gel chromatography (10 to 60% EtOAc/petroleum 
ether) to give the 3-methoxypropyl 4-methylbenzenesulfonate (3.6) as colorless oil (2.6 




C) were consistent with those previously reported.277 
1H NMR ( CDCl3, 500 MHz): δ 7.72 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 2H), 4.05 
(t, J = 6.3 Hz, 2H), 3.31 (t, J = 6.0 Hz, 2H), 3.17 (s, 3H), 2.38 (s, 3H), 1.82 (p, J = 6.1 
Hz, 2H).13C NMR (CDCl3, 126 MHz): δ 144.72, 133.05, 129.82, 127.90, 67.98, 67.71, 
58.66, 29.26, 21.63. ESI-HRMS: Expected for C11H16O4SNa (M+Na
+) = m/z 267.0662. 
Found: m/z 267.0692. HPLC: column HiQ sil C18 HS (150 x 4.60 mm). Mobile phase: 
isocratic: (0.75 mL/minutes) 35% MeCN: 65% water. Detection at 280 nm. Retention 
time: 16.30 minutes, purity: 96.7%. 
3-methoxypropyl 3-chlorobenzenesulfonate (3.7) 
 
3-Chlorobenzenesulphonyl chloride 3.16 (3.02 g, 14.4 mmol, 1.3 equiv.) was added to a 
solution of 3-methoxypropan-1-ol 3.18 (1.0 g, 11 mmol) in a mixture of anhydrous 
pyridine (1.05 mL, 13.3 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The reaction 
was left to stir under N2 overnight at room temperature. The solution was then 
concentrated under reduced pressure and subjected to standard work-up (EtOAc). The 
resultant residue was purified by silica gel chromatography (10 to 60% 
EtOAc/petroleum ether) to give the 3-methoxypropyl 3-chlorobenzenesulfonate (3.7) as 
colorless oil (2.7 g, 93%). 1H NMR (CDCl3, 400 MHz): δ 7.85 – 7.84 (m, 1H), 7.76- 
7.74 (m, 1H), 7.58- 7.56 (m, 1H), 7.45 (t, 1H, J = 8 Hz), 4.14 (t, J = 6.4 Hz, 2H), 3.35 (t, 
J = 5.6 Hz, 2H), 3.20 (s, 3H), 1.96 – 1.84 (m, 2H). 13C NMR ( CDCl3, 100 MHz): δ 
137.84, 135.41, 133.73, 130.40, 127.84, 125.87, 68.32, 67.73, 58.59, 29.19. ESI-HRMS: 
Expected for C10H13O4SClNa (M+Na
+) = m/z 278.0115. Found: m/z 287.0171. Infrared 
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(NaCl disc): 1584, 1364, 1185, 1127, 929, 674 cm-1. HPLC: column HiQ sil C18 HS 
(150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/minutes), 35% MeCN: 65% water. 
Detection at 280 nm. Retention time: 20 minutes, purity: 99.7%.  
3-methoxypropyl 4-Nitrobenzenesulfonate (3.8) 
 
4-nitrobenzenesulphonyl chloride 3.17 (3.19 g, 14.4 mmol, 1.3 equiv.) was added to a 
solution of 3-methoxypropan-1-ol 3.18 (1.0 g, 11 mmol) in a mixture of anhydrous 
pyridine (1.05 mL, 13.3 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). The reaction 
was left to stir under N2 for 2 h at room temperature. The solution was concentrated 
under reduced pressure and subjected to standard work-up (EtOAc). The resultant 
residue was purified by silica gel chromatography (10 to 60% EtOAc/petroleum ether) 
to give the 3-methoxypropyl 4-nitrobenzenesulfonate (3.8) as yellow solid (2.5 g, 82%). 
1H NMR ( CDCl3, 400 MHz): δ 8.51 – 8.20 (m, 2H), 8.19 – 7.89 (m, 2H), 4.19 (t, 2H, J 
= 6.4 Hz), 3.35 (t, 2H, J = 5.9 Hz,), 3.19 (s, 3H), 1.89 (p, 2H, J = 6.1 Hz). 13C NMR 
(CDCl3, 100 MHz):  δ 150.69, 141.89, 129.13, 124.33, 68.92, 67.58, 58.59, 29.17. ESI-
HRMS: Expected for C10H13O6SNNa (M+Na
+) = m/z 298.0361. Found: m/z 298.0349. 
HPLC: column HiQ sil C18 HS (150 x 4.60 mm), isocratic: (0.75 mL/minutes) 35% 








2-hydroxy-N-(2-methoxyethyl)acetamide (3.21)  
 
2-methoxyethan-1-amine 3.19 (2.88 g, 38.5 mmol, 4 equiv.) was added to a stirring 
solution of ethyl glycolate 3.20 (1.0 g, 9.6 mmol) in ethanol and refluxed for two days. 
Excess 2-methoxyethan-1-amine was removed under reduced pressure to afford 2-
hydroxy-N-(2-methoxyethyl)acetamide (3.21) as yellow liquid (1.1 g, 86%). 1H NMR 
(CDCl3, 400 MHz): δ 7.15 (s, 1H), 4.86 (s, 1H), 3.90 (s, 2H), 3.36 – 3.21 (m, 4H), 3.21 
(s, 3H). 13C NMR (CDCl3, 100 MHz):  δ 172.28, 70.94, 66.00, 58.85, 38.61. ESI-
HRMS: Expected for C5H12O3N (M+H
+) = m/z 134.0812. Found: m/z 134.0826. 
 2-((2-methoxyethyl)amino)-2-oxoethyl 4-methylbenzenesulfonate (3.9) 
 
4-methylbenzenesulphonyl chloride 2.22 (1.86 g, 9.77 mmol, 1.3 equiv.) was added to a 
solution of 2-hydroxy-N-(2-methoxyethyl)acetamide 3.21 (1.0 g, 7.5 mmol) in a mixture 
of anhydrous pyridine (0.710 mL, 9.02 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). 
The reaction was left to stir under N2 for 2 h at room temperature. The solution was then 
concentrated under reduced pressure and subjected to standard work-up (EtOAc). The 
resultant residue was then purified by silica gel chromatography (10 to 60% 
EtOAc/petroleum ether) to give the 2-((2-methoxyethyl)amino)-2-oxoethyl 4-
methylbenzenesulfonate (3.9) as white solid (1.5 g, 69%).  1H NMR (CDCl3, 400 MHz): 
δ 7.76 (d, J = 8.2 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 6.55 (s, 1H), 4.37 (s, 2H), 3.39 (s, 
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4H), 3.31 (s, 3H), 2.42 (s, 3H). 13C NMR (CDCl3, 101 MHz):  δ 165.07, 145.71, 131.72, 
130.10, 128.06, 70.56, 66.86, 58.77, 38.95, 21.62. ESI-HRMS: Expected for 
C12H17O5SNNa (M+Na
+) = m/z 310.0725. Found: m/z 310.0743. HPLC: column HiQ 
sil C18 HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/minutes), 35% MeCN: 
65% water. Detection at 280 nm. Retention time: 8.179 minutes, purity: 94.4%.  
2-((2-methoxyethyl)amino)-2-oxoethyl 4-methylbenzenesulfonate (3.10) 
 
Methansulphonyl chloride 3.22 (1.11 g, 9.77 mmol, 1.3 equiv.) was added to a solution 
of 2-hydroxy-N-(2-methoxyethyl)acetamide 3.21 (1.0 g, 7.5 mmol) in a mixture of 
anhydrous pyridine (0.710 mL, 9.02 mmol, 1.2 equiv.) and anhydrous DCM (10 mL). 
The reaction was left to stir under N2 for 2 h at room temperature. The solution was 
concentrated under reduced pressure and subjected to standard work-up (EtOAc). The 
resultant residue was then purified by silica gel chromatography (10 to 60% 
EtOAc/petroleum ether) to give the 2-((2-methoxyethyl)amino)-2-oxoethyl 
methansulfonate (3.10) as white solid (1 g, 63%). 1H NMR (CDCl3, 400 MHz): δ 6.60 
(s, 1H), 4.59 (s, 2H), 3.52 – 3.36 (m, 4H), 3.30 (s, 3H), 3.07 (s, 3H). 13C NMR (CDCl3, 
101 MHz):  δ 165.16, 70.57, 66.51, 58.73, 39.04, 37.83.ESI-HRMS: Expected for 
C6H13O5SNNa (M+Na
+) = m/z  234.0407. Found: m/z 234.0395. 
8.4.2 Determination of aqueous stability of sulfonate derivatives using 1H NMR 
(solvent suppression method) 
8.4.2.1 1H NMR solvent suppression method 
NMR spectra were recorded using a Bruker Avance III NMR spectrometer operating at 
500.13 MHz for 1H. Solvent suppression for samples analysed in proteo-solvents was 
achieved using a pre-saturation pulse sequence (noesygppr1d). Typical parameters used 
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were; TD 65536 points, 64 transients, spectral width 20.66 ppm and acquisition time 
3.17 s, D1 2. 
8.4.2.2 Sample preparation and determination of stability  
Stability of sulfonate derivatives (1 mg/mL) was determined in 100 mM phosphate 
buffer, pH 7, 8 or 8.5 containing 10% deuterated solvent using solvent suppression 
method (solvent suppression experiment at 4.7 ppm). 
A stock solution of each sulfonate (10 mg)  was prepared in deuterated solvent and 100 
µL of which was added to 900 µL of aqueous phosphate buffer just before analysing by 
1H NMR experiment (less than 3 minutes after sulfonate reactant was added to buffer).  
1H-NMR spectra were acquired at 3, 6, 24, 48 and 96 h.  
1H-NMR (solvent suppression experiment) was acquired over 4 days to evaluate the 
stability and to calculate the hydrolysis rates. The percentage (%) of remaining sulfonate 
derivatives was calculated using Equation 3.1.  
8.4.3 Determination of glutathione reactivity of sulfonates using 1H NMR (solvent 
suppression method) 
For determination of rates of reactivity of sulfonates with GSH, the sulfonate reactant (1 
mg, 1 equiv.) was incubated at room temperature with glutathione (3 equiv.) in 100 mM 
potassium phosphate buffer, pH 7.5 containing 10% DMF-d7 or acetone-d6. A stock 
solution of each sulfonate (10 mg) was prepared in deuterated solvent and 100 µL of 
which was added to 900 µL of glutathione solution in aqueous phosphate buffer just 
prior to analysis by 1H NMR (less than 3 minutes after sulfonate reactant was added to 
buffer). In a parallel experiment, the sulfonate derivatives 3.4, 3.7 and 3.8 were held in 
phosphate buffer (100 mM, pH 7.5) without glutathione. 
To calculate the rates of reactivity of sulfonates 3.4, 3.7 and 3.8, aliquots were taken at 
specific time intervals with and without glutathione and the percent of remaining for 
each sulfonate was calculated using Equation 3.1. To exclude the hydrolysis factor, the 
percent of remaining of sulfonate derivatives in presence of glutathione (reactivity rate) 
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was calculated by subtraction from the percentage remaining of sulfonate derivatives in 
the absence of glutathione. 
For sulfonate derivative 3.9 the reaction rate was calculated using equation 3.1 assuming 
the rate of hydrolysis is negligible. For sulfonate derivative 3.10, the reaction rate was 
calculated using Equation 3.3 assuming the rate of hydrolysis is negligible. 
8.4.4 Conjugation buffer 
In this study, conjugation buffer refers to 100 mM Tris.HCl (pH 7.5), containing 150 
mM NaCl, and 5 mM EDTA. The pH of the buffer was adjusted directly before 
commencing conjugation reaction by using pH meter (Hanna instrument HI2210). 
Calibration of pH meter was performed on a regular basis. 
8.4.5 Expression of Sbi IV-Cys 
The expression of Sbi IV-Cys was performed according to the general method of protein 
over-expression (see Section 8.2.3). Briefly, a single colony Escherichia coli strain 
BL21 (DE3) with transformed Sbi IV-Cys construct (pET-15b) was inoculated in 
primary LB media and held at 37°C with shaking at 180 rpm overnight which was 
inoculated with 1 L of LB medium containing ampicillin (100 μg/mL) and held under 
the same conditions. The expression of Sbi IV-Cys protein was induced during the 
exponential phase of bacterial growth by adding IPTG and held at 37°C with shaking at 
180 rpm for 3 h. Cells from the secondary culture were harvested, suspended in HisA 
buffer and lysed by sonication. Then, the insoluble cell debris was removed and the 
supernatant was collected (15 mL) and purified using immobilized metal affinity 
chromatography using nickel column attached to an AKTA purifier (Figure 8.3 A). 
Sbi IV-Cys containing fractions (F6-13) were collected and appraised by 15% SDS-
PAGE analysis (Figure 8.3 B). Then, the collected fractions were concentrated and 
finally buffer exchanged into PBS buffer and stored at -20 . Protein concentration was 
determined used BCA assay. The concentration of Sbi IV-Cys was calculated using 






Figure 8.3. A) Chromatogram of immobilized metal affinity purification of the lysate containing Sbi IV-
Cys protein using nickel column. B) SDS-PAGE (15%) analysis of the eluted F6-13.  
8.4.6 Sbi IV-Cys reactivity with sulfonate derivatives 
Sbi IV-Cys was buffer exchanged to 100 mM Tris.HCl buffer (pH 7.5), containing 150 
mM NaCl, and 5 mM EDTA at and concentrated to (2 mg/mL, 0.187 µmol, 0.187 mM) 
using Amicon® Ultra-0.5 mL (3 kDa) centrifugal filter. Stock solution of TCEP 2.2 (4.0 
mg/mL, 0.042 mmol, 14 mM) was prepared in Tris.HCl (100 mM, 150 mM NaCl, 5 
mM EDTA, pH 7.5). The protein was first reduced by incubation with TCEP 2.2 (2 





samples for each reaction (4 reactions). The reduced control protein sample was held at 
room temperature overnight. A stock solution of each sulfonate was prepared in DMF to 
a final concentration of 10 mg/mL, with working solutions of sulfonate derivatives then 
prepared by serial dilution with DMF. Sulfonate derivatives 3.6, 3.8, 3.9 and 3.10 (10 
equiv.) were mixed with the protein (up to 10% DMF final concentration) and held at 
room temperature overnight. 
The reactions were then desalted, concentrated down using the previously mentioned 
method and analysed by protein MS according to the general method for protein MS 
analysis (see Section 8.2.5). 
8.5 Chapter 4 Experimental  
8.5.1 Chemical synthesis  
2-chloro-N-(2-methoxyethyl)acetamide (4.3) 
 
Sodium hydride (NaH, 67 mg, 28 mmol, 2.1 equiv.) was added to a solution 2-
methoxyethan-1-amine 4.47 (1.0 g, 13 mmol) in THF. Subsequently, 2-chloroacetyl 
chloride 4.4 (2.9 g, 26 mmol, 2 equiv.) was added dropwise, and the resulting mixture 
was stirred at room temperature for 24 h. THF was evaporated under reduced pressure, 
ice-cooled water was added, the resulted aqueous mixture was extracted with DCM, 
dried over MgSO4 and the solvent was evaporated under reduced pressure to give 2-
chloro-N-(2-methoxyethyl)acetamide (4.3) as a white solid. (1.8 g, 90%). 
1
H NMR 
spectrum was consistent with that previously reported.278 1H NMR (CDCl3, 400 MHz): δ 
6.84 (s, 1H, NH), 4.00 (s, 2H), 3.44 (s, 4H), 3.32 (s, 3H). 13C NMR (CDCl3, 100 MHz): 
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δ 165.93, 70.65, 58.75, 42.51, 39.50.  ESI-HRMS: Expected for C5H10ClNO2Na 
(M+Na+) = m/z 174.0298. Found: m/z 174.0294.  
Attempted synthesis of 2-chloro-N-(2-chloroacetyl)-N-(2-methoxyethyl)acetamide (4.1) 
 
Attempt using pyridine as base  
Pyridine (1.30 g, 16.4 mmol, 2.5 equiv.) was added to a cooled solution of 2-chloro-N-
(2-methoxyethyl)acetamide 4.3 (1.0 g, 6.6 mmol) in DCM. 2-chloroacetyl chloride 4.12 
(1.48 g, 13.1 mmol, 2 equiv.) was added dropwise, and the resulting mixture was stirred 
at room temperature for 24 h. The reaction was then concentrated under reduced 
pressure and subjected to standard work-up (DCM). Purification of the crude product 
attempted by silica gel chromatography: (5% to 10% MeOH/DCM). A mixture of 
products was obtained and no product could be isolated for characterisation. 
Attempt using TEA as base  
TEA (2.5 equiv.) was added to a solution of 2-chloro-N-(2-methoxyethyl)acetamide 4.3 
(1.0 g, 6.6 mmol) in DCM. 2-chloroacetyl chloride 4.4 (1.48 g, 13.2 mmol, 2 equiv.) 
was added dropwise, and the resulting mixture was refluxed for 4 h. The reaction was 
then concentrated under reduced pressure and subjected to standard work-up (DCM). 
The crude product was further purified by silica gel chromatography: (5% to 10% 
MeOH/DCM). A mixture of undefined products was obtained though the desired 





Base free attempt  
2-chloroacetyl chloride 4.4 (1.48 g, 13.2 mmol) was added dropwise to a solution of 2-
chloro-N-(2-methoxyethyl)acetamide 4.3 (1.0 g, 6.6 mmol) in dry toluene (10 mL) and 
refluxed for 24 hr.  After 24 h of reflux, the reaction was then concentrated under 
reduced pressure, subjected to standard work-up (DCM) and analysed by MS. Analysis 
of MS identified only the starting material (4.3) and a product of elimination of the 
methoxy group. Expected mass for C4H7OClN (M+H




2-chloroacetylchloride 4.4 (2.41 g, 21.5 mmol, 2 equiv.) was added dropwise to a cooled 
solution of aniline 4.48 (1.0 g, 11 mmol) in DCM. The mixture was allowed to warm 
and stirred at room temperature for 2 h. The obtained solution was washed with water, 
saturated ammonium chloride solution, dried over MgSO4 and the solvent was 
evaporated under reduced pressure to give the acetamide 4.5 as a white solid (1.64 g, 




C) were consistent with those previously reported.279 1H 
NMR (CDCl3, 400 MHz):  δ 8.16 (s, 1H, NH), 7.50 (d, J = 8 Hz, 2H, Ar), 7.31 (t, J = 8 
Hz, 2H, Ar), 7.13 (t, J = 8 Hz, 1H, Ar), 4.14 (s, 2H). 13C NMR (CDCl3, 100 MHz): δ 
163.63, 136.60, 129.07, 125.17, 120.03, 42.79. ESI-HRMS: Expected for C8H8OClN Na 









2-chloro-N-phenylacetamide 4.5 (1.0 g, 5.9 mmol) was refluxed with 2-
chloroacetylchloride 4.4 (6.6 g, 59 mmol, 10 equiv.) to boiling in toluene for 48 h. The 
solution was then concentrated under reduced pressure and subjected to standard work-
up (DCM). The crude was further purified by silica gel chromatography: (5% to 10% 
MeOH/DCM) to give the acetamide 4.2 as a white solid (1.08 g, 75%). 1H NMR 
(CDCl3, 400 MHz):  δ 7.50-7.46 (m, 3H, Ar), 7.18-7.15 (m, 2H, Ar), 4.33 (s, 4H, CH2). 
13C NMR (CDCl3, 100 MHz): δ 168.65, 136.14, 130.26, 130.10, 128.66, 45.28. ESI-
HRMS: Expected for C10H9O2Cl2NNa (M+Na
+) = m/z 267.9908. Found: m/z 267.9883. 
Reaction of thiophenol with 2-chloro-N-phenylacetamide  
 
Thiophenol 4.6 (19.53 mg, 177.5 µmol, 3 equiv.) was added to a solution of 2-chloro-N-
phenylacetamide 4.5 (10.0 mg, 59.2 µmol) in aqueous Tris.HCl buffer (100 mM, pH 
7.5, 1 mL) and MeCN (1 mL). The reaction was monitored by HRMS after 6 h. The 







Reaction of thiophenol with 2-chloro-N-(2-chloroacetyl)-N-phenylacetamide  
 
Thiophenol 4.6 (26.94 mg, 244.9 µmol, 6 equiv.) was added to a solution of 2-chloro-N-
(2-chloroacetyl)-N-phenylacetamide 4.4 (10.0 mg, 40.8 µmol) in aqueous Tris.HCl 
buffer (100 mM, pH 7.5, 1 mL) and MeCN (1 mL). The reaction was monitored by 
HRMS after 6 h. The product was confirmed as 4.8 by HRMS (m/z 416.0756 (M+Na+)). 
Reaction of thiophenol with 2-chloro-N-(2-chloroacetyl)-N-(3,4,5-
trimethoxyphenyl)acetamide 
 
Thiophenol 4.6 (19.7 mg, 180 µmol, 6 equiv.) was added to a solution of 2-chloro-N-(2-
chloroacetyl)-N-(3,4,5-trimethoxyphenyl)acetamide 4.9 (10 mg, 30 µmol, purchased 
from Enamine EN300-31080) in aqueous Tris.HCl buffer (100 mM, pH 7.5, 1 mL) and 
MeCN (1 mL). The reaction was monitored by HRMS after 6 h. The product was 






Ethyl 4-(2-chloroacetamido)benzoate (4.12) 
 
2-Chloroacetyl chloride 4.4 (0.90 g, 7.9 mmol, 1.3 equiv.) was added dropwise to a 
cooled solution of benzocaine 4.49 (1.0 g, 6.1 mmol) in DCM. The mixture was allowed 
to warm and stirred at room temperature for 2 h. The obtained solution was washed with 
water and saturated ammonium chloride solution, dried over MgSO4 and the solvent was 
evaporated under reduced pressure to give the acetamide 4.12 as a white solid (1.4 g, 




C) were consistent with those previously reported.280 1H 
NMR (CDCl3, 400 MHz):  δ 8.32 (s, 1H, NH), 8.00 (d, J = 8.8 Hz, 2H, Ar), 7.60 (d, J = 
8.8 Hz, 2H, Ar), 4.35-4.29 (q, J = 7.2 Hz, 2H, CH2), 4.16 (s, 2H, CH2), 1.43 (t, J =7.2 
Hz, 3H, Me). 13C NMR (CDCl3, 100 MHz): δ 165.85, 163.87, 140.55, 130.78, 126.93, 
119.04, 60.94, 42.80, 14.27. ESI-HRMS: Expected for C11H12ClNO3Na (M+Na
+) = m/z 
264.0398. Found: m/z 264.0439.  
Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate (4.11) 
 
Ethyl 4-(2-chloroacetamido)benzoate 4.12 (1.0 g, 4.2 mmol) was refluxed with 2-
chloroacetyl chloride 4.4 (4.6 g, 42 mmol, 10 equiv.) to boiling in toluene for 48 h. The 
product was extracted with DCM and dried over MgSO4, filtered and concentrated 
under reduced pressure. The crude was further purified by silica gel chromatography: 
(10% to 30% EtOAc/petroleum ether) to give the acetamide 4.11 as a white solid (1g, 
76%). 1H NMR (CDCl3, 400 MHz):  δ 8.16 (d, J = 8 Hz, 2H), 7.26 (d, J = 8 Hz, 2H), 
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4.37 (q, J = 8 Hz, 2H), 4.32 (s, 4H), 1.37 (t, J = 8 Hz, 3H). 13C NMR, (CDCl3, 100 
MHz): δ 168.36, 165.08, 139.91, 132.28, 131.49, 128.88, 61.57, 45.14, 14.23. ESI-
HRMS: Expected for C13H13Cl2NO4Na (M+Na
+) = m/z 340.0114. Found: m/z 340.0104. 
Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate reaction with glutathione 
 
Ethyl 4-(2-chloro-N-(2-chloroacetyl)acetamido)benzoate 4.11 (100 mg, 0.315 mmol) 
was dissolved in a solution of THF (2 mL) and added gradually to the aqueous solution 
of glutathione 3.23 (0.58 g, 1.9 mmol, 6 equiv.) in aqueous sodium phosphate (500 mM, 
pH = 7.5, 8 mL). The reaction was stirred at room temperature overnight. The reaction 
was subsequently purified by C-18 chromatography (100% H2O to 40% MeCN/H2O) to 
give the compound 4.13 as a sticky solid (100 mg, 63%). 1H NMR (D2O, 500 MHz): δ 
7.89 (d, J = 9 Hz, 2H), 7.49 (d, J = 9 Hz, 2H), 4.58 – 4.47 (m, 1H), 4.26 (q, J = 7 Hz, 
2H), 3.71- 3.62 (m, 3H), 3.41 (s, 2H), 3.12 – 2.85 (m, 2H), 2.41 (t, J = 7.5 Hz, 2H), 
2.03- 1.97 (m, 2H), 1.28 (t, J = 7 Hz, 3H). 13C NMR (D2O, 126 MHz): δ 176.17, 174.86, 
174.06, 171.66, 170.91, 168.30, 141.57, 130.54, 125.92, 120.29, 62.13, 54.11, 52.91, 
43.36, 36.22, 33.65, 31.40, 26.22, 13.39. HRMS: Expected for C21H28O9SN4Na 






Methyl 3,5-bis(2-chloroacetamido)benzoate (4.15) 
 
2-Chloroacetyl chloride 4.4 (1.4 g, 12 mmol, 2 equiv.) was added dropwise to a cooled 
solution of methyl 3,5-diaminobenzoate 4.50 (1.0 g, 6.0 mmol) in DCM. The mixture 
was allowed to warm and stirred at room temperature for 2 h. The obtained precipitate 
was filtered, washed with water 5-6 times, and completely dried under high vacuum to 
give the acetamide 4.15 as a white solid (1.7 g, 89%). 1H NMR (CDCl3, 400 MHz):  δ 
8.31 (s, 2H, NH), 8.20 (s, 1H, Ar), 7.93 (s, 2H, Ar), 4.16 (s, 2H, 2x CH2), 3.88 (s, 3H, 
Me). 13C NMR (CDCl3, 100 MHz): δ 165.82, 164.10, 137.58, 131.88, 117.45, 115.56, 
52.45, 42.71. ESI-HRMS: Expected for C12H12Cl2N2O4Na (M+Na
+) = m/z 341.0066. 
Found: m/z 341.0077. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: 
isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 
8.26 minutes, purity: 99.1%.  
Methyl 3,4-bis(2-chloroacetamido)benzoate (4.16) 
 
2-Chloroacetyl chloride 4.4 (1.4 g, 12 mmol, 2 equiv.) was added dropwise to a cooled 
solution of methyl 3,4-diaminobenzoate 4.51 (1.0 g, 6.0 mmol) in DCM. The mixture 
was allowed to warm and stirred at room temperature for 2 h. The obtained precipitate 
was filtered, washed with water 5-6 times and completely dried under high vacuum to 
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give the acetamide 4.16 as a white solid (1.5 g, 79%). 1H NMR (CDCl3, 400 MHz):  δ 
8.84 (s, 1H, NH), 8.54 (s,1H, NH), 8.04 (d, J = 2 Hz, 1H, Ar), 7.94 (dd, J = 8.4, 2 Hz, 
1H, Ar), 7.75 (d, J = 8.4 Hz, 1H, Ar), 4.19 (d, J = 12 Hz, 4H, 2 x CH2), 3.88 (s, 3H, 
Me). 13C NMR (CDCl3, 100 MHz): δ 165.82, 164.10, 137.58, 131.88, 117.45, 115.56, 
52.45, 42.71. ESI-HRMS: Expected for C12H12Cl2N2O4Na (M+Na
+) = m/z 341.0066. 
Found: m/z 341.0086. HPLC: column: HiQ Sil HS (150 x 4.60 mm), isocratic: (0.75 
mL/minutes) 35% MeCN: 65% water. Detection at 280 nm. Retention time: 9.03 
minutes, purity: 98.1%. 
N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.38) 
 
2-Chloroacetyl chloride 4.4 (9.3 g, 84 mmol, 6 equiv.) was added dropwise to a cooled 
aqueous NaOH (0.55 M) solution of benzene-1,3-diamine 4.52 (1.5 g, 14 mmol). The 
mixture was allowed to warm and stirred at room temperature overnight. The obtained 
precipitate was filtered, washed with water 5-6 times and completely dried under high 




C) were consistent with those previously reported.281 1H NMR (DMSO-d6, 400 MHz):  
δ 10.34 (s, 2H, NH), 7.96 (t, J = 2.0 Hz, 1H, Ar), 7.37- 7.25 (m, 3H, Ar), 4.25 (s, 4H, 2 
x CH2). 
13C NMR (DMSO-d6, 100 MHz): δ 164.61, 138.82, 129.14, 114.81, 110.36, 
45.53. ESI-HRMS: Expected for C10H10Cl2N2O2Na (M+Na
+) = m/z 283.0012. Found: 









2-Chloroacetyl chloride 4.4 (9.3 g, 84 mmol, 6 equiv.) was added dropwise to a cooled 
aqueous NaOH (0.55 M) solution of benzene-1,2-diamine 4.53 (1.5 g, 14 mmol). The 
mixture was allowed to warm and stirred at room temperature overnight. The obtained 
precipitate was filtered, washed with water 5-6 times and the obtained solid compound 
obtained was completely dried under high vacuum to give the acetamide 4.39 as a white 




C) were consistent with those previously 
reported.282 1H NMR (DMSO-d6, 400 MHz):  δ 9.69 (s, 2H, NH), 7.55 (dd, J = 7.4, 3.7 
Hz, 2H, Ar), 7.23 (dd, J = 6.1, 3.5, 2 Hz, 2H, Ar), 4.34 (s, 4H, 2 x CH2). 
13C NMR 
(CDCl3, 100 MHz): δ 165.12, 130.17, 125.61, 125.08, 43.19. ESI-HRMS: Expected for 
C10H10Cl2N2O2Na (M+Na
+) = m/z 283.0012. Found: m/z 283.0010.  
Ethyl 4-(2-bromoacetamido)benzoate (4.20) 
 
2-bromoacetyl bromide (1.6 g, 7.9 mmol, 1.3 equiv.) was added dropwise to a cooled 
solution of benzocaine 4.49 (1.0 g, 6.1 mmol) and TEA (1.35 g, 13.3 mmol, 2.2 equiv.) 
in DCM. The mixture was allowed to warm and stirred at room temperature for 2 h. The 
obtained precipitate was filtered and washed with water 5-6 times before washing with 
ether. The solid compound was dried under high vacuum to give the acetamide 4.20 as a 
white solid (1.2 g, 69.2%). 1H NMR (CDCl3, 500 MHz):  δ 8.30 (s, 1H, NH), 8.26 – 
8.03 (m, 2H, Ar), 8.03 – 7.54 (m, 2H, Ar), 4.40 (q, J = 7.1 Hz, 2H, CH2), 4.06 (s, 2H, 
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COCH2Br), 1.42 (t, J = 7.1 Hz, 3H, OMe). 
13C NMR (CDCl3, 126 MHz): δ 165.94, 
163.49, 140.87, 130.83, 126.94, 119.01, 61.02, 29.36, 14.35. ESI-HRMS: Expected for 
C11H11ClNO3 (M-H
+) = m/z 283.9920. Found: m/z 283.9928. The general procedure to 
synthesise bromo-derivtives was done according to previously mentioned method by 
Tripathi et al.283 
Methyl 3,5-bis(2-bromoacetamido)benzoate (4.22) 
 
2-bromoacetyl bromide (2.65 g, 13.2 mmol, 2.2 equiv.) was added dropwise to a cooled 
solution of methyl 3,4-diaminobenzoate 4.50 (1.0 g, 6.0 mmol) and TEA (1.35 g, 13.2 
mmol, 2.2 equiv.) in DCM. The obtained precipitate was filtered and washed with water 
5-6 times before washing with ether. The solid compound was dried under vacuum to 
give the acetamide 4.22 as a white solid (1.83 g, 75%). 1H NMR (DMSO-d6, 500 MHz):  
δ 10.68 (s, 2H, NH), 8.20 (s, 1H, Ar), 7.98 (s, 2H, Ar), 4.06 (s, 4H, 2 X CH2), 3.87 (s, 
3H, OMe). 13C NMR (DMSO-d6, 126 MHz): δ 165.66, 165.17, 139.35, 130.58, 115.02, 
113.88, 52.34, 30.24. ESI-HRMS: Expected for C12H13Br2N2O4Na (M+Na
+) = m/z 
406.9261. Found: m/z 406.9237. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile 
phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. 








Methyl 3,4-bis(2-bromoacetamido)benzoate (4.23) 
 
2-bromoacetyl bromide (2.65 g, 13.2 mmol, 2.2 equiv.) was added dropwise to a cooled 
solution of methyl 3,4-diaminobenzoate 4.51 (1.0 g, 6.0 mmol) and TEA (1.35 g, 13.3 
mmol, 2.2 equiv.) in DCM. The obtained precipitate was filtered and washed with water 
5-6 times before washing with ether. The solid compound was dried under high vacuum 
to give the acetamide 4.23 as a white solid (1.59 g, 65%). 1H NMR (DMSO-d6, 500 
MHz):  δ 9.92 (d, J = 5.3 Hz, 2H, NH), 8.10 (s, 1H, Ar), 7.82 (d, J = 2.8 Hz, 2H, Ar), 
4.15 (d, J = 13.2 Hz, 4H, 2 X CH2), 3.85 (s, 3H, OMe). 
13C NMR (DMSO-d6, 126 
MHz): δ 165.39, 134.98, 129.32, 126.55, 126.13, 123.94, 52.19, 30.17. ESI-HRMS: 
Expected for C12H11Br2N2O4 (M-H
+) = m/z 404.9130. Found: m/z 404.9091. HPLC: 
column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/min), 35% 
MeCN: 65% water. Detection at 280 nm. Retention time: 8.77 minutes, purity: 96.57%.  
N,N'-(1,3-phenylene)bis(2-bromoacetamide) (4.28) 
 
2-bromoacetyl bromide (2.05 g, 10.2 mmol, 2.2 equiv.) was added dropwise to a cooled 
solution of benzene-1,3-diamine 4.52 (0.5 g, 4.6 mmol) and TEA (1.35 g, 13.3 mmol, 
2.2 equiv.) in DCM. The obtained precipitate was filtered and washed with water 5-6 
times before washing with ether. The solid compound was dried under high vacuum to 







were consistent with those previously reported.163 1H NMR (DMSO-d6, 500 MHz):  δ 
10.42 (s, 2H, 2 X NH), 7.96 (t, J = 2.0 1H, Ar), 7.37-7.24 (m 3H, Ar), 4.04 (s, 4H, 2 X 
CH2). 
13C NMR (DMSO-d6, 126 MHz): δ 164.79, 138.95, 129.14, 114.72, 110.17, 
30.36. ESI-HRMS: Expected for C10H10Br2N2O2Na (M+Na
+) = m/z 370.9001. Found: 
m/z 370.9039.  
N,N'-(1,2-phenylene)bis(2-bromoacetamide) (4.29) 
 
2-bromoacetyl bromide (2.05g, 10.2 mmol, 2.2 equiv.) was added dropwise to a cooled 
solution of benzene-1,2-diamine 4.53 (0.50 g, 4.6 mmol) and TEA (1.03 g, 10.2 mmol, 
2.2 equiv.) in DCM. The obtained precipitate was filtered and washed with water 5-6 
times before washing with ether. The solid compound was dried under vacuum to give 





consistent with those previously reported.163 1H NMR (DMSO-d6, 500 MHz):  δ 9.71 (s, 
2H, NH), 753 (dd, J = 7.5, 3.7 Hz, 2H, Ar), 7.23 (dd, J = 6.0, 3.5 Hz 2H, Ar), 4.13 (s, 
4H, 2 X CH2). 
13C NMR (DMSO-d6, 126 MHz): δ 165.14, 130.27, 125.56, 124.93, 
30.14. ESI-HRMS: Expected for C10H10Br2N2O2Na (M+Na
+) = m/z 370.9001. Found: 
m/z 370.9012.   
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Ethyl 4-(2-Iodoacetamido)benzoate (4.21) 
 
KI (1.38 g, 8.30 mmol, 2 equiv.) was added to a solution of Ethyl 4-(2-chloroacetamido) 
benzoate 4.12 (1.0 g, 4.2 mmol) in dry acetone (20 mL). The mixture was refluxed for 3 
h. The obtained mixture was filtrated and the solvent was evaporated under reduced 





C) were consistent with those previously reported.284 1H NMR (CDCl3, 400 MHz):  
δ 7.98 (d, J = 8.4, 2H, Ar), 7.81 (s, 1H, NH), 7.54 (d, J = 8.4, 2H, Ar), 4.34- 4.29 (q, J = 
7.2 Hz, 2H, CH2), 3.82 (s, 2H, CH2), 1.34 (t, J = 6.8 Hz, 3H, Me). 
13C NMR (CDCl3, 
100 MHz): δ 165.90, 165.04, 141.24, 130.73, 118.82, 60.92, 14.26, -0.57. ESI-HRMS: 
Expected for C11H12INO3Na (M+Na
+) = m/z 355.9754. Found: m/z 355.9773. The 
followed procedure to synthesise iodo-derivatives was done according to previously 
mentioned method by Lalit et al.285 
Methyl 3,5-bis(2-iodoacetamido)benzoate (4.24) 
 
KI (1.6 g, 9.4 mmol, 3 equiv.) was added to a solution of Methyl 3,4-bis(2-
chloroacetamido) benzoate 4.15 (1.0 g, 3.1 mmol) in dry acetone (20 mL). The mixture 
was refluxed for 3 h. The obtained mixture was filtrated and the solvent was evaporated 
under reduced pressure to give the acetamide 4.24 as a yellow solid (1 g, 63%). 1H 
NMR (CD3COCD3, 500 MHz):  δ 9.91 (s, 2H, NH), 8.20 (s, 1H, Ar), 8.16 (s, 2H, Ar), 4 
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(s, 4H, 2 X CH2), 3.89 (s, 3H, OMe). 
13C NMR (CD3COCD3, 126 MHz): δ 166.82, 
166.09, 140.01, 127.53, 131.52, 115.56, 114.00, 51.85, -0.00. HRMS: Expected for 
C12H13I2N2O4 (M+H
+) = m/z 502.8969, Found: m/z 502.8959. HPLC: column: HiQ Sil 
HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. 
Detection at 280 nm. Retention time: 12.35 minutes, purity, 97.9%.  
Methyl 3,4-bis(2-iodoacetamido)benzoate (4.25) 
 
KI (1.6 g, 9.4 mmol, 3 equiv.) was added to a solution of methyl 3,4-bis(2-
chloroacetamido) benzoate 4.16 (1.0 g, 3.1 mmol) in dry acetone (20 mL). The mixture 
was refluxed for 3 h. The obtained mixture was filtrated and the solvent was evaporated 
under reduced pressure to give the acetamide 4.25 as a yellow solid (1 g, 63%). 1H 
NMR (CDCl3, 500 MHz):  δ 9.73 (s, 1H, NH), 9.61 (s, 1H, NH), 8.02 (s, 1H, Ar), 7.80 
(d, J = 8.5 Hz, 1H, Ar), 7.65 (d, J = 8.5 Hz, 1H, Ar), 3.86 (s, 3H, OMe), 3.86 (s, 4H, 2 X 
CH2). 
13C NMR (CDCl3, 126 MHz): 167.79, 167.15, 165.94, 127.53, 127.36, 126.65, 
124.22, 52.11, -0.74, -1.0. HRMS: Expected for C12H13I2N2O4 (M+H
+) = m/z 502.8969. 
Found: m/z 502.8959. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: 
isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 








KI (1.3 g, 7.7 mmol, 4 equiv.) was added to a solution of N,N'-(1,3-phenylene)bis(2-
chloroacetamide)  4.38 (0.50 g, 1.9 mmol) in dry acetone (20 mL). The mixture was 
refluxed for 3 h. The obtained mixture was filtrated and the solvent was evaporated 
under reduced pressure to give the acetamide 4.30 as a yellow solid (0.63 g, 74%). 1H 
NMR (DMSO-d6, 500 MHz):  δ 10.36 (s, 2H, NH), 7.92 (t, J = 2.0 Hz, 1H, Ar), 7.33-
7.22 (m, 3H, Ar), 3.83 (s, 4H, 2 X CH2). 
13C NMR (DMSO-d6, 126 MHz): δ 166.56, 
139.18, 129.10, 114.36, 109.86, 1.58. HRMS: Expected for C10H10I2N2O2Na (M+Na
+) = 
m/z 466.8724, Found: m/z 466.8758. HPLC: column: HiQ Sil HS (150 x 4.60 mm). 
Mobile phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. 
Retention time, 8.89 minutes, purity, 93.4%.  
N,N'-(1,2-phenylene)bis(2-iodoacetamide) (4.31) 
 
KI (1.3 g, 7.7 mmol, 4 equiv.) was added to a solution of N,N'-(1,3-phenylene)bis(2-
chloroacetamide)  4.39 ( 0.50 g, 1.9 mmol) in dry acetone (20 mL). The mixture was 
refluxed for 3 h. The obtained mixture was filtrated and the solvent was evaporated 
under reduced pressure to give the acetamide 4.31 as a yellow solid (0.63 g, 45%). 1H 
NMR (DMSO-d6, 500 MHz):  δ 9.63 (s, 2H, NH), 7.49 (dd, J = 7.4, 3.7 Hz, 2H, Ar), 
7.20 (dd, J = 6.1, 3.5 Hz, 2H, Ar), 3.90 (s, 4H, 2 X CH2). 
13C NMR (DMSO-d6, 126 
MHz): δ 166.92, 130.42, 125.35, 124.70, 1.49. HRMS: Expected for C10H10I2N2O2Na 
(M+Na+) = m/z 466.8724. Found: m/z 466.8770.  
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Reaction of TCEP with methyl 3,5-bis(2-chloroacetamido)benzoate 
 
TCEP (0.25 g, 0.92 mmol, 3 equiv.) was dissolved in a solution of aqueous sodium 
phosphate buffer (500 mM, pH 7.5, 10 mL). Methyl 3,5-bis(2-
chloroacetamido)benzoate 4.15 (100 mg, 0.310 mmol) was dissolved in THF (2 mL) 
and added gradually to TCEP aqueous solution and held overnight at room temperature. 
The reaction was subsequently concentrated down under reduced pressure and purified 
by C-18 chromatography (100% H2O to 20% MeCN/H2O) to give compound 4.40 as a 
transparent sticky solid (0.1 g, 50%). 1H NMR (500 MHz, D2O): δ 7.84 (d, J = 2.0 Hz, 
2H, Ar), 7.67 (t, J = 2.0 Hz, 1H, Ar), 3.81 (s, 4H, OMe), 2.60 – 2.37 (m, 28H, 6x 
CH2CH2OH, 2x CH2). 
13C NMR (D2O, 126 MHz): δ 178.03, 119.09, 99.98, 52.92, 
28.68, 16.81, 16.41. 31P NMR (202 MHz, D2O): δ 34.92. ESI-HRMS: Expected for 
C30H40N2O16 (M-H
+) = m/z 745.1780. Found: m/z 745.1804. IR cm-1: 3396.42, 2527.16, 




The compound 4.41 was also isolated as a transparent solid (0.1g, 40%). 1H NMR (500 
MHz, D2O): δ 7.81 – 7.53 (m, 3H, Ar), 4.17 (s, 2H, COCH2Cl), 3.78 (s, 3H, OMe), 
2.55-2.43 (m, 14H, 3x CH2CH2OH, COCH2P). 
13C NMR (D2O, 126 MHz):  δ 178.07, 
167.87, 167.70, 137.51, 130.78, 118.47, 117.72, 52.90, 43.01, 28.69, 16.81, 16.41. 31P 
NMR (202 MHz, D2O): δ 34.91. ESI-HRMS: Expected for C12H26N2O10ClP (M-H
+) = 




Glutathione 3.23 (290 mg, 0.943 mmol, 3 equiv.) was dissolved in a solution of aqueous 
sodium phosphate buffer (100 mM, pH 7.5, 8 mL). Methyl 3,5-bis(2-
chloroacetamido)benzoate 4.15 (100 mg, 0.314 mmol) was dissolved in THF (2 mL), 
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added gradually to glutathione aqueous solution and held overnight at room 
temperature. The reaction was subsequently concentrated down under reduced pressure 
and purified by C-18 chromatography (100% H2O to 20% MeCN/H2O) to give the 
product 4.17 as a sticky solid (0.20 mg, 74%).  1H NMR (D2O, 500 MHz): δ 7.73 (s, 1H, 
Ar), 7.56 (s, 2H, Ar), 4.57-4.54 (m, 2H, 2 x NHCHCO), 3.79 (s, 3H, OMe), 3.73 – 3.63 
(m, 6H, 2 x NHCH2COOH, CH2CHNH2), 3.40 (s, 4H, 2 x SCH2CO), 3.13-2.89 (m, 4H, 
2 x SCH2CH), 2.43 (t, J = 8 Hz, 4H, 2 x CH2CH2CO), 2.06-2.01 (m, 4H, 2 x 
CH2CH2CO). 
13C NMR (126 MHz, D2O): δ 176.17, 174.81, 174.00, 171.69, 170.39, 
167.65, 137.89, 130.43, 117.32, 54.11, 52.92, 52.89, 43.42, 36.24, 33.77, 31.37, 26.19. 
HRMS: Expected for C32H44O16S2N8Na (M+Na+) = m/z 883.2209 Found: m/z 
883.2187. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (1 
mL/min), 10% MeCN: 90% water: 0.1% TFA. Detection at 214 nm. Retention time: 




Glutathione 3.23 (290 mg, 0.943 mmol, 3 equiv.) was dissolved in a solution of aqueous 
sodium phosphate buffer (100 mM, pH 7.5, 8 mL). Methyl 3,4-bis(2-
chloroacetamido)benzoate 4.16 (100 mg, 0.314 mmol) was dissolved in THF (2 mL), 
added gradually to glutathione aqueous solution and held overnight at room 
temperature. The reaction was subsequently concentrated down under reduced pressure 
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and purified by C-18 chromatography (100 % H2O to 20 % MeCN/H2O) to give the 
product 4.18 as a sticky solid (0.17 mg, 63%). 1H NMR (500 MHz, D2O): δ 8.00 (s, 1H, 
Ar), 7.93 (dd, J = 8.5, 2 Hz, 1H, Ar), 7.63 (d, J = 8.5 Hz, 1H, Ar), 4.70-4.56 (m, 2H, 2 x 
NHCHCO), 3.86 (s, 3H, OMe), 3.76–3.65 (m, 6H, 2 x NHCH2COOH, CH2CHNH2), 
3.52-3.45  (m, 4H, 2 x SCH2CO), 3.15–2.90 (m, 4H, 2 x SCH2CH), 2.47-2.43 (m, 4H, 2 
x CH2CH2CO), 2.07 -2.02 (m, 4H, 2 x CH2CH2CO). 
13C NMR (126 MHz, D2O): δ 
176.11, 174.88, 173.88, 171.63, 171.22, 167.95, 135.56, 128.79, 128.22, 128.04, 125.81, 
54.08, 52.90, 52.81, 43.35, 35.72, 35.52, 33.85, 33.79, 31.36, 26.09. HRMS: Expected 
for C32H44O16S2N8Na (M+Na
+) = m/z 883.2209. Found: m/z 883.2187. HPLC: column: 
HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (1 mL/min), 10% MeCN: 90% 
water: 0.1% TFA. Detection at 214 nm. Retention time: 14.25 minutes, purity: 99%.  
L-γ-Glutamyl-S-(1-ethyl-2,5-dioxo-3-pyrrolidinyl)-L-cysteinylglycine (4.19) 
 
Glutathione 3.23 (419 mg, 1.60 mmol, 2 equiv.) was dissolved in a solution of aqueous 
sodium phosphate buffer (100 mM, pH 7.5, 8 mL). N-ethylmaleimide 2.4 (0.1 g, 0.8 
mmol) was dissolved in THF (2 mL), added gradually to glutathione aqueous solution 
and held overnight at room temperature. The reaction was subsequently concentrated 
down under reduced pressure and purified by C-18 chromatography (100% H2O to 20% 
MeCN/H2O) to give the product 4.19 as a sticky solid (0.23 mg, 66%). 
1H NMR (500 
MHz, D2O): δ 4.58 (dd, J = 8.5, 5.0 Hz, 1H, SCH2CHNH), 3.98 – 3.95 (m, 1H, 
CH2CHNH2), 3.88 (s, 2H, NHCH2COOH), 3.73 (t, J = 6.5 Hz, 1H, SCHCH2CO), 3.46 
(q, J = 7.5 Hz, 2H, NHCH2CH3), 3.29 – 3.05 (m, 2H, SCHCH2CO), 2.94 (dd, J = 14.5, 
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5.5 Hz, 1H, SCH2CHNH), 2.64 – 2.57 (m, 1H, SCH2CHNH), 2.52-2.41 (m, 2H, 
CH2CH2CO), 2.09 (q, J = 7.5 Hz, 2H, CH2CH2CO), 1.04 (t, J = 7.5 Hz, 3H, CH2CH3). 
13C NMR (126 MHz, D2O): δ 179.39, 178.23, 174.78, 173.68, 173.59, 172.15, 53.79, 
52.77, 41.65, 39.94, 35.79, 34.29, 32.49, 31.19, 26.02, 11.74. Expected for 
C16H24O8SN4Na (M+Na
+) = m/z 455.1207. Found: m/z 455.1204. 
Synthesis of 3,5-bis(2-chloroacetamido)benzoic acid (4.42) 
 
 
2-Chloroacetyl chloride 4.12 (1.62 g, 14.5 mmol, 2.2 equiv.) was added dropwise to a 
cooled solution of methyl 3,4-diaminobenzoate 4.54 (1.0 g, 6.6 mmol) in THF. The 
mixture was allowed to warm and stirred at room temperature for 2 h. The obtained 
precipitate was filtered, washed with water 5-6 times and then completely dried under 





C) were consistent with those previously reported.286 1H NMR 
(CD3COCD3, 400 MHz): δ 9.64 (s, 2H, NH), 8.24 (d, J = 78.3 Hz, 3H, Ar), 4.30 (s, 4H, 
CH2). 
13C NMR (CD3COCD3, 101 MHz) δ 166.91, 140.07, 132.58, 117.11, 115.48, 
44.07. ESI-HRMS: Expected for C11H9Cl2N2O4 (M-H















A solution of EDC.HCl (0.63 g, 3.3 mmol, 1.1 equiv.) in DMF (5 mL) was added to a 
stirred solution of acid 4.42 (1 g, 3 mmol) and N-hydroxysuccinimide (0.38 g, 3.3 
mmol, 1.1 equiv.) in THF at room temperature. The reaction was then stirred at room 
temperature for 2 h before being concentrated under reduced pressure. The obtained 
residue was dissolved in EtOAc and washed with water, dried over MgSO4 and the 
solvent was evaporated under reduced pressure giving a foamy solid. The crude was 
further purified by precipitation (EtOAc/petroleum ether) to give acetamide the 4.43 a 
yellow solid (0.75 g, 57%). 1H NMR (CD3COCD3, 400 MHz,): δ 9.78 (s, 2H, NH), 8.34 
(d, J = 64.1 Hz, 3H, Ar), 4.32 (s, 4H, 2 x ClCH2CO), 2.99 (s, 4H, COCH2CH2CO). 
13C 
NMR (CD3COCD3, 101 MHz): δ 170.86, 170.43, 170.37, 165.95, 162.44, 140.81, 
127.32, 117.21, 117.15, 44.06, 26.40. ESI-HRMS: Expected for C15H13Cl2N3O6Na 
(M+Na+) = m/z 424.0074. Found: m/z 424.0106. 
2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethan-1-amine (4.46) 
 
A solution of Ph3P (0.54 g, 2.1 mol, 1 equiv.) in ether (5 mL) was added dropwise to 
aqueous HCl (5%, 5 mL) solution of tri-PEG azide 2.11 (0.50 g, 2.1 mmol), the mixture 
was left stirring for 24 h. Then, the ether was removed under reduced pressure, and the 
aqueous layer was extracted with DCM until Ph3P oxide was not detected in the aqueous 
layer. The aqueous layer was adjusted to pH = 12, and azide-linked amine was extracted 
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from the aqueous layer with DCM. The combined DCM solution was evaporated under 
reduced pressure to give the azide-linked amine 4.46 as a light yellow liquid (0.25 g, 




C) were consistent with those previously reported.287 1H 
NMR (CDCl3, 400 MHz): δ 3.65 – 3.53 (m, 11H), 3.44 (td, J = 5.2, 1.3 Hz, 2H), 3.41 – 
3.22 (m, 3H), 2.79 (td, J = 5.3, 1.4 Hz, 2H). 13C NMR (CDCl3, 101 MHz): δ 73.41, 
70.65, 70.60, 70.58, 70.23, 69.95, 50.63, 41.75. ESI-HRMS: Expected for C8H19N4O3 
(M+H+) = m/z 219.1452. Found: m/z 219.1464. The followed procedure to synthesise 





2-(2-azidoethoxy)ethan-1-amine 4.46 (0.34 g, 1.6 mmol, 1.3 equiv.) was added to an 
anhydrous solution of activated ester 4.43 (0.50 g, 1.2 mmol)  in THF. The reaction 
mixture was then stirred at room temperature for 1 h before being concentrated under 
reduced pressure. The obtained residue was dissolved in DCM and washed with water, 
dried over MgSO4 and the solvent was evaporated under reduced pressure. The crude 
was further purified by silica gel chromatography: (5% to 20% MeOH/DCM) to give 
azide-linked acetamide 4.36 as a white solid (0.39 g, 62%). 1H NMR (CDCl3, 400 
MHz,): δ 8.78 (s, 2H, NHCH), 8.02 (s, 1H, Ar), 7.68 (s, 2H, Ar), 7.20 (d, J = 8.8 Hz, 
1H, CONHCH2), 4.13 (s, 4H, 2 x ClCH2CO), 3.75 – 3.41 (m, 14H), 3.27 (t, J = 5.0 Hz, 
2H, CH2CH2N3). 
13C NMR (CDCl3, 101 MHz): δ 166.77, 164.69, 137.88, 135.96, 
115.04, 114.31, 70.57, 70.51, 70.47, 70.24, 69.84, 69.55, 50.57, 42.96, 40.08. ESI-
HRMS: Expected for C15H13Cl2N3O6Na (M+Na
+) = m/z 424.0074. Found: m/z 
424.0106. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 
271  
 
mL/min), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 6.54 minutes, 




KI (1.0 g, 8.0 mmol, 4 equiv.) was added to a solution of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-chloroacetamide) 
4.36 (1.0 g, 2.0 mmol) in dry acetone (20 mL). The mixture was refluxed for 3 h. The 
obtained mixture was filtrated and the solvent was evaporated under reduced pressure. 
The crude was further purified by silica gel chromatography: (50 % to 70 % 
acetone/chloroform) to give azide-linked acetamide 4.33 as a yellow solid (1.19 g, 
88%). 1H NMR (CD3COCD3, 500 MHz): δ 9.98 (s, 2H, 2 x NHCH), 7.93 (d, J = 3.7 Hz, 
3H, Ar), 7.69 (d, J = 5.3 Hz, 1H, CONHCH2), 3.95 (s, 4H, ICH2CO), 3.60 – 3.11 (m, 
16H). 13C NMR (CD3COCD3, 126 MHz): δ 170.49, 167.51, 140.48, 137.24, 114.46, 
113.41, 71.14, 70.58, 51.42, 40.42, 1.34. ESI-HRMS: Expected for C19H27Cl2N6O6 
(M+H+) = m/z 505.1364. Found: m/z 505.141600. HPLC: column: HiQ Sil HS (150 x 
4.60 mm). Mobile phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection 






3,4-bis(2-chloroacetamido)benzoic acid (4.44) 
 
2-chloroacetyl chloride 4.4 (1.62 g, 14.5 mmol, 2.2 equiv.) was added dropwise to a 
cooled solution of methyl 3,4-diaminobenzoate 4.55 (1.0 g, 6.6 mmol) in THF. The 
mixture was allowed to warm and stirred at room temperature for 2 h. The obtained 
precipitate was filtered, washed with water 5-6 times and the obtained solid compound 
was completely dried under high vacuum to give the acetamide 4.44 as a white solid 
(1.8 g, 90%). 1H NMR (DMF-d7, 500 MHz):  δ 10.09 (d, J = 20.4 Hz, 2H, NH), 8.30 (d, 
J = 1.9 Hz, 1H, Ar), 8.00 – 7.83 (m, 2H, Ar), 4.45 (d, J = 7.7 Hz, 4H, CH2). 
13C NMR 
(126 MHz, DMF-d7): δ 166.86, 166.02, 165.84, 135.31, 129.94, 128.03, 127.15, 127.00, 
124.12, 43.64, 43.56. ESI-HRMS: Expected for C11H11Cl2N2O4Na (M+Na
+) = m/z 
305.0090. Found: m/z 305.0092. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile 
phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. 









2,5-dioxopyrrolidin-1-yl 3,4-bis(2-chloroacetamido)benzoate (4.45) 
 
A solution of EDC.HCl (0.63 g, 3.3 mmol, 1.1 equiv.) in DMF (5 mL) was added to a 
stirred solution of acid 4.44 (1 g, 3 mmol) and N-hydroxysuccinimide (0.38 g, 3.3 
mmol, 1.1 equiv.) in THF at room temperature. The reaction mixture was then stirred at 
room temperature for 2 h before being concentrated under reduced pressure. The 
obtained residue was dissolved in EtOAc and washed with water, dried over MgSO4 and 
the solvent was evaporated under reduced pressure giving foamy solid. The crude was 
further purified by precipitation (EtOAc /petroleum ether) to give the acetamide 4.45 as 
a yellow solid (0.6 g, 45%). 1H NMR (CD3COCD3, 400 MHz):  δ 9.51 (d, J = 16.2 Hz, 
2H, NH), 8.34 (s, 1H, Ar), 8.18 – 7.89 (m, 2H, Ar), 4.38 (s, 4H, 2 x ClCH2CO), 2.98 (s, 
4H, COCH2CH2CO). 13C NMR (CD3COCD3, 100 MHz): δ 170.48, 166.85, 166.31, 
161.95, 138.26, 130.66, 129.04, 128.65, 125.21, 122.83, 43.88, 26.39. ESI-HRMS: 
Expected for C15H13Cl2N3O6Na (M+Na











2-(2-azidoethoxy)ethan-1-amine 4.46 (0.34 g, 1.6 mmol, 1.3 equiv.) was added to an 
anhydrous solution of activated ester 4.45 (0.50 g, 1.2 mmol)  in THF. The reaction 
mixture was then stirred at room temperature for 1 h before being concentrated under 
reduced pressure. The obtained residue was dissolved in DCM and washed with water, 
dried over MgSO4 and the solvent was evaporated under reduced pressure. The crude 
was further purified by silica gel chromatography: (5% to 20% MeOH/DCM) to give the 
azide-linked acetamide 4.37 as a white solid (0.25 g, 40%). 1H NMR (CDCl3, 500 
MHz):  δ 9.05 (s, 2H, 2 x NHCH), 7.66 (s, 1H, Ar), 7.58 – 7.40 (m, 2H, Ar), 7.14 (t, J = 
5.4 Hz, 1H, CONHCH2), 4.15 (d, J = 10.6 Hz, 4H, 2 x ClCH2CO), 3.69 – 3.46 (m, 
14H), 3.26 (t, J = 5.0 Hz, 2H, CH2CH2N3). 
13C NMR (CDCl3, 126 MHz): δ 166.29, 
166.09, 165.49, 132.96, 132.74, 129.15, 125.57, 125.10, 124.86, 70.63, 70.60, 70.51, 
70.24, 69.94, 69.65, 50.63, 42.91, 42.68, 40.01. ESI-HRMS: Expected for 
C19H27Cl2N6O6 (M+H
+) = m/z 505.1364. Found: m/z 505.1365. HPLC: column: HiQ Sil 
HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. 










KI (1.0 g, 8.0 mmol, 4 equiv.) was added to a solution of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-chloroacetamide) 
4.37 (1.0 g, 2.0 mmol) in dry acetone (20 mL). The mixture was refluxed for 3 h. The 
obtained mixture was filtrated and the solvent was evaporated under reduced pressure. 
The crude was further purified by silica gel chromatography: (50 % to 70 % 
acetone/chloroform) to give the azide-linked acetamide 4.35 as a yellow solid (1 g, 
73%). 1H NMR (CDCl3, 500 MHz): δ 9.30 (s, 1H, 2 x NHCH), 9.17 (s, 1H, NH), 7.61 
(s, 1H, Ar), 7.41 (s, 1H, CONHCH2), 7.27 (s, 2H, Ar), 3.93 (d, J = 10.8 Hz, 4H, 2 x 
ICH2CO), 3.75 – 3.48 (m, 14H), 3.36 (t, J = 5.0 Hz, 2H, CH2CH2N3). 
13C NMR (CDCl3, 
126 MHz): δ 170.97, 168.13, 166.49, 129.71, 125.31, 125.01, 70.48, 70.31, 70.24, 
69.73, 50.60, 40.09, -0.33, -0.53. ESI-HRMS: Expected for C19H27I2N6O6 (M+H
+) = m/z 
689.0076. Found: m/z 689.0108. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile 
phase: isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. 










KBr (1.4 g, 12 mmol, 6 equiv.) was added to a solution of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,2-phenylene)bis(2-chloroacetamide) 
4.37 (1.0 g, 2.0 mmol) in dry acetone (20 mL). The mixture was refluxed for 4 days. 
The obtained mixture was filtrated and the solvent was evaporated under reduced 
pressure. The crude was further purified by silica gel chromatography: (50 % to 70 % 
acetone/chloroform) to give the azide-linked acetamide 4.34 as a white solid (0.5 g, 
43%). 1H NMR (CDCl3, 500 MHz,): δ 9.02 (s, 1H, NHCH), 8.96 (s, 1H, NHCH), 7.79 
(d, J = 2.0 Hz, 1H, Ar), 7.70 – 7.60 (m, 2H, Ar), 7.15 (s, 1H, CONHCH2), 4.09 (d, J = 
12.2 Hz, 4H, BrCH2CO), 3.78 – 3.50 (m, 14H), 3.37 (t, J = 5.0 Hz, 2H, CHCH2N3). 
13C 
NMR (CDCl3,126 MHz): δ 166.31, 165.79, 165.13, 133.28, 132.55, 132.28, 125.68, 
125.14, 124.79, 70.64, 70.62, 70.52, 70.26, 69.96, 69.63, 50.65, 40.10, 29.71, 29.09, 
28.71. ESI-HRMS: Expected for C19H27Br2N6O6 (M+H
+) = m/z 593.0353. Found: m/z 
593.0344. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 
mL/min), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 7.62 minutes, 









KBr (1.4 g, 12 mmol, 6 equiv.) was added to a solution of N,N'-(4-((2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethyl)carbamoyl)-1,3-phenylene)bis(2-chloroacetamide) 
4.36 (1.0 g, 2.0 mmol) in dry acetone (20 mL). The mixture was refluxed for 4 days. 
The obtained mixture was filtrated and the solvent was evaporated under reduced 
pressure. The crude was further purified by silica gel chromatography: (50 % to 70 % 
acetone/chloroform) to give the azide-linked acetamide 4.32 as a yellow solid (0.6 g, 
51%). 1H NMR (CDCl3, 500 MHz,): δ 8.79 (s, 2H, 2 x NHCH), 7.96 (s, 1H, Ar), 7.67 
(s, 2H, Ar), 7.10 (s, 1H, NHCH), 3.95 (s, 4H, BrCH2CO), 3.84 – 3.44 (m, 14H), 3.27 (t, 
J = 5.0 Hz, 2H, CHCH2N3). 
13C NMR (CDCl3,126 MHz): δ 167.04, 164.62, 138.22, 
135.84, 114.87, 114.14, 70.67, 70.59, 70.55, 70.36, 69.94, 69.59, 50.64, 40.24, 29.42. 
ESI-HRMS: Expected for C19H27Br2N6O6 (M+H
+) = m/z 593.0353. Found: m/z 
593.0344. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 
mL/min), 40% MeCN: 60% water. Detection at 280 nm. Retention time: 6.52 minutes, 
purity: 99.4%. 
8.5.2 Evaluation of the aqueous stability of bis-haloacetamides using 1H NMR 
(solvent suppression method) 
Bis-haloacetamide (1 mg/mL) stability was determined in 100 mM phosphate buffer at 
pH 7.5 containing30% deuterated acetone-d6 or DMF-d7 using the general 
1H-NMR 
solvent suppression method (see Section 8.4.2.1). 1H-NMR spectra were acquired at 
zero time (within 3 minutes of addition of aqueous buffer), 24 h, 48 h and 96 h. 
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Percentage remaining of bis-haloacetamide derivative was determined by following the 
change in the integration of the α-methylene protons (XCH2CONH) over time.  
For bis-chloroacetamide derivatives, the change in the integration of α-methylene 
protons at δ 4.32 ppm (ClCH2CONH) was followed over time. For bis-bromoacetamide 
derivatives, the change in the integration of integration of α-methylene protons at δ 4.17 
ppm (BrCH2CONH) was followed over time and for iodo-acetamide derivatives 
integration of α-methylene protons at δ 3.85 ppm (ICH2CONH) was followed over time 
(see appendix 10.5). 
8.5.3 Determination of bis-haloacetamides reactivity with glutathione of using 1H 
NMR (solvent suppression method) 
For determination of rates of reaction of bis-haloacetamides with glutathione, each bis-
haloacetamide reagent (1 mg) was incubated at room temperature with glutathione (2.2 
or 6 equiv.) in 100 mM potassium phosphate buffer, pH 7.5 containing 10% DMF-d7 or 
acetone-d6. A stock solution of each bis-haloacetamide (10 mg/mL) was prepared in 
deuterated solvent. 100 µL of stock acetamide solution was added to 900 µL of 
glutathione solution in aqueous phosphate buffer just before analysis by 1H NMR (less 
than 3 min after bis-haloacetamide reagent was dosed into buffer). Spectra were 
acquired at specific time points using 1H NMR the general solvent suppression method 
(see Section 8.4.21). 
The reaction rates were calculated based on the disappearance of the signal feom 
acetamide protons (XCH2CONH) and appearance of a peak at δ 3.43 ppm 
corresponding to the acetamide-glutathione adduct. The percentage remaining of each 
linker was determined using the ratio of integral of the acetamide peak to the sum of 
integrals of acetamide signal and the acetamide-glutathione adduct signal at 3.8 ppm 





                                 
  
        
                           (Equation 8.2) 
Where; 
Ia= Integration of the α-methylene protons (XCH2CONH). 
Iag= Integration of the acetamide-glutathione adduct signal at δ 3.8 ppm which 
corresponds to (2 x CH2SCH2CONH) protons. 
8.5.4 Determination of the aqueous stability of glutathione conjugates (4.17-4.19) 
using HPLC  
Each glutathione conjugate (1 mg) was dissolved in phosphate buffer (100 M, pH 7) with 
or without DTT (50 mM), samples were evaluated weekly over 4 weeks.  Peak areas were 
acquired at zero time and percentage remaining was calculated by comparison with peak 
area obtained at zero time.  
The following HPLC method was used to evaluate the stability of each glutathione 
conjugate: A mobile phase consisting of water: acetonitrile (90:10, v/v) contain 0.1 % TFA 
(pH 1.98) was passed through a reversed column (HiQ sil C18 HS) with particle size of 4.4 
µm and dimensions of (150 x 4.60 mm). The flow rate was 0.7 mL/minutes for 
glutathione-Mal conjugate (4.19) and 1 mL/min for bis-glutathione conjugates (4.17 and 
4.18) with injection volume of 5 µL. Absorption was measured at 214 nm wavelength.  
The retention times for glutathione-Mal conjugate (4.19), 3,5-bis-glutathione conjugate 
(4.17) and 3,4-bis-glutathione conjugate (4.18) were approximately 9.60 and 10.85, 36.93, 
and 14.25 minutes, respectively. 
Linearity of the methods used was determined by calibration of five concentrations of 
each analyte (0.1 mg/mL to 1 mg/mL). Peak areas of the calibration standards were 
plotted in the Y-axis against the nominal standard concentration, and the linearity of the 
plotted curve was evaluated through the value of the correlation coefficient (R2) which 




8.6 Chapter 5 Experimental 
8.6.1 TCEP quantification using 5,5'-Dithiobis(2-nitrobenzoic acid) (DNTP) 
reagent  
In order to quantify TCEP, DNTP reagent was used as described by Han & Han in 
1994.124 Briefly, TCEP stiochiometrically reduces DNTP forming two equivalent of 2-
nitro-5-thio-benzoic acid. The latter has a molar extension coefficient of 14,150 M-1 cm-
1 at 412 nm. Stock solution of TCEP (20 mM) was prepared in water which was diluted 
40 times in water to get 0.5 mM working solution. 10 µL was taking of the working 
solution and added to 990 µL of DNTP solution (100 µM). The absorbance was 
measured at 412 nm and found 0.1413 + 0.00153 (n=3). With back calculation of the 
concentration of 2-nitro-5-thio-benzoic acid, TCEP concentration was found 4.98 µM.  
8.6.2 Procedure for TCEP reduction of Tmab  
Tmab was buffer exchanged to conjugation 100 mM Tris.HCl buffer (pH 7.5) 
containing 150 mM NaCl and 5mM EDTA and diluted to (5 mg/mL, 0.033 µmol) using 
Amicon® Ultra-0.5 mL (3 kDa) centrifugal filters. Stock solution of TCEP.HCl was 
prepared in the same buffer (4 mg/mL, 0.042 mmol, 14 mM). Calculated volume of 
TCEP solution was added to Tmab solution and incubated at room temperature for 2 h 
unless other conditions are stated. 
8.6.3 Tmab bioconjugates 1-4 
The following acronyms are used in this project to describe antibody fragments: Heavy 
chain (HC), light chain (LC), heavy-heavy (HC-HC), light-light (LC-LC), heavy-light 
(HC-LC, half antibody). 





Table 8.2. Tmab-bioconjugates prepared in this project.  
Tmab bioconjugate Description Acronyms  
Tmab bioconjugate 1 
(5.1) 
 
Fully rebridging inter HC-LC 
and intra HC-HC disulfide 






Tmab bioconjugate 2  
(5.2) 
 
Rebridging of both intra HC-
LC disulfide bonds to produce 
partially cross-linked Tmab by 
the same linker 
Tmabbis-(o-HL-OMe) 
Tmab bioconjugate 3  
(5.3) 
 
Rebridging of one inter HC-LC 
disulfide bond  
Tmabo-HL-OMe 
Tmab bioconjugate 4  
(5.4) 
 
Rebridging inter HC-LC and 
intra HC-HC disulfide bonds 
with different linkers to 





o (ortho) or m 
(meta)  
Aryl substitution 
OMe (ester derivatives), N3 (azide-




8.6.3.1 Construction of Tmab bioconjugate 1 (5.1) with methyl 3,4-bis(2-
bromoacetamido) benzoate linker (4.23) 
Tmab was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) and diluted to (5.0 
mg/mL, 0.034 µmol, 1 ml) using Amicon® Ultra-0.5 mL (10 kDa) centrifugal filters. A 
stock solution of TCEP (4.0 mg/mL, 0.042 mmol, 14 mM) was prepared in the same 
conjugation buffer. Tmab was reduced by incubation with TCEP (5 equiv. relative to 
Tmab) for 2 h at room temperature. The reduced protein was aliquoted into 100 µL 
aliquots for each reaction. 
A stock solution of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) was prepared in 
DMF at final concentration (1.0 mg/mL, 2.5 µmol, 2.5 mM). 5 equiv. of methyl 3,4-
bis(2-bromoacetamido) benzoate 4.23 (7 µL, 5 equiv. relative to Tmab aliquot) was 
added to reduced protein and held at room temperature overnight. 
For other linkers, just refer to this method. 
8.6.3.2 Construction of Tmab bioconjugate 2 (5.2) using a portion-wise 
reduction method 
Tmab was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) and diluted to (5.0 
mg/mL, 0.034 µmol, 1 ml) using Amicon® Ultra-0.5 mL (10 kDa) centrifugal filters. 
Tmab was reduced by incubation with TCEP (1 equiv. relative to Tmab) for 2 h at 4 . 
The reduced protein was aliquoted into 100 µL samples for each reaction.  
A stock solution of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) was prepared in 
DMF at final concentration (1.0 mg/mL, 2.5 µmol, 2.5 mM). Working solution of 4.23 
(0.2 mg/mL) was prepared by serial dilution with DMF. 1 equiv. of working solution of 
methyl 3,4-bis(2-bromoacetamido) benzoate 4.23 (7 µL, 1 equiv. relative to Tmab 
aliquot) was added to the reduced protein and held at room temperature overnight. 
Another reduction step (1 equiv.) for 2 h at 4°C was followed by incubation with the 
same linker (1 equiv.) overnight. 
For other linkers, just refer to this method. 
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8.6.3.3  Construction of Tmab bioconjugate 2 (5.2) using Direct in-situ  method 
Tmab was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) and diluted to (5.0 
mg/mL, 0.034 µmol, 1 ml) using Amicon® Ultra-0.5 mL (10 kDa) centrifugal filters. 
Tmab was reduced by incubation with TCEP (2.2 equiv. relative to Tmab) for 2 h at 
4°C. The reduced protein was aliquoted into 100 µL samples for each reaction. 
A stock solution of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) was prepared in 
DMF at final concentration (1.0 mg/mL, 2.5 µmol, 2.5 mM). Working solution of 4.23 
(0.44 mg/mL) was prepared by serial dilution with DMF. 2.2 equiv. of working solution 
of methyl 3,4-bis(2-bromoacetamido) benzoate 4.23 (7 µL, 2.2 equiv. relative to Tmab 
aliquot) was added to the reduced protein and held at room temperature overnight.  
For other linkers, just refer to this method. 
8.6.3.4 Construction Tmab bioconjugate 3 (5.3) 
Tmab was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) and diluted to (5.0 
mg/mL, 0.034 µmol, 1 ml). Tmab was reduced by incubation with TCEP 2.2 (1.1 equiv. 
relative to Tmab) for 2 h at 4°C. The reduced protein was aliquoted into 100 µL samples 
for each reaction.  
A stock solution of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) was prepared in 
DMF at final concentration (1.0 mg/mL, 2.5 µmol, 2.5 mM). Working solution of 4.23 
(0.2 mg/mL) was prepared by serial dilution with DMF. 1.1 equiv. of working solution 
of methyl 3,4-bis(2-bromoacetamido) benzoate 4.23 (7.7 µL, 1.1 equiv. relative to Tmab 
aliquot) was added to the reduced protein and held at room temperature overnight.  
For other linkers, just refer to this method. 
8.6.3.5   Construction of Tmab bioconjugate 4 (5.4) 
Tmab was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) and diluted to (5.0 
mg/mL, 0.034 µmol, 1 ml). Tmab was reduced by incubation with TCEP (2.2 equiv. 
relative to Tmab) for 2 h at 4°C.  
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A stock solution of methyl 3,4-bis(2-bromoacetamido) benzoate (4.23) was prepared in 
DMF at final concentration (1.0 mg/mL, 2.5 µmol, 2.5 mM). Working solution of 4.23 
(0.44 mg/mL) was prepared by serial dilution with DMF. 2.2 equiv. of working solution 
of methyl 3,4-bis(2-bromoacetamido) benzoate 4.23 (7 µL, 2.2 equiv. relative to Tmab 
aliquot) was added to the reduced protein and held at room temperature overnight.  
Mono-functionalised Tmab (Tmabbis-(o-HL-OMe)) was buffer exchanged to the same 
conjugation buffer. Second reduction step using 2.2 equiv. of TCEP for 2 h at 4°C was 
followed. A stock solution of 4.33 was prepared in DMF at final concentration (1.0 
mg/mL, 1.5 µmol, 1.5 mM). 4 equiv. of 4.33 (10 µL, 2.2 equiv. relative to Tmab 
aliquot) was added to the reduced protein and held at room temperature overnight.  
8.6.4 Rmab bioconjugate 1 
Rmabbis-[(o-HL,o-HHintra)-OMe] was synthesised using the same previously described method 
to construct Tmab bioconjugate 1 (5.1).  
8.6.5 CD spectrum analysis of Rmabbis-[(o-HL,o-HHintra)-O Me]  
The secondary structure compositions of Rmab was analysed by circular dichroism 
(CD) using a Chirascan spectrometer (Applied Photophysics). For CD measurement, 
Rmab (0.1 mg/mL) was buffer exchanged to phosphate buffer (10 mM, pH 7.4). The CD 
experiments were carried out using a using a Quartz Suprasil Cuvette (Hellma Analytics, 
Essex, UK) of pathlength 0.1 cm. The same buffer was used to blank before CD 
spectrum acquiring. CD spectrum measured far-UV region (205–260 nm) over a 
temperature range of 25–90°C in steps of +1 °C/minutes. CD data were averaged, 
smoothed, and the buffer signal was subtracted. Finally, the measurements were 
converted to mean residual ellipticity (θ). The averaged CD spectra of Rmab were 
deconvoluted using CDNN software. CDNN software compares the acquired CD 
spectrum with a range of reference spectra of known protein structure, to get estimation 




8.6.6 DLS analysis of Rmab bioconjugate 1 (Rmabbis-[(o-HL,o-HHintra)-OMe]) 
Before commencing the DLS analysis, samples were centrifuged at 20,000 g for 10 
minutes to remove any aggregates. Then, around 150 µL of 2 mg/mL was exposed to 
laser light in optical microcuvette (ZEN0040, Malvern) using Zetasizer NanoSeries 
Nano S. (Malvern).  
8.6.7 Stability of Rmab bioconjugate 1 (Rmabbis-[(o-HL,o-HHintra)-OMe]) in plasma 
mimicking condition and at 4  for 2 months 
Rmabbis-[(o-HL,o-HHintra)-OMe] (5.0 mg/mL, 0.035 µmol) was buffer exchanged into a fresh 
buffer (pH 7.4) by spinning into fresh buffer using Amicon® Ultra-0.5 mL (10 kDa) 
centrifugal filters several times then, human serum albumin (HSA) (final concentration 
600 μM) and glutathione (GSH) (final concentration 20 μM) were added. The solution 
was incubated at 37°C for 7 days. The reaction was monitored by SDS-PAGE (10 %). 
Rmabbis-[(o-HL,o-HHintra)-OMe] (5.0 mg/mL, 0.035 µmol) was buffer exchanged into a fresh 
buffer (pH 7.4) by spinning into fresh buffer using Amicon® Ultra-0.5 mL (10 kDa) 
centrifugal filters several times then, the reaction was held at 4°C and samples were 











8.7 Chapter 6 Experimental 




1,11-Diamino-3,6,9-trioxaundecane 6.3 (100 mg, 0.520 mmol) was added to an 
anhydrous solution of activated ester 4.45 (0.52 g, 1.3 mmol, 2.5 equiv.) in THF. The 
reaction mixture was then stirred at room temperature for 1 h before being concentrated 
under reduced pressure. The crude was purified by silica gel chromatography: (5 % to 
20 % MeOH/DCM) to give the acetamide 6.4 as a white solid (300 mg, 75%). 1H NMR 
(DMSO-d6, 500 MHz,): δ 9.80 (d, J = 24.1 Hz, 4H, NHCH), 8.54 (s, 2H, CONHCH2), 
7.98 (s, 2H, Ar), 7.73 (s, 4H, Ar), 4.35 (d, J = 9.0 Hz, 8H, 2 x ClCH2CO), 3.66 – 3.42 
(m, 12H), 3.40 (q, J = 5.9 Hz, 4H).13C NMR (DMSO-d6, 126 MHz): δ 172.72, 165.39, 
165.19, 133.26, 131.12, 129.15, 124.99, 124.60, 123.81, 69.68, 69.55, 68.82, 43.28, 
43.21. ESI-HRMS: Expected for C30H36Cl4N6O9Na (M+Na
+) = m/z 787.1190. Found: 
m/z 787.1231. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: 
(0.75 mL/minutes), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 6.18 






KI (435 mg, 2.62 mmol, 10 equiv.) was added to a solution of N,N',N'',N'''-((5,8,11-
trioxa-2,14-diazapentadecanedioyl)bis(benzene-4,1,2-triyl))tetrakis(2-chloroacetamide) 
6.4 (200 mg, 0.262 mmol) in mixture of dry acetone and DMF (400 mL). The mixture 
was refluxed for 3 h. The resultant mixture was filtrated and the solvent was evaporated 
under reduced pressure. The obtained solid was washed with water 5-6 times and 
completely dried under high vacuum to give the acetamide 6.2 as a white solid (200 mg, 
67.6%). 1H NMR (DMSO-d6, 500 MHz,): δ 9.76 (d, J = 19.4 Hz, 4H, NHCH), 8.54 (t, J 
= 5.6 Hz, 2H, CONHCH2), 7.92 (s, 2H, Ar), 7.69 (d, J = 2.1 Hz, 4H, Ar), 3.91 (d, J = 
10.9 Hz, 8H, 2 x ClCH2CO), 3.66 – 3.42 (m, 12H), 3.40 (q, J = 5.9 Hz, 4H).
13C NMR 
(DMSO-d6, 126 MHz): δ 165.72, 165.60, 163.84, 132.11, 129.38, 127.89, 123.16, 
122.88, 121.94, 68.25, 68.13, 67.40, 0.07, -0.00. ESI-HRMS: Expected for 
C30H36I4N6O9Na1 (M+Na
+) = m/z 1154.8615. Found: m/z 1154.8667. HPLC: column: 
HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/minutes), 35% MeCN: 










LiBr (450 mg, 5.23 mmol, 20 equiv.) was added to a solution of N,N',N'',N'''-((5,8,11-
trioxa-2,14-diazapentadecanedioyl)bis(benzene-4,1,2-triyl))tetrakis(2-chloroacetamide) 
6.4 (200 mg, 0.262 mmol) in mixture of dry TFF. The mixture was refluxed for 24 h. 
The resultant mixture was filtrated and the solvent was evaporated under reduced 
pressure. The obtained solid was washed with water 5-6 times and completely dried 
under high vacuum to give the acetamide 6.1 as a white solid (120 mg, 48.8 %). 1H 
NMR (DMSO-d6, 500 MHz,): δ 9.87 (d, J = 17.3 Hz, 4H, NHCH), 8.57 (d, J = 6.4 Hz, 
2H, CONHCH2), 7.96 (s, 2H, Ar), 7.73 (s, 4H, Ar), 4.15 (d, J = 9.1 Hz, 8H, 2 x 
ClCH2CO), 3.52 (s, 12H), 3.44-3.38 (m, 4H).
13C NMR (DMSO-d6, 126 MHz): δ 165.41, 
165.20, 133.37, 131.06, 131.06, 124.83, 124.57, 123.64, 69.68, 69.55, 68.82, 30.18, 
30.12. ESI-HRMS: Expected for C30H36Br4N6O9Na (M+Na
+) = m/z 962.9169. Found: 
m/z 962.9150. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: 
(0.75 mL/minutes), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 6.63 
minutes, purity: 97%. 
3,6,9,12,15,18,21-heptaoxatricosane-1,23-ditosylate (6.9) 
 
4-Toluenesulphonyl chloride 2.22 (1.33 g, 7.02 mmol, 2.6 equiv.) was added to a 
solution of anhydrous pyridine (0.51 g, 6.5 mmol, 2.4 equiv.) and 3,6,9,12,15,18,21-
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heptaoxatricosane-1,23-ditol 6.8  (1.0 g, 2.7 mmol) in anhydrous DCM (10 mL) and the 
mixture left to stir under N2 overnight at room temperature. The solution was then 
concentrated under reduced pressure and subject to standard work-up (EtOAc). The 
resultant residue was then purified by silica gel chromatography (40 to 80% 
EtOAc/petroleum ether) to give 3,6,9,12,15,18,21-heptaoxatricosane-1,23-ditosylate 




C) were consistent with 
those previously reported.288 1H NMR (CDCl3, 400 MHz): δ 7.81 – 7.68 (m, 4H, Ar), 
7.34 – 7.26 (m, 4H, Ar), 4.23 – 4.01 (m, 4H, 2x SO2OCH2), 3.70 – 3.48 (m, 28H), 2.39 
(d, J = 1.5 Hz, 6H, CHCCH3). 
13C NMR (CDCl3, 101 MHz): δ 144.74, 132.87, 129.77, 
127.92, 70.67, 70.54, 70.49, 70.44, 69.20, 68.60, 21.60. ESI-HRMS: Expected for 
C30H47O13S2 (M+H
+) = m/z 679.2453. Found: m/z 679.2448.  
1,23-diazido-3,6,9,12,15,18,21-heptaoxatricosane (6.10) 
 
Sodium azide (2 g, 30 mmol, 10 equiv.) was added to a solution of the ditosylate 6.9 
(2.0 g, 3.0 mmol) in DMF and the mixture allowed to stir at 80°C overnight. The 
mixture was then concentrated under reduced pressure to remove DMF and the product 
extracted using ethyl acetate (3 x 20 mL). The organic extract was then washed with 
saturated brine solution, dried over MgSO4, concentrated to give diazide 6.10 as a 




C) were consistent with those 
previously reported.285 1H NMR (CDCl3, 400 MHz): δ 3.66 – 3.54 (m, 28H), 3.36 – 3.28 
(m, 4H, 2x N3CH2). 
13C NMR (CDCl3, 101 MHz): δ 
13C NMR δ 70.62, 69.96, 50.60. 
ESI-HRMS: Expected for C16H33O7N6 (M+H
+) = m/z 421.2405. Found: m/z 421.2466. 
Synthesis procedure of 6.12 was carried out according to the reported procedure by 








Triphenylphosphine (1.87 g, 7.14 mmol, 3 equiv.) was added portion-wise to a stirred 
solution of diazide 6.10 (1.0 g, 2.4 mmol) in dry THF. The reaction was stirred at room 
temperature overnight. Water (50 mL) was added and the reaction was left stirring at 
room temperature overnight. The THF was evaporated under reduced pressure and the 
reaction was filtrated and the filtrate was then washed with DCM (3 x 100 mL) to 
remove phosphine oxide. The filtrate was evaporated under reduced pressure to yield 





consistent with those previously reported.289 1H NMR (CDCl3, 400 MHz,) δ: δ 3.58 (dd, 
J = 2.4, 1.1 Hz, 24H), 3.44 (t, J = 5.2 Hz, 4H, 2x NH2CH2CH2O), 2.80 (t, J = 5.2 Hz, 
4H, 2x NH2CH2CH2O), 1.67 (s, 4H, 2x NH2). 
13C NMR (CDCl3,101 MHz,) δ: δ 73.27, 
70.48, 70.18, 41.68. ESI-HRMS: Expected for C16H37O7N2 (M+H
+) = m/z 369.2600. 
Found: m/z 369.2850. Synthesis procedure of 6.6 was carried out according to the 


















1,23-diamino-3,6,9,12,15,18,21-heptaoxatricosane 6.6 (150 mg, 0.407 mmol) was added 
to an anhydrous solution of activated ester 4.45 (409 mg, 1.02 mmol, 2.5 equiv.) in 
anhydrous THF. The reaction mixture was then stirred at room temperature for 2 h 
before being concentrated under reduced pressure. The crude was purified by silica gel 
chromatography: (5 % to 20 % MeOH/DCM) to give the acetamide 6.7 as a white solid 
(340 mg, 89%). 1H NMR (DMSO-d6, 500 MHz,): δ 9.81 (d, J = 25.2 Hz, 4H), 8.54 (t, J 
= 5.6 Hz, 2H), 7.98 (s, 2H), 7.73 (d, J = 1.4 Hz, 4H), 4.35 (d, J = 9.3 Hz, 8H), 3.64 – 
3.45 (m, 28H), 3.41 (q, J = 5.9 Hz, 4H).13C NMR (DMSO-d6, 126 MHz): δ 172.72, 
165.38, 165.20, 165.17, 133.26, 131.12, 129.13, 124.98, 124.59, 123.79, 69.71, 69.56, 
68.83, 43.28, 43.21. ESI-HRMS: Expected for C38H53Cl4N6O13 (M+H
+) = m/z 941.2419. 
Found: m/z 941.2451. HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: 
isocratic: (0.75 mL/min), 35% MeCN: 65% water. Detection at 280 nm. Retention time: 









KI (176 mg, 1.06 mmol, 10 equiv.) was added to a solution of N,N',N'',N'''-
((5,8,11,14,17,20,23-heptaoxa-2,26-diazaheptacosanedioyl)bis(benzene-4,1,2-
triyl))tetrakis(2-chloroacetamide) 6.7 (100 mg, 0.106 mmol) in mixture of dry acetone 
(400 mL). The mixture was refluxed for 3 h. The resultant mixture was filtrated and the 
solvent was evaporated under reduced pressure. The crude was purified by silica gel 
chromatography: (50 % to 70 % Acetone/Chloroform) to give acetamide 6.5 as a white 
solid (130 mg, 93.5%). 1H NMR (DMSO-d6, 500 MHz,): δ 9.62 (d, J = 16.8 Hz, 4H), 
8.31 (d, J = 4.9 Hz, 3H), 7.98 (s, 2H), 7.84 – 7.59 (m, 4H), 3.98 (d, J = 7.0 Hz, 8H), 
3.75 – 3.30 (m, 32H). 13C NMR (DMSO-d6, 126 MHz): δ 167.18, 167.09, 165.31, 
133.53, 130.78, 129.30, 124.57, 124.29, 123.34, 69.64, 68.87, 1.67, 1.59. ESI-HRMS: 
Expected for C38H52I4N6O13Na1 (M+Na
+) = m/z 1330.9669. Found: m/z 1330.9765. 
HPLC: column: HiQ Sil HS (150 x 4.60 mm). Mobile phase: isocratic: (0.75 mL/minu), 
35% MeCN: 65% water. Detection at 280 nm. Retention time: 9.55 minutes, purity: 
98%.  
8.7.2 Expression of Sbi III/IV-2xCys  
The expression procedure was done according to the general procedure provided in 
Section 8.2.3. The differences in expression of Sbi III/IV-2xCys are highlighted next. 
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Primary LB media (100 mL with final concentration of ampicillin 100 μg/mL) was 
inoculated with a single colony of SHuffle® T7 E. coli with transformed Sbi III/IV-
2xCys construct (pET-15b) and held at 30°C with shaking at 180 rpm overnight. The 
overnight primary culture was then inoculated with 1-liter of LB medium containing 
ampicillin (100 μg/mL). The secondary culture was held at 30°C with shaking at 180 
rpm until the OD600 value reached 0.7. 
Then, the expression of Sbi III/IV-2xCys protein was induced by adding IPTG to final 
concentration of 1 mM in the culture. The culture held at 22°C with shaking at 180 rpm 
for overnight.   
Cells from the secondary culture were harvested, suspended in HisA buffer contains 
protease inhibitor cocktail mini tablets (EDTA free, Roche) and lysed by sonication. 
Cells were kept cold during the sonication cycles (4 cycles with 10 minutes interval 
between each sonication to cool down cells) at 80% amplitude. 
Then, the insoluble cell debris was removed by centrifugation and the supernatant was 
collected and purified through immobilized metal affinity chromatography using nickel 
column (1mL, HisTrap HP) attached to an AKTA purifier. The loaded column was 
washed with 15 column volumes of HisA buffer and the bound protein was eluted with a 
0-100% gradient of HisB buffer. 
Sbi III/IV-2xCys. containing fractions (F14-21) were collected and appraised by 15% 
SDS-PAGE analysis (Figure 8.4). Collected fractions were concentrated and finally 





Figure 8.4. A) AKTA purification of the lysate using HisTrap column. B) SDS-PAGE gel 15%. P 
(Pellet), S (supernatant), FT (flow through). 
The concentration of Sbi III/IV-2xCys was calculated by measuring the absorbance 







8.7.3 Construction of Tmabo-HL-PEG7-Sbio-bis-Cys conjugate (6.11) with bis-o-
diiodoacetamide (PEG)7 6.5 
1- Sbi III/IV-2xCys was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) 
and diluted to (5.0 mg/mL, 0.32 µmol) using Amicon® Ultra-0.5 mL (3 kDa) 
centrifugal filters. Stock solution of TCEP (4.0 mg/mL, 0.042 mmol, 14 mM) 
was prepared in the same conjugation buffer. Sbi III/IV-2xCys was reduced by 
incubation with TCEP (2 equiv. relative to Sbi III/IV-2xCys) for 1 h at room 
temperature. Then quenching step using penta-PEG azide (2.13) for 1 h was 
followed. 
2- The reduced Sbi III/IV-Cys. with bis-o-diiodoacetamide (PEG)7 linker 6.5 (10 
µL of 20 mg/mL stock solution, 5 equiv. relative to Sbi III/IV-2xCys) for 3 h at 
room temperature. 
3- Excess reagent was removed by using quick step of purification using Ni+2 
column to remove excess linkers from functionalized Sbi III/IV-2xCys solution 
prior to conjugation with partially reduced Tmab 
4- Meanwhile Tmab was buffer exchanged to Tris.HCl (100 mM, 150 mM NaCl, 
5mM EDTA, pH 7.5) and diluted to (5.0 mg/mL, 0.034 µmol) using Amicon® 
Ultra-0.5 mL (10 kDa) centrifugal filters. Tmab was reduced by incubation with 
TCEP (1.1 equiv. relative to Tmab) for 2 h at 4°C.  
5- Functionalised Sbi III/IV-Cys. (4 equiv. relative to Tmab) was then added to the 
reduced Tmab and left at room temperature overnight. 
8.7.4 Sequential purification of Tmabo-HL-PEG7-Sbiortho-bis-Cys conjugate (6.11) 
using IMAC followed by size exclusion chromatography (SEC). 
IMAC purification was performed using Ni2+ column (1 mL HisTrap, FF) to separate 
Tmab-Sbi conjugate from unfunctionalised Tmab as Sbi III/IV-2xCys is a his-tagged 
protein. Before performing the purification the reaction was buffer exchanged sample 




The column was loaded with the reaction mixture. The loaded column washed with 4-10 
mLs of HisA buffer and the bound his-tagged proteins were eluted with a 0-100% 
gradient of HisB buffer (around 20 column volume).  
The collected protein samples were concentrated using Amicon® Ultra-15mL (3 kDa) 
centrifugal filters and finally buffer exchanged into phosphate buffer saline (PBS) buffer 
stored at -20 . Samples from each combined fraction were analysed by SDS-PAGE 
(10%) 
The pure concentrated fractions were further purified using SEC, which was performed 
using superdex column (HiLoad 16/600, Superdex 200 pg, GE Healthcare). Before 
loading into the column, samples were centrifuged at 20,000 g for 10 minutes to remove 
any aggregates. The used buffer and the details regarding the run are summarised in 
Table 8.3. The collected fraction containing the conjugate were buffer exchanged into 
conjugation buffer, sterilised using 0.45 µm membrane filters and stored at -20 . 
Table 8.3. The details regarding the buffer used in SEC and the run specifications. 
Buffer 
Tris.HCl buffer (20 mM, 150 mM NaCl, 
pH 7.4) 
Flow rate 1 mL/min 
Total run time 2 h 
Collected fraction size 1 mL 
 
8.8 Chapter 7 Experimental 
8.8.1 Construction and purification of the trifunctionalTmab: Tmabo-HL-PEG7-
IFabo-HL conjugate (7.1) with bis-o-diiodoacetamide (PEG)7 6.5 linker 
1. IFab was buffer exchanged to conjugation Tris.HCl buffer (pH 7.5) and diluted to 
(5 mg/mL, 0.1 µmol) using Amicon® Ultra-0.5 mL (3 kDa) centrifugal filters. 
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Stock solution of TCEP (4.0 mg/mL, 0.042 mmol, 14 mM) was prepared in the 
same conjugation buffer. IFab was reduced by incubation with TCEP (2 equiv. 
relative to IFab) for 1 h at room temperature. Then quenching step using penta-
PEG azide (2.13) for 1 h was followed. 
2. The reduced IFab was incubated with bis-o-diiodoacetamide (PEG)7 linker 6.5 (10 
µL of stock solution (7 mg/mL), 5 equiv.) for 3 h at room temperature. 
3. Excess reagent was removed by using quick step of purification using protein A 
column (1 mL HisTrap, FF) to remove excess linkers from functionalized IFab 
solution prior to conjugation with partially reduced Tmab. The binding buffer 
Tris.HCl (20 mM, 500 mM NaCl, pH 7.4) was used to collect Fab fractions, then 
the collected faction were concentrated using were concentrated using Amicon® 
Ultra-15 mL (3 kDa) centrifugal filters and finally buffer exchanged into 
conjugation buffer. 
4. Meanwhile Tmab was buffer exchanged to Tris.HCl (100 mM, 150 mM NaCl, 5 
mM EDTA, pH 7.5) and diluted to (5.0 mg/mL, 0.03 µmol) using Amicon® Ultra-
0.5 mL (10 kDa) centrifugal filters. Tmab was reduced by incubation with TCEP 
(1.1 equiv. relative to Tmab) for 2 h at 4°C.  
5. Functionalised IFab (4 equiv. relative to Tmab) was then added to the reduced 
Tmab and left at room temperature overnight. 
6. SEC was performed using superdex column (HiLoad 16/600, Superdex 200 pg, 
GE Healthcare). Before loading into the column, samples were centrifuged at 
20,000 g for 10 minutes. The used buffer and the details regarding the run are 
summarised in Table 8.3. The collected fraction containing the conjugate were 







9 General discussion, conclusion and future implications  
Bioconjugation chemistry is a wide range set of techniques that covalently links a 
biomolecule with an exogenous moiety to provide it with desirable properties. This novel 
construct shares the combined properties of its individual components. This field has 
received a huge attention as it has revolutionised the therapeutic perspective of cancer 
disease. It has provided means to formulate more stable and efficient therapeutics, facilitated 
in vivo dynamic studying of proteins in the biological systems and contributed widely in 
diseases diagnostic approaches. Although it has received huge attention, the effectiveness of 
bioconjugation techniques are still inadequate and limited to certain applications. The work 
herein aimed to tackle a couple of substantial limitations and explore possible new 
applications, which  was divided into two main subsequent themes, optimizing pre-
labelling conditions of proteins and developing a novel conjugation chemistry to 
construct various anti-cancer antibody-protein immunoconjugates. 
Starting with the first aim of this project, we have developed a one-pot approach to 
optimise and facilitate protein reduction protocol and activate thiolate side chains of 
cysteine residues toward conjugation reactions. Protein labelling procedure through their 
reactive cysteine residues offers a number of advantages, including its good 
nucleophilicity and low availability, which have put cysteine-targeted approaches in the 
spotlight. Provided that most of the cysteine amino acids are paired together in disulfide 
bonds, therefore a pre-reduction step is essential to attain free reactive thiolate group. 
Removing excess reducing agents before thiol alkylation is essential to obtain optimum 
labelling and reduce off-target reactions.  
A series of water-soluble PEG-azides were employed to quench excess phosphine 
reductants though Staudinger reaction. In Chapter 2, we provided the synthesis of a 
series of water-soluble PEG azides, determination of their aqueous solubility and the 
rates of oxidation of phosphine reductants. Combining both the desired aqueous 
solubility characteristics of these quenchers with the improved yield of protein labelling, 
we can conclude that the newly developed in situ method can be widely applied in 
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protein conjugation reactions facilitating the labelling of cysteine residues and avoid the 
requirements of purification methods after commencing the reduction step.   
Therefore, in this work we have provided an efficient method to remove excess reducing 
agents, which will eventually improve the level of protein labelling. The importance of 
this work centered at its wide possible applicability in protein conjugation reactions. 
Throughout this thesis, we have found it very efficient to apply this quenching method 
prior to protein labelling using different thiol alkylating approaches, such as our 
developed sulfonate-based method (Chapter 3) and bis-haloacetmide linkers (Chapter 
4).  
In the following Chapters of this project, we aimed to provide a new conjugation 
approach that can be applied in the construction of novel immunoconjugates. We deeply 
looked at different parameters affecting the electrophilic characteristics of various 
sulfonate esters derivatives in Chapter 3. Generally, one conclusion that can be drawn is 
the poor aqueous stability of these linkers which was directly correlated with the pKa 
values of their corresponding sulfonic acids.  
The nature of the α-substituent groups was the most relevant parameter, which has 
enabled us to identify the lead sulfonate-based linker. The α-amide group was identified 
as a very good acceptor group through significantly increasing the reactivity rate of 
tosylate groups toward glutathione with excellent observed aqueous stability. The 
provided results in Chapter 3 were in line with the previously published work regarding 
the reactivity of electrophiles bearing α-amide acceptor with thiolate anion of cysteine. 
The reactivity of tosyl-acetamide with proteins has been evaluated using model protein 
with one cysteine residue, which confirmed our drawn conclusions and proved that tosyl 
acetamide was the optimum identified sulfonate linker amongst the evaluate derivatives.  
The provided linkers in Chapter 3 could be considered as an alternative approach to the 
well-known maleimide-based approach with the advantage of constructing a more stable 
conjugate consistent with what has been shown before regarding iodoacetamide linkers. 
We based this conclusion on the same constructed conjugate with both approaches 
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(sulfonyl acetamide and halo acetamide). One of the offered advantages of using tosyl 
acetamide linker over maleimide is the significant higher aqueous stability of the former 
linker, especially at basic conditions where the half-life of N-ethylmaleimide drops 
dramatically to 1.7 h and it is advised that the solution of maleimide linker should be 
prepared fresh for each labelling reaction.290 
However, with the slow reaction kinetics of the proposed sulfonate ester derivatives, on 
this occasion, we could not apply them to develop our devoted new chemistry in order 
to construct the novel immunoconjugates. Nevertheless, the interesting findings 
regarding tosyl acetamide linker (3.9) could find another implication where the slow 
kinetics and size of our sulfonate linker is favorable in certain conjugation reactions. 
One example could be developing bifunctional linkers with two different electrophiles, 
such as sulfonate acetamide and other well-known electrophiles to specifically label 
certain reactive sites on proteins through a very reactive electrophile, which leaves our 
sulfonate acetamide to be activated with tracking probe, PEG or cytotoxic drug when 
required. Alternatively, PEGylation of proteins using sulfonates, such as PEG 
tresylate6,291 is one of the early developed approaches to enhance the solubility and 
stability of therapeutic proteins, our current work provides a more reactive and stable 
sulfonate derivative that can be employed to prepare PEGs functionalised with tosyl-
acetamide group. 
To our delight, we have developed stable and reactive bis-haloacetamide linkers that 
have been applied in the rebridging of the reduced disulfide bonds of antibodies as 
described in Chapter 4 and 5. The novel scaffold of these linkers was developed based 
on preliminary findings regarding the stability of mono-haloacetamide derivatives and 
the previously published work related to DNA cross-linking.  
Detailed synthesis, aqueous stability and glutathione reactivity of various aryl bis-
haloacetamide derivatives have been described in Chapter 4. Generally, the provided 
results reflect the inherent reactivity of iodo- and bromo-derviavtives in comparison to 
chloro-derivatives. Different factors were evaluated, including the regiochemistry of the 
haloacetamide groups relative to each other, and the impact of aryl substituent. 
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Regardless of the aryl substituent, meta-derivatives were more stable and less reactive 
toward thiol alkylation of glutathione in comparison to ortho-derivatives. Aryl 
substitution did not influence the reactivity of the bis-haloacetamide derivatives, which 
have enabled us to prepare bis-haloacetamide derivatised with bioorthogonal group, 
which is suitable for Click reactions.  
Given that the plasma stability 84,196 of the constructed protein conjugates is one of the 
most essential challenges that needed to be considered when a new conjugation 
chemistry is proposed, in Chapter 4 we studied the stability of bis-glutathione 
conjugates in aqueous buffer and in the presence of DTT over 4 weeks in comparison to 
maleimide-glutathione conjugate. With very stable conjugates in the presence and the 
absence of DTT, we can conclude that the provided scaffold of aryl bis-haloacetamide 
holds more advantages over the current available chemistries.  
Having established a full stability and reactivity study of aryl bis-haloacetamide linkers, 
we evaluated the rebridging of the reduced disulfide bonds of model antibodies, namely 
Trastuzumab and Rituximab (Chapter 5). With interesting rebridged half antibody 
(rebridging both intra-chain heavy-heavy disulfide bonds and inter-chain heavy-light 
disulfide bonds), our bis-haloacetamide linkers interacted differently to the currently 
available rebridging approaches.156,185 The developed half-antibody was confirmed as a 
major product by using protein MS analysis, which was observed with all the developed 
aryl bis-haloacetamide linkers.  
The obtained rebridged half antibody could find interesting applications in anti-cancer 
and chronic diseases treatments. With significantly smaller size, the obtained rebridged 
half antibody could have good tissue penetration potential without the need to misplace 
the effector function of the Fc region, which could be used in the treatment of solid 
tumors. In addition, half-antibody (monovalent antibody) represents a class of 
therapeutic antibodies that have received considerable attention particularly when 
bivalency of antibodies can produce dimerisation of receptors and agonistic effect.292 
One example of the currently approved half-antibodies is onartuzumab (MetMAb), 
which blocks interaction between hepatocyte growth factor receptor (MET) receptors 
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and its hepatocyte growth factor (HGF) ligand and interferes with this signalling 
pathway. It consists of a single antigen-binding fragment (Fab) fused to a complete 
constant domain fragment (Fc).293 Moreover, recently, ADCs of IgG4 subclass have 
been constructed showing a favorable safety profile in comparison to IgG1 subclass.294 
One of the attractive characteristics of IgG4 subclass is its tendency to form half 
antibodies and half antibody exchange forming bispecific antibodies.295 In this work, we 
have provided a solid method to form well-defined half antibodies, which might afford 
attractive approach to form bispecific antibodies of IgG4 subclass.  
Herein, it was demonstrated that well-defined and stable rebridged half antibodies were 
obtained with aryl bis-haloacetamide linkers under plasma mimicking conditions, which 
as described earlier is one of the essential desired characteristic of the immunoconjugate 
of antibodies, particularly ADCs.  
The construction of ADCs is considered as a revolutionary milestone and one of the 
recent cutting-edge approaches in the field of oncology, which are capable of specific 
targeting of highly potent cytotoxic drugs toward tumour site. However, with the long 
list of encountered drawbacks ranging from heterogeneity of ADCs species to poor 
plasma stability of the antibodies construct, different approaches were developed to 
overcome the drawbacks experienced with the first generation ADCs, including genetic 
and enzymatic-based approaches, and the recently introduced disulfide re-bridging 
approaches. Both of the disulfide re-bridging approaches ThioBridge® (form 3-carbon 
bridges) and bis-reactive maleimide (form 2-carbon bridges) were established to obtain 
a well-defined fully cross-linked mAb of 150 kDa mass. Employing of the aryl bis-
haloacetamide linkers to attach a cytotoxic payload, while maintaining the post-
reduction structure of antibodies, could be one of the most promising application of this 
novel linkers in the oncology field. 
Moreover, functionalisation of mAbs with a clickable handle (azide) was achievable 
affording mAbs that could be used in azide cyclooctyne cycloaddition reaction (Click 
reaction). There is a wide range of applications of the provided stable, well-defined 
rebridged half-antibodies functionalised with azide bio-orthogonal chemistry.  
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Click reaction especially SPAAC has been widely garnered substantial attention in the 
broad field of biomedical sciences due to the outstanding selectivity, favourable reaction 
rates and biocompatibility. It has been chiefly used in specific tumor cell imaging for 
diagnostic purposes and for dynamic intracellular tracking strategies. Recently, Click 
chemistry has been widely used in the development of nanoparticles modified with 
biological ligands, such as antibodies for targeted imaging or drug delivery.296,297  
The rebridged half-antibodies functionalised with azide group (for example the 
constructed Tmabbis-[(o-HL,o-HHintra)-N3]) can be widely employed in a huge number of 
applications, including medical therapeutics and diagnostics areas. It could be used to 
construct ADCs through cycloaddition reaction of derivatised cytotoxic drugs, or it can 
be linked to radiolabel or fluorescein confirming the utility of our promising 
applications of this conjugation method.   
Alternatively, this approach could be used to construct protein-protein conjugates of 
mAbs or antibody fragments with other proteins to achieve bi-specificity. In a similar 
approach to Yu Cao et al. where they employ Click chemistry to develop various 
formats of Anti-HER2/AntiCD3 bsAbs,111 herein we provided a chemical method to 
construct bsAbs without the need to genetically incorporate non-canonical amino acids.  
Moreover, in most cases, antibody fragments are modified to modulate their 
characteristics, such as their short plasma half-life which widely tackled through 
attachment of human serum Albumin298 to the native proteins. Therefore, the developed 
azide-functionalised bis-haloacetamides can be utilised to tackle the shortcoming of 
employing antibody fragments through utilising Click chemistry to construct the well-
accepted albumin protein approach.  
One of the most interesting findings regarding aryl bis-haloacetamide derivatives is their 
pattern of selectivity towards the four reduced disulfide bonds of mAbs (heavy-light and 
heavy-heavy disulfide bonds) which, to the best of our knowledge, has not been shown 
before. We found that the regiochemistry of haloacetamide groups relative to each other 
was the most relevant parameter. Meta-linkers were more selective toward cross-linking 
intra-heavy-heavy disulfide bonds. These results have enabled us to understand the 
order of the reduction susceptibility of disulfide bonds and more importantly to 
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construct hetero-bifunctional mAbs. With versatile applications of these conjugates, the 
provided constructs with site-selective conjugation provided a facile method to 
manipulate the quantity and functionalities attached to mAbs. For example, combining 
unique anti-cancer properties of cytotoxic payload with fluorescence emission or 
radiolabelling.  
One of the possible advantages of site-selective conjugation at heavy-heavy disulfide 
bonds is to manipulate the effector function of mAbs. This could be achieved through 
the attachment of a bulky group that hinders the binding sites for Fc R or C1q. Such 
method could provide a ground-breaking technique where the effector function of the 
mAbs could be selectivity modified without the need to genetically modify the antibody 
or use antibody fragments.299   
Lastly, we can conclude from the last conducted experiment in Chapter 5 to produce 
homodimers of C3dg, the utility of employing aryl bis-haloacetamide linkers to not only 
produce homodimers of proteins, but possibly heterodimers. These results are 
particularly important to study and understand protein-protein interactions.300 
As described before, bioconjugation chemistry has revolutionised the targeted 
therapeutic prospects and delivery approaches. Beyond the context of this thesis, aryl 
bis-haloacetamide could found a huge number of promising applications in other areas, 
for instance in the construction of bioconjugated oligonucleotides, which recently have 
started to be successfully interpreted to the clinical practice with the potential to treat 
long list of diseases. Bioconjugation has provided oligonucleotides with a wide range of 
features to modulate their physical properties, enhance tissue penetration, promote target 
specificity and develop resistance to nucleases. These properties have been achieved 
through different adopted conjugation approaches, including binding to antibodies, fatty 
acids, cell penetrating peptides, and α-tocopherol.301 Given that aryl bis-haloacetamides 
were used before in cross-linking of oligonucleotides,163 therefore our developed azide-




In the last 2 Chapters of this work, we provided a novel cross-coupling approach to 
efficiently construct antibody-protein conjugates. In general, this platform affords a 
stable, well-defined and facile chemical method to construct bsAbs and trispecific 
antibodies, which could be widely applied in the construction of various formats of 
bsAbs in good yield and feasible procedure. We provided the construction of two 
different immunoconjugates of Tmab using bis-o-diiodoacetamide (PEG)7 linker (6.5): 
Tmab-Sbi (Chapter 6) and Tmab-IFab (Chapter 7).  
In Chapter 6, we inspired by the basic concept behind ACDs where Tmab was utilised 
as a carrier of Sbi III-IV protein, which activates the human complement protein C3 
against cancer tissue.  
S. aureus produces an arsenal of immune evasion proteins to particularly, interfere with 
the function of the human complement system. These immune evasion proteins have 
different modes of action, ultimately to block convertase proteins, to interfere with 
opsonization and to counteract the action of the chemotactic molecules, mainly C5a. 
Rather than direct inhibition, Sbi III-IV is Staphylococcal protein that uniquely activates 
the C3 component of complement system through AP thus, Sbi III-IV ensures that C3 is 
consistently activated and consumed, while stabilizing the nascent C3b fragments.302 
Taking advantage of the unique mode of action of Sbi III-IV as C3 activator, it has been 
shown that utilizing Sbi as a vaccine adjuvant with mycobacterium tuberculosis antigen 
Ag85b, has significantly enhanced the immune response through efficient opsonisation 
of Ag85b with C3 fragments.302 
In this work, we aimed to exploit Sbi protein as AP activator of the complement system 
in cancer treatment. Given that antibody-based therapy has transformed the landscape of 
cancer treatment, we speculated that by conjugating the Sbi together with mAbs, 
targeted immunotherapy approach would be achieved along with the significantly 
enhancing the antibody-mediated killing of cancerous cell. The constructed 
immunomodulating conjugate could be a ground-breaking strategy in the treatment of 
various types of cancers by conjugating different antibodies or antibody fragments to 
Sbi protein.  
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The constructed immunoconjugates of Tmab-Sbi will be further evaluated in vitro 
against cancer cell lines and possibly in vivo against xenograft cancer model. 
Appropriate drug delivery approach, possibly through the previously described 
nanoparticles, could be further developed to achieve higher stability of the construct.  
Bi-specific antibodies are a present-day trend of cancer treatment, which has gained 
particular to achieve multiple intervention mechanisms in order to overcome the limited 
benefits of employing mAbs in cancer therapy. This field has received extensive 
consideration with more than 50 bsAbs are under investigation in clinical trials for 
various malignancies.244,245 In Chapter 7, we have described the conjugation and 
purification methods to construct trispecific antibody of Tmab with one of the 
checkpoint inhibitors, namely Ipilimumab. The obtained good yield provide a promising 
preliminary foundation to produce various classes of rebridged bsAbs in good yield and 
through an easily adaptable procedure. In this work, we were able to provide a proof of 
concept for our trispecific immunomodulating platform, the obtained results could be 
further implemented into other mAbs or antibody fragments to achieve bi-specificity 
and possibly tri-specificity.  
It has been widely acknowledged the direct association between cancer growth and 
progression with the developed immune suppression by cancer cells. Cancer cells are 
able to modulate various immune checkpoint pathways in order to interfere with 
immunosuppressive mechanisms. Recently, mAbs that inhibit immune checkpoints have 
been considered as a massive breakthrough in cancer therapeutics. Amongst the 
approved immune checkpoints inhibitors, PD-1/PD-L1 and CTLA-4 inhibitors have 
shown encouraging therapeutic outcomes with various types of malignancies.303 
Nevertheless, with the relatively limited response and the observed immune-mediated 
adverse effects in some cancer patients, we speculated that construction of bsAbs of 
these immune checkpoint inhibitors could enhance the observed benefits amongst 
cancer patients. Future studies, possibly pre-clinical studies, will be conducted to 
evaluate treatment outcomes of Tmab-IFab construct in HER2 positive and negative 
breast cancer model. 
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11.1 Cloning vector   
 
11.2 HPLC standard curves of glutathione conjugates  
 
Figure 11.1. Standard curve of Mal-glutathione conjugate (4.19) 
y = 5E+06x - 25180 




















Figure 11.2.  Standard curve of 3.5 DAB-glutathione conjugate (4.17) 
 
 
Figure 11.3. Standard curve of 3.4 DAB-glutathione conjugate (4.18) 
11.3 Cell line and toxicity assay  
11.3.1 Materials and methods 
The breast cancer cell lines BT474 were purchased from ATCC. BT474 cells were 
y = 3E+06x - 35935 



















y = 5E+06x - 5865 



















maintained in at 37 , 5% CO2 in RPMI 1640, HyClone™ medium supplemented with 
10% foetal calf serum and 1% of antibiotic mixture: cell culture grade streptomycin 
10mg/ml and cell culture grade penicillin 10,000 units/ml (named as complete medium). 
Medium renewed three times weekly, and 1:3 subcultivation ratio was conducted on 
weekly basis.  
BT474 Cells (ATCC® HTB-20™) were plated in 96-well plates at 10,000 cells/well and 
allowed to attach for 24 h. Cells were counted using haemocytometer counting device. 
Briefly, cells in T-75 flask (10 mls) were harvested using 2 mls TrypLETM express 
enzyme (Trypsin Replacement) and incubated for 5 minutes at 37  , 5% CO2. Then, 
cells were suspended in complete medium (8 mls), centrifuged for 3 minutes at 1000 
rpm, and re-suspended in complete medium. Cells were counted in the 4 corner large 
squares (1 mm2) of the haemocytometer and averaged.   
Serial dilution of Tmab, Tmab-Sbi conjugates were incubated with the cells at 
concentrations ranging from 100 to 0 mg/ml in complete growth medium in presence of 
2% HCS. After 96 h cell viability was measured using the LIVE/DEAD® 
Viability/Cytotoxicity Kit. The assay was followed according to the manufacture 
protocol, calcein AM was prepared in sterile PBS with final concentration of 0.5 µM.  
100 µL of the reagents solution was added to each well which pre-incubated with 100 
µL of PBS and held in dark place for 30 minutes at 37 . 
The fluorescence measurements were analysed using plate reader (SPECRTOstar 
OMEGA plate reader, BMG-LAB TECH, MARS data analysis software 3.00R2). Green 
Fluorescence of live cells was measured at ex/em ~495 nm/~515 nm. 
11.3.2 In vitro cytotoxicity assay 
With the pure Tmab-Sbi conjugate in hand, we set out to evaluate their activity in vitro. 
BT-474 cancer cell lines belong to Luminal B subtype of cancer, which was shown to be 
ER negative, PR positive, HER-2 positive.304 These cells were cultivated according to 
the product specifications (ATCC® HTB-20™).  
Cell survival percent was measured using LIVE/DEAD® Viability/Cytotoxicity Kit to 
345  
 
construct dose response curve for Tmab and Tmab-Sbi IV conjugate. 
This assay is based on using two reagents: the nonfluorescent, cell-permeant calcein AM 
which activated upon internalisation in live cells via the activity of the intracellular 
ubiquitous esterase enzyme to the intensely fluorescent calcein (green fluorescence in 
live cells) and EthD-1 which enters damaged cells and undergoes a 40-fold 
enhancement of fluorescence upon binding to nucleic acids (bright red fluorescence in 
dead cells). We tend to mainly focus on using calcein AM to test cellular viability. 
In order to evaluate the optimum and compatible concentration of calcein AM reagents 
with BT-474 cells, optimization tests of the working concentration of the reagents were 
conducted according to the manufacturer‘s instructions. The best working concentration 
of was chosen as the lowest reagent concentration that gives sufficient signal as 
observed under fluorescence microscope. As such a range between 0.1-10 µM 
concentrations of calcein AM were evaluated and 0.5 µM calcein AM concentration was 
found the optimum concentration to work with. 
Cellular density was appraised at 5,000, 10,000 and 25,000 cells/well. Both 5,000 and 
25,000 cells/well were not optimum to attain reflective fluorescence measurements. As 
5,000 cells/well was very low density and 25,000 cells/well was very dense and cells 
have died because of lack of sufficient nutrients. Therefore, BT474 Cells (ATCC® HTB-
20™) were plated in 96-well plates at 10,000 cells/well and allowed to attach for 24 h. 
In vitro cytotoxicity of Tmab and Tmab-Sbi conjugate were compared over the 
concentration range between 0.001 µg/ml to 100 µg/ml.  
Tmab and Tmab-Sbi conjugates were incubated with the cells in complete growth 
medium in presence of 2% human serum complement (HSC). After 96 h cell viability 
was measured using the LIVE/DEAD® Viability/Cytotoxicity Kit. The assay was 
followed according to the manufacture protocol. The fluorescence measurements at 




Figure 11.4. Inhibition of the survival in BT 474-cancer cell line by using different concentration levels 
of Tmab and Tmab-Sbi. HCS: human complement serum. 
From the obtained preliminary tests we can conclude that there is no significant cellular 
death observed with 2% HSC. Moreover, Tmab-Sbi conjugate significantly (P< 0.05) 
reduced the percent of survival of cancer cells at all the tested doses (Figure 11.4).  
It worthwhile mentioning that the preliminary obtained results do not represent the 
actual anti-cancer activity of Tmab-Sbi conjugate because of the earlier explained 
instability issues. These assays were conducted directly after preparation and 
purification of the Tmab-Sbi conjugates. The current limitations of the conducted test 
are as follows: The test should be conducted again with shorter incubation time (48 h) to 
be able to compare the activity of Tmab-Sbi conjugate with Tmab. In addition, we 
observed that BT-474 cells tend to adhere to the walls of the well and nor speared all 
over it and that explain the high variability of some of the measurements. Therefore, it is 
suggested to harvest the cells using TrypLETM express enzyme (Trypsin Replacement) 
before conducting the measurements. Lastly, the fluorescence measurements using plate 
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